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II. Abbreviations
5-HT – 5-hydroxytryptamine or serotonin 
5-HT1A - serotonin 1A receptor
α-MSH - α-Melanocyte-stimulating hormone
A. muciniphila - Akkermansia muciniphila
Aβ - Amyloid β
ACTH  Adrenocorticotropic hormone
AD – Alzheimer’s disease
ADHD - Attention deficit hyperactivity disorder
AH - After-hyperpolarization
ALS - Amyotrophic Lateral Sclerosis
AMPA - α-amino-3-hydroxy-5-methylisoxazole-4-propionate
ANS – Autonomic nervous system
APP - Amyloid precursor protein
ASD - Autism spectrum disorder
ASF - Altered schaedler flora
ASO - α- synuclein overexpressing
ATP - Adenosine triphosphate 
B. acidophilus– Bifidobacterium acidophilus
B. adolescentis – Bifidobacterium adolescentis
B. animalis – Bifidobacterium animalis
B. bifidum – Bifidobacterium bifidum
B. breve – Bifidobacterium breve
B. catenulaturm– Bifidobacterium catenulaturm
B. dentium– Bifidobacterium dentium
B. fragilis – Bifidobacterium fragilis
B. infantis– Bifidobacterium infantis
B. lactis – Bifidobacterium lactis
B. longum – Bifidobacterium longum
B. subtilis – Bifidobacterium subtilis
B. fragilis - Bacteroides (B.) fragilis
B-GOS® - Bimuno-galactooligosaccharide
BBB – Blood-brain barrier 
BCAA – Branched-chain amino acid
BCAAem – BCAA mixture
BCE – Before current era
BDNF – Brain-derived neurotrophic factor
BMI – Body mass index
BPA - Bisphenol A
BSH - Bile salt hydrolase
C. rodentium – Citrobacter rodentium
C. butyricum - Clostridium butyricum
C. perfringens - Clostridium perfringens
C. difficile - Clostridium difficile
C-section – cesarean section
CA - Cornu ammonis
CCK - Cholecystokinin
CDI - Clostridium difficile infection
ClpB - Caseinolytic protease B
CNS – Central nervous system
CRD – Colorectal distension
CRF - Corticotropin-releasing factor
CSF - Cerebrospinal fluid
CVD - Cardiovascular disease 
DNA - Deoxyribonucleic acid
E - Embryonic day
E. coli - Escherichia coli
E. rectale - Escherichia rectale
eAAs – Essential amino acids
EC - Enterochromaffin cell
EECs - Enteroendocrine cells
ENS – Enteric nervous system
EPM - Elevated plus maze
EU - European union
FBA - Flux Balance Analysis
FFAR – Free fatty acid receptor
FGF - Fibroblast growth factor
FGID - Functional gastrointestinal disorder
fMRI – Functional magnetic resonance imaging
FMT - Fecal microbiota transplant
FODMAP - Fermentable oligosaccharides, disaccharides, monosaccharides and polyols
FOS – Fructooligosaccharide
FST - Forced-swim test
FXR - Farnesoid X receptor
GABA - γ-aminobutyric acid
GENREs - Generation and refinement of genome-scale metabolic reconstructions
GCN2 - General control nonderepressible 2
GF – Germ-free
GI – Gastrointestinal
GLP-1 - Glucagon-like peptide-1 
GOS – Galactooligosaccharide
GPCR – G-protein coupled receptor
GRIN - Glutamate [NMDA] receptor subunit
GWAS - Genome wide association studies
HDAC – Histone deacetylase 
HFD – High-fat diet
HIV – Human immunodeficiency virus 
HPA - Hypothalamic-pituitary-adrenal
HSV-1- Herpes simplex virus 1
IBD - Inflammatory bowel disease




L. acidophilus – Lactobacillus acidophilus 
L. brevis– Lactobacillus brevis
L. bulgaricus – Lactobacillus bulgaricus 
L. casei – Lactobacillus casei
L. curvatus – Lactobacillus curvatus
L. delbrueckii – Lactobacillus delbrueckii 
L. farciminis– Lactobacillus farciminis
L. fermentum– Lactobacillus fermentum
L. helveticus – Lactobacillus helveticus  
L. johnsonii– Lactobacillus johnsonii
L. paracasei – Lactobacillus paracasei 
L. plantarum – Lactobacillus plantarum 
L. reuteri – Lactobacillus reuteri
L. rhamnosus – Lactobacillus rhamnosus
L. salivarius– Lactobacillus salivarius
LPS – Lipopolysaccharides
LTP – Long-term potentiation
MDD - Major depressive disorder
MDS - Multidimensional scaling
mGlu - Metabotropic glutamate 
MMSE - Mini mental state exam
MRI - Magnetic resonance imaging
mRNA - Messenger ribonucleic acid
MRS - Magnetic resonance spectroscopy
MS - Multiple sclerosis
mTOR – Mammalian target of rapamycin 
MWM - Morris water maze
NFKB - Nuclear factor kappa-light-chain-enhancer of activated B cells
NMDA - N-methyl-D-aspartate 
NMDAR - NMDA receptor
NOD1/2 - Nucleotide-binding oligomerization domain-containing protein ½
NOR – Novel object recognition
NPY - Neuropeptide Y
NSAIDs – Non-steroidal anti-inflammatory drugs
NTS - Nucleus tractus solitarii (the nucleus of the solitary tract)
OCD - Obsessive-compulsive disorders zf
Olfr78 – Olfactory receptor 78
OFT - Open-field test
OR51E1 - Olfactory receptor 51E1 is
OSA - Obstructive sleep apnea 
PCB - Polychlorinated biphenyl
PCR – Polymerase chain reaction 
PCA - Principle component analysis
PCR - Polymerase chain reaction
PD - Parkinson’s disease
PFC – Prefrontal cortex
PGLN - Peptidoglycan
PGLYRP - Peptidoglycan recognition proteins
PICRUSt - Phylogenetic investigation of communities by reconstruction of unobserved states
PNS - Peripheral nervous system
PPI – Proton pump inhibitor
PRRs - Pattern recognition receptors
PS1 – Presenilin 1
PTSD - Post traumatic stress disorder
PUFA - Polyunsaturated fatty acids
PVN - Paraventricular nucleus
PYY – Peptide YY
Rag2 - Recombination activation gene 2
RNA - Ribonucleic acid
RS - Resistant starche
S. thermophilus - Streptococcus (S.) thermophilus 
SCFA – Short-chain fatty acid
SIT - Social interaction test
SPF – Specific pathogen-free
T2DM - Type II diabetes mellitus
TBI - Traumatic brain injury 
TCA - Tricyclic antidepressants
TDO - tryptophan-2,3-dioxygenase
TGF - Transforming growth factor
TGR5 - G-protein coupled bile acid receptor Gpbar1 receptor
TLR – Toll-like receptor
TNF-α/β - Tumor necrosis factor alpha/beta
TPH1 - Tryptophan hydroxylase
TRPV1 - Transient receptor potential vanilloid 1
UPDRS - Unified Parkinson’s disease rating scale
VNS - Vagus nerve stimulation
VPA - Valproic acid
WGS - Whole genome shotgun sequencing
III. Abstract
The importance of the gut-brain axis in maintaining homeostasis has long been appreciated. However, the 
past 15 years have seen the emergence of the microbiota (the trillions of microorganisms within and on our 
bodies) as one of the key regulators of gut-brain function and has led to the appreciation of the importance 
of a distinct microbiota-gut-brain axis. This axis is gaining ever more traction in fields investigating the bio-
logical and physiological basis of psychiatric, neurodevelopmental, age-related and neurodegenerative dis-
orders. The microbiota and the brain communicate with each other via various routes including the immune 
system, tryptophan metabolism, the vagus nerve and the enteric nervous system (ENS), involving microbial 
metabolites such as short-chain fatty acids (SCFAs), branched chain amino acids (BCAAs) and peptidoglycans. 
Many factors can influence microbiota composition in early life, including infection, mode of birth delivery, 
use of antibiotic medications, the nature of nutritional provision, environmental stressors, and host genetics. 
At the other extreme of life, microbial diversity diminishes alongside with aging. Stress, in particular, can sig-
nificantly impact the microbiota-gut-brain axis at all stages of life. Much recent work has implicated the gut 
microbiota in many conditions including autism, anxiety, obesity, schizophrenia, Parkinson’s disease and Alz-
heimer’s disease. Animal models have been paramount in linking the regulation of fundamental neural pro-
cesses, such as neurogenesis and myelination, to microbiome activation of microglia. Moreover, translational 
human studies are ongoing and will greatly enhance the field. Future studies will focus on understanding the 
mechanisms underlying the microbiota-gut-brain axis and attempt to elucidate microbial-based intervention 
and therapeutic strategies for neuropsychiatric disorders.
IV. Introduction
“All disease begins in the gut.”
– Hippocrates of Kos (Hippokrátēs ho Kṓos: c. 460 – c. 370 BCE)
It was over two thousand years ago when the Greek physician Hippocrates, oft-lauded as the father of mod-
ern medicine, is purported to have made this proclamation. Although the attribution to Hippocrates has 
been questioned, its inherent wisdom continues to influence researchers and practitioners in medicine (and 
beyond) regardless of its authenticity (Dinan and Cryan, 2016). 
Although the links between rural Michigan and ancient Greece are not obvious, it was there in the 1800s 
that an unfortunate injury to a Canadian fur-trader Alexis St. Martin created a serendipitous opportunity to 
advance the study of the gut and digestion in line with the sentiments of Hippocrates and the other great 
Greek physician-philosopher, Galen of Pergamon (Mattern, 2013). St. Martin was accidentally shot at close 
range and, during his treatment by the US Army surgeon William Beaumont, became one of the most famous 
patients in gastroenterology (Beaumont, 1833). The surgery left St. Martin with a fistula in his gut, a window 
into the intestine, for Beaumont to study. The doctor took careful notes throughout the recovery period 
and discovered the manner in which many aspects of digestion occurred via experiments where he inserted 
food into St. Martin’s stomach, then later removing it to observe the extent of digestion. He took gastric 
secretion samples and sent them to chemists of the day for analysis, a very uncommon medical process for 
the mid-19th century. This was one of the first recorded observations of human digestion taking place in real 
time. Even more fascinating were Beaumont’s notes of “pain and uneasiness” at corporeal sites far from the 
wound, linking digestion with disease, and emotionality. Moreover, when St Martin became angry or irrita-
ble, it greatly affected the rate of digestion, indicating that the subject’s emotional state affected digestion 
i.e. there was a brain-gut axis. Notwithstanding the discomfort of his patient, Beaumont’s work moved the 
field beyond the 2nd-century teachings of Galen (Mattern, 2013) to pioneer a new era of precise clinical data 
collection, observation, and recording of conclusions for future reference. Other great historical scientists, 
including Charles Darwin (Ayala, 2009) and Claude Bernard (Bernard, 1949 (Originally 1865)), continued the 
effort to formally establish and standardize the use of the scientific method in medicine. While Darwin was 
fastidiously investigating, collecting and cataloging biological specimens to build evidence for his famed the-
ory of natural selection (Darwin, 1859), Bernard was practicing the scientific method at the Sorbonne and the 
Natural History Museum in Paris, France. Through his feeding experiments with rabbits, Bernard determined 
the process for the emulsification and saponification of fats by the pancreas and identified that the process 
of digestion took place not in the stomach but the small intestine. Further studies of glycogen stores in the 
liver and blood sugar levels illustrated that digestion not only breaks up complex molecules from food but 
also stores them for future energy requirements. Encapsulating his body of research, Bernard developed the 
concept of milieu intérieur, stating that “The stability of the internal environment is the condition for the 
free and independent life” (Bernard, 1878). This would later become the foundation for our understanding 
of corporeal homeostasis. 
Bernard, as one of the earliest pioneers of animal experimentation, also paved the way for future scientif-
ic discovery. Amongst those following in this tradition was Ivan Pavlov, whose defining studies of classical 
conditioning were directly inspired by William Beaumont’s observations of digestion. Under the tutelage 
of Carl Ludwig in Leipzig, Germany, Ivan Pavlov helped develop the Pavlov pouch (Pavlov, 1897), a piece of 
exteriorized dog intestine used to study the processes of digestion in dogs. He perfected the technique by 
maintaining the innervation to the exteriorized intestine section to allow more accurate measurement of 
digestive processes in real time over extended periods; it is believed that this is one of the first recorded uses 
of a chronic model of animal experimentation in modern science. These studies set the basis for our under-
standing of the critical role that the gut-brain axis plays in homeostatic processes in health and disease. With 
the advent of brain imaging technology in the 1980s, the full appreciation of the bidirectionality of this axis 
emerged. Studies showed that distention of the gut, resulted in activation of key pathways within the brain 
and that such pathways are exaggerated in disorders such as irritable bowel syndrome (IBS), a functional GI 
disorder with dysregulated microbiota-gut-brain axis (Farmer and Aziz, 2014; Kennedy et al., 2014; Mayer, 
2000). Moreover, the gut-brain axis is seen as an important node in mammalian interoception (Craig, 2009).
Finally, in the past decades, a new player has emerged as a key regulator of the gut-brain axis, the trillions of 
microbes within the gut, the microbiota. Five separate lines of evidence converged to establish this. Firstly, 
studies in germ-free (GF) animals showed that the brain is affected in the absence of microbiota (see Table 
2) (Clarke et al., 2013; Diaz Heijtz et al., 2011; Gareau et al., 2011; Hegstrand and Hine, 1986; Neufeld et 
al., 2011; Sudo et al., 2004). Secondly, animals given specific strains of bacteria had alterations in behavior 
(Bercik et al., 2011a; Bravo et al., 2011; Desbonnet et al., 2015; McKernan et al., 2010; Savignac et al., 2014; 
Verdu et al., 2008) and human studies of such strains confirmed the potential translatability of such findings 
(Allen et al., 2016; Pinto-Sanchez et al., 2017b; Tillisch et al., 2013). Thirdly, population-based studies of peo-
ple exposed to infection, most notably in Walkerton in Canada, demonstrated alterations in gut-brain symp-
toms (Thabane et al., 2010). These findings were also echoed in animal studies where low-level infections 
altered behavior even in the absence of immune activation (Lyte et al., 1998). Fourthly, preclinical studies 
with antibiotic administration, either in early life (O’Mahony et al., 2014) or adulthood (Verdu et al., 2008), 
have shown long-lasting effects on brain, spinal cord, and the ENS. Finally, these data synergized with the 
long known clinical situation that hepatic encephalopathy could be broadly treated by targeting the micro-
biota with antibiotics in humans (see (Collins, 2016)). Once it was understood that our commensal friends 
in the gut could effectively communicate with our brain, a rush of studies sought to understand the intricate 
processes involved. The concept of the microbiota-gut-brain axis thus emerged (Cryan and O’Mahony, 2011; 
De Palma et al., 2014; Rhee et al., 2009) based upon the rich historical legacy of the illustrious scientific fig-
ures discussed above, amongst many others. 
In this review, we aim to give the reader a comprehensive overview of how this field has pushed the frontiers 
of our understanding about the influence of the microbiota on our bodies and on our minds, and what still 
remains to be understood in order to fully realize the potential for microbiota-based medicine.
D. Microbiota: Friends with Benefits
We are living in a microbial world. Microbes have inhabited the earth for hundreds of millions of years longer 
than humans, and there has never been a time when our body has not received signals from microbes. The 
human microbiota is the collective term for the trillions of microorganisms that live in and on us (Ursell et al., 
2012)Ribosomal, 16S/analysis</keyword><keyword>Sequence Analysis</keyword></keywords><dates><-
year>2012</year><pub-dates><date>Aug</date></pub-dates></dates><isbn>1753-4887 (Electronic. Over 
the past two decades, microbiome research has accelerated at an incredible pace and is revealing the myriad 
of ways these microscopic inhabitants are impacting our daily lives. It is now apparent that the microbiota is 
a critical determinant of human health and disease and a key regulator of host physiology. In terms of num-
bers, the sheer scale of the microbiota is so vast. Advances in sequencing technologies coupled with microbi-
ome bioinformatic pipeline development are making analysis of microbiota composition cheaper and more 
sophisticated.  Indeed, initial estimates that we had ten times more microbial cells than human cells have 
recently been revised downwards from a 10:1 ratio to that of 1.3:1 (Sender et al., 2016). This is still an awe-in-
spiring figure to wrestle with. Even more so at the genetic level, more than 99% of the genes in our bodies are 
microbial, numbering over 10 million (D’Argenio and Salvatore, 2015; Dinan et al., 2015; Donia et al., 2014; 
Gill et al., 2006; Nicholson et al., 2005; Qin et al., 2010). As we have co-evolved with this microbiota, it plays 
a key role in programming all other bodily systems (D’Argenio and Salvatore, 2015; Walsh et al., 2014). While 
our inherited genome is essentially stable for the lifetime of the host, the microbiome is immensely diverse 
(Mosca et al., 2016; Pasolli et al., 2019), dynamic (Lloyd-Price et al., 2017), and responsive to external input, 
enhancing its potential as a target for therapeutic intervention (see Section III).
There is a distinct microbiome in almost every niche of the human body. However, the main sites of human 
microbial colonization are the skin, the airways, the urogenital tract, the eyes, and the gastrointestinal (GI) 
tract. While it is appreciated that other sites such as the oral (Kilian et al., 2016) and pulmonary microbio-
ta (Lynch, 2016) are important, the majority of our microbial inhabitants reside in the gut. The intriguing 
complexity of this microbial community, alongside the fact that certain gut microbes tend to grow well in 
laboratory environments, has resulted in the gut microbiota being historically the most well studied of our 
microbial biogeographical niches. The gut hosts a diverse population of microorganisms including yeasts, 
archaea, parasites such as helminths, viruses, and protozoa, but the bacterial population is currently the 
most well characterized (Eckburg et al., 2005; Gaci et al., 2014; Lankelma et al., 2015; Scarpellini et al., 2015; 
Williamson et al., 2016). 
Current ongoing large collaborative efforts including the Human Microbiome Project (Human Microbiome 
Jumpstart Reference Strains et al., 2010; Human Microbiome Project, 2012), MetaHIT (Li et al., 2014; Qin et 
al., 2010), American Gut Project (McDonald et al., 2018), British Gut Project (Jackson et al., 2018), as well as 
important gut microbiome cohort analyses (Falony et al., 2016; Zhernakova et al., 2016) have been instru-
mental in surveying and describing the gut microbiota at a population level. Current combined Human Mi-
crobiome Project and MetaHIT data estimate that there are at least 2776 prokaryotic species that have been 
isolated from human fecal matter. These have been classified into 11 different phyla with Proteobacteria, 
Firmicutes, Actinobacteria and Bacteroidetes comprising over 90% of the microbiome (Bilen et al., 2018; Hu-
gon et al., 2015; Li et al., 2014), while Fusobacteria and Verrucomicrobia phyla are present in low abundance 
(Eckburg et al., 2005). 
We are only at the beginning of understanding what relative shifts in the microbiome correspond to func-
tionally. Thus in this review, although we endeavor to report broad correlations between large obvious com-
positional changes in the microbiota, in many instances it is not yet possible to define a causal role for these 
correlational observations. This endeavor is further complicated by the fact that the fine structure of the 
healthy microbiota seems to be unique to individuals; intra-individual differences across time are typically 
much smaller than differences between individuals (Caporaso et al., 2011; Costello et al., 2009). Incredibly, 
recent findings have identified an elementary layer of variability in the microbiome identified as microbial 
genomic structural variants (the term pertaining to the existence of a few genes which are different between 
otherwise identical bacterial strains) that are specifically unique to the host microbiota and demonstrate 
a strong association with host metabolic health (Zeevi et al., 2019). As a result, throughout this review, we 
will state outcomes from studies on a case-by-case basis and will discuss where possible when it is known if 
the changes seen are causative or correlative. What does appear to be important, however, is maintenance 
of homeostasis for each balanced compositional signature with disruption of this homeostasis conferring 
disease susceptibility (Lin and Zhang, 2017), such as that found with colorectal cancer (Wirbel et al., 2019). 
Despite the challenges posed by such wide inter-individual variation, some have attempted to classify human 
gut microbiota colonies into different enterotypes (Arumugam et al., 2011). While this classification system 
remains somewhat controversial (Costea et al., 2018) and over-simplistic (Knights et al., 2014) three distinct 
enterotypes have been proposed, each of which is characterized by relatively high levels of a single microbial 
genus: Bacteroides., Prevotella. or Ruminococcus. (Arumugam et al., 2011; Roager et al., 2014). These en-
terotypes do seem to have some functional relevance with the Bacteroides. enterotype being associated with 
high fat or protein diets, and the Prevotella. enterotype with high-carbohydrate diets (Wu and Hui, 2011). 
It is hoped that future studies in the field will capitalize on newer technologies, such as whole-genome shot-
gun metagenomics, which provide higher resolution and sensitivity in microbiome analysis. Currently, metag-
enome-wide association studies are being conducted (Wang and Jia, 2016; Wang et al., 2018b) (see Section 
II.G). If lessons are learned from Genome-Wide Association Studies (GWAS) in human genetics, such studies 
will not only allow more reliable estimates of the composition and diversity of our microbiome, but also pro-
vide valuable insight into the functional potential of the microbiome as we seek to understand its influence 
on the host and the gut-brain axis in particular (Poretsky et al., 2014; Tessler et al., 2017). Moreover, the 
importance of metabolomic analysis in going beyond describing what microbes are there to what they are 
doing has become increasingly informative (Zierer et al., 2018). The most recent combination analysis using 
GWAS of the microbiome and metagenomic sequencing has discovered a causal effect of the gut microbiome 
on metabolic traits, suggesting increased gut butyrate production associated with improved insulin response 
after an oral glucose-tolerance test, but errors in production or absorption of propionate causally related to 
enhanced risk of type II diabetes (Sanna et al., 2019). One can only hope that studies like these propagate 
quickly in the field given their immense potential to inform alternative therapies for human diseases. 
E. Gut-Brain Axis
As previously described, the GI tract exerts an influence on brain function, and vice versa (See also Section 
IV). Much of the earlier work regarding gut-brain communication concentrated on digestive function and sa-
tiety (Berthoud, 2008a; Konturek et al., 2004; Tache et al., 1980), but recent research has taken an increasing 
focus on higher-order cognitive and psychological effects of gut-to-brain and brain-to-gut communication 
(Agusti et al., 2018; Carabotti et al., 2015; Rhee et al., 2009; Sarkar et al., 2016). Through this research, we 
now understand some of the pathophysiological consequences of an aberrant reciprocal gut-brain network, 
including exacerbated gut inflammation disorders (Bernstein, 2017; Breit et al., 2018; Mayer et al., 2015b), 
altered responses to acute and chronic stress (Dinan and Cryan, 2017; Foster et al., 2017; Gao et al., 2018; 
Maniscalco and Rinaman, 2018; Marin et al., 2017; Partrick et al., 2018; Provensi et al., In Press; Sun et al., 
2018), as well as altered behavioral states (Arentsen et al., 2018; Dinan and Cryan, 2017; Foster et al., 2017; 
Heintz-Buschart et al., 2018; Jaglin et al., 2018; Luk et al., 2018; Maniscalco and Rinaman, 2018). As a result, 
the gut-brain axis presents an attractive target for the development of novel therapeutics for an ever-growing 
list of disorders related to mental health and cognitive function (Clapp et al., 2017; Dinan and Cryan, 2017; 
Jiang et al., 2017; Tognini, 2017) obesity (Torres-Fuentes et al., 2017), and GI disorders such as inflammatory 
bowel disease (IBD) (Bernstein, 2017; Bonaz and Bernstein, 2013) and IBS (Collins et al., 2012; Mayer, 2011). 
Improved targeting of the gut-brain axis, for example through application of psychobiotics (targeted microbi-
ota interventions that support good mental health) (Allen et al., 2016; Sarkar et al., 2016; Valles-Colomer et 
al., 2019), is expected to pave the way for the development of novel disease therapies (Sherwin et al., 2018) 
(see Section VIII).
F. Microbiota-Gut-Brain Axis
Over recent decades, the fields of microbiology and neuroscience have become ever more entwined. Al-
though the concept of a microbiota-gut-brain axis is relatively new, it is becoming increasingly accepted that 
the resident microbiota can exert considerable influence over host behavior (Cleary et al., 2017; Clemente 
et al., 2012; Karst, 2016; Sekirov et al., 2010; Turroni et al., 2018), which we shall illustrate in Section X. (Be-
havior and the Microbiota-Gut-Brain Axis), and Section XI. (Diseases and Disease Processes). Bidirectional 
communication along the gut-brain axis is a fundamental aspect of the synergy between microbiota and 
host in accessing gut-brain signaling pathways to modulate host brain and behavior (see Section VII. (Cryan 
and Dinan, 2012; Dinan and Cryan, 2017; Grenham et al., 2011; Mayer et al., 2015b; McVey Neufeld et al., 
2015; Rhee et al., 2009). The studies conducted to identify and examine the microbiota-gut-brain axis have 
used different, yet complementary microbiota interventions, including GF rodents (see Table 2) (Luczynski 
et al., 2016a; Luk et al., 2018), antibiotic-induced depletion (see Table 3) (Desbonnet et al., 2015; Guida et 
al., 2018; Staley et al., 2017), prebiotic/probiotic supplementation (see Tables 4 and 5) (Burokas et al., 2017; 
Fukui et al., 2018; Grimaldi et al., 2018; Kao et al., 2018; Kazemi et al., 2019; Tabouy et al., 2018), GI infection 
(Harris et al., 2017; Zuo et al., 2018), and fecal microbiota transplantation (FMT) (see Section V.C.) (Cryan 
and Dinan, 2015b; Sherwin et al., 2016a; Singh et al., 2018a; Zhou et al., 2017), all of which will be discussed 
in greater detail in Section IV. 
G. Evolution, Microbiota and the Holobiont
It is important to contextualize the recent appreciation of the microbiome on host health in an evolutionary 
context. Over time the microbiota has co-evolved with host organisms, becoming mutually co-dependent 
for survival (Bordenstein and Theis, 2015; Gaulke et al., 2018). Given that there has never been a time when 
mammals existed without microbes (apart from under highly restrictive laboratory conditions), there has 
also never been a time when the brain has been without signals from the gut, and it is important to con-
sider the relationship between the host and its microbiota from an evolutionary perspective (Stilling et al., 
2014a). The concept of the holobiont has been developed to describe the ecological unit comprising both 
the host species and its symbiotic microbiota (Bordenstein and Theis, 2015; Shropshire and Bordenstein, 
2016; Zilber-Rosenberg and Rosenberg, 2008). This, in turn, has led to the hologenome theory of evolution, 
which suggests that the holobiont and its associated hologenome acts as a unit of evolutionary selection (Zil-
ber-Rosenberg and Rosenberg, 2008). One key principle of the hologenome theory is that genetic variation 
in the holobiont is facilitated by both the host genome and its associated microbial genome.
Moreover, genetic variation of the hologenome can be enhanced through transmission of different microbial 
symbiont populations that facilitate the optimum adaption to different environmental demands (e.g., chang-
es in nutrition, stress, temperature). The hologenome theory may even account for complex biological phe-
nomena such as certain behaviors. For instance, behavior that facilitates social interaction among holobionts 
might be considered evolutionarily adaptive/advantageous as it gives rise to greater transmission of micro-
biota, thereby enhancing genetic variation (Rosenberg et al., 2010; Rosenberg et al., 2009; Zilber-Rosenberg 
and Rosenberg, 2008). In light of these inextricable links between the microbiota and the brain throughout 
evolutionary history, it is imperative for the study of our own biology (and that of the entire animal kingdom) 
to understand how microbial symbionts influence brain physiology and behavior. 
V. Studying the Microbiota-Gut-Brain Axis
Although we do not yet fully understand the functional significance of the symbiotic relationship between 
host and microbe especially in the context of brain health, a number of tools and animal models have been 
invaluable in allowing the scientific research community to constantly narrow the gaps in our understanding 
of the microbiota-gut-brain axis (see Table 1).
A. Germ-Free Models
GF animals (Bisgaard et al., 2011; Williams, 2014) have been invaluable tools for understanding microbe-host 
relationships (see Table 2). Lacking exposure to microorganisms since birth, GF animals provide insights into 
how the microbiota is integral in shaping the behavior, physiology, and neurobiology of its host (Weger et al., 
2019). 
In 1885, Louis Pasteur hypothesized that certain microbes were essential for the survival of complex life due 
to the co-existence and co-evolution of micro- and macro-organisms (Pasteur, 1885). Yet in the post-World 
War II era, coinciding with the discovery of antibiotics, public distrust of bacteria evolved to a point where the 
dream of living GF increasingly appeared in fictional futuristic fantasies (Kirk, 2012). The concept of humans 
living in sterile worlds was even realized in 1971, when David Vetter was isolated in GF conditions as a new-
born due to a severe combined immune deficiency and thus became known as the “Bubble Boy” (Kirk, 2012). 
Perhaps the first reported GF animals were guinea pigs produced in 1897 via aseptic cesarean section (C-sec-
tion) and kept free of microbes for two weeks (Nuttall and Thierfelder, 1987). However, successive gener-
ations of GF rodents were not produced until the mid-20th century (Gustafsson, 1946). Currently, similar 
methods are typically used to generate many generations of GF animals. To avoid inoculation of pups by 
microbiota, C-section is carried out carefully to avoid contact between pup and the microbes residing on both 
the dam’s vagina and skin, and pups are then hand-raised in an aseptic isolator (Al-Asmakh and Zadjali, 2015; 
Gordon et al., 1966a; Luczynski et al., 2016a; Moya-Perez et al., 2017a; Stilling et al., 2014a). From this point 
on, colonies are maintained GF with sterile food, bedding, and water. Cages and feces are regularly swabbed 
to confirm that no bacteria are present (Bibiloni, 2012). Subsequent GF animals can then be bred in an isola-
tor and GF pups born per vaginum. Alternatively, GF animals can be produced by embryonic transfer at the 
2-cell stage into a GF host mother (Bibiloni, 2012).
Animals lacking microbiota have extraordinarily different development and physiology than animals hosting 
commensal bacteria, (see Table 2 for a comprehensive summary of studies involving GF animals). GF animals 
are smaller in body weight and have impaired intestinal function (Aluwihare, 1971; Jeppsson et al., 1979; Sav-
age et al., 1981), have lower concentrations of most gastrointestinal luminal amino acids than SPF mice (Ya-
mamoto et al., 2018), and actually live longer (Gordon et al., 1966b; Reyniers and Sacksteder, 1958; Tazume 
et al., 1991; Wostman, 1968). Due to the lack of commensal microbes, GF animals have impaired immune 
systems, dysregulated hormone signaling, altered metabolism, and differences in neurotransmission from 
conventional counterparts (Kawase et al., 2017; Neufeld et al., 2011; Pan et al., 2018; Sudo et al., 2004; We-
ger et al., 2019). Interestingly, phenotypes of GF animals vary across species, sex, research group, and even 
strain, demonstrating that both microbiota and host genetics are important influencers of phenotype. For 
example, some studies involving GF Swiss Webster mice show a decreased anxiety-like behavior (Arentsen et 
al., 2018; Clarke et al., 2013; Neufeld et al., 2011) whereas the opposite has been found in male GF BALB/c 
mice (Chen et al., 2017b; Nishino et al., 2013). 
Although an important tool, GF mice have many limitations in terms of aberrant physiology, neurodevelop-
ment and immunity, as well as limited translatability to human situations (Nguyen et al., 2015). Nonetheless, 
they have been an important starting point in answering the question of whether the microbiota is involved 
in a given process or not (Luczynski et al., 2016a). Moreover, GF studies are now being extended to other 
non-rodent species including porcine models to enhance the translational value of findings (Charbonneau et 
al., 2016).
Alternatively, colonization of mice with specific, known strains of bacteria has also shown to be a useful ap-
proach to interrogate microbiota-physiology interactions (Gordon and Pesti, 1971). From these gnotobiotic 
animals, it is possible to decipher mechanisms of communication between specific members of the micro-
biota and the host organism. Among such approaches, the altered Schaedler flora (ASF) mouse line is most 
utilized (Lyte et al., 2019a; Orcutt et al., 1987; Wymore Brand et al., 2015). ASF mice are colonized with just 
eight bacterial species allowing a more simplified study of microbiota involvement in brain function relative 
to conventionally colonized strains, but with more clinical relevance than GF studies. The minimalist bacterial 
colonization of the ASF mouse avoids the complications of the high abundance and diversity in conventional 
mice, while overcoming the host developmental hurdles seen in GF mice, such as an underdeveloped im-
mune system (Atarashi et al., 2011; Helgeland et al., 1996), slower intestinal epithelial turnover (Savage et 
al., 1981), differing nutritional requirements and less body fat (Backhed et al., 2004)., The ASF model thus 
presents an attractive alternative option for translational microbiota-gut-brain axis research, particularly in-
volving stress (Lyte et al., 2019a).
B. Antibiotics
While initially developed to fight infections, antibiotics are also a useful pharmacological tool for investigat-
ing the impact of microbiota perturbations on brain and behavior (see Table 3). They offer much greater 
temporal flexibility and specificity compared to the GF model of microbiota ablation as they can be delivered 
acutely or chronically at any stage across an animal’s lifespan (e.g., during periods of potential vulnerability 
such as the early postnatal period (Leclercq et al., 2017; O’Mahony et al., 2014), adolescence (Desbonnet 
et al., 2015), or in aging). Additionally, the ability to titrate the dose of antibiotics allows for a greater level 
of control over the extent of microbiota depletion, from minor perturbations to the microbiota through 
sub-therapeutic doses of a single antibiotic, to cocktails of antibiotics designed to substantially ablate the en-
tire microbiota. An important consideration in the use of antibiotics to investigate the microbiota-gut-brain 
axis is their absorption from the GI tract. Non-absorbable antibiotics (i.e. vancomycin, neomycin, and baci-
tracin (Tochitani et al., 2016)) offer the advantage that they knockdown the microbiota in the gut while not 
entering systemic circulation, thereby avoiding any potential systemic and even central nervous system (CNS) 
effects and allowing us to directly assess the effect of a loss of a microbiota on the brain. Other antibiotics 
such as metronidazole and minocycline can potentially enter the central nervous system and can have direct 
action on brain and behavior (261) (e.g., microglial inhibition with minocycline; Riazi et al., 2015), so these re-
sults must be interpreted with caution. Despite such limitations, antibiotics have been crucial in corroborat-
ing the behavioral and biological observations documented in GF animals. Indeed, antibiotic administration 
to laboratory animals has been shown to influence behaviors such as sociability and anxiety (Degroote et al., 
2016; Frohlich et al., 2016; Guida et al., 2018). 
 
A final advantage of antibiotics is that they offer a tool to model the clinical scenario in humans. Adminis-
tration schedules can be made to model the courses of antibiotics that millions of people take each year for 
multiple conditions, allowing us to determine the effect that such treatments may be having on the brain 
and behavior. The flexibility and translational relevance of antibiotics make them a hugely valuable tool in 
the study of the microbiota-gut-brain axis and they will form a key component of future studies in the field. 
Table 3 summarizes the current state of knowledge regarding the impact of antibiotics on brain physiology 
and behavior.
C. Fecal Microbiota Transplant (FMT)
FMT is a procedure that involves the transfer of intestinal microbiota from one individual to another, 
commonly performed via oral administration of fecal material in rodents or colonoscopy in humans. 
When effective, this technique initially establishes a donor-like microbiome in the GI tract of the recip-
ient, allowing stronger inferences to be made regarding the causal relationships between gut microbi-
ota and host outcomes. The use of FMT in human medical treatment is gaining popularity, though it 
is not novel. Around 1,700 years ago, Ge Hong, a traditional Chinese medical doctor, documented the 
treatment of patients with food poisoning and severe diarrhea via oral administration of human fecal 
suspension (Zhang et al., 2012b). Later, in the 17th century, Italian anatomist Fabricius Aquapendente 
described bacteriotherapy using fecal flora in veterinary medicine (Brandt et al., 2012). 1958 marked 
the first documented use of FMT for therapeutic treatment of pseudomembranous colitis in humans 
(Eiseman et al., 1958; Han et al., 2016). Since that time, the FMT procedure has become most well-
known for its remarkable success rate in the treatment of refractory C. difficile infection (CDI) (Han et 
al., 2016; Sekirov et al., 2010; van Beurden et al., 2017; van Nood et al., 2013). Moving from the clinic 
to the laboratory, FMT has opened up possibilities for more mechanistic investigations of the micro-
biota’s role in various clinical conditions via “humanization” of the rodent microbiota.
Such studies have found that various behavioral phenotypes can be transferred by FMT, including 
anxiety-like behavior and aspects of depressive symptomatology, suggesting that gut microbiota are 
key components of regulating anxiety and depression (Bercik et al., 2011a; Bruce-Keller et al., 2015; 
Kelly et al., 2016; Zheng et al., 2016b). Furthermore, the composition of the gut microbiota has been 
linked to obesity and insulin resistance (Caricilli and Saad, 2014; Everard and Cani, 2013; Tai et al., 
2015). GF mice were shown to have reduced body weight, and when conventionalized with nor-
mal intestinal microbiota, the animals experienced a 60% increase in body fat content and insulin 
resistance, combined with reduced food consumption (Backhed et al., 2004). Furthermore, the hu-
manization of GF mice with microbiota from obese individuals resulted in a significant increase in 
body weight compared to individuals colonized with microbiota from lean individuals (Turnbaugh et 
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Typical FMT administration in non-GF rodents generally consists of treating the recipient with a cock-
tail of antibiotics, often provided via drinking water, followed by a single or repetitive oral gavage of 
inoculum consisting of donor fecal material over several days. Broad-spectrum antibiotics are often 
used to deplete existing microbiota and provide administered bacteria a less competitive environ-
ment in which to proliferate. Various studies use different combinations of antibiotic cocktails that 
differ in concoction, concentration, and dosage time. Commonly used cocktails usually do not exceed 
a combination of five antibiotics at various individual doses and may include ampicillin, ciprofloxacin, 
neomycin, vancomycin, metronidazole, streptomycin and penicillin (Bruce-Keller et al., 2015; Ericsson 
et al., 2017; He et al., 2015; Kelly et al., 2016; Suez et al., 2014; Yano et al., 2015; Zhou et al., 2017). 
Antibiotic treatment time generally ranges from 3 days to 35 days, with a common treatment time of 
1-2 weeks (Bruce-Keller et al., 2015; Ubeda et al., 2013; Yano et al., 2015; Zhou et al., 2017). 
Some studies have shown successful transfer of the microbiota, even with no pretreatment of anti-
biotics, occasionally utilizing group housing of coprophagic animals, such as mice, to induce passive 
gut microbiota transfer, (Elinav et al., 2011; Manichanh et al., 2010; Stecher et al., 2010). However, a 
recent study compared three methods of FMT: pretreatment with antibiotics (ampicillin, neomycin, 
and vancomycin), pretreatment with bowel cleansing solution, and no pretreatment, all followed by 
three days of high-volume oral gavage, and found that pretreatment with antibiotics allowed for high-
er FMT efficacy (Ji et al., 2017). Interestingly, FMT can be achieved between different animal strains 
and species, including FMT from human to rodents (Kelly et al., 2016; Staley et al., 2017). Ultimately, 
utilizing GF animals as recipients of FMT provides an easier environment for introduced microbiota to 
colonize, and eliminates the potential need for antibiotic treatment prior to FMT but comes with the 
caveat that the GF animals are markedly altered before FMT (de Groot et al., 2017)
FMT is increasingly being utilized in humans for the treatment of CDI in the clinic (Cammarota et 
al., 2017) and, in a research setting, FMT has also been tested for the treatment of IBD, IBS, and 
chronic constipation. In a double-blind, randomized trial treating IBS with FMT, 65% of participants 
receiving FMT showed a response to treatment at three months, compared to 43% receiving a pla-
cebo (Johnsen et al., 2018). CDI is generally treated with antibiotics, but in the case of recurrent CDI, 
treatment with FMT ultimately cured 98% (Brandt et al., 2012). The potential of FMT in research and 
as a medicinal therapy provides promise for the treatment of GI-related diseases and conditions, 
including the practice of autologous FMT. Here, a patient is given an FMT of their own pre-surgery/ 
‘healthy’ fecal matter during the recovery phase, effectively reconstituting their major commensal 
bacterial populations and reestablishing the patient’s gut microbiota diversity as well as composition 
(Suez et al., 2018; Taur et al., 2018). This may well result in an increase in the practice of fecal matter 
banking for post-treatment recolonization of a patient’s gut microbiota, a practice could become 
commonplace in the very near future. 
D. Prebiotics and Fermented Foods
The definition of prebiotics as determined by the International Scientific Association for Probiotics and Prebi-
otics is “a substrate that is selectively utilized by host microorganisms conferring a health benefit” (Gibson et 
al., 2017). One of the main classes of prebiotics is dietary fiber, often defined as “carbohydrates with a degree 
of polymerization greater than 2, which fail to be hydrolyzed or absorbed in the small intestine” (Stephen et 
al., 2017). These include inulin, fructooligosaccharides (FOS), galactooligosaccharides (GOS), resistant starch 
and other soluble dietary fibers, amongst others (though not all dietary fibers are prebiotic). Typical dietary 
sources of prebiotics include fruits and vegetables such as asparagus, leek, banana, chicory, and grains such 
as oats and wheat. As Western-style diet consumption increases, a drop in prebiotic intake that correlates 
with a rise in the incidence of inflammatory diseases, obesity, metabolic syndrome and anxiety, stress and 
other ‘lifestyle’ disorders have been seen. Importantly, prebiotics do not always change the composition 
and activity of the gut microbiota in a selective and predictable manner (Bindels et al., 2015). Nonetheless, 
prebiotic supplementation has been demonstrated to reduce stress-responsiveness, anxiety- and depres-
sive-like behavior, as well as facilitate changes in hippocampal synaptic efficacy, including increased hippo-
campal brain-derived neurotrophic factor (BDNF) expression, general hypothalamic neuronal activity, and 
enhanced cognition and learning (see Table 4). Most studies thus far have been descriptive and are limited 
to demonstrating prebiotic influence on brain physiology and behavior (see Table 4). Further studies should, 
therefore, aim to understand the mechanisms by which prebiotics can affect brain physiology and behavior, 
with a specific focus on which gut microbial-derived metabolites are involved, and through which pathways 
these effects are mediated. Following is a more detailed description of different prebiotics currently in use. 
Resistant Starch 
Resistant starches (RS) are undigested carbohydrates and classified into four different types: the 
physically inaccessible RS1, a native granular starch consisting of ungelatinized granules called RS2, a 
retrograde amylose known as RS3 and the indigestible chemically modified RS4 (Haub et al., 2010). 
Different resistant starches have been shown to induce different changes in the gut microbiota com-
position in animal models (Lyte et al., 2016; Maier et al., 2017). One study has shown that rodents on 
a resistant starch diet demonstrated a reduction in exploratory behaviors in an open-field test (Lyte 
et al., 2016). Consumption of resistant starch for ten weeks significantly increased the abundance of 
Ruminococcus bromii, constituting 17% of total bacteria compared with 3.8% on the non-starch diet. 
Furthermore, individuals on a resistant starch diet showed an increase in relative abundance of uncul-
tured Oscillibacter and Eubacterium rectale (Walker et al., 2011). A randomized study of 39 individu-
als found that a high resistant starch diet resulted in a significant increase in the Firmicutes:Bacteroi-
detes, along with an increase in the overall relative abundance of Firmicutes, alongside an increase in 
enzymatic pathways and metabolites associated with lipid metabolism in the gut (Maier et al., 2017). 
The Firmicutes:Bacteroidetes is a correlational and observational output of microbiome analysis that 
is currently somewhat informative based on the direction of change from a known starting or control 
point, where Firmicutes and Bacteroidetes represent over 99% of the known bacteria in the gut.
Inulin 
Inulins are well-established prebiotics, which are predominantly found in a variety of fruits, vegeta-
bles and wheat. Numerous studies have shown that inulin can stimulate the growth of Bifidobacte-
rium spp. and Faecalibacterium prausnitzii, while increasing butyrate production (de Preter et al., 
2008; Kolida et al., 2007; Ramirez-Farias et al., 2009). Furthermore, administration of inulin to a dex-
tran sulfate sodium-induced colitis mouse model resulted in an attenuation of the colitis symptoms 
in addition to an increase in Lactobacillus composition (Videla et al., 2001). Moreover, exposure to 
inulin/GOS prebiotic supplementation during pregnancy and lactation has been shown to bring about 
protection against food allergies with a decrease in histamine levels and intestinal permeability in the 
offspring (Bouchaud et al., 2016).
GOS and FOS
Galacto-oligosaccharides are well-established prebiotics known to be present in human milk (Barile and 
Rastall, 2013; Vandenplas, 2007). Infants fed formula supplemented with Bimuno-galactooligosaccharide 
(B-GOS®; Bimuno™, Clasado Biosciences Ltd, Buckinghamshire, UK), a proprietary product containing at least 
65% GOS, had increased abundance of Bifidobacterium and Lactobacillus compared to unsupplemented in-
fants, similar to levels reported in breastfed infants (Garrido et al., 2013; Vandenplas et al., 2014). Adminis-
tration of B-GOS® in an elderly population reported a significant increase in Bacteroides and Bifidobacterium 
spp. with elevated levels of lactic acid in fecal water. Moreover, they also reported administration of B-GOS® 
resulted in a reduction in proinflammatory cytokines with an increase in both IL-10 and IL-8, anti-inflammato-
ry cytokines (Vulevic et al., 2015). Studies have demonstrated a significant increase in pro-inflammatory cyto-
kine with stress (Rea et al., 2016). However, administration of B-GOS® in mice attenuated post-inflammatory 
anxiety (Savignac et al., 2016). In addition, B-GOS® prevented a lipopolysaccharide (LPS)-mediated increase 
in cortical 1L-1β and 5-HT2A receptor levels (Savignac et al., 2016). Administration of B-GOS® to individuals 
induced suppression of the neuroendocrine stress response and an increase in the processing of positive ver-
sus negative attentional vigilance, thus resulting in an early anxiolytic-like phenotype (Schmidt et al., 2015). 
Fructo-oligosaccharide (FOS), are oligosaccharides known to be predominantly present in fruits. A dou-
ble-blind intervention study in obese women with FOS showed an enhanced abundance in Bifidobacterium 
and Faecalibacterium prausnitzii (Dewulf et al., 2013). In a randomized, double-blind crossover study admin-
istration of FOS and GOS for 14 days showed significant increases in Bifidobacterium along with a reduction 
in butyrate-producing bacteria with adverse glycemic metabolism (Liu et al., 2017b). Administration of FOS-
+GOS and GOS has been shown to reduce stress-induced corticosterone release, combined with a significant 
increase in cecal acetate and propionate concentrations, with a reduction in iso-butyrate levels. Moreover, 
mice fed FOS+GOS spent more time in the center of an open-field test, with an increase in the percentage of 
entries into the open area (Burokas et al., 2017), indicating a reduced anxiety phenotype.
H. Probiotics and Psychobiotics
Probiotics refer to candidate species of live bacteria that, when ingested in adequate amounts, confer ben-
eficial health effects upon the host (Butel, 2014). Through interacting with the host microbiota and intesti-
nal epithelium, probiotics have been shown to exert a wide range of effects upon host health, with various 
strains improving metabolism, immunity, endocrine function, and slowing aging in preclinical studies (El Aidy 
et al., 2015; Patterson et al., 2016). Although looking forward towards utilizing candidate probiotics for host 
health, we must acknowledge the potential impact that the inherent host diet and microbiota complexity 
can have on the probiotic itself, such as that seen recently with cumulative genetic mutations occurring to 
E. coli Nissle during passage through the murine gut (Crook et al., 2019). Perhaps the most intriguing effect 
of probiotics on the host is their modulation of brain physiology and behavior. Faecalibacterium prausnitzii 
(ATCC 27766) may function as a promising psychobiotic where it recently demonstrated an anxiolytic and an-
tidepressant-like phenotype in rats, probably via increasing cecal SCFA and plasma IL-10 levels while reducing 
corticosterone and IL-6 levels (Hao et al., 2019). Considerable research over the last decade has documented 
how probiotics can influence various central neuronal processes such as neurotransmission, neurogenesis, 
expression of neuropeptides, neuroinflammation, and even behavior (Sherwin et al., 2016b). Indeed, certain 
bacterial strains or cocktails of multiple bacteria have demonstrated efficacy in improving behavioral symp-
toms of various disorders from depression and anxiety to autism (see also Section VIII) (Allen et al., 2016; 
Bravo et al., 2011; Buffington et al., 2016; Hsiao et al., 2013; Kang et al., 2017; Savignac et al., 2014). These 
findings, (summarized in Table 5), have led to the concept of psychobiotics for the treatment of various neu-
rological and psychiatric disorders through targeting of the gut microbiota (Dinan et al., 2013). Psychobiotics 
are now defined as microbiota-targeted interventions such as ‘beneficial bacteria (probiotics) or support for 
such bacteria (e.g., prebiotics) that influence bacteria–brain relationships’ (Sarkar et al., 2016). As the evi-
dence to support the effects of psychobiotics on brain and behavior grows (Chong et al., 2019), the field is 
now turning to mechanistic studies in order to elucidate the biological underpinnings of psychobiotic effects.
I. Brain Imaging
The advent of human brain imaging techniques such as positron emission tomography in the 1980s allowed 
for conclusive demonstrations that alterations in the gut (e.g. by distension) lead to activation of key brain 
networks (Mayer et al., 2009; Van Oudenhove et al., 2007). Currently, studies that examine the interaction 
between gut microbes, brain and behavior in humans are limited. Magnetic resonance imaging (MRI) as a 
brain imaging tool became widely available in the early 2000s, with the field of neuroimaging reaching a stage 
where the once limited practical applications of structural and functional brain imaging have now become 
feasible to utilize, offering an ideal method of studying gut-brain interactions, in vivo (Mayer et al., 2015b)
Preclinical studies 
A variety of different brain imaging techniques have been used to understand the microbiota-gut-brain axis. 
Using magnetic resonance spectroscopy (MRS), it has been shown that the bacterial strain L. rhamnosus- 
JB-1 was capable of increasing the neurotransmitter glutamate and its precursor glutamine in addition to 
N-acetyl aspartate and γ-aminobutyric acid (GABA) (Janik et al., 2016). Interestingly, the scale and timing of 
the response varied across the affected metabolites. In a recent study, diffusion tensor imaging was used 
to identify global changes in white matter structural integrity occurring in a diet-dependent manner in rats 
(Ong et al., 2018); although not surprising, microbiota analysis indicated changes in bacterial populations as 
a function of diet. By using a machine learning classifier for quantitative assessment of the strength of micro-
biota-brain region associations, changes in brain structure were found to be associated with diet-dependent 
changes in the gut microbiome.
Human studies 
By combining human brain imaging techniques with neuropsychological measures, a landmark study investi-
gated how ingestion of a fermented milk drink, combining four different bacterial strains, was able to affect 
brain function in healthy women (Tillisch et al., 2013). Alterations were observed in resting brain activity 
showing that ingestion of the fermented milk product was associated with changes in midbrain connectivity 
centered on the periaqueductal gray, along with other brain network regions including the prefrontal cortex 
(PFC), precuneus, basal ganglia, and the parahippocampal gyrus, which likely explain the differences ob-
served in activity during the tasks. Efforts have also been made to evaluate interactions among gut microbio-
ta composition, brain microstructure, and a cognitive test (i.e., the Trail Making Test - an easily administered 
test that involves motor speed, attention, and cognitive flexibility) in obese (N=20) and non-obese (N=19) 
individuals (Fernandez-Real et al., 2015). The gut microbiota composition, specifically the abundance of the 
Actinobacteria phylum, of obese and non-obese subjects was linked with the cognitive testing scores, as well 
as alterations in neural activity in the thalamus, hypothalamus, and amygdala, suggesting that obesity affects 
the microbiota composition and subsequent cognitive performance (Fernandez-Real et al., 2015).
Two separate studies have investigated the association between IBS, changes in the microbiota, and brain-re-
lated alterations (Labus et al., 2017; Pinto-Sanchez et al., 2017b). An fMRI analysis showed that a  B. longum 
strain reduced responses to negative emotional stimuli in multiple brain areas, including the amygdala and 
fronto-limbic regions, compared with placebo (Pinto-Sanchez et al., 2017a). Simply, the probiotic marginally 
reduced depression but not anxiety while increasing quality of life scores in patients with IBS, with improve-
ments associated with changes in brain activation. The second study (Labus et al., 2017) investigated the re-
lationship between brain region activation using fMRI, behavioral characteristics and microbiota composition 
in healthy women. The analyzed participants (N=39) were separated into two identifiable groups based on 
microbiota composition: a Prevotella-high group with 7 participants, and a Bacteroides-high group of 32 par-
ticipants. Differential responses to negatively-valenced images were observed such that negative affect was 
associated with functional and structural differences in the right hippocampus within the Prevotella group. 
Although small scale, this is one of the first reports of behavioral and neurobiological differences related to 
microbial composition in healthy humans. It represents an exciting prospect for a better understanding of 
how differences in emotional, attentional, and sensory processing responses may be directed by the gut. 
 
Brain imaging techniques have also begun to be used to explore the possible interactive role of gut microbi-
ota and brain function in various neuropsychiatric disorders. For example, a recent study investigated both 
gut microbiota and choline concentrations in the anterior cingulate cortex in the prodromal stage of schizo-
phrenia (He et al., 2018). Increased relative abundance of the orders Clostridiales, Lactobacillales and Bac-
teroidales were observed in fecal samples from individuals who were designated ultra-high-risk. Moreover, 
changes in the composition of gut microbiota indicated the increased production of short-chain fatty acid 
(SCFAs) which was coupled with increases in the levels of choline in the anterior cingulate cortex (He et al., 
2018).
Preclinical studies have increasingly shown compelling evidence and consensus that microorganisms inhabit-
ing the gut influence brain structure and function from birth and through the first years of life (Codagnone et 
al., 2018). In an essential first step in translating neonatal data into clinical neonatal populations, one group 
(Carlson et al., 2018) tested whether microbial composition at one year of age is associated with cognitive 
outcomes and fMRI measures. The investigators subtyped three different groups of infants based on their 
bacterial composition. Cognitive function at two years of age differed significantly between clusters. A higher 
α diversity was associated with lower scores on the overall composite score, and the visual reception scale, 
as well as the expressive language scale by two years of age, suggesting a slower rate of development. Ex-
ploratory analyses of neuroimaging data suggested that the gut microbiota had minimal effects on regional 
brain volumes at one and two years of age (Carlson et al., 2018). 
Ongoing work in the field of brain imaging includes an approach to connect gut microbial ecology (Saulnier et 
al., 2011) with large-scale brain networks (Irimia and Van Horn, 2013). Such approaches will aid in our ability 
to determine how the microbiota influences brain function and potentially identify multiple mediators of 
the gut-brain axis. To date, the number of studies from which to draw a consensus is few, and further exam-
ination of the interaction between gut microbes, brain, and effect in humans is needed to inform preclinical 
reports that microbial modulation may or may not successfully influence cognitive function and subsequent 
behavior.
J. Techniques to Measure the Microbiome: Who is There and What are They Doing?
In microbiome research, answering these two headline questions (of who is there and what are they doing?) 
is central to investigating and understanding the dynamics not only within the microbiome but also between 
it and other systems, such as the brain. It involves the multi-collaborative efforts in both bioinformatic and 
sequencing approaches in tandem with biology and medicine.
Bioinformatics
The field of bioinformatics includes all work where computational algorithms are used to study biological 
phenomena (Luscombe et al., 2001; Ma, In Press). Generally, bioinformatics refers to biostatistics, data anal-
ysis, and computational biology. Due to the massive amounts of data that need to be processed when work-
ing with the microbiota, bioinformatics has played an important role in developing the field, and vice versa 
(Gevers et al., 2012; Hao et al., 2017). Indeed, endeavors such as the Human Microbiome Project (Group 
et al., 2009) and MetaHIT (Qin et al., 2010) have only been possible thanks to our rapidly improving capac-
ity to handle big data(Ma, 2015). Fortunately, fields like ecology and statistics have dealt with comparable 
problems in the past, albeit often on a different scale (Gloor et al., 2017; Ma, 2015, In Press). Methods like 
multidimensional scaling and metrics such as diversity originate from these fields and are frequently used as 
powerful tools to analyze the microbiome, once they have been modified to suit microbiome data. Here, we 
will focus on the analysis of the microbiome, as well as alternate datasets like proteomics and metabolom-
ics, which are often incorporated into microbiome analysis. For a review of metabolomics, metagenomics or 
transcriptomics, please see (Durack and Lynch, 2018), and see Table 6. (Gloor et al., 2017; Ma, 2015, In Press)
Microbiome Sequencing
Rapid improvements in sequencing technology have facilitated the development of two techniques that are 
integral to answering these questions: 16S sequencing and whole genome shotgun sequencing (Claesson 
et al., 2017). While the techniques are arguably similar, they are not mutually exclusive but provide com-
plementary readouts that can inform each other (Clooney et al., 2016), see Fig. 2. A consequence of these 
rapid improvements in sequencing technology has been a multitude of similar protocols that each have their 
own set of biases in their results. This makes pooling the data from two different studies more complicated 
(Clooney et al., 2016)Ribosomal, 16S/genetics</keyword><keyword>Sequence Analysis, RNA</keyword></
keywords><dates><year>2016</year></dates><isbn>1932-6203 (Electronic. Recent efforts have been made 
to consolidate and standardize sequencing and analysis protocols, to improve overall quality and compatibil-
ity of research in the microbiome field (Knight et al., 2018; Mallick et al., 2017; Pollock et al., 2018).
16S amplicon sequencing
16S or amplicon sequencing represents a comparatively cheap way to measure the relative abundance of 
microbes present in a sample using next-generation sequencing technology. The idea behind the technique is 
to use PCR to amplify a highly conserved genetic sequence that is present in all bacterial members of the mi-
crobiota. These amplified sequences, or amplicons, can then be clustered based on their genetic relatedness 
and tallied to give an estimate of their relative abundance in a sample. While the technique can theoretically 
be performed using any amplicon, in practice, regions of the highly conserved 16S ribosomal RNA subunit 
are often used. 
The relative composition of the microbiota on its own can be used to classify and differentiate samples. In addi-
tion, the popular bioinformatics tool PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of 
Unobserved States) (Langille et al., 2013), along with Tax4Fun (Asshauer et al., 2015)Factual</keyword><key-
word>Databases, Nucleic Acid</keyword><keyword>Genes, Bacterial/*genetics</keyword><keyword>-
Genetic Markers</keyword><keyword>Metagenome</keyword><keyword>Metagenomics/*methods</
keyword><keyword>Phylogeny</keyword><keyword>RNA, Bacterial/genetics</keyword><keyword>R-
NA, Ribosomal, 16S/*genetics</keyword><keyword>Sequence Analysis, RNA/*methods</keyword><key-
word>*Software</keyword></keywords><dates><year>2015</year><pub-dates><date>Sep 1</date></
pub-dates></dates><isbn>1367-4811 (Electronic and Piphillin (Iwai et al., 2016), enable the prediction of 
the functional potential of the microbiota from 16S output by cross-referencing the identified microbiota 
with known genetic sequences (Langille et al., 2013). Thus, there is valuable information to be gained from 
16S sequencing, although there are also important limitations. Firstly, 16S sequencing cannot identify novel 
microbial species nor account for intraspecies variation and mutations as the technique is restricted to ge-
netic reference sequences that must be defined in a database a priori. Secondly, PCR introduces a bias in 16S 
tables, as some amplicon sequences will inevitably be amplified more efficiently than others (Acinas et al., 
2005; Schloss et al., 2011) (Fig. 2). 
Whole genome shotgun sequencing (WGS) 
Whole genome shotgun sequencing (WGS) is more expensive and demanding on computational resources 
than 16S sequencing, but also capable of providing a strain level resolution of both microbiota abundance 
and functional capacity. In WGS, all DNA in a sample is isolated and sequenced using next-generation se-
quencing technology. After filtering out unwanted DNA (e.g., human DNA from a human stool sample), the 
remaining sequences can be used to either construct de novo genomes or align the sequences to a reference 
database. 
WGS offers several advantages over 16S (Clooney et al., 2016; Ranjan et al., 2016). Notably, there is usually 
no PCR amplification step in WGS, removing one source of bias. Furthermore, because the entire genome 
is sequenced, a much more reliable estimation can be made of the functional potential of the microbiome, 
and it is also possible to identify novel strains or mutations in a sample. Overall, the higher resolution of the 
information generated by WGS makes it possible to infer more about the microbiota in the sample. 
Besides the cheaper cost, there are some situations where 16S is preferable to WGS. In samples that are 
heavily contaminated by off-target DNA (usually from the host, e.g., in biopsy samples), the signal of WGS 
can be too low for accurate measurement. Because 16S sequencing relies on the 16S subunit ribosomal RNA, 
which is unique to prokaryotes, most host contamination is not an issue. Furthermore, 16S sequencing can 
be performed when lower amounts of genetic material are available, which can be a key consideration when 
working with environmental samples like soil. 
Metrics to Describe the Microbiome
Working with a highly complex ecosystem such as the microbiome, introduces many challenges, especially 
with regards to parsing a large amount of high-dimensional data into human-readable metrics. Fortunately, 
fields like ecology and statistics have dealt with comparable problems in the past, albeit often on a differ-
ent scale. Methods like multidimensional scaling and metrics such as diversity originate from these fields 
and are frequently used as powerful tools to analyze the microbiome, once they have been modified to 
suit microbiome data (Fig. 2.). Perhaps the most important point to consider when analyzing microbiome 
data is that both 16S and WGS produce compositional data, data that contains information about the ratios 
between parts of the whole, but never contains information about absolute counting numbers (Aitchison, 
1986). Many of the properties of compositional data are distinct from those of classical datasets and classical 
statistical tools such as Pearson’s correlation coefficient are often not appropriate (Pearson, 1897). Fortu-
nately, compositional data analysis is a well-studied and documented field of statistics (Aitchison, 1986). 
Recently, great efforts have been made to apply compositional data analysis techniques to the microbiome 
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The most straightforward method of comparing two samples is to compare the presence of specific mi-
crobes. It should be noted that because of the nature of the output of both 16S sequencing and WGS, it is 
very rare to be able to work with absolute counts of organisms. Rather, relative abundance is used to com-
pare samples. This is an important point since relative abundance can change in situations where absolute 
levels may not, and vice versa
Diversity
Going one level further than comparative relative abundance, microbiome diversity can be used to quan-
tify the degree of heterogeneity within a sample or the difference between two samples. There are many 
different formulas that produce diversity metrics, all of which can be categorized into three closely related 
classes: α, β and γ diversity (Tuomisto, 2010a, b). α-diversity describes the diverseness within a sample, while 
β-diversity describes the diversity, or dissimilarity, between samples (Tuomisto, 2010a). γ-diversity is rarely 
used and describes the total species diversity over all samples, comparable to α-diversity in a single sample. 
Different formulas for diversity lay different weights on factors like the richness of a sample in terms of the 
number of different species represented, or the evenness of the distribution of the species in a sample. It can 
often be valuable to calculate diversity using several different metrics, depending on the research question. 
Principal component analysis (PCA) 
A common way to visualize high-dimensional data, like relative abundance, is by applying a multidimensional 
scaling (MDS) algorithm. Principal component analysis (PCA) is both common and appropriate in microbiome 
research, but other algorithms are available and sometimes useful. In PCA, the distances between every 
combination of two points in a set are taken as an input, and a set of coordinates is generated as an output. 
These coordinates can be used to plot each sample as a point in 2-dimensional or 3-dimensional space, using 
the principal coordinates as the axis. On the plot, points that are closer together represent samples that are 
more similar in composition. 
Functional metagenomics
The analysis of function represents a high-level readout of the microbiome that can give insight into the ef-
fect or consequence that a change in the microbial community can have on its host. Functional metagenom-
ics are often a product of either WGS or the application of functional prediction tools on 16S datasets. The 
reliability of functional analysis depends on the availability of high-quality curated data on the metagenome 
in question (Heintz-Buschart and Wilmes, 2018). Promisingly, the classical ecology concept of functional 
“guilds,” groups of taxonomically distinct but functionally related organisms, has been proposed to apply to 
the microbiome (Zhao et al., 2018).
Robustness
Recently, robustness has been explored in the context of the microbiome (Eng and Borenstein, 2018). Ro-
bustness as a metric expresses information about the degree of change a community will undergo after a 
perturbation and how fast and to what degree it can recover, if at all. Robustness highlights an interesting 
aspect of complex ecosystems. For example, a species, or clade (a branch of a phylogenetic/ contextual tree), 
can have little or no effect on its environment by itself but plays an important role in the maintenance of a 
steady state. This phenomenon is known in ecology as a keystone species, whereby the disappearance of 
that species will cause the ecosystem to drastically change or even collapse (Mills et al., 1993). 
In Silico Models of the Microbiome
Although human and animal models have many advantages, there are numerous situations where the spe-
cific constraints of an in vivo model can over-complicate an experiment. In cases like this, in silico models of 
the microbiome can be utilized. Metabolic models of the microbiome, often utilizing our growing capacity 
to produce, process and handle big data, have yielded invaluable understanding in microbe-microbe interac-
tions and microbe-environment interactions (Magnusdottir and Thiele, 2018; Sung et al., 2016). For instance, 
Flux Balance Analysis (FBA) models have been used to predict and understand the behavior of microbes 
given their environment (Orth et al., 2010; Thiele et al., 2013; Zelezniak et al., 2015). The generation and 
refinement of genome-scale metabolic reconstructions (GENREs) is essential for realistic modeling of these 
types of interactions, which will be facilitated by the recent publication of a large database containing 773 
high-quality human gut GENREs (Magnusdottir et al., 2017). In silico models of the microbiome can be used 
not only to answer experimental questions but also to verify the reliability of the results. One of the current 
limitations of the field is the difficulty in finding a gold standard dataset with which to validate statistical mod-
els for microbiome data. Often, there is no sufficiently large dataset of the required type available. However, 
synthetic datasets, generated by programs like SparseDOSSA (Human Microbiome Project, 2012), can be 
used to tackle this problem by generating realistic samples from a completely known and controllable source. 
Hopefully, with the development of evermore powerful computing technologies, and intricately designed 
programming suites, in silico modeling will increasingly complement the necessary use of animal models in 
fundamental microbiome research.
VI. Microbiota-Gut-Brain Axis across the Lifespan
As stated earlier the microbiota has been our constant companion in life throughout evolutionary history. 
This rich ecosystem is not static, but rather is in a constant state of flux across the lifespan. Within individu-
als, small day-to-day variations in microbiota composition are generally observed (Costello et al., 2009), but 
these fluctuations become most obvious when we take a wider view across the lifespan (see Fig. 3). At both 
extremes of life, the microbiota is characteristically different from the typical adult gut microbiota in both 
levels of diversity and representation of specific taxa (Claesson et al., 2012; Salazar et al., 2014; Yatsunenko 
et al., 2012). It has been hypothesized that these periods of transformation in the microbiota may be likened 
to sensitive periods, during which the microbiota is not only responsive to external influences (and therefore 
amenable to treatment) but also highly influential with regards to the overall health of the host (Borre et al., 
2014; Gensollen et al., 2016; Gur et al., 2015). In the neuroscience literature, a sensitive period is defined 
as a developmental time window during which the brain is more sensitive/vulnerable to environmental in-
puts (Hensch, 2005). Originally applied to the development of different sensory systems, sensitive periods 
are now being investigated for higher order behaviors as well, such as language development and cognition 
(Callaghan et al., 2013; Hensch and Bilimoria, 2012; Werker and Hensch, 2015). It is likely to be biologically 
relevant that sensitive periods in the microbiota align with sensitive periods in the development or decline of 
other bodily systems; this includes, but is not limited to, the innate immune system, the hypothalamic-pitu-
itary-adrenal (HPA) axis, and brain development in general (Borre et al., 2014; Gensollen et al., 2016; Goyal et 
al., 2015). In this section, we discuss three broad sensitive periods – early-life, adolescence, and aging – and 
examine the role of the microbiome in determining host brain function during these critical windows. 
A. Early Life
There is some controversy about when the human GI tract is first colonized, with recent studies reporting 
the existence of a placental microbiota and in utero colonization of the fetus (Aagaard et al., 2014; Collado 
et al., 2016; Jimenez et al., 2008), while others suggest that this evidence is limited by a lack of contamina-
tion controls (Lauder et al., 2016; Lim et al., 2018; Perez-Munoz et al., 2017; Theis et al., 2019), maintaining 
that the placenta and womb are sterile (Kim et al., 2017; Lauder et al., 2016; Lim et al., 2018; Milani et al., 
2017; Perez-Munoz et al., 2017). If in utero colonization does occur, it seems to have a limited effect on the 
early postnatal microbiota composition relative to the initial seeding of the microbiota during birth (either 
by Cesarean section or per vaginum; see Section VI. B). This is not to discount the potential impact of prena-
tal transfer of even small numbers of bacteria and other microorganisms from the mother to the infant. As 
stated earlier, GF mice, which have never had microbial colonization, (but see: (Hornef and Penders, 2017), 
have been invaluable tools in parsing the role of the microbiota in gut-brain signaling across the lifespan 
(Luczynski et al., 2016a); see Section II.A, and Fig. 1). Indeed, GF status during pregnancy has dramatic effects 
on offspring development in rodents. For example, the blood-brain barrier (BBB) typically develops around 
the second week of embryonic life, with permeability decreasing sharply at approximately embryonic day 15 
in the mouse (Braniste et al., 2014). However, GF mouse embryos exhibit increased BBB permeability and 
low expression of the tight junction protein occludin on embryonic days16-18, effects that were maintained 
postnatally and into adulthood (Braniste et al., 2014). Importantly, this study identified that BBB integrity 
could be restored by postnatal recolonization of the microbiota, implying a causal role for the microbiota in 
ensuring development of the BBB. Aside from maternal GF status, other prenatal maternal factors such as 
diet, obesity, immune activation, and stress, all of which are known to alter offspring mental and physical 
health outcomes, have also been found to influence offspring microbiota composition in rodents and/or hu-
mans (Buffington et al., 2016; Galley et al., 2014; Hsiao et al., 2013; Jasarevic et al., 2017; Rincel et al., 2019; 
Sugino et al., 2019; Zijlmans et al., 2015).
As for all stages of life, it is difficult to give a strict definition of what constitutes a healthy microbiota during 
early life. However, it is known that the microbiota tends to follow one of a few trajectories of development, 
with early-colonizing species shaping the long-term composition (Martinez et al., 2018). Soon after birth, the 
microbiota is typically characterized by relatively high abundances of Enterobacteriaceae, Bifidobacteriaceae, 
and Clostridiaceae, but low levels of Lachnospiraceae and Ruminococcaceae at the family level (Bokulich et 
al., 2016; Chu et al., 2017; Yassour et al., 2016). As the infant matures, strict anaerobes gradually take over as 
the dominant taxa, and there is an increase in overall diversity to adult-like levels by around 1-3 years of age, 
coinciding with weaning and a shift to solid food intake (Koenig et al., 2011; Palmer et al., 2007; Yatsunenko 
et al., 2012). This rapid development at weaning is observed across species and was recently shown to be 
critical for protection against later development of immunopathology in mice (Al Nabhani et al., 2019). How-
ever, even after weaning, the microbiota continues to change (Al Nabhani et al., 2019). The composition and 
function of the microbiota in healthy children (measured at 7-12 years of age) remains significantly different 
from the healthy adult microbiota (Hollister et al., 2015). In particular, the gut microbiota of children is func-
tionally enriched in pathways supporting ongoing development (e.g., genes involved in vitamin synthesis and 
de novo folate synthesis, anti-inflammatory pathways; Hollister et al., 2015).
The infant and child microbiota is susceptible to a range of environmental influences, from birth mode (vagi-
nal vs C-section), and birth location (home vs hospital) , to diet, (including breastfeeding versus formula feed-
ing) (Azad et al., 2013; Biasucci et al., 2010; Dominguez-Bello et al., 2010; Ho et al., 2018), maternal gesta-
tional diet and weight gain (Baumann-Dudenhoeffer et al., 2018; Seppo et al., 2019), pet ownership (Azad et 
al., 2013; Tun et al., 2017), physical illness (Combellick et al., 2018; Kan et al., 2019), antibiotic use (Korpela et 
al., 2016; Yassour et al., 2016), and stress (Gur et al., 2015; Rincel et al., 2019; Zhong et al., 2019; Zijlmans et 
al., 2015). Although some of these factors exert a diminishing influence on the microbiota over time (e.g., the 
effects of birth mode on microbiota composition are no longer apparent by 6 weeks of age; Chu et al., 2017; 
Hill et al., 2017), these early life factors may still have long-lasting implications for the physical and mental 
health of the individual (Callaghan et al., 2019; Gensollen et al., 2016; Milani et al., 2017), consistent with the 
idea that there are sensitive periods for microbiota-gut-brain interactions. Longitudinal studies testing this 
hypothesis are currently limited, but emerging research in both humans and rodents suggests that early-life 
microbiota manipulations can alter trajectories of physical and mental health or cognitive performance. 
In humans, the currently available evidence for enduring effects of early-life microbiota changes on host 
physiology and brain health, although moving more towards mechanism and causation, is largely correla-
tional. The evidence supports a link between early-life microbiota composition, or antibiotic use, and later 
metabolic and immune function (specifically overweight/obesity and asthma/allergy; Abrahamsson et al., 
2014; Azad et al., 2014; Penders et al., 2007; Sjogren et al., 2009; Stanislawski et al., 2018a; Sugino et al., 
2019). Correlations have also been observed between childhood microbiota composition and behavioral 
temperament (Christian et al., 2015), functional activity/connectivity in the brain (Callaghan et al., 2019; Gao 
et al., 2019), and cognitive function (Carlson et al., 2018). Beyond correlation, preliminary clinical trials of 
probiotic interventions for at-risk children have yielded promising results with regards to reducing risk for GI 
problems (Indrio et al., 2014; Weizman et al., 2005), sepsis (Panigrahi et al., 2017), and even autism spectrum 
disorder (ASD) (Parracho et al., 2010; Partty et al., 2015) and attention deficit hyperactivity disorder (Partty et 
al., 2015), although a recent study of post-natal probiotics (L. rhamnosus HN001 or B. animalis HN019) found 
no effect of either strain on later neurocognitive outcomes (Slykerman et al., 2018). Such investigations are 
becoming more widespread based on strong preclinical evidence that early-life disruption of the microbiota 
alters a wide range of behavioral and neural outcomes both during development and later in life (Clarke et 
al., 2013; Diaz Heijtz et al., 2011; Leclercq et al., 2017; Minter et al., 2017; O’Mahony et al., 2014; Olszak 
et al., 2012; Stilling et al., 2015). Preclinical research also provides cause to focus on early-life microbiota 
interventions. Several groups have now shown that early probiotic interventions mitigate the effects of anti-
biotic-treated and C-section delivered infants, early-life stress, maternal high-fat diet, and maternal immune 
activation on infant outcomes (see Table 5) (Buffington et al., 2016; Callaghan et al., 2016; Cowan et al., 2016; 
Fukui et al., 2018; Gareau et al., 2007; Hsiao et al., 2013; Korpela et al., 2018).
B. Adolescence
Adolescence has been labeled a time of “storm and stress,” reflecting the unique challenges associated with 
this stage of life (Hall, 1904). In addition to the well-known hormonal fluctuations that occur during adoles-
cence, the brain undergoes vast re-shaping, including pruning, myelination, volumetric changes in various 
regions and changes in functional connectivity (Blakemore, 2012; Blakemore and Choudhury, 2006; Casey et 
al., 2008; Spear, 2000) (Fig. 3). Rapid physical development of the body and brain coincides with dramatic 
shifts in social networks (notably increased independence from caregivers), diet, sleep patterns, and expo-
sure to alcohol and drugs. Faced with this cocktail of stressful new experiences on a background of unstable 
hormones and altered brain function, it is perhaps unsurprising that adolescents are vulnerable to mental 
health problems (Kessler et al., 2005; Lee et al., 2014; Paus et al., 2008). Given that all of these factors have 
been linked to alterations in the microbiota-gut-brain axis in adults, exploration of the microbiota during the 
sensitive period of adolescence has the potential to provide both insights and interventions to improve ado-
lescent well-being (Flannery et al., 2019; McVey Neufeld et al., 2016a; McVey Neufeld et al., 2016b).
There have been very few studies directly comparing the adolescent and adult microbiota in humans. In 
a small cohort (n = 22) of healthy 11-18-year-old adolescents, a correlation between age and microbiota 
composition was observed such that older adolescents were more similar to (but generally still separate 
from) the adult microbiota profile (Agans et al., 2011)Bacterial/genetics</keyword><keyword>Female</key-
word><keyword>Genome, Bacterial</keyword><keyword>Humans</keyword><keyword>Intestines/*mi-
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Chain Reaction</keyword><keyword>Principal Component Analysis</keyword><keyword>Young Adult</
keyword></keywords><dates><year>2011</year><pub-dates><date>Aug</date></pub-dates></
dates><isbn>1574-6941 (Electronic. At the genus level, adolescents had higher relative abundances of Bi-
fidobacterium and Clostridium, but lower relative abundances of Prevotella and Sutterella. These differences 
are similar to those reported in other studies of the child microbiota (Hopkins et al., 2001), indicating that 
there is a gradual transition from childhood to adulthood rather than a distinct adolescent profile, although 
further work is needed to confirm this result. Initial reports show that certain features of the microbiota 
correlate with both diet and metabolic outcomes in adolescent populations (Del Chierico et al., 2018; Jang 
et al., 2017; Stanislawski et al., 2018b), suggesting that more in-depth analyses of the functional relevance 
of the microbiota in adolescence are warranted. This pursuit would be aided by more preclinical studies in 
this area as there is a paucity of research addressing the question of age-specificity. In rodents, it has been 
shown that sex differences in the microbiota emerge only after puberty onset (Markle et al., 2013) and that 
probiotic treatment during a period of early-life stress reverses stress-induced changes in the timing of pu-
berty onset (Cowan and Richardson, 2018). Further, long-term antibiotic-induced depletion of the microbiota 
from adolescence alters adult cognition, social behavior, and anxiety (Desbonnet et al., 2015). This chronic 
treatment also reduced central levels of BDNF, oxytocin and vasopressin and altered tryptophan metabolism 
in adulthood. While this particular study did not provide clarity with regards to the idea that adolescence is 
a sensitive period (because the treatment continued into adulthood and no adulthood-only treatment was 
included). However, there are now a number of reports that early-life microbiota interventions are more 
efficacious when directly compared to the same interventions administered in adulthood (Buffington et al., 
2016; Diaz Heijtz et al., 2011; Ellekilde et al., 2014; Olszak et al., 2012; Sudo et al., 2004). Overall, this work 
provides further support for the existence of early-life sensitive periods of microbiota-gut-brain interaction 
for at least some behavioral and neural outcomes.
C. Aging
Aging is a slow process of deterioration of various homeostatic functions accompanied by an increased prev-
alence of disease (Lopez-Otin et al., 2013). The United Nations defines ‘older persons’ as those over 60 years 
of age, which roughly translates to 20 months in a rodent model (Prenderville et al., 2015). Distinct hallmarks 
of aging are apparent from the genetic level (genomic instability, epigenetic alterations, telomere attrition) 
to the cellular level (mitochondrial dysfunction, cellular senescence, stem cell exhaustion, oxidative stress, 
altered proteasomal activity and autophagy), including an imbalance of key messengers (decline in growth 
factors, neurotransmitter imbalance, dysregulated immunity) and altered receptor sensing (altered stress 
axis activity, deregulated nutrient sensing), ultimately disrupting the homeostasis of the aging organism (Lo-
pez-Otin et al., 2013) (Fig. 3.). Aging is also associated with changes in gut physiology, including hypochlo-
rhydria, gastric motility disorders, and degenerative changes in the ENS, yielding dramatic effects on the 
composition and function of the gut microbiome (Konturek et al., 2015). 
While the composition of the adult human gut microbiota is generally stable if unperturbed, its stability de-
teriorates in old age (Claesson et al., 2011). Diet and physical activity, two factors that generally decline in 
later life, can dramatically affect well-being, cognitive performance, and the microbiota at any stage of life, 
but their effects seem to be exaggerated in older individuals (Vauzour et al., 2017). Aside from this loss of 
stability, or perhaps because of it, characterization of the aging gut microbiome has proven difficult. First, 
the timing of the transition to an “elder-type” microbiome is not as clearly demarcated as the shift from an 
infant-type to an adult-type microbiome. Furthermore, while comparisons of adult and elderly individuals 
have identified clear differences in the microbiota composition between these two groups, the differences 
between studies have been sizable, perhaps due to cultural, geographical or methodological variances (Biagi 
et al., 2016; Biagi et al., 2017; Claesson et al., 2012; Mueller et al., 2006; Odamaki et al., 2016; Salazar et 
al., 2017; Shen et al., 2018). Decreasing diversity of the gut microbiota, generally associated with adverse 
outcomes in adults, has been linked to aging (Biagi et al., 2010) and age-related impairments like frailty in 
humans (Claesson et al., 2012; Jackson et al., 2016). In contrast, aged (24-month old) mice have been shown 
to exhibit increased diversity compared to younger adult mice (Scott et al., 2017). In terms of specific taxa, 
some studies have observed a decrease in beneficial Lactobacillus and Bifidobacterium in aging (Hebuterne, 
2003). A reduced Firmicutes:Bacteroidetes ratio has been reported in Irish and French elderly compared to 
young adults (Claesson et al., 2011; Mariat et al., 2009), although this effect was not observed in a compar-
ison of Italian centenarians, elderly and young adults (Biagi et al., 2010). Studies in semi-supercentenarians 
(people between 105-109 years of age) have found specific taxa such as Akkermansia to be more abundant, 
suggesting distinct gut microbiota changes at this extreme of life might be promoting healthy aging and lon-
gevity (Biagi et al., 2016; van der Lugt et al., 2018), as well as restore intestinal permeability and subsequent 
immunomodulation in aged mice (Bodogai et al., 2018).
Despite difficulties in identifying consistent aging-related compositional changes in the microbiota, further 
evidence supports the hypothesis that the microbiota plays a functional role in (un)healthy aging. A recent 
study demonstrated that that suppression of the gut microbiome using broad-spectrum antibiotics restored 
arterial function in old mice (20-24 months old) to levels observed in young animals (8-10 weeks old), which 
was coupled with normalization of both oxidative stress and inflammation (Brunt et al., 2019). Earlier stud-
ies in rodents demonstrated that GF mice live longer than conventional controls, linking gut microbiota to 
the decline of immune system function, or senescence (Glimstedt, 1959; Gustafsson, 1946). More recently 
in a human population, the ELDERMET study reported breakthrough research in which age-related shifts in 
gut microbiota composition were linked to various functional health measures, including frailty, cognition, 
depression, and inflammatory markers (Claesson et al., 2011; Claesson et al., 2012). For example, one study 
found that the more diverse the diet, the more diverse the microbiota, which was linked to improved health 
and reduced frailty (Claesson et al., 2012). Specific microbial taxa are also associated with reduced frailty in 
elderly populations, including Bacteroidetes (Bartosch et al., 2004; Hopkins et al., 2001; van Tongeren et al., 
2005), Clostridium cluster XIVa and Faecalibacterium prausnitzii, one of many butyrate-producing bacteria 
with anti-inflammatory properties (Bartosch et al., 2004; van Tongeren et al., 2005; Zwielehner et al., 2009). 
In contrast, the bacterial family Porphyromonadaceae has been linked to declines in cognition and affective 
disorders (Bajaj et al., 2012; Collins et al., 2012). This nicely parallels results in a preclinical study showing 
that aged mice have a higher relative abundance of Porphyromonadaceae and that the levels of this family 
correlate with increased anxiety-like behavior (Scott et al., 2017). 
Altered aged gut microbiota compositions have also been proposed to contribute to “inflammaging” (Theva-
ranjan et al., 2017), the heightened proinflammatory status and decline in adaptive immunity progressively 
expressed in older age (Franceschi et al., 2000). Inflammaging contributes to the speed of the aging process 
and may progress the development of age-related diseases (Xia et al., 2016), from neurological disorders 
like Alzheimer’s disease (Giunta et al., 2007) to metabolic and other physical disorders like heart disease, 
osteoporosis, and type II diabetes (Boren and Gershwin, 2004; Franceschi et al., 2001; Lencel and Magne, 
2011). Both aging and stress weaken the integrity and function of the GI barrier (Kelly et al., 2016; Theva-
ranjan et al., 2017) and negatively affect BBB permeability (Esposito et al., 2002; Montagne et al., 2015) po-
tentially accelerating inflammaging. By utilizing various models targeting the gut microbiome including pre-, 
pro- and postbiotics recent studies have shown a role for the gut microbiome in regulating neuroimmunity 
from middle- to old age which have implications for therapeutic interventions combatting age-related neu-
rodegeneration and cognitive decline (Boehme et al., In Press; Fonken et al., 2018; Matt et al., 2018). One 
prebiotic study examining the effect of diets differing in sugar, fat, and fiber content on the gut microbiota 
of mice humanized with microbiota from healthy or frail older people, reported that the frailty-associated 
gut microbiota did not reciprocally switch to a younger healthy-subject like state (Tran et al., 2019). Further, 
supplementation with prebiotics was associated with fewer detected effects in humans than diet adjustment 
in animal models (Tran et al., 2019).
 
Further evidence of a  link between the microbiota and inflammaging comes from studies showing compo-
sitional changes in the microbiota that occur with age induce subclinical intestinal inflammation in elderly 
individuals with a high incidence of chronic disease (Guigoz et al., 2008), while reduced levels of Akkerman-
sia following FMT from old mice into young GF mice was associated with an inflammaging phenotype in the 
recipient young mice (Fransen et al., 2017). An important component of the immune system and potential 
contributor to inflammaging are microglia, which are the brain’s resident immune cells. As key players in 
the brain’s immune orchestra, microglia shape neuronal wiring and activity, synaptic plasticity, phagocytosis 
and support the survival of neurons and neuronal progenitors via the secretion of growth factors (London 
et al., 2013; Tay et al., 2017) (see Sections IV C., E., and V). However, during aging, microglia develop into a 
highly reactive and unbalanced state promoting cognitive dysfunction including altered brain plasticity and 
neurodegeneration (Boehme et al., 2014; Lui et al., 2016; Tay et al., 2017; von Bernhardi et al., 2015). Recent 
studies have shown that GF mice display deficits in microglia maturation and function, while recolonization 
or administration of key gut microbiota metabolites such as SCFAs restore microglial function (Erny et al., 
2015). Such studies suggest that targeting microglia could present an interventional approach to ameliorate 
neurodegenerative disease (Boehme et al., In Press; Matt et al., 2018). 
Indeed, administration of microbiota-targeted diets to prevent the age-associated decline of beneficial Bi-
fidobacterium has been found to have positive effects on gut microbiota composition and associated health. 
A recent study found that a 14-week long dietary intervention with prebiotics increased both Bifidobacte-
rium and Akkermansia in middle-aged mice (Boehme et al., In Press). Moreover, the abundance of Bifido-
bacterium strongly correlated with genes involved in colonic health in the early phase of aging (van der Lugt 
et al., 2018). Similarly, Bifidobacterium species have been shown to be negatively correlated with pro- and 
anti-inflammatory cytokine levels in humans indicating that modulation of Bifidobacteria may represent a 
target for reducing the inflammatory response (Ouwehand et al., 2008).
Thus far, dietary restriction has been the most effective strategy to demonstrate an increase in lifespan across 
a whole range of investigated species, including nonhuman primates (Colman et al., 2009; Fontana et al., 
2010; Fraumene et al., 2018; Lin et al., 2002; Mattison et al., 2012; Rusli et al., 2018; Zhang et al., 2013). This, 
once again, highlights diet as a key determinant of healthy aging, possibly via modulation of the gut micro-
biota. Studies in rodents support this interpretation, finding that short-term to life-long caloric restriction 
leads to structural changes of the gut microbiota (Fabbiano et al., 2018; Fraumene et al., 2018; Zhang et al., 
2013) with the genus Lactobacillus, amongst others, positively correlated with lifespan (Zhang et al., 2013) 
and accompanied with changes in microbial metabolite production such as SCFAs (Tanca et al., 2018). More-
over, an intriguing FMT study in the short-living killifish showed that exchange of microbial communities from 
young to old increased longevity in the older group (Smith et al., 2017). This illustrates the potential for gut 
microbiota modulation as a therapeutic strategy to benefit an aging host.
VII. Pathways of Communication
There are many pathways of potential communication between the gut microbiota and the brain, from intri-
cately innervated and highly modifiable neuronal pathways to incredibly subtle and difficult to measure small 
molecule messaging systems, both locally in the gut and distally in the brain. In the following section, we will 
introduce many of these communication methods (Fig. 4.). However, much work is needed to fully resolve 
the exact mechanisms as to how bacteria in the lumen of the gastrointestinal tract can exert such marked 
effects on brain and behavior.
A. Autonomic Nervous System (ANS)
The autonomic nervous system (ANS) is a neural relay network, with neurons located within the central and 
peripheral nervous systems, controlling bodily functions without conscious effort (autonomously), such as 
breathing, heartbeat and digestion. The ANS is comprised of the sympathetic and parasympathetic branches. 
Combined with activity from the ENS and modulation by the CNS, the ANS is responsible for physiological 
homeostasis, as well as responding to endocrine, motor, autonomic, and behavioral areas. The individual 
components of the microbiota-gut-brain axis communicate with each other bi-directionally, both antagonis-
tically and synergistically, within the ANS (Mulak and Bonaz, 2004). In combination with the HPA axis, the ANS 
comprises a vast and complex network of integrated communication between the brain and the gut, involun-
tarily establishing and regulating host physiological homeostasis (Janig, 2006). The ANS, in combination with 
neuronal and neuroendocrine signaling, can induce CNS-modulated changes in the gut (top-down effects) 
(Mayer et al., 2015b). Key GI functions such as gut motility and permeability, epithelial fluid maintenance, 
luminal osmolarity, secretion of bile, carbohydrate levels, mechanical distortion of the mucosa, bicarbonate 
and mucus production as well as the mucosal immune response and intestinal-fluid handling, are all controlled 
by the ANS (Wehrwein et al., 2016). 
Incoming visceral information from the gut via the ANS is processed by the CNS, which then directs responses 
essential for survival. Further processing of this information involves positive and negative feedback loops 
which act on peripheral organs (Bonaz and Bernstein, 2013). The ANS provides the gut with the most direct 
neurological response available, leading to rapid changes in gut physiology, through innervation of the target 
organ, in both health and disease (Bienenstock et al., 2015), such as with the pain response (Mayer and Til-
lisch, 2011), and stress (Ulrich-Lai and Herman, 2009). 
Direct or indirect ENS-microbiota interactions can occur as a result of ANS activity. The sympathetic and 
parasympathetic systems can influence ENS neurocircuitry, resulting in changes in motility which can affect 
the rate of delivery of pre and pro-biotics to the small intestine and colon, including resistant starches and 
dietary fibers, and other critical microbial nutrients (Maier et al., 2017). Local GI autonomic activation can 
be triggered by interoceptive afferent feedback from the gut as well as CNS cognitive and emotional efferent 
modulation (Mayer and Tillisch, 2011). 
Microbes can communicate with each other via metabolites, similar to those recognized by host cells and can 
thereby interact with gut ANS synapses (Rhee et al., 2009). Microbiota-derived neuromodulatory metabolites 
include tryptophan precursors and metabolites, serotonin (5-hydroxytryptamine, 5-HT), GABA and catechol-
amines (Fig. 4.). Multiple research groups (Chey et al., 2001; Hsiao et al., 2013; Lyte, 2013; Sokol and Adolph, 
2018; Wall et al., 2014) have demonstrated that the microbially-modulated metabolite 4-ethylphenylsulfate 
is sufficient to induce anxiety-like behavior in mice. Indeed, the gut microbiota has been shown to modulate 
locomotor activity in Drosophila, probably via bacterial-derived metabolites (Schretter et al., 2018), (Chen et 
al., 2019). Further, vagal sensory neuron activation via Campylobacter jejuni gut inoculation of mice resulted 
in direct activation of the neuronal activation marker c-Fos in the vagal sensory ganglia and the primary sen-
sory relay nucleus for the vagus nerve, the nucleus tractus solitarius (NTS) in the medulla oblongata (Goehler 
et al., 2005). These findings indicate that gut autonomic nerves carrying sensory information that can signal 
directly to the brain upon local GI microbial metabolite stimulation. 
Sympathetic gut innervation involves subclasses of postganglionic vasoconstrictor as well as secretion and 
motility suppressing neurons. Altered neurophysiology of sympathetic innervation results in altered GI tran-
sit, motility and secretion, primarily via modification of cholinergic transmission and sphincter contractions 
on smooth muscle (Furness, 2000; Janig, 2006). The size and quality of the intestinal mucus layer is believed 
to be mediated by sympathetic innervation where mucosal immune system modulation (Elenkov et al., 2000) 
and microbial composition and behavior alterations (commensal and pathogenic) were seen (Macfarlane 
and Dillon, 2007; Rhee et al., 2009) 
The Vagus Nerve and Beyond
The vagus nerve is the 10th cranial nerve and the fastest and most direct route that connects the gut and the 
brain. Its name is derived from the Latin for wandering, due to its extensive innervation, which allows col-
lection of information from different visceral organs (Berthoud and Neuhuber, 2000). It is composed of 80% 
afferent and 20% efferent fibers (Agostoni et al., 1957; Prechtl and Powley, 1990), which tonically transmit 
vital information from the GI, respiratory and cardiovascular systems (bottom-up), and provide feedback to 
the viscera (top-down). 
The gut is innervated by the hepatic and celiac branches of the vagus nerve, with decreasing density moving 
caudally from the proximal duodenum, ileum and the ileocecal junction as well as the remainder of the small 
and large intestines up to the level of the transverse colon (Wang and Powley, 2007). Vagal afferents form 
three different types of connections in the gut: Intraganglionic laminar endings and intramuscular arrays, 
which both end in muscle wall, as well as terminal axonal endings in the mucosa, and a recently described 
connection with a subset of enteroendocrine cells, now referred to as neuropods, which form synapses with 
vagal neurons (Kaelberer et al., 2018). Depending on their location and type, vagal afferents are ideally suited 
to detect stretch, tension or intestinal molecules such as bacterial by-products, gut hormones or neurotrans-
mitters. Due to the vast variety of receptors expressed on vagal afferents, they are thought to be polymodal, 
in that they respond to a variety of signals which are mechanical, chemical or hormonal in nature (Berthoud 
et al., 2004). Nevertheless, evidence suggests that there are distinct populations and subpopulations of vagal 
afferents responding to specific stimuli, including stretch (Williams et al., 2016a) or gut hormones (Egerod et 
al., 2018).
The vago-vagal anti-inflammatory reflex loop comprises vagal efferents originating mostly in the medullary 
dorsal motor nucleus of the vagus, which can modulate circulating levels of proinflammatory cytokines. Stim-
ulation of the reflex can result in vagal modification of macrophage activation (Pavlov and Tracey, 2005), 
which is an important and well-documented mechanism involved in the pathophysiology of inflammatory 
bowel diseases (Mulak and Bonaz, 2004) (see Section VIII.M.). A reduction in parasympathetically controlled 
intestinal transit has been associated with an increase in small intestinal bacterial overgrowth and bacterial 
translocation (Van Felius et al., 2003). Moreover, pain responses in functional bowel disorders of the gut-
brain axis such as  IBS are associated with altered parasympathetic activity (Chey et al., 2001). Further, a bi-
phasic vagal activation consisting of gastro-vagal inhibition and sacral activation has been correlated with the 
incidence of acute stress (Martinez et al., 1997) which potentially could lead to altered regional regulation of 
the microbiota. 
Sensory vagal fiber cell bodies reside in the nodose ganglia and synapse on various nuclei of the brainstem. 
Vagal fibers from the GI tract mostly synapse bilaterally on the NTS; whereas afferents from the intestine 
synapse within the subnucleus commisuralis and medialis in the intermediate to caudal part of the NTS (Alt-
schuler et al., 1993). From there Information is relayed to other brainstem nuclei and forebrain structures (Ri-
naman, 2010). Also, multisynaptic pathways ascending from the NTS link information from the viscera with 
the entire brain. Most of the sensory vagal afferents are glutamatergic, where second-order NTS neurons 
express α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA), N-methyl-D-aspartate (NMDA) and me-
tabotropic glutamate (mGlu) receptors (Ambalavanar et al., 1998). In addition, NTS neurons express a variety 
of neuropeptides including cholecystokinin (CCK), prolactin-releasing peptide or pro-opiomelanocortin (Ro-
man et al., 2016), and their receptors. Expression patterns of these neuropeptides and the target region of 
the axons can be used to sub-categorize NTS neurons, allowing the identification of NTS neurons responsible 
for specific emotional and behavioral responses (Maniscalco and Rinaman, 2018). For example, activation 
of projections of CCK and immunopositive neurons to the parabrachial nucleus results in decreased food 
intake without influencing anxiety-related behavior (Roman et al., 2016). In contrast, projections to the lat-
eral hypothalamic area induce feeding behavior upon activation and projections from the NTS to the bed 
nucleus of the stria terminalis, and the central amygdala are involved in anxiety as well as fear and avoidance 
behaviors, respectively (Bienkowski and Rinaman, 2013). Furthermore, neuronal projections to the nucleus 
accumbens and the basolateral amygdala are capable of modulating memory facilitation after physiological 
arousal (Kerfoot et al., 2008; Roozendaal et al., 1999). By either direct or multisynaptic projections, the NTS 
is capable of influencing major neurotransmitter systems such as noradrenaline (A2 cell group in the NTS and 
locus coeruleus), dorsal amygdala (nucleus accumbens, ventral tegmental area) and 5-HT (dorsal raphe). It 
appears that the NTS is well suited to coordinate the integration of interoceptive feedback transmitted via 
the vagus nerve from the gut to the brain and from the brain to the periphery, thereby acting as an excellent 
hub for microbiota-gut-brain signaling.
Studies utilizing vagotomy have clearly demonstrated the importance of constant bidirectional vagal signal-
ing for appropriate brain function including host behavior. In humans, there have been older reports that 
ablation of the vagus nerve, a facet of gastrectomy formerly used for the treatment of peptic ulcer, resulted 
in an increase in the incidence of psychiatric-related disorders (Browning and Houseworth, 1953; Whitlock, 
1961). Moreover, neurogenic bowel dysfunction is quite common in patients with chronic traumatic com-
plete spinal cord injury (Zhang et al., 2018). In rodents, vagotomy results in decreased locomotor activity 
during the dark phase (Itoh et al., 1981) and increased epinephrine concentrations in plasma at baseline and 
after immobilization stress (Khasar et al., 2003; Mravec et al., 2015). Furthermore, vagotomy reduced prolif-
eration and survival of newborn cells, decreased the number of immature neurons (O’Leary et al., 2018) and 
activation of microglia in the dentate gyrus (DG) of the hippocampus (Ronchi et al., 2012), all symptoms that 
can also be found in psychiatric disease (Section VIII). In addition, subdiaphragmatic vagal deafferentation 
(Vazquez et al., 2016) a method that eliminates abdominal vagal afferents, but keeps most efferents intact 
(Norgren and Smith, 1994) highlights the involvement of vagal afferents in anxiety-like (elevated plus maze, 
open-field test, food neophobia) and fear-related behavior (auditory-cued fear conditioning) (Klarer et al., 
2014). Further, it demonstrated an enhancement in reinforced left-right discrimination and reversal learning 
(Klarer et al., 2017), sensorimotor gating (pre-pulse inhibition) and attentional control of associative learning 
such as conditioned taste aversion (Klarer et al., 2018).
Consistent with the data collected on vagotomy, studies on vagus nerve stimulation (VNS) support the role 
of the vagus nerve in mood regulation. In humans, VNS is used for the treatment of refractory depression 
(Breit et al., 2018) in addition to chronic pain (Chakravarthy et al., 2015; Ren et al., 1989) Crohn’s disease 
(Bonaz et al., 2016), and certain epilepsies (Krahl, 2012; Penry and Dean, 1990). VNS in rodent models has 
shown to increase adult hippocampal neurogenesis (Grimonprez et al., 2015), and modulate the release of 
norepinephrine, 5-HT and dopamine in brain regions related to anxiety and depression (Breit et al., 2018), as 
well as increase hippocampal BDNF expression improving depressive-like behaviors in chronic restraint stress 
animals (Shin et al., 2019). Furthermore, a recent study in mice has shown that activation of GI vagal affer-
ents influence reward behavior in mice (Han et al., 2018), further reinforcing the concept that vagal signaling 
is involved in behavior.
Evidence that gut bacteria utilize vagal afferents to alter their hosts’ emotional and behavioral responses 
comes from studies observing changes in c-Fos expression in the cell bodies of vagal afferents following 
oral administration of Campylobacter jejuni (Goehler et al., 2005). Campylobacter jejuni administration had 
previously been shown to induce anxiety-related behavior without initiating a systemic immune response 
(Lyte et al., 1998). Moreover, vagotomy inhibited the effects of the prebiotic 2’-Fucosyllactose in associative 
learning related paradigms and hippocampal LTP (Vazquez et al., 2016). Interestingly, animals subjected to 
subdiaphragmatic vagal deafferentation show altered gene expression in the nucleus accumbens (Klarer et 
al., 2018). Further, an increase in the concentration of indole in the gut, a microbial metabolite, has been 
linked to the activation of the vagus nerve (Jaglin et al., 2018), similar to findings which show that administra-
tion of L. rhamnosus increases the firing rate of the mesenteric nerve bundle, which contains vagal and spi-
nal afferents (Perez-Burgos et al., 2013)Cellular</keyword><keyword>Mice</keyword><keyword>*Neural 
Conduction</keyword><keyword>Pressure</keyword><keyword>*Probiotics</keyword><keyword>Reac-
tion Time</keyword><keyword>Time Factors</keyword><keyword>Vagotomy</keyword><keyword>Vagus 
Nerve/*physiology/surgery</keyword></keywords><dates><year>2013</year><pub-dates><date>Jan 15</
date></pub-dates></dates><isbn>1522-1547 (Electronic. Finally, recent studies in a genetic mouse model 
of autism (Shank3B−/− mouse) shows that the effects of L. reuetri on social behavior are no longer present in 
vagotomized animals (Sgritta et al., 2019). Despite plenty of evidence implicating the vagus as a conduit for 
microbiome to brain signaling, it has thus far not been possible to map the neuronal networks underlying 
microbiota-gut-brain axis in detail, and more work will be required to disentangle such circuits. 
B. Enteric Nervous System (ENS)
At the interface between the microbiota and the host lies a network of neurons known as the enteric ner-
vous system (ENS), positioned to respond either directly, or indirectly, to the microbiota and its metabolites. 
Broadly, the ENS is structured into two ganglionated plexi, the submucosal and myenteric plexus, and is large-
ly responsible for the coordination of gut functions such as motility and control of fluid movement (Furness, 
2012). In the context of gut-brain signaling, the ENS communicates with the CNS via intestinofugal neurons 
to sympathetic ganglia with sensory information traveling via extrinsic primary afferent neurons that follow 
spinal and vagal afferent routes (Furness, 2012). These intrinsic and afferent neural pathways provide oppor-
tunities for factors derived from the gut lumen, and therefore potentially the microbiota, to influence not 
only gut function but also the CNS. 
ENS structure and neurochemistry resembles that of the CNS, and therefore any mechanisms implicated in 
CNS dysfunction may also lead to ENS dysfunction (Rao and Gershon, 2016) or vice versa. While the develop-
ment of the ENS occurs primarily during embryogenesis, key events such as proliferation of progenitor cells, 
differentiation of mature neuronal phenotypes and formation of functional neural circuits continue during 
the postnatal period (Goldstein et al., 2013a), concurrent with the development of the gut microbiota (Wo-
pereis et al., 2014). For example, the density of ganglion cells decreases significantly across the first 3 to 4 
years of life (Burns and Thapar, 2013). This provides a critical window for the microbiota to influence the ENS 
during critical neurodevelopmental periods. We have recently reviewed the mechanisms by which the mi-
crobiota influences ENS development and function which includes activation of pattern recognition receptors 
including Toll-like receptors (TLR), in particular, TLR2 and TLR4, which are involved in recognition of microbial 
molecules (Hyland and Cryan, 2016). Inferences on the role of the microbiota on ENS development can also 
be drawn from studies in GF rodents (Hyland and Cryan, 2016; Kabouridis and Pachnis, 2015) (see Table 2).
Regarding the expression of pattern recognition receptors, the ENS has the molecular machinery to respond 
to viral RNA and LPS (the membrane component of gram-negative bacteria) (Raio and Phelps, 2015), through 
expression of TLRs 3,7 and 4 respectively (Barajon et al., 2009). Though an interesting observation, whether 
microbial factors can directly access the ENS, at least in a healthy state, remains unclear. Nonetheless, func-
tionally, the absence of TLRs impacts functions dependent on the ENS. For example, TLR4 deficient mice dis-
play a decrease in fecal pellet output and stool water content, perhaps reflective of alterations in myenteric 
and submucosal plexus function, respectively (Caputi et al., 2017), while TLR2 deficient mice display dys-
regulated small intestinal motility (Brun et al., 2015). A consistent finding across studies investigating mem-
bers of the TLR family and the ENS have identified ultrastructural and neurochemical, as well as functional 
alterations between mice lacking TLRs, and their wild-type counterparts (Hyland and Cryan, 2016). Perhaps 
providing a more definitive role for the microbiota in this regard, GF mice also display significant ENS abnor-
malities in terms of ultrastructure and neurochemistry in the early postnatal period (Collins et al., 2014). 
These abnormalities observed in GF mice were not apparent in colonized animals, or following colonization 
with a defined bacterial consortia (ASF). This suggests that there is potential for particular bacterial species 
to play a role in determining the fate of ENS development and hints at the possible therapeutic application 
to offset detrimental factors which may negatively influence the trajectory of normal ENS development and 
function. In addition, GF animals also appear to display deficits in intrinsic sensory signaling, which one could 
infer might also consequently influence communication with the CNS. Moreover, this could be reversed upon 
conventionalization of the animals with microbiota from specific pathogen-free (SPF) donors (McVey Neufeld 
et al., 2015).
A recent study has provided mechanistic insight into how the microbiota might influence the ENS, implicating 
a role for 5-HT in this regard (De Vadder et al., 2018). Colonization of GF mice increased enteric neural 5-HT 
and expression of 5-HT4 receptors while colonization of GF mice lacking tryptophan hydroxylase 1 (TPH1) 
failed to restore enteric neuron numbers to those observed in GF and conventional Tph1 transgenic mice 
and decreased Nestin+ neural precursors indicating reduced levels of neurogenesis (De Vadder et al., 2018). 
Moreover, colonization of GF mice in the presence of a 5-HT4 receptor antagonist negatively influenced the 
ENS. In contrast stimulation of 5-HT4 receptors in GF animals had the opposite effect and restored normal 
gut physiology (De Vadder et al., 2018). This work provides a body of evidence implicating a role for micro-
biota-induced effects on 5-HT and its impact on the ENS, though there are subtleties in the findings that 
would suggest this pathway may differentially influence neurogenesis, differentiation, cell turnover and gut 
function depending on the nature and timing of the interventions (Fig. 4.).
Antibiotic-induced disruption of the gut microbiota has also been applied as a method to determine the 
impact of this microbial community on the ENS and resulted in wide-ranging effects on ENS architecture 
(neuronal and glial), neurochemistry and function (Caputi et al., 2017) (see Table 3). Within enteric ganglia 
reside glial cells, which in antibiotic-treated animals were decreased (Caputi et al., 2017), and evidence from 
GF animals suggests a more specific role for the microbiota in modulating mucosal enteric glial cell migration 
which was not restricted to the early postnatal developmental period (Kabouridis et al., 2015). Notably, the 
density and proportion of Substance P-containing neurons, a neurotransmitter involved in motor and sensory 
neurotransmission in the gut, were increased in response to antibiotic-induced disruption of the gut micro-
biota as was the density of TLR2, which when activated partially recovered deficits in gut function (Caputi 
et al., 2017). These changes occurred concomitantly with a rebalancing of fecal bile acid profile reflected as 
increased levels of fecal taurocholic acid and a reduction of cholic acid in antibiotic-treated animals (Caputi 
et al., 2017). However, whether such changes in bile acid profile are mechanistically linked to the structural 
and functional alterations in the ENS warrants further investigation. Notwithstanding this, in a mouse model 
of autism, not only was abnormal gut function observed, characterized by a constipation-like phenotype, 
ultrastructural and neurochemical changes in the ENS but also changes in fecal bile acid profile not dissimilar 
to those observed in antibiotic-treated mice, with elevated fecal taurocholic acid also observed in this mouse 
model of autism (Golubeva et al., 2017). However, shifts in the microbiota composition associated with stress 
and ENS abnormalities can occur independently of each other as observed in offspring of dams exposed to 
prenatal stress in which the most significant stress-induced changes in the gut microbiota failed to correlate 
with gut physiological and ENS parameters (Golubeva et al., 2015). Therefore, one must exert a degree of 
caution in interpreting concomitant changes in the microbiota and ENS as being intrinsically linked. 
Microbial status, however, is not the only determinant of ENS function/ activity, which also displays sensi-
tivity to exposure to early-life stress (De Palma et al., 2015). In a recent study, stress-induced alterations in 
ENS activity, characterized by stimulated acetylcholine release, was influenced by both maternal separa-
tion and the microbiota (De Palma et al., 2015), thus providing evidence that the microbiota may underpin 
ENS-related gut dysfunction associated with early-life stress. At a single cell level, GF status is accompanied 
by significant alterations in the electrophysiology and characteristic  profile of after-hyperpolarization-type 
enteric neurons (intrinsic primary afferent neurons) reflected as decreased excitability and discharge (McVey 
Neufeld et al., 2013), which in the context of the microbiota-gut-brain axis may be especially important as 
these intrinsic afferent neurons may represent the first neural elements to sense changes in the microbiota 
with consequential effects on the gut and the brain. However, these single cell changes may not necessarily 
manifest as changes in gut function, where secretomotor responses, and those stimulated by capsaicin, and 
presumably driven by the submucosal plexus, were comparable in colonic segments from GF animals and 
colonized controls (Lomasney et al., 2014b). 
In addition to displaying sensitivity to colonization with complex or simplified microbiota, the ENS also re-
sponds to specific bacterial strains, or components thereof, perhaps providing some insight into the microbi-
al mechanisms which may affect ENS function. While some of these studies have taken a direct approach by 
stimulating enteric neurons with bacterial supernatants or conditioned media (Khoshdel et al., 2013; Kunze 
et al., 2009), others have considered the epithelial barrier which separates the gut lumen from its underly-
ing nervous system (Al-Nedawi et al., 2015; Kunze et al., 2009). The latter approach has demonstrated that 
not only do different bacterial strains differentially influence enteric nerve activity but that they may do so 
by different mechanisms (Mao et al., 2013). Bacteroides (B.) fragilis for example, likely as a consequence of 
its capsular exopolysaccharide, can influence ENS function while an L. rhamnosus strain (JB-1) does so via a 
G-protein-coupled receptor-mediated pathway (Mao et al., 2013). Of note in this latter study, the authors 
show that the effects on the ENS are not dependent on diffusion of molecules from the epithelium to the 
myenteric neurons. Using a similar methodology, the same laboratory also demonstrated that the micro-
bial-derived SCFA, butyrate, and epithelial-applied 5-HT, could affect ENS activity providing some further 
insight into additional mechanisms by which the microbiota may interact with the ENS (Kunze et al., 2009). 
Functional studies support that different microbial strains can differentially affect neurally-driven secretomo-
tor responses (Lomasney et al., 2014a). Further characterization of the mechanism underlying the effect of 
the L. rhamnosus strain (JB-1) on ENS function confirmed that an intact epithelium was required to mediate 
the effect of microvesicles derived from JB-1, which themselves recapitulated the effects of the strain per se 
on the ENS (Al-Nedawi et al., 2015), indicative that epithelial elements may be an important intermediary in 
transducing microbial signals from the gut lumen to the ENS. The ENS is also central to facilitating changes in 
motility consequential to diet-microbe interactions (Dey et al., 2015).
Evidence now also suggests that there may be a reciprocal relationship between the ENS and the gut micro-
biota. Thus far, we have considered the impact of the microbiota on the ENS. However, the ENS appears to 
be able to exert control of the microbiota (Rolig et al., 2017). In zebrafish lacking an ENS as a consequence 
of a mutation in an SRY-related HMG-box (sox10 transcription factor gene), a ‘pro-inflammatory’ microbiota 
profile developed, the effects of which could be ameliorated by transplantation of wild-type ENS precursors 
into sox10 mutants or by the introduction of ‘anti-inflammatory’ microbes (Rolig et al., 2017). These data 
might challenge the dogma that alterations in the microbiota precede alterations in the ENS and thus lead to 
the proposal that changes in neural activity may precede alterations in the gut microbiota. 
Abnormalities in the ENS are associated with life-threatening GI disorders including, Hirschsprung disease 
and neuropathic chronic intestinal pseudo-obstruction (Gariepy, 2001). Also, the ENS has now also been 
implicated in disorders of the CNS, including ASD, Alzheimer’s disease and Parkinson’s disease, generally 
considered primary disorders of the CNS (Rao and Gershon, 2016). ASD is particularly noteworthy given the 
high level of comorbid GI symptoms observed (Rao and Gershon, 2016) (see Section VIII. A.). Future studies 
are needed to fully appreciate the relative contribution of the microbiota in shaping the pathological effects 
of ENS dysfunction.
C. Immune System and Neuroimmunity
The GI tract harbors the densest concentration of immune cells in the body and is in constant communica-
tion with the trillions of microbes that inhabit our gut, either through direct physical contact or the release 
of secreted compounds (Fig. 4.). As such, one critical function of the single-cell layer of our gut is to limit 
the contact of intestinal microbiota with the visceral tissue, which it does by secreting a protective viscous 
mucus layer from goblet cells of the epithelium. This luminal-mucosal interface is where the majority of 
host-microbe interaction occurs, and the exchange of molecules through the mucous layer and epithelium 
serve to facilitate communication between the gut and the immune system through the recognition of self 
and non-self antigens (Fasano and Shea-Donohue, 2005), and thus to prime the immune system to identify 
potentially harmful pathogens.
As well as providing a physical barrier, the epithelium contains a number of different cell types including en-
terocytes, secretory cells, chemosensory cells and gut-associated lymphoid tissue (Pott and Hornef, 2012). 
The enterocytes express innate immune receptors and can release cytokines and chemokines, while the 
gut-associated lymphoid tissue utilizes lymphocytes to mount a more specific immune response (immuno-
globulins). Chemosensory cells play a key role in defense against helminths (Allaire et al., 2018), while secre-
tory cells are involved in mucus release from goblet cells, the release of antimicrobials from Paneth cells and 
the release of neuroendocrine compounds including ghrelin, somatostatin, cholecystokinin, peptide YY and 
5-HT amongst others from enteroendocrine cells (Cani et al., 2013). 
Peptidoglycans, polysaccharides and other antigens on bacteria that confer beneficial roles for the bacteria 
(protection against degradation) also allows the host immune cells to identify the numerous and diverse 
bacteria to the host, and to identify a change in the homeostatic balance of the gut. Epithelial pattern recog-
nition receptors recognize molecular patterns unique to bacteria and other microorganisms (pathogen-asso-
ciated molecular patterns) (Duerkop et al., 2009; Vaishnava et al., 2008) of which the TLR family are the most 
studied, and once activated can recruit inflammatory mediators, cytokine production and chemokine-medi-
ated recruitment of acute inflammatory cells (Takeda and Akira, 2004). 
Along with activating the innate immune system, many commensal bacteria metabolites including neuro-
modulators, bacteriocins, bile acids, choline and SCFA’s are immunomodulatory (Fig. 4.). A growing body of 
evidence suggests that microbiota-host interactions at the level of the gut leads to the release of cytokines, 
chemokines, neurotransmitters, neuropeptides, endocrine messengers and microbial by-products that can 
infiltrate the blood and lymphatic systems, or influence neural messages carried by the vagal and spinal 
afferent neurons to constantly communicate with the brain and update as to health status, and possibly to 
regulate brain and behavior. However, it seems unlikely that any one of these classes of compounds is individ-
ually responsible for mediating all microbiota-gut-brain interactions and these will be discussed individually 
in subsequent sections. 
Innate Immune System
The immune system is subdivided into two separate subsystems –innate and adaptive/ acquired. Innate im-
munity is regarded as the body’s primary line of defense against potentially infectious organisms and involves 
the activity of cells derived from the myeloid lineage – monocytes and macrophages, basophils, eosinophils, 
and neutrophils, in addition to mast cells, platelets, and natural killer cells (Stewart, 2012). The gut microbi-
ota influences the relative populations, migration, and function of various subsets of immune cells including 
Helper T cells, Regulatory T cells, mononuclear phagocytes and innate lymphoid cells (Dorrestein et al., 2014; 
Rooks and Garrett, 2016), and the mechanisms as to how a microbial population of the gut can modulate 
both the innate and adaptive immune responses at mucosal surfaces during infection, inflammation, stress, 
and autoimmunity are being unraveled (Cassel et al., 2008; El Aidy et al., 2015; Kamada et al., 2013a; Mazma-
nian et al., 2005; Powell et al., 2017). However, until recently, the interaction between microbes confined to 
the gut and immune cells of the brain had not been investigated.
As alluded to in earlier sections microbiota-microglia interactions are receiving much attention of late as 
key mechanisms underlying microbiota-immune-brain interactions (Abdel-Haq et al., 2019; Rea et al., 2016; 
Vuong et al., 2017). The CNS-restricted microglia are innate sentinel immune cells that can detect subtle 
changes in the surrounding molecular milieu (Bilbo and Schwarz, 2012; Delpech et al., 2015; Hickman et 
al., 2013; Kim and de Vellis, 2005; Nimmerjahn et al., 2005; Tremblay et al., 2011), and are responsible for 
the mounting of neuroinflammatory responses (Kettenmann et al., 2011; Ransohoff and El Khoury, 2015; 
Yamasaki et al., 2014). These resident cells compromising 5-12% of all cells in the brain are highly ramified 
and extremely plastic, and once activated can release a number of cytokines and chemokines, express nu-
merous antigenic markers, regulate neurotransmitters and undergo extreme morphological changes (Pocock 
and Kettenmann, 2007). Cytokines and chemokines are chemical messengers involved in recruiting other 
immune cells to the vicinity, the repair of damaged tissue and the restoration of homeostasis (Charo and 
Ransohoff, 2006). Cytokines are generally classed as pro-inflammatory or anti-inflammatory, which facilitate 
or inhibit inflammatory processes respectively, and both play an equally important role in the mounting of 
a suitable physiological neuroinflammatory response, and the return to homeostasis. Indeed, the balance 
between these anti- and pro-inflammatory cytokines and chemical messengers are key determinants in an 
appropriate defense of the host against infection or tissue damage. 
Along with their established immune role in the CNS, the constitutively active microglia are critically involved 
in neuronal events at various stages in development and adulthood, including synaptic remodeling to im-
prove neuronal network signaling (Schafer and Stevens, 2015). Recently, it was determined that a diverse 
GI microbiota is necessary for the maintenance of, and maturation of, microglia in a healthy functional state 
(Erny et al., 2015). In contrast, the absence of a complex host microbiota (when using GF animals or antibi-
otic-treated mice) increased microglial populations, caused defects in microglia maturation, activation state 
and differentiation, altered microglia morphology (with longer processes and increased branching, terminal 
points and clubbing at synaptic boutons), and compromised immune response to bacterial or viral infection 
(Erny et al., 2015). These alterations in microglial phenotype were reversed with recolonization of gut mi-
crobiota, following six weeks co-habitation of GF mice with control mice. These findings demonstrate that a 
healthy and diverse GI microbiota is essential for the continuous preservation of healthy microglia and prop-
er brain function throughout our lifespans (Cryan and Dinan, 2015a; Thion et al., 2018).
Aside from releasing cytokines and chemokines to recruit local immune cells, microglia also recruit mono-
cytes from the periphery to the brain to aid in defense and cell debris clearing. While the multimodal in-
fluence of microbiota on physiological events at the level of the CNS has gained credence, more recently 
there has been a shift toward understanding the role of the microbiota in regulating neuroinflammation via 
intervention in the recruitment of local immune regulators (trafficking monocytes) from the periphery to the 
brain (Wohleb et al., 2014). Evidence suggests that the trafficking of these monocytes to the brain appeared 
to be governed by TNFα-mediated microglia activation (D’Mello et al., 2009) and was reversible in preclinical 
studies with probiotic intervention with VSL#3 (D’Mello et al., 2015). Indeed, the mediation of certain be-
havioral phenotypes as a consequence of prolonged HPA axis activation involves the trafficking of monocyte 
from the spleen (Wohleb et al., 2014), a tissue with a high density of free fatty acid receptor type 2 (FFAR2) 
(Erny et al., 2015). These FFAR2 receptors are G-protein coupled receptors that have been localized to pe-
ripheral lymphocytes (Nilsson et al., 2003)FFA2R, expressed on leukocytes and activated by short-chain fatty 
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FAs, the natural ligands for FFARs, which were shown to reverse the detrimental effects on microglia density, 
morphology, and maturity in the absence of a complex microbiota (Erny et al., 2015). Taken together these 
findings suggest that GI microbiota may govern centrally mediated events indirectly through regulation of 
monocyte trafficking to the brain and subsequent microglia activation, possibly via SCFA-mediated mecha-
nisms.
Adaptive Immune System
Adaptive immunity induces a specifically targeted response to pathogens and is comprised of cells originat-
ing in the lymphoid lineage (i.e. B and T lymphocytes). The adaptive immune system distinguishes itself by 
its specialization, specificity, memory, regulation, diversity and tolerance (Vanguri, 2014). Furthermore, these 
cells are also capable of secreting both pro- and anti-inflammatory (Chung, 2009). The adaptive immune sys-
tem develops postnatally and is, therefore, critically shaped by exposure to microbes. Further, disease states 
such as allergy and asthma and/or the immune hypothesis of depression/schizophrenia, are linked to the 
disruption of microbes and immune function. 
Over the last decade, efforts have been made to increase our understanding of the potential role the adap-
tive immune system plays in the brain and behavior (Amor and Woodroofe, 2014; Filiano et al., 2015; Mon-
teiro et al., 2016). Recent intriguing studies in recombination activation gene 2 knockout (Rag2) transgenic 
mice, which lack mature B and T lymphocytes , showed that adoptive transfer of lymphocytes from stressed 
mice reduced anxiety, increased social behavior, and increased hippocampal cell proliferation compared with 
those receiving no cells or cells from unstressed donors (Brachman et al., 2015), and that transferred lym-
phoid cells infiltrate the choroid plexus and the meninges (Scheinert et al., 2016). Recently, intraepithelial 
lymphocytes (CD4CD8αα+ double-positive T cells specifically) were shown to require the presence of L. reu-
teri, in combination with a tryptophan-rich diet, to reprogram intraepithelial CD4+ T cells into immunoregu-
latory T cells (Cervantes-Barragan et al., 2017), evidence that gut microbiome influences/interacts with the 
adaptive immune system. Further, Drosophila social behavior appears to be regulated through immunoregu-
lation and microbiota maintenance (Chen et al., 2019).  This finding reveals that adaptive immune cells might 
be mediating the behavioral response to stress thus representing an interesting novel pathway, which needs 
to be further explored.
Interestingly, adaptive immunity and the intestinal microbiota also seem to be acting synergistically towards 
modulating homeostasis. IgA plasma cells from the gut are able to access the CNS in the induction of ex-
perimental autoimmune encephalomyelitis multiple sclerosis mouse model, and that these cells suppress 
inflammation in a pathway that involves IL-10 (Rojas et al., 2019). In Rag2 transgenic mice, adaptive immunity 
influences microbiota composition (Galvez et al., 2017). A link between stress, the microbiota, and the adap-
tive immune system has been illustrated in a recent study examining the impact of chronic stress on long-last-
ing altered levels of IL-10+ T regulatory cells (Bharwani et al., 2016). The expression of IL-10 was associated 
with an increased abundance of Clostridium, therefore reinforcing the hypothesis that microbes in the gut, 
the adaptive immune system, and the central nervous system may be working synergistically. Subsequently, 
it was shown that the impairment in the adaptive immune system in Rag1 transgenic mice is linked to alter-
ations in cognition and anxiety-like behavioral tasks, which were ameliorated by treatment with a combina-
tion of L. rhamnosus and L. helveticus. This study, therefore, establishes that lymphocyte deficiency results 
in impairments in behavior, which can be normalized by probiotic treatment, implicating a specific role of 
adaptive immunity in the microbiota-gut-brain axis (Smith et al., 2014). Adaptive immunity has also been 
shown to respond to specific bacterial antigens which are modulated by dietary components, suggesting 
that dietary modifications could be a therapeutic avenue for human disease such as IBD (Wegorzewska et al., 
2019). A link between the adaptive immune system, IFNy signaling in the meninges, and social behavior was 
also illustrated (Filiano et al., 2016). This study showed how IFNy acts as a link between meningeal immunity 
and neural circuits recruited for social behavior. Given the importance of the microbiome in shaping social 
behavior (see Section X.B) further studies should focus on the possible role of the microbiome in shaping 
such immune-brain communication.
K. Enteroendocrine Signaling
Though enteroendocrine cells (EECs) represent only 1% of epithelial cells in the GI tract, they are critically 
important for the maintenance of gut homeostasis due to the pleiotropic effects of their secreted signaling 
molecules. Ten different types of EECs have been described so far, all of which are sensory cells, coordinating 
changes in the gut-nutrient luminal content with metabolic and behavioral responses, such as the regulation 
of insulin secretion or food intake (Gribble and Reimann, 2016). Two of the best understood EEC’s are en-
teroendocrine L cells and enterochromaffin cells which are abundant in the distal small and large intestines, 
where the majority of bacterial taxa reside. They can establish direct contact with the luminal constituents 
via the apical surface, including bacterial metabolites. They have a long lifespan (Bohorquez et al., 2015; 
Tsubouchi and Leblond, 1979), potentially enabling them to integrate into the local signaling network of the 
enteric nervous system, glia and immune cells of the GI submucosa.
Enteroendocrine L cells
Enteroendocrine L cells secrete glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) in the postprandial 
state. Both peptides are potent anorexigenic hormones involved in the modulation of eating. The receptors 
to these peptides are expressed locally in the gut enteric neurons and vagal afferents, as well as in the central 
nervous system (CNS), including the brainstem and hypothalamus (De Silva and Bloom, 2012; Richards et al., 
2014). GLP-1 and PYY can stimulate satiation and inhibit eating, acting either directly on the hypothalamic 
centers of appetite control, or indirectly via the vagal-brainstem-hypothalamic pathway (Latorre et al., 2016; 
Steinert et al., 2017). Which of these pathways is more important for the effects of peripherally released 
hormones on food intake is still not fully understood. Notably, a new route of communication between L 
cells and the enteric nervous system has recently been discovered (Bohorquez et al., 2014; Bohorquez et al., 
2015; Kaelberer et al., 2018). A basolateral cytoplasmic process of the L cells – the neuropod – was shown 
to establish a functional synaptic contact with the enteric glia and vagal afferents. The existence of synaptic 
connections between L cells and the ENS suggests that the EECs signaling from the gut to the brain can re-
spond more precisely and much faster than we initially thought and that the CNS can have a tuning effect on 
the L cells.
In the proximal gut, the release of GLP-1 and PYY is activated mainly by luminal nutrients, providing a post-
prandial spike of peptide release. For instance, L cells can sense carbohydrates via the sodium-coupled glu-
cose transporter (SLC5A1) (Gorboulev et al., 2012; Reimann et al., 2008), long-chain fatty acids via FFAR1 and 
FFAR4 receptors (Edfalk et al., 2008; Hirasawa et al., 2004), and monoacylglycerols via the GPR119 receptor 
(Reimann et al., 2008). Strikingly, in the distal gut, the activation of L cells is triggered almost exclusively by 
bacteria-derived metabolites. Moreover, SCFAs can stimulate the secretion of GLP-1 and PYY through the 
FFAR2 and, to a lesser extent, the FFAR3 receptor (Lin et al., 2012; Psichas et al., 2015; Tolhurst et al., 2012). 
Bacteria-derived secondary bile acids (lithocholic acid, deoxycholic acid) can activate the G-protein coupled 
bile acid receptor Gpbar1 receptor (TGR5) in L cells, promoting the peripheral release of GLP-1 and PYY 
(Katsuma et al., 2005; Thomas et al., 2009; Ullmer et al., 2013). Indole was shown to induce GLP-1 secretion 
(Chimerel et al., 2014). Further, bacterial LPS were recently shown to enhance GLP-1 secretion, suggesting 
the involvement of TLR’s in L cell activity (Larraufie et al., 2017; Nguyen et al., 2014).
Because bacterial fermentation of non-digested nutrients continues between meals, bacterial metabolites 
can support the activity of colonic L cells and the secretion of anorexigenic hormones for many hours after a 
meal (Gribble and Reimann, 2016). This basal secretion of GLP-1 and PYY is thought to play an important role 
in the control of food intake, body weight, and metabolism since obese individuals are generally character-
ized by decreased serum levels of both GLP-1 and PYY (De Silva and Bloom, 2012). Changing the fermentation 
capacity of the gut microbiota through chronic dietary supplementation of prebiotics or probiotics was quite 
successful in decreasing food intake, body weight and improving glucose tolerance in preclinical models of 
obesity and diabetes (see Tables 4, 5; for further details, see review (Plovier and Cani, 2017)). Some prebi-
otics, a polysaccharide inulin as well as FOS and GOS were shown to increase the production of both GLP-1 
and PYY (Cani et al., 2005; Everard et al., 2011). Certain Lactobacillus strains were capable of stimulating 
GLP-1 production both in vitro and in vivo (Balakumar et al., 2018; Panwar et al., 2016; Simon et al., 2015). 
Altogether, these findings clearly demonstrate the importance of bacterial metabolites and adequate diet 
in the maintenance of metabolic health, and that gut microbes can regulate the secretion of GLP-1 and PYY. 
Although EEC L cells are perhaps the best-studied component of the host-microbe dialogue at the entero-
endocrine interface other protagonists have also emerged. Autoantibodies directed against the peptide 
α-Melanocyte-stimulating hormone (α-MSH), which is involved in appetite control, have been discovered 
in both healthy individuals and in subjects with eating disorders (Fetissov et al., 2002; Fetissov et al., 2008). 
Many of these antibodies represented the IgA class, which points to an intestinal origin of such antigens. 
This was a genuinely intriguing discovery because it raised the possibility that across evolution, in close 
interactions with the host, bacterial taxa could have acquired protein mimetics of mammalian appetite-reg-
ulating hormones. This endows gut bacteria with a powerful tool to control nutrient supply by manipulating 
host food intake. A few years later a caseinolytic protease B (ClpB) heat-shock protein was discovered in gut 
commensal E. coli, an antigen-mimetic of α-MSH which confirmed this hypothesis (Tennoune et al., 2014). 
Moreover, it was shown that ClpB plasma levels were elevated in a variety of eating disorders, and its concen-
tration has been correlated with various psychopathologic traits (Breton et al., 2016a). Moreover, chronic in-
tragastric delivery of ClpB-expressing E. coli in mice stimulated the production of α-MSH-reactive antibodies 
and decreased food intake (Breton et al., 2016b; Tennoune et al., 2014). Interestingly, peripheral α-MSH was 
shown to trigger the release of PYY and GLP-1 from EEC L cells in the gut via activation of the melanocortin 
4 receptor (Panaro et al., 2014). This suggests PYY and GLP-1 could mediate the effects of bacterial ClpB on 
satiety. These ground-breaking findings posit that evolution of molecular mimicry between gut bacteria and 
the host (Oldstone, 2005) can affect host eating behavior. Most intriguingly, humans seem to carry autoanti-
bodies to some appetite-regulating peptides including PYY and ghrelin (Fetissov et al., 2008), and the corre-
sponding bacterial antigens, as well as their physiological role, have yet to be unraveled.
Enterochromaffin Cells
Enterochromaffin cells (ECs) produce the majority of 5-HT in the body from dietary tryptophan (see also Sec-
tion VII E). 5-HT activates a diverse family of receptors on intrinsic and extrinsic afferent nerve fibers in the 
GI tract and mediates many GI functions including intestinal peristalsis, electrolyte secretion, pain perception 
and inflammatory responses (Mawe and Hoffman, 2013). Unlike L cells, interactions between gut microbiota 
and ECs are much less understood.
Taking advantage of GF mice, recent studies have shown that specific gut bacterial strains, such as the 
spore-forming clostridia taxa, can up-regulate the expression of colonic TPH1 (the rate-limiting enzyme in the 
production of 5-HT), boosting 5-HT biosynthesis in the gut, and increasing intestinal transit in the host (Reig-
stad et al., 2015; Yano et al., 2015). It is unclear whether this was a direct interaction of bacteria with ECs or 
indirect stimulation of ECs with bacterial metabolites. However, a single intrarectal injection of deoxycholic 
acid (a secondary bile acid produced by clostridia) could partially replicate the effects of the bacteria (Yano et 
al., 2015). Interestingly, earlier findings suggest that secondary bile acids can mediate the effect of gut bac-
teria on 5-HT synthesis in the host. ECs were shown to express TGR5, and administration of deoxycholic acid 
increased 5-HT secretion in colonic tissue of the wild-type, but not Tgr5 transgenic mice (Alemi et al., 2013). 
There is also evidence that bacterial LPS can increase 5-HT secretion via TLR4 activation in ECs isolated from 
Crohn’s disease patients, but not from healthy subjects (Kidd et al., 2009). 
Variations in intestinal 5-HT production are unlikely to have a direct effect on the brain because 5-HT cannot 
cross the BBB (Donovan and Tecott, 2013). The availability of tryptophan for the brain, as a source for 5-HT 
synthesis, is also partially determined by the metabolism of tryptophan along the physiologically dominant 
kynurenine pathway (Kennedy et al., 2017) (see Section IV.E.). However, by modulating vagal afferent activity 
(Mawe and Hoffman, 2013) and inflammatory responses in the gut (Shajib et al., 2017), 5-HT released from 
EC cells can potentially have an impact on gut-brain signaling. Perhaps the best-known example of such an in-
teraction is during chemotherapy-induced nausea and emesis, caused by a massive release of intestinal 5-HT 
and consequent activation of vagal afferents in the gut (Gale, 1995). More recently, altered 5-HT signaling 
has been associated with IBS (Mawe et al., 2006) (see Section VIII.M.). Moreover, in a mouse model of ASD 
(the BTBR T+ Itpr3tf/J mouse), (see section VIII.A.) (Kong et al.; Meyza et al., 2013; Moy et al., 2007), a strong 
association between the reduction in the relative abundance of Blautia species from Clostridiales order and a 
decrease in 5-HT production in the gut was observed (Golubeva et al., 2017). Further studies utilizing specific 
bacterial strains with pro-5-HT activity (such as bile-metabolizing clostridia) are required to shed more light 
on the role of gut microbiota and intestinal 5-HT in gut-brain communication.
Adding to the complexity of this task, it is worth noting that EC-produced 5-HT is not only secreted towards 
the intestinal submucosa, but a substantial amount of 5-HT is continuously released in the apical direction, 
which can be easily detected in the gut lumen (Patel, 2011). Furthermore, gut bacteria were shown to decon-
jugate host-produced catecholamines via the β-glucuronidase enzyme pathway, and thus generate free lumi-
nal 5-HT (Asano et al., 2012; Hata et al., 2017). The physiological consequences of these processes, either for 
the host or the microbiota, are not yet known or will be the subject of future studies.
L. Neurotransmitters
Microbial endocrinology is becoming an important concept in advancing our knowledge of the microbio-
ta-gut-brain axis, helping move our understanding from correlation to causation (Lyte, 2014). One of the 
main facets of the concept of microbial endocrinology is based on the shared neurochemical language that 
exists between host and microbe. It has been long understood that microbes are capable of producing neu-
rochemicals that we typically associate with mammalian organisms. Landmark studies in the 1990s were 
the first and demonstrate that bacteria respond to host neuroendocrine signaling molecules (Lyte and Ernst, 
1992, 1993), including norepinephrine and epinephrine, and that the microbiota can affect host behavior 
via the gut-brain axis (Lyte et al., 1998). Since that time, the microbiota has been shown to synthesize and 
respond to several key neurochemicals (e.g. 5-HT, GABA, amongst others) that are involved in host mood, be-
havior, and cognition. Many of these host- and microbial-derived neuroactive molecules are also important 
signaling molecules in host-microbiota interactions at the intestinal interface.
Catecholamines
Catecholamines play diverse roles in host physiology, ranging from the stress-induced fight-or-flight response 
(Starkman et al., 1990) to influencing gut integrity (Meddings and Swain, 2000) and affecting host motiva-
tional behavior as well as decision-making (Terbeck et al., 2016). Likewise, norepinephrine and epinephrine 
induce wide-ranging responses in bacteria, including the promotion of pathogenesis and growth (Lyte et al., 
2016). The catecholaminergic system was one of the first demonstrated to mediate host-microbe cross-talk, 
and holds important clinical implications for both animals and humans (Lyte, 1993). Although it was previous-
ly accepted that susceptibility to illness following acute stress was a consequence of a suppressed immune 
system, it was shown that the host production of norepinephrine caused the induction of bacterial virulence 
genes, thereby driving infection and mortality (Lyte, 2014). Norepinephrine signals these changes in bacteria 
via several methods, including possible receptor-based mechanisms. At increasing levels within the host, 
norepinephrine exerts a chemotactic effect on bacteria, which can increase bacterial migration toward the 
host intestinal mucosa (Lyte et al., 2018). Second, catecholamines can behave as siderophores, which cause 
the release of iron from host-iron sequestering proteins, increasing the availability of iron for bacteria, there-
by enhancing bacterial growth (Freestone et al., 2012). Also, norepinephrine can act as a quorum sensing 
molecule to increase the expression of bacterial virulence genes through interaction with bacterial quorum 
sensing histidine kinase (Curtis et al., 2014; Moreira et al., 2016). In GF rodents circulating norepinephrine 
concentration is higher compared to conventional rodents (Kingsley et al., 1991), and within ileal, cecal, and 
colonic lumens, dopamine, norepinephrine, and epinephrine are detectable (Asano et al., 2012). 
Enteric nerves contain the requisite genetic machinery to synthesize dopamine and norepinephrine, but 
lack phenylethanolamine N-methyltransferase, the enzyme that converts norepinephrine into epinephrine 
(Costa et al., 2000). This is an important consideration because the microbiota, and in particular the bacterial 
enzyme β-glucuronidase, have been demonstrated to play a critical role in converting host norepinephrine 
and dopamine from a biologically-inactive to a biologically-active form (Asano et al., 2012). It was recently 
demonstrated that certain bacteria contain plasma membrane monoamine transporter and organic cation 
transporter proteins which enable the transfer of extracellular norepinephrine into the bacterial cell (Lyte 
and Brown, 2018). 
A variety of bacteria, many of which are found within the human GI tract, are recognized to produce cate-
cholamines that are identical in chemical structure to those produced by the host. Evolutionary adaptations, 
including late horizontal gene transfer (Iyer et al., 2004), have been proposed to explain bacterial metabolic 
pathways of neuroendocrine molecules. Briefly, members of the genus Escherichia, including human gut 
commensals, are known to produce catecholamines, such as norepinephrine (Shishov et al., 2009). Bacillus 
are likewise known to produce norepinephrine in addition to dopamine (Tsavkelova et al., 2000). Although 
several host cell types in the GI tract are responsive to catecholamines (Bellono et al., 2017), it is largely un-
known how catecholamines of bacterial origin influence host physiology.
Gamma-amino-butyric acid (GABA)
Both host and bacteria have the capacity to convert the amino acid glutamate to GABA (Smith et al., 1992; 
Strandwitz et al., 2019), the major inhibitory neurotransmitter of the host nervous system. Indeed, Escherich-
ia spp. (Richard and Foster, 2003) and Lactobacillus spp. (Siragusa et al., 2007) have been demonstrated to 
synthesize GABA. Additionally, several fermented foods used by Lactobacillus spp. also contain millimolar lev-
els of GABA, such as the Chinese paocai (Li et al., 2008). Interestingly, certain Lactobacillus spp. identified in 
fermented foods are also known to synthesize glutamic acid (Zareian et al., 2012). Although the importance 
of the bacterial production of GABA in the host intestinal lumen is unclear, GF mice exhibit significantly lower 
luminal GABA levels compared to mice that have a microbiota (Matsumoto et al., 2012). Interestingly, it has 
been shown that the probiotic E. coli strain Nissle 1917 (EcN) can produce a GABA associated analgesic lipo-
peptide, C12AsnGABA OH (Perez-Berezo et al., 2017). They were able to demonstrate that the addition of the 
C12AsnGABA OH moiety to GABA facilitated diffusion across the epithelial barrier, allowing the activation of 
GABA receptors on sensory neurons. It is currently unknown if this is a common feature of other microorgan-
isms in the GI tract. In a study examining Lactobacillus spp. and Bifidobacterium spp. isolated from the human 
GI tract, five strains were found to convert GABA from monosodium glutamate (Barrett et al., 2012). Recently, 
evidence from the Human Microbiome Project has suggested the fecal microbiome contains the capacity to 
encode glutamate decarboxylase, the enzyme that converts glutamic acid to GABA (Pokusaeva et al., 2017). 
The oral administration of B. dentium, a GABA-producing bacterial species isolated from human feces, was 
shown to inhibit visceral hypersensitivity in rats suggesting functional insight into the in vivo function of bac-
terial-produced GABA (Pokusaeva et al., 2017). Likewise, bacteria express receptors capable of sensing extra-
cellular, GABA (Guthrie and Nicholson-Guthrie, 1989). It is therefore likely that host production of GABA can 
influence the microbiota. Indeed the administration of GABA to Pseudomonas aeruginosa culture has been 
demonstrated to increase the organism’s virulence (Dagorn et al., 2013). Further studies are required to re-
veal the functional dynamics and importance of glutamate and GABA as mediators of host-microbe crosstalk.
Histamine
Histamine is a biogenic amine that is synthesized from histidine via histidine decarboxylase. This enzymatic 
pathway is conserved among mammals and certain species of bacteria, and therefore represents an import-
ant area of host-microbe communication (Bailey et al., 2011). In mammals, histamine plays several roles in 
host physiology including modulating wakefulness (Thakkar, 2011) as well as a diverse array of immune func-
tions. Several host immune cell-types synthesize histamine, including mast cells and gastric enterochromaf-
fin-like cells (Andersson et al., 1998), which are found in the GI mucosa, are at the interface of host-microbe 
interaction. Mucosal mast cell degranulation within the gut can affect host intestinal integrity (Santos et al., 
2001) and has been related to visceral pain (Barbara et al., 2004). The bacterial production of histamine has 
long been recognized as an important food safety concern (Colombo et al., 2018). Interestingly vagal afferents 
can respond to histamine (Keita and Soderholm, 2010), suggesting a route by which microbial-derived hista-
mine may interact with the host nervous system. Although the microbiota contains bacterial species capable 
of synthesizing histamine, it is not yet clear how this influences host physiology. For example, commensals 
Morganella morganii and E. coli, have been shown to produce biogenic amines (Pugin et al., 2017), including 
histamine (Behling and Taylor, 1982; Kim et al., 2000). Indeed, the human fecal microbiota is enriched with 
bacterial species that express the histidine decarboxylase gene, suggesting a capacity to synthesize hista-
mine within the host gut (Barcik et al., 2016). Although little is known about how the microbial production 
of histamine in the host gut affects host physiology, in vitro evidence has shown histamine produced by L. 
reuteri suppressed human monocytoid production of tumor necrosis factor (TNF)-α via the TLR (Thomas et 
al., 2012). Perhaps most interestingly, L. reuteri was shown to modulate host gut immune function (Ferstl et 
al., 2014), as well as intestinal inflammation via the histamine H2 receptor (Gao et al., 2015). It is clear that 
histamine functions as a neuroendocrine-immune mediator of host-microbe crosstalk; however, how host 
histamine may impact microbial function remains to be uncovered.
Serotonin, Tryptophan, and Kynurenine
Serotonin (5-HT) is a neurotransmitter produced from tryptophan via the enzyme tryptophan hydroxylase 
(TPH). The capacity to synthesize 5-HT from tryptophan is widely conserved among mammals and several 
bacterial species (Bailey et al., 2011). In mammals, 5-HT plays diverse roles ranging from modulation of host 
behavior to impacting GI motility as well as influencing bone remodeling and erythrocyte health (Spohn and 
Mawe, 2017). Although enterochromaffin (EC) cells of the GI tract are responsible for over 95% of the body’s 
5-HT production (Foster et al., 2017), the gut microbiota are understood to impact the host GI serotonergic 
system (Hata et al., 2017; O’Mahony et al., 2015). Indeed, it has been long appreciated that the bacterial 
species C. perfringens, a member of the human and rodent microbiota, modulates gut production of 5-HT 
(Beaver and Wostmann, 1962). It was recently demonstrated that C. perfringens modulates host colonic 5-HT 
synthesis via host TPH-1 (Yano et al., 2015). Since microbial products such as SCFAs modulate host TPH-1 
(Reigstad et al., 2015), there may be microbial regulation of host GI motility via the gut serotonergic system 
(Ge et al., 2018). Likewise, 5-HT concentrations in the cecal and colonic lumens are significantly reduced in 
GF mice (Hata et al., 2017). The conventionalization of GF mice with a microbiota resulted in increased con-
centrations of intestinal luminal 5-HT. Moreover, in the same study, the conjugated, biologically inactive form 
of 5-HT was found at a higher percentage in GF mice, whereas the unconjugated, biologically-active form of 
5-HT was found in greater concentration in conventionalized GF mice. Indeed, transporter-based mechanisms 
for the update of extracellular 5-HT were recently highlighted in a probiotic strain of Lactobacillus. As a neu-
roendocrine signal of host-microbe crosstalk, 5-HT has been shown to modulate bacterial motility and induce 
the expression of virulence genes in bacteria via a quorum-sensing mechanism (Biaggini et al., 2015; Knecht 
et al., 2016). GF animals exhibit increased circulating tryptophan levels, which are corrected following colo-
nization with a microbiota (Clarke et al., 2013). This was associated with elevated hippocampal 5-HT, which 
was not corrected by colonization. GF rats, on the other hand, have reduced circulating 5-HT levels (Wikoff et 
al., 2009), as well as reduced 5-HT in the hippocampus (Crumeyrolle-Arias et al., 2014). As the serotonergic 
system is involved in several human behavioral and physical maladies (see Section VIII), it has become ever 
more important to understand how the microbiota influence 5-HT along the microbiota-gut-brain axis.
Tryptophan can be diverted away from 5-HT production, into the kynurenine pathway. Indeed, it has been 
estimated that approximately 90% of available tryptophan is funneled towards the production of kynurenine 
(O’Mahony et al., 2015; Ruddick et al., 2006). This activity consists of several enzymatic steps that can differ 
depending on tissue type. For example, indoleamine-2,3-dioxygenase (IDO-1) is found in most tissues includ-
ing the intestine, and tryptophan-2,3-dioxygenase (TDO) is found in the liver (Badawy, 2017). Kynurenine 
and its metabolites, including kynurenic acid and quinolinic acid, have been implicated in mental health (Cer-
venka et al., 2017; Schwarcz et al., 2012). In GF mice, there is reduced metabolism of tryptophan along the 
kynurenine pathway, which is likely partly responsible for the increased circulating availability of tryptophan 
(Clarke et al., 2013; Kennedy et al., 2017). Importantly, hepatic TDO is strongly regulated by glucocorticoids 
(Danesch et al., 1983; Ohta et al., 2017), while IDO is immune responsive. Since the microbiota modulates 
host circulating glucocorticoids and their production in response to stress (Sudo et al., 2004), as well as 
educating the immune system, the microbiota may indirectly affect host kynurenine production via gluco-
corticoid control of liver TDO (Badawy, 2017; O’Farrell and Harkin, 2017) or immune-based IDO activation 
(Strasser et al., 2017). Moreover, a correlation was seen between the reduction of L. reuteri in mice following 
chronic stress with an increase in serum kynurenine concentrations, mediated via a proposed mechanism 
based on bacterial-regulation of GI IDO via H2O2 production (Marin et al., 2017). This is consistent with the 
fact that kynurenine pathway enzymes such as IDO are sensitive to the redox environment (Gonzalez Esquiv-
el et al., 2017). 
In addition to the metabolic pathways leading to the production of 5-HT and kynurenine, microbial-derived 
indole derivatives of tryptophan are increasingly recognized as vital in the crosstalk between microbiota and 
host (Agus et al., 2018). For example, indole production from the bacterial metabolism of L-tryptophan can 
result in diverse changes in host physiology. It can be further metabolized by the host and/or microbial path-
ways into biologically active metabolites (Lee et al., 2015). Indeed, indole has been demonstrated to affect 
host intestinal epithelial barrier integrity (Bansal et al., 2010), modulate intestinal inflammation (Lamas et 
al., 2016) and protect against mortality following chemically-induced colitis (Shimada et al., 2013), as well as 
positively affect host longevity (Sonowal et al., 2017). In human feces, indole is detectable at micromolar con-
centrations (Darkoh et al., 2015), thereby warranting increased translational investigation of indole effects 
on host-microbe crosstalk in humans. Recently, microbial metabolites derived from tryptophan have been 
implicated in microglial control of astrocytes in the CNS (Dodd et al., 2017).
Indole-3-propionic acid and other biologically-active compounds are produced in the liver from microbio-
ta-derived indole, supplied via hepatic portal circulation (Lee et al., 2015). Indole-3-propionic acid has also 
been reported to be produced by C. sporogenes (Dodd et al., 2017) and is usually undetectable in GF animals. 
GF mice were found to only have indole-3-propionic acid following colonization with C. sporogenes (Wikoff 
et al., 2009). Indole-3-propionate has been shown to affect host intestinal inflammation and to be reduced 
in patients with active colitis (Alexeev et al., 2018). Also, indole-3-propionic acid may affect other aspects of 
host physiology, including glucose metabolism (Abildgaard et al., 2018).
 
Isatin, another bacterial and host metabolite of indole (Gillam et al., 2000) has been demonstrated to af-
fect anxiety-like behavior in rodents (Jaglin et al., 2018). Interestingly, isatin is detectable in a range of host 
tissues, including human cerebral spinal fluid and the hippocampus (Medvedev et al., 2007), and has been 
shown to be elevated in patients diagnosed with bulimia nervosa (Brewerton et al., 1995). Although isatin 
has been reported in micromolar concentrations in both blood and host tissues (Medvedev et al., 2007), 
the precise details of the pathway control points (be they microbial, host or at the host-microbe interface) 
leading from microbial-produced indole to the subsequent potential impact of isatin on host health, brain 
and behavior, such as anxiety, remain unclear. Indole metabolites have also been recognized to act on the 
aryl hydrocarbon receptor, a xenobiotic receptor distributed throughout the GI tract (Lee et al., 2015). Mi-
crobial-endocrinology-based media has recently been developed to study the production mechanisms of 
microbial neuroendocrine signals within different host-simulated environments (Villageliu et al., 2018) and 
may help shed some light on this important issue.
In addition to bacterial-derived indole and its byproducts, the gut microbiota is also associated with the pro-
duction of tryptamine from tryptophan, a monoamine similar to 5-HT, and at least 10% of the human popula-
tion have the necessary gut microbiota decarboxylases for this reaction (Williams, 2014). Although there are 
data from neuropharmacological and electrophysiological studies to suggest that it might activate postsyn-
aptic receptors for tryptamine independent of those for 5-HT, its CNS function remains unclear (Jones, 1982). 
Much attention has been directed towards the GI tract, in which tryptamine activates the 5-HT4 receptor 
expressed in the colonic epithelium to control colonic transit (Bhattarai et al., 2018; Cryan et al., 2018).
M. Branched Chain Amino Acids (BCAAs)
Branched-chain amino acids (BCAAs), such as valine, leucine, and isoleucine are considered essential amino 
acids because they cannot be synthesized de novo and must be obtained from the diet. They participate 
indirectly and directly in a variety of biochemical functions in the peripheral and central nervous systems 
(Brosnan and Brosnan, 2006; Fernstrom, 2005; Sperringer et al., 2017). These include protein synthesis, insu-
lin secretion, energy production, brain amino acid uptake, and immunity in humans and animals. In addition, 
BCAAs are considered key nitrogen donors involved in inter-organ and intracellular nitrogen shuttling. The liv-
er and skeletal muscle play a role in inter-organ shuttling of BCAA nitrogen, whereas in the brain intercellular 
shuttling is predominant (Sperringer et al., 2017). Although vital for normal physiological function, excessive 
amounts of BCAAs are considered toxic and can cause severe tissue damage, especially to the CNS, as evi-
denced from the neuropathology associated with maple syrup urine disease, an autosomal recessive met-
abolic disorder affecting BCAA levels (Menkes et al., 1954). Further, disruption of BCAA levels by branched 
chain ketoacid dehydrogenase kinase and SLC7A5 mutations has been shown to have extensive implications 
for survival and function of several neuronal circuits (Novarino et al., 2012). 
BCAAs and other large neutral amino acids are transported quite readily across the BBB for transamination 
or delivery to neurons (Conway and Hutson, 2016; Oldendorf, 1971). However, the influx of leucine exceeds 
that of all others (Smith et al., 1987; Yudkoff, 1997). BCAAs also act as a regulator to promote intestinal de-
velopment, nutrient transporters, and immune-related function. 
Gut bacteria produce a higher proportion of BCAAs relative to the other amino acids but whether this influ-
ences host BCAAs availability remain to be determined (Dai et al., 2011; Neis et al., 2015), although a num-
ber of amino acids are altered in GF animals (Wikoff et al., 2009). Microbial-derived BCAAs include valerate, 
isobutyrate, and isovalerate. Notably, these bacterial metabolites have been shown to influence epithelial 
physiology and the mucosal immune system of the host (Blachier et al., 2007; Schaible and Kaufmann, 2005). 
It has been shown that the addition of BCAA’s to trypticase yeast extract increases the yield of BCAA’s in 
Clostridia (Elsden and Hilton, 1978) suggesting that amino acids can be used for SCFA and BCAA production 
by gut bacteria. Interestingly, supplementation with a BCAA cocktail has been shown to promote well-being 
and extend the lifespan of mice (D’Antona et al., 2010) similar to the benefits conferred by caloric restriction 
(Guarente, 2008; Valerio et al., 2011). A recent study showed that caloric restriction could establish a struc-
turally balanced composition of the gut microbiota in mice indicating a potential association between caloric 
restriction, BCAA supplementation and the gut ecosystem (Zhang et al., 2013). Further, BCAA mixture sup-
plementation has been shown to influence gut microbiota and metabolism (Yang et al., 2016). At 15 months 
of age, BCAA mixture -supplemented BALB/c mice compared with the control group was showed to display 
decreased Bacteroidetes and increased Firmicutes phyla (Yang et al., 2016). The decrease of Bacteroidetes 
phylum was related to reduced LPS-binding protein leading to reduced inflammation in BCAA mixture -sup-
plemented mice (Raio and Phelps, 2015; Yang et al., 2016). Other findings have reported a strong relationship 
between changes in Firmicutes:Bacteroidetes ratio and obesity (Castaner et al., 2018). Interestingly, previous 
studies have found that BCAA supplementation modulates the expression of endogenous intestinal β‑Defen-
sin, which can regulate porcine LPS (Ren et al., 2016). Consistent with the role BCAAs play in inflammatory 
disorders, acute amino acid starvation was reported to suppress intestinal inflammation via a mechanism de-
pendent on the serine/threonine-protein kinase general-control-nonderepressible 2 (GCN2), an amino acid 
deficiency sensing enzyme (Ravindran et al., 2016). More recently, the role of amino acids was associated 
with assessing seizure susceptibility. Specifically, it was demonstrated that the restriction of peripheral keto-
genic amino acids is necessary for mediating microbiota- and ketogenic diet-dependent increases in seizure 
resistance (Olson et al., 2018). 
N. Bile Moieties
Bile acids are best known for facilitating the absorption of dietary lipids and lipid-soluble vitamins from the 
gut lumen. Primary bile acids are synthesized in the liver from cholesterol: cholic acid and chenodeoxycho-
lic acid in humans, and cholic acid and α/β-muricholic acid in mice (Russell, 2003). After conjugation with 
either taurine or glycine, primary bile acids are released into the intestine to assist with lipid digestion and 
are recycled back into the liver (Thomas et al., 2008). Bile acids have been recognized as potent and versatile 
signaling molecules in and around the GI tract. By activating nuclear farnesoid X receptor (FXR) and plasma 
membrane TGR5 receptor, bile acids were shown to regulate systemic lipid, cholesterol, and glucose metab-
olism, as well as energy and immune homeostasis (Calmus and Poupon, 2014; de Aguiar Vallim et al., 2013; 
Thomas et al., 2008). 
Recent advances in deciphering genome and metabolic capacities of the gut microbiota have shown bidirec-
tional communication between the host bile system and gut bacteria, potentially leading to neural modula-
tion. On the host side, bile acids help to limit the expansion of the bacterial population within the GI tract. 
Deficits in luminal bile acid levels have been associated with small intestine bacterial overgrowth, activation 
of inflammation, and subsequent damage to the epithelium (Inagaki et al., 2006; Lorenzo-Zuniga et al., 2003). 
Bile acids can exert antimicrobial effects directly, due to their membrane-solubilizing properties (Begley et 
al., 2005). Furthermore, by activating FXR signaling, bile acids can induce the expression of anti-microbial 
defense genes in the host (such as the inducible isoform of nitric oxide synthases - iNOS, and the antibacte-
rial lectin - RegIIIγ) protecting the gut from epithelial deterioration and bacterial translocation (Inagaki et al., 
2006; Joyce et al., 2014). These findings suggest that bile acids act as an important component of intestinal 
antimicrobial defense.
On the bacterial side, selective pressure of conjugated bile acids has favored the expansion of bile-metabo-
lizing bacterial taxa in the human gut. Strikingly, all major gut-associated bacterial divisions, including Lacto-
bacillus, Bifidobacterium and Bacteroidetes taxa, were shown to express bile salt hydrolase (BSH) enzymes 
which allow de-conjugation of bile acids from taurine and glycine (Begley et al., 2006; Jones et al., 2008). 
Bacteria with BSH activity have benefited from enhanced tolerance against bile and better survival in the gut 
environment (Begley et al., 2006; Devkota et al., 2012). The expansion of microbial BSH activity has increased 
the diversity of bile acids in the host (Joyce and Gahan, 2016). De-conjugated bile acids are less effectively 
re-absorbed from the small intestine and thus can leak into the large intestine, as recently reviewed (Hegyi 
et al., 2018). Numerous studies have explicitly demonstrated that bacteria-mediated transformation of host 
bile has a notable impact on host physiology, regulating bile acid and cholesterol metabolism, host energy 
balance and weight gain (Hartmann et al., 2018; Pathak et al., 2018; Sayin et al., 2013; Wahlstrom et al., 
2016).
From the perspective of microbiota-gut-brain signaling, the role of bile acids in the regulation of barrier func-
tion and immune status of the GI tract is of particular interest. Activation of TGR5 has generally been associ-
ated with anti-inflammatory effects and protective features towards the intestinal epithelium (Sarathy et al., 
2017; Ward et al., 2017). The beneficial effects of TGR5 activation are at least in part mediated through direct 
action on the GI immune system (Biagioli et al., 2017; Cipriani et al., 2011; Haselow et al., 2013; Ichikawa et 
al., 2012). Multiple reports regarding TGR5 function (Gadaleta et al., 2011; Hartmann et al., 2018; Inagaki et 
al., 2006; Vavassori et al., 2009) have indicated that a very fine balance between host- and microbiota-pro-
duced bile acids is required to support epithelial barrier function and control the inflammatory response in 
the intestine. Maintenance of epithelial integrity is critically important not only for the gut but also for brain 
health (see Section VIII). To this end, alterations in gut microbiota composition which result in changes to the 
repertoire of bile acids present can have an impact on the gut-brain axis signaling via the inflammatory route 
of communication.
In support of this, it was recently shown that deficient bile acid de-conjugation was associated with impaired 
intestinal barrier function and behavior in a mouse model of ASD (the BTBR T+ Itpr3tf/J mouse) (Golubeva et 
al., 2017). Moreover, such changes were coincident with a substantial reduction in the relative abundance 
of bile-metabolizing bacterial taxa (Bifidobacterium and Blautia). An understanding of the bile-metabolizing 
capacities of specific probiotic strains would be important in parsing the relationships between bile and the 
brain. However, even though the two of the most widely used probiotic genera – Bifidobacterium and Lac-
tobacillus species –demonstrate on average very high BSH activity, there are only scarce data available on 
their impact on host bile metabolism. For example, the multispecies VSL#3 probiotic (carrying Lactobacillus 
and Bifidobacterium strains) was shown to enhance bile acid de-conjugation and upregulate hepatic bile 
acid synthesis via the intestinal FXR/FGF15 signaling pathway (Degirolamo et al., 2014). BSH-active L. reuteri 
NCIMB 30242 reduced cholesterol levels and increased plasma bile acid levels in hypercholesterolemic sub-
jects (Martoni et al., 2015). 
Intriguingly, some recent evidence indicated that bile acids can affect the brain function directly. First, it has 
been shown that bile-induced activation of FXR/FGF signaling in the ileum can suppress hypothalamic AGRP/
NPY (Agouti-related peptide/Neuropeptide Y) neurons in the brain through the centrally expressed FGF re-
ceptors, and markedly improve glucose tolerance in obese mice (Liu et al., 2018). It was further demonstrat-
ed that the murine olfactory system is capable of discriminating between male and female feces, based on 
sex-dependent differences in the fecal composition of bile acids (Doyle et al., 2016); some olfactory neurons 
were firing exclusively in response to either primary or secondary bile acid application. This suggests that 
bile acids can act as natural murine pheromones. Further studies are required to examine the possible link 
between gut microbiota, bile signaling and neural function, potentially implicating bile acids directly in gut-
brain axis signaling.
O. Short-Chain Fatty Acids (SCFAs)
Perhaps the most examined gut microbial-derived metabolites are SCFAs, of which more than 95% consists 
of acetate, propionate and butyrate. SCFAs have been implicated in a variety of host processes including GI 
function (Gill et al., 2018), blood-pressure regulation (Pluznick, 2017), circadian rhythm (Tahara et al., 2018), 
and (neuro)immune function (Erny et al., 2017), even though their role in brain physiology and behavior has 
received less attention. Nonetheless, decreased fecal SCFA levels have been reported in various disorders 
where brain physiology and behavior are changed, including anorexia nervosa (Morita et al., 2015) and Par-
kinson’s disease (Unger et al., 2016). In animal models, decreased gastrointestinal SCFA levels have been as-
sociated with Alzheimer’s disease (Zhang et al., 2017a) (see Section VIII) and in some studies chronic stress, 
including (Maltz et al., 2018). Conversely, in humans, increased SCFA levels have been associated with obesi-
ty (Fernandes et al., 2014; Rahat-Rozenbloom et al., 2014; Schwiertz et al., 2010), chronic psychosocial stress 
in children (Michels et al., 2017) and ASD (Wang et al., 2012b). Although, a more recent report demonstrated 
decreased fecal acetate and butyrate levels in children with ASD (Liu et al., 2019). Such data implicates the 
potential of SCFAs to be a key player in microbiota-gut-brain axis communication, which we will explore in 
this section.
The primary source of SCFAs is the microbial fermentation of specific host-indigestible dietary fibers (Baxter 
et al., 2019; Macfarlane and Macfarlane, 2003), which is supported by the fact that GF animals and antibiotic 
treatment results in drastically lower SCFA levels (Backhed et al., 2007; Hoverstad and Midtvedt, 1986; Palleja 
et al., 2018; Zhao et al., 2016). Other sources of endogenous SCFAs include the breakdown of proteins by the 
microbiota (Yao et al., 2016), host metabolism of long-chain fatty acids and pyruvate into acetate (Knowles 
et al., 1974), as well as the consumption of alcohol (Sarkola et al., 2002). Finally, minor amounts of SCFAs can 
be attained by the consumption of fermented foods (Gill et al., 2018). Levels of SCFAs in human feces are ap-
proximately 60 g/kg for acetate, 10–20 g/kg for propionate and 3.5–32.6 g/kg for butyrate (Macfarlane and 
Macfarlane, 2003; McOrist et al., 2011), which is in line with the typically cited 60:20:20 ratio (den Besten et 
al., 2013). Gut-derived SCFAs are absorbed by the host epithelium, after which butyrate, in particular, is used 
as an energy source for colonocytes (Clausen and Mortensen, 1994; Hamer et al., 2008). The remainder of 
butyrate, as well as the majority of propionate, is subsequently metabolized by hepatocytes, resulting in 1- to 
15- µmol/L concentrations of propionate and butyrate in circulation, whereas acetate is found within a range 
of 100–200 µmol/L (Bloemen et al., 2009; Cummings et al., 1987; Peters et al., 1992). This is supported by 
reports showing that exogenously administered SCFAs are metabolized in the same SCFA-specific preferential 
manner (i.e., butyrate > propionate > acetate) (Boets et al., 2017). As such, only acetate has been detected 
in cerebral spinal fluid (CSF) at approximate concentrations of 35 µmol/L (Nagashima et al., 2010), whereas 
no data on human physiological concentrations of propionate and butyrate in the brain or CSF has been pub-
lished to our knowledge. 
SCFA Uptake and Metabolism
SCFAs can diffuse through epithelia as non-ionized SCFA (Mascolo et al., 1991), or through transporters such 
as the pH-dependent hydrogen-coupled monocarboxylate transporter 1 and 4 (Kekuda et al., 2013; Tamai et 
al., 1995), the sodium-coupled monocarboxylate transporter 1 (Miyauchi et al., 2004), and, specifically for 
butyrate, the liver organic anion transporter 7 (Shin et al., 2007). In the cell, SCFAs are mainly metabolized 
via the Krebs cycle as an energy source. This subsequently boosts mTOR (mammalian target of rapamycin), 
which is known to be an ATP and a homeostatic cellular energy sensor (Dennis et al., 2001) has been shown 
to be implicated in brain physiology (O’Riordan et al., 2014) and behavior (Xu et al., 2018).
Epigenetic Modulation of SCFAs
All SCFAs induce histone deacetylase (HDAC) inhibitory effects, with butyrate being the most potent inhibitor 
of class I and IIa HDACs (Cleophas et al., 2016; Davie, 2003). In addition, acetate can be converted to ace-
tyl-CoA, which leads to increased histone acetylation (Soliman et al., 2012). Finally, SCFAs have recently been 
implicated in histone crotonylation, even though the relevance to brain physiology and behavior needs to be 
further investigated (Fellows et al., 2018).
Butyrate has been used as a tool for investigating the role of HDAC inhibition in brain physiology and behavior 
(for a comprehensive review covering this topic, see (Stilling et al., 2016)). This is usually achieved by acute 
intraperitoneal or subcutaneous administration of supraphysiological doses of butyrate, resulting in an im-
mediate burst of increased histone acetylation. As such, studies using this methodology might not necessar-
ily translate to gut microbiota-derived butyrate. These studies revealed that such an acute dose of butyrate 
enhances (re-)learning and memory, decreases depressive-like and perseverative behavior, and increases 
sociability in a mouse model of ASD (Bredy et al., 2007; Fischer et al., 2007; Kratsman et al., 2016; Levenson 
et al., 2004; Schroeder et al., 2007; Tsankova et al., 2006). It is also interesting to note that, using this meth-
od of administration results in a stress-like effect and increased anxiety-like behavior (Gagliano et al., 2014; 
Gundersen and Blendy, 2009). This might be explained by the fact that FFAR3 is expressed in the peripheral 
nervous system, activation of which results in increased sympathetic nervous system activity (Kimura et al., 
2011). 
SCFA Receptors
SCFAs can activate several G-protein coupled receptors (GPCR), of which free fatty acid receptor 2 (FFAR2, 
also referred to as GPR43) and 3 (FFAR3, also referred to as GPR41) are the most investigated (Brown et al., 
2003; Le Poul et al., 2003; Nilsson et al., 2003). Expression of both receptors has been reported in the colon, 
various immune cells, and the heart. Only FFAR2 is expressed in adipocytes and skeletal muscle, whereas 
FFAR3 is expressed in the peripheral nervous system and the BBB (Hoyles et al., 2018; Koh et al., 2016). No 
expression of FFAR2 has been reported in the brain to our knowledge (Nohr et al., 2015).
A lesser-known colonic GPCR activated by butyrate is the receptor for niacin: hydroxycarboxylic acid receptor 
2 (Thangaraju et al., 2009). Another receptor activated by butyrate is the olfactory receptor family 51 sub-
family E member 1 (OR51E1 for humans, olfactory receptor 558 - Olfr558 for mice) (Priori et al., 2015). Im-
portantly, since both receptors are activated by butyrate in higher micromolar to millimolar concentrations, 
it is unlikely that circulating butyrate could activate either of these receptors in non-gut or -liver tissue. The 
only one activated by acetate and propionate is the GPCR olfactory receptor family 51 subfamily member 2 
(OR51E2 for humans, olfactory receptor 78 – Olfr78 for mice) (Pluznick et al., 2013), which has been detected 
in the brain of rodents, but not humans (Yuan et al., 2001). It is clear that more work is needed to understand 
the relative contribution of these receptors especially at key time windows across the lifespan where their 
expression may vary, to microbiota-brain signaling.
SCFA-Induced Enteroendocrine Signaling
FFAR2, FFAR3, OR51E1, and Olfr78 are expressed by colonic enteroendocrine L cells (Fleischer et al., 2015; 
Karaki et al., 2006; Karaki et al., 2008; Priori et al., 2015; Tazoe et al., 2008), of which FFAR2 and FFAR3 acti-
vation results in the secretion of GLP-1 and peptide YY (PYY) into the peripheral circulation (Cherbut et al., 
1998; Dumoulin et al., 1998; Psichas et al., 2015). Also, SCFA signaling stimulates the production of PYY in en-
teroendocrine cells, which is mostly mediated by HDAC inhibition (Larraufie et al., 2018). Importantly, acute 
delivery of propionate to the human colon using an inulin-propionate ester resulted in increased PYY and 
GLP-1 levels (Chambers et al., 2015), even though this was not replicated in a later study (Byrne et al., 2016). 
Interestingly, an infusion of acetate into the human distal, but not proximal colon, also results in increased 
circulating PYY, stressing the importance of spatial differences across the colon in regard to SCFA-induced 
enteroendocrine signaling (van der Beek et al., 2016). 
Another well-studied hormone affected by SCFA-induced signaling is leptin, of which the secretion from adi-
pocytes is enhanced following SCFA stimulation (Xiong et al., 2004; Zaibi et al., 2010). In addition, administra-
tion of butyrate to fasting mice results in elevated levels of GLP-1, GIP, PYY, insulin and amylin. The same was 
reported for propionate regarding GIP, insulin and amylin, whereas no effects were observed in acetate-treat-
ed mice (Lin et al., 2012). These data may implicate the diurnal variation of anorexigenic hormones (Fetissov, 
2017), as SCFA levels also show a diurnal variation (Leone et al., 2015; Tahara et al., 2018), potentially in-
volving SCFA-driven changes in anorexigenic hormones in daily host eating behavior. Interestingly, long-term 
supplementation of tributyrin, a butyrate prodrug, to high-fat diet (HFD) -induced obese mice, resulted in 
an amelioration of heightened leptin, resistin and insulin levels associated with obesity (Vinolo et al., 2012). 
In diet-induced obese, low-density-lipoprotein receptor transgenic mice, butyrate decreased insulin levels 
(Arnoldussen et al., 2017). As such, the acute administration of propionate and butyrate led to an increase 
in various anorexigenic hormones, while long-term supplementation decreased levels of such hormones in 
models of diet-induced obesity. Importantly, it has been reported that acetate promotes glucose-stimulated 
insulin and ghrelin secretion as well as obesity (Perry et al., 2016), which is in line with some reports indicat-
ing that obesity is associated with increased SCFA levels (Fernandes et al., 2014; Rahat-Rozenbloom et al., 
2014; Schwiertz et al., 2010). As such, more research is needed regarding the mechanisms by which SCFAs 
affect host metabolism and endocrine systems, to achieve a better understanding of the exact role SCFAs play 
herein under conditions of increased endogenous SCFAs and SCFA supplementation. 
Initial reports illustrated that SCFAs can stimulate the secretion of the neurotransmitter 5-HT into the lumen 
of the gut, as well as into the vasculature (Fukumoto et al., 2003). Later it was shown that the central, but 
not the orad or caudad compartment of the colon secreted 5-HT in response to SCFAs, highlighting once 
again the importance of spatial differences across the colon (Grider and Piland, 2007)Nonesterified/*phar-
macology</keyword><keyword>Intestinal Mucosa/drug effects/physiology</keyword><keyword>Kinetics</
keyword><keyword>Muscle, Smooth/drug effects/physiology</keyword><keyword>Peristalsis/drug ef-
fects/*physiology</keyword><keyword>Physical Stimulation</keyword><keyword>Rats</keyword><key-
word>Serotonin/*metabolism</keyword></keywords><dates><year>2007</year><pub-dates><date>Jan</
date></pub-dates></dates><isbn>0193-1857 (Print. In addition, butyrate induces the secretion of 5-HT in 
vitro, which was not the case for acetate (Yano et al., 2015). Conversely, SCFAs failed to stimulate 5-HT secre-
tion from primary mouse enterochromaffin cells (Martin et al., 2017). Further, SCFAs stimulate colonic TPH1 
gene expression indicating increased 5-HT production (Reigstad et al., 2015; Yano et al., 2015). Overall, more 
research is needed to be performed on the mechanisms as to how SCFAs affect colonic, systemic and CNS se-
rotonergic signaling, with an emphasis on spatial differences across the colon, including the 5-HT receptors, 
seeing that acetate has been shown to decrease 5-HT3B expression (Bhattarai et al., 2017). 
SCFA-induced Vagus Nerve Activation
It is well established that SCFAs can activate the PNS, where FFAR3 receptor has been detected in the en-
teric neural plexus, the portal nerve and autonomic and sensory ganglia (De Vadder et al., 2014; Kaji et al., 
2016; Nohr et al., 2015; Won et al., 2013). Also, Olfr78 has also been detected in the PNS (Pluznick et al., 
2013). Locally, in the gut, FFAR3 is expressed on nitrergic and cholinergic enteric neural plexuses (Kaji et al., 
2018; Kaji et al., 2016). Interestingly, butyrate can increase the proportion of myenteric cholinergic neurons 
through HDAC inhibition (Soret et al., 2010), indicating that SCFAs might play a role in the homeostasis of 
ENS physiology. Particularly important for gut-brain axis signaling, activation of FFAR3 on the vagus nerve 
innervating the portal vein results in increased neuronal activity in the dorsal vagal complex, parabrachial 
nuclei and hypothalamus (De Vadder et al., 2014). Even though oral administration of butyrate to fasting 
mice results in decreased neuronal activity in the NTS and dorsal vagal complex, as well as decreased ac-
tivity of orexigenic NPY-positive neurons in the hypothalamus, indicating a dynamic regulation of SCFAs on 
hypothalamic neuronal circuitry (Li et al., 2018c). Overall, it is clear that SCFA-induced vagus nerve signaling 
results in the activation of various neurons in the central nervous system. However, more research needs to 
be performed investigating which specific neuronal populations are activated by SCFAs-induced vagus nerve 
signaling throughout the brain and how this relates to behavior.
SCFAs and Host Systemic Immunity
SCFAs have been implicated in the first line of defense between the microbiota and host intestinal barrier 
permeability. First of all, SCFAs can enhance the mucosal barrier through the stimulation of mucus produc-
tion (Barcelo et al., 2000; Finnie et al., 1995; Jung et al., 2015; Willemsen et al., 2003), which is likely mediat-
ed through FFAR3 (Said et al., 2017). In addition, SCFAs have been demonstrated to alleviate impairments in 
epithelial barrier integrity by stimulating tight junction assembly (Peng et al., 2009; Tong et al., 2016; Wang 
et al., 2012a). Further, SCFAs have been shown to modulate immune cells themselves (Correa-Oliveira et al., 
2016; Kim et al., 2014). These include the regulation of neutrophils chemotaxis and inflammation (Le Poul et 
al., 2003; Vieira et al., 2017; Vinolo et al., 2011), the suppression of cytokine production from myeloid cells 
(Nastasi et al., 2015; Park et al., 2007) and by regulating T regulatory, T helper 1, and T helper 17 cell differ-
entiation (Al Nabhani et al., 2019; Asarat et al., 2016; Park et al., 2015; Smith et al., 2013; Tan et al., 2016). 
Overall, SCFAs influence the immune system in an anti-inflammatory manner. 
SCFAs: Direct Effects on the Brain?
Current research indicates that gut microbial-derived SCFAs might be able to affect brain physiology through 
direct interactions. Specifically, acetate has been reported to be present in the cerebrospinal fluid, and gut 
microbial-derived acetate has been shown to reach the brain and trigger PNS signaling (Nagashima et al., 
2010; Perry et al., 2016). It is therefore interesting to note that acetate signaling in the hypothalamus pro-
motes an expression profile of regulatory neuropeptides that favor appetite suppression (Frost et al., 2014). 
Considering the relatively low levels of propionate and butyrate in the circulation, whether these SCFAs can 
directly impact the brain is still very much uncertain. However, it is important to note that a propionate con-
centration as low as 1 μM can affect the BBB, indicating that physiologically relevant SCFAs could potentially 
impact the brain (Hoyles et al., 2018). Notably, a study tracing radio-labeled butyrate in primates found that 
only 20% remained after 5 minutes post-administration, with the brain only taking up less than 0.006% (Kim 
et al., 2013). As such, more research needs to be performed to validate whether gut microbial-derived pro-
pionate and butyrate can directly affect brain physiology. 
Gut-Derived SCFAs, Brain Physiology, and Behavior
As stated earlier, SCFAs have been shown to ameliorate deficits in microglia morphology and immaturity as 
seen in GF mice (Erny et al., 2015). In addition, FFAR2 transgenic mice have severely malformed microglia 
even though microglia do not express FFAR2, indicating that FFAR2 plays an indirect role in microglia function 
and homeostasis (Erny et al., 2015). GF mice also have increased BBB permeability, which can be rescued 
by SCFAs (Braniste et al., 2014). Interestingly, the latter study also reported that butyrate rescued deficits in 
histone acetylation in the frontal cortex of GF mice (Braniste et al., 2014). This is in line with previous reports 
showing that butyrate supplementation in drinking water increased brain histone acetylation (Bonthuis et al., 
2011; Minamiyama et al., 2004)
Pigs supplemented with butyrate have increased hippocampal granular cell layer volume, hippocampal neu-
rogenesis and altered hippocampal glucose metabolism (Val-Laillet et al., 2018). In addition, 9-month old, 
but not 12-month old diet-induced obese, low-density-lipoprotein receptor transgenic mice have decreased 
hippocampal cerebral blood flow and functional connectivity, spatial memory, and increased hippocampal 
microglia activation, all of which were rescued by butyrate supplementation (Arnoldussen et al., 2017). Acute 
and targeted administration of propionate to the human colon using an inulin-propionate ester results in a 
reduced anticipatory reward response to high-energy foods in the striatum (Byrne et al., 2016). Furthermore, 
intrarectal administration of propionate in rats undergoing chronic unpredictable mild stress ameliorates 
deficits in reward-seeking and anxiety-like behaviors (Li et al., 2018b). Also, pigs supplemented with butyrate 
have increased glucose metabolism in the nucleus accumbens (Val-Laillet et al., 2018).
Overall, data from GF mice indicates that SCFAs play a role in the maintenance of homeostasis within the 
CNS. In addition, particularly the hippocampus and striatum seem to be affected by gut-derived SCFAs, indi-
cating that SCFAs may play a modulatory role in learning and cognition (Arnoldussen et al., 2017; Val-Laillet 
et al., 2018), as well as reward-associated behaviors (Byrne et al., 2016; van de Wouw et al., 2018). A recent 
study has shown that supplementation of a mix of the principle SCFAs (i.e., acetate, propionate, and butyr-
ate) in drinking water ameliorated long-lasting psychosocial stress-induced HPA axis hyperactivity, intestinal 
permeability and alterations in anhedonia in mice (van de Wouw et al., 2018). Also, SCFAs decreased anxiety- 
and depressive-like behavior in selective behavioral tests, which was not present when mice had previously 
undergone psychosocial stress. This was accompanied by decreased gene expression of the mineralocorti-
coid receptor in the hypothalamus, hippocampus, and the colon, as well as decreased CRF receptor 1 and 2 
in the colon. Such data further implicate SCFAs in stress-related disorders and reinforce the role SCFAs play in 
microbiota-gut-brain axis communication (van de Wouw et al., 2018).
It is worth noting that not all of the effects of SCFAs on behavior have been positive. For instance, increased 
SCFA levels have been implicated in the pathophysiology of Parkinson’s disease in mice (Sampson et al., 
2016). In addition, intraventricular infusions of propionate result in increased repetitive behaviors, impaired 
sociability, epileptic and convulsive responses and is therefore used a reliable model of autism spectrum dis-
order (MacFabe et al., 2007; MacFabe et al., 2011). As such, the authors of these latter studies hypothesized 
that one of the underlying mechanisms in ASD pathophysiology is an overproduction of propionate by the 
gut microbiota, resulting in elevated propionate levels in the brain and contributing to the ASD phenotype 
(MacFabe et al., 2007). However, more research is needed to understand whether propionate can influence 
the brain directly and whether this results in the same phenotype as that found in intraventricular propio-
nate infusion-induced ASD.
P. Spinal Mechanisms
From an anatomical perspective, it is usually described that there are two distinct neuroanatomical routes for 
neural signaling from the intestine to the brain with the non-painful (satiety, distension, motility and other 
homeostatic functions) mediated predominantly by vagal/ pelvic innervation as described previously, and 
the painful sensory stimuli conveyed by splanchnic innervation (Vermeulen et al., 2014). However, it must 
be stated that the sensory tone of these signaling pathways is not mutually exclusive, and that physiological 
events relating to the status of the gut including distension, motility, inflammation, pain, pH change, cellular 
damage or temperature (Brookes et al., 2016) can also be transmitted through spinal splanchnic innervation 
via NTS of the brainstem (Christianson et al., 2009; Ren et al., 1989) to higher centers in the brain. 
Stimuli associated with pain, inflammation, discomfort, and injury are carried through spinoreticular, 
spinomesencephalic, spinohypothalamic and spinothalamic tracts to the brain (Millan, 2002), and the specif-
ic role of the GI microbiota in visceral pain response will be discussed further later (Section VIII.L.) The spin-
oreticular tract projects to the dorsal reticular nucleus in the brainstem to regulate the affective-motivational 
component of pain. The spinomesencephalic tract relays information about the intensity and location of 
the painful stimulus to the periaqueductal gray and other brain regions. In contrast, the spinohypothalamic 
tract communicates with the hypothalamus, which together with other neuroanatomical loci co-ordinates 
emotional, autonomic and behavioral responses to the nociceptive information, mediating the sensation of 
pain, heat, cold and touch (Millan, 2002). The thalamus functions as a relay station where multiple somatic 
and visceral information converge. Once the information has been processed, further inputs are conveyed 
to cortical regions including the anterior cingulate cortex, the insula and somatosensory cortex to be inter-
preted as a painful stimulus. Once the nociceptive information has been processed, the descending pathways 
(from brain to spinal cord) can exert an inhibitory or facilitatory effect on the sensation of pain. However, 
under normal physiological conditions, at the level of the spinal cord, the neurons involved in nociception are 
under ‘gated’ control. Until a certain threshold of stimulation is surpassed, these neurons are quiescent, and 
no nociceptive information is propagated to supraspinal sites.
Q. Hypothalamic-Pituitary-Adrenal (HPA) Axis
The HPA axis is one of the main neuroendocrine systems in the human body and one of the key non-neuronal 
routes of communication within the microbiota-gut-brain axis. It is best known as the principal neuroendo-
crine coordinator of the response to stress (Mayer, 2000). Upon disturbance of homeostasis, corticotrophin 
releasing factor (CRF) is released from paraventricular nucleus (PVN) of the hypothalamus, stimulating the 
release of adrenocorticotrophic hormone (ACTH) from the anterior pituitary (Fig. 4). This hormone is secret-
ed into systemic circulation and targets the adrenal cortex, ultimately resulting in a release of glucocorticoids 
(de Wied et al., 1993). Once in systemic circulation, they are distributed throughout the body. In the brain, 
glucocorticoids interact with high-affinity mineralocorticoid receptors and lower affinity glucocorticoid re-
ceptors (Herman et al., 2016; Smith and Vale, 2006; Tsigos and Chrousos, 2002). The primary function of 
the HPA axis activation is to prime the body for the ‘fight or flight’ response (Mayer, 2000). One of the main 
outputs is negative feedback in which glucocorticoids act back on the hypothalamus and pituitary gland 
inhibiting adrenal secretion. At the same time, the activity of the (PVN is regulated by multiple afferent sym-
pathetic, parasympathetic and limbic circuits (Smith and Vale, 2006).
Connecting the Microbiota to the HPA Axis
The seminal research linking the gut microbiota to the HPA axis has come from work with GF mice (see Ta-
ble 2). In response to restraint stress, male GF mice exhibited a hyper-responsive HPA axis, characterized by 
elevated levels of plasma corticosterone (Clarke et al., 2013; Sudo et al., 2004) suggesting that the exposure 
to microbiota has a specific timeframe of functionality (Sudo et al., 2004). Alterations in hippocampal NMDA 
and 5-HT1A receptor mRNA expression have also been recorded in GF mice (Neufeld et al., 2011). Both of 
these receptors are known to influence CRF release from the hypothalamus and changes in their expression 
may contribute to altered HPA function in GF animals. In humans, patients with irritable bowel syndrome had 
exaggerated ACTH and cortisol responses to CRF infusion (Dinan et al., 2006) together with an altered mi-
crobiota (Eisenstein, 2016; Grenham et al., 2011). It is clear that although the microbiome regulates the HPA 
axis, the opposite is also true. In animal models of stress with HPA axis alterations, there are marked changes 
in microbiota composition (see Section VII. H. and Table 2).
Dialogue between the HPA Axis and Other Pathways of Microbe to Brain Communication
The HPA axis interacts with other non-neuronal as well as neuronal pathways of communication between the 
gut and the brain. Interestingly, there is an interplay between the vagus nerve and the HPA axis. In rodents, 
vagal stimulation increased the expression of CRF mRNA in the hypothalamus (Hosoi et al., 2000). Further-
more, plasma levels of ACTH and corticosterone were strikingly elevated after vagal stimulation. 
Immunity-HPA axis interactions are implicated in a variety of stress and inflammatory disorders; thus it is not 
surprising that such cross-talk may also affect microbiota-gut-brain signaling. In animal models of psycholog-
ical stress, gut permeability is increased, and translocation of native bacteria into the host occurs (Demaude 
et al., 2006). Activation of the mucosal immune response via exposure to bacteria and bacterial antigens 
beyond the epithelial barrier induces pro-inflammatory cytokine secretion and ultimately activates the HPA 
axis. In the absence of the resident microbiota, members of the TLR family have low or absent expression 
profiles in the gut, thus compromising appropriate neuroendocrine responses to pathogenic threats (O’Hara 
and Shanahan, 2006). In TLR4 transgenic mice, activation of the HPA axis in response to Gram-negative bac-
teria is absent (Gosselin and Rivest, 2008). Although much has been learned from these and other important 
studies linking the microbiota to HPA activity, it is evident that more scrutiny needs to be placed on this in-
fluential relationship.
R. Peptidoglycans
Pattern recognition receptors (PRRs), as their name suggests, detect distinct microbial patterns or struc-
tures of microorganisms such as proteins, lipids, glycans and nucleic acids (amongst others) known as patho-
gen-associated molecular patterns (Qureshi et al., 1999), for example, LPS (Raio and Phelps) on the surface 
of gram-negative bacteria and peptidoglycan (PGLN) on the surface of gram-positive bacteria (Medzhitov, 
2007). Consisting of sugars and amino acids, PGLN are a critical part of most bacterial cell walls. The thickness 
of the bacterial cell wall is governed by the thickness of the peptidoglycan. In Gram-positive bacteria the cell 
wall can be between 20 and 80 nm thick whereas in Gram-negative bacteria it is much thinner, measuring 7 
to 8 nm (Costerton et al., 1974). Throughout evolution, multicellular organisms were required to develop the 
capacity to differentiate self from non-self, given the large number of microorganisms in the environment, 
the host had to evolve a controlled and specific structural recognition of these bacterial cell wall components 
(Rogers and Perkins, 1980; Vollmer et al., 2008). Similarly, PGLN is a large polymeric molecule which structur-
ally is similar between organisms, but critically the core sugar backbone is made of repeating disaccharides, 
which vary significantly between bacterial species (Schleifer and Kandler, 1972; Vollmer et al., 2008). This 
sugar backbone is also cross-linked with amino-acid side chains, which can be cross-linked in different confir-
mations, adding an additional layer of complexity (Vollmer et al., 2008). 
The innate immune system has evolved to detect both complete and fragmented peptidoglycan using nu-
merous PRRs both intracellularly and at the cell surface (Medzhitov, 2007), (Kawai and Akira, 2009). There 
are four peptidoglycan recognition proteins (PGLYRP 1-4) which bind to peptidoglycan in bacterial cell walls 
via recognition of the muramyl pentapeptide (or tetrapeptide) structures (Royet et al., 2011). Interestingly, 
PGLYRPs are also capable of binding LPS using different binding sites to those used for binding PGLN, meaning 
they can bind to both Gram-positive and Gram-negative bacterial cell walls (Royet et al., 2011). The exact 
method by which PGLYRPs induce cell death through binding to PGLN are unclear, but it is thought to be 
facilitated by the activation of enzymes that induce oxidative and stress response cell suicide (Kashyap et 
al., 2017; Kashyap et al., 2014). Interestingly, a recently discovered anti-inflammatory protein, Micro Integral 
Membrane Protein, found on the surface of L. Plantarum, has been shown to enhance gut barrier function 
and can modulate microbiota and inflammatory cytokines (Yin et al., 2018).
The gut microbiota is an important source of PGLN where it translocates from the mucosa to the systemic 
circulation under physiological conditions (Clarke et al., 2010). In the circulation it has been found to interact 
with bone-marrow-derived neutrophils, a cell not normally observed in the gut, indicating that PGLN may 
be present also at body sites far removed from the gut (Arentsen et al., 2017). Interestingly, these studies 
revealed that PGLNs and their receptors from commensal microbes resident in the gut were present in the 
brain of normal developing mice. The PRR nucleotide-binding oligomerization domain-containing protein-1 
(Nod1) which identifies meso-2,6-Diaminopimelic acid -containing PGLN was recognized as the key regu-
lator of the systemic effects of PGN. Moreover, these results suggest that PGLN can cross the BBB under 
normal conditions and that viral or bacterial infection is not required for this breach. PGLYRP-2 was highly 
expressed (along with Nod1) in neurons implying that PGLN may influence neurons directly (Arentsen et al., 
2017). While PGLYRPs have predominately been implicated in innate immunity, their role in behavior has also 
recently been explored. In the bacterial peptidoglycan sensing molecule Pglyrp2-transgenic mouse, major 
sex-dependent alterations of motor and anxiety-like behaviors in aged mice were observed. Furthermore, 
there were subtle alterations of synaptic-related gene expression in brain regions associated with the pro-
cessing of emotional stimuli (Arentsen et al., 2018). This data suggests that bacteria are sensed by the innate 
immune system and may affect brain function and development. 
VIII. Microbiota and Synaptic Plasticity
Neuroplasticity is an important aspect of neural function in both the GI tract and the brain, and as a result, 
should be a crucial consideration when examining microbiota-gut to brain communication processes. How-
ever, the extent that the microbiota can exact long-lasting neuroplastic changes in the host’s gut or brain is 
understudied, and currently unresolved. In the following section, we examine what the current state of the 
field is and identify important future potential avenues of study. 
 
One important and well-characterized method of measuring any potential long-term effects of microbial 
influence on the innervation of the gut, and neural network of the brain, is through the measurement of 
synaptic plasticity. Plasticity specifically refers to a long-lasting change to a system, with a specific functional 
purpose. Plasticity of the synapse involves alteration of the synaptic strength, where increased or decreased 
neuronal activity results in long-lasting changes in synaptic weights distributed throughout a network (Bliss 
and Lomo, 1973). Much work has been performed studying synaptic plasticity of the CNS, but recently it has 
become ever more apparent that neuronal plastic changes also occur in the ENS (Demir et al., 2013; Lomax 
et al., 2005). In the following section, we will examine what is known and what future directions are most 
compelling. 
A. Synaptic Plasticity in the CNS
From initial observations by Ramón y Cajal over a century ago (Jones, 1994), to the development of Hebb’s 
rule in 1949 (Hebb et al., 1994), with first experimental evidence emerging from seminal work by Eric Kandel 
and colleagues soon after (Byrne et al., 1978; Castellucci et al., 1978), investigating synaptic plasticity has 
long been at the forefront of our quest to understand the mechanisms of the working brain. CNS synaptic 
plasticity specifically refers to the cellular molecular and physiological processes underlying cognitive and 
emotional behavioral phenotypes such as learning and memory (Bailey et al., 2015). In the brain, activity-de-
pendent modification of the synapse is believed to be pivotally involved in the brains capacity to assimilate 
transient experiences to form perseverant memory engrams (Citri and Malenka, 2008). Here, an activity-de-
pendent persistent strengthening of synaptic efficacy is described as long-term potentiation (LTP) (Madison 
et al., 1991). In the widely studied unidirectional tri-synaptic excitatory pathway of the rodent hippocampus 
(Knierim, 2015), any significant enhancement in synaptic efficacy lasting at least an hour after a conditioning 
stimulus is believed to be LTP (Nicoll, 2017). LTP is used as an indicator of healthy brain function and is im-
paired in many rodent models of neurodegenerative disease (Nicoll, 2017). Further, deficits in LTP usually ac-
company cognitive dysfunction (Li et al., 2015; Lin et al., 2014; Wiescholleck and Manahan-Vaughan, 2013), 
and it is regarded as a reliable, functional readout for neurophysiological processes. 
A change in the state of plasticity can involve presynaptic, postsynaptic or extrinsic factors modifying the 
synapse. These changes can be short-lived, resulting in a more dynamic synaptic state, or long-term, resulting 
in a change in synaptic efficacy that can last for several months if not longer (Kandel et al., 2014). Synaptic 
plasticity in the brain is particularly vulnerable to disruption by factors that alter cognition in neurological 
and psychiatric disease. Examples of processes that involve alteration of synaptic plasticity include synaptic 
remodeling (Ziv and Brenner, 2018), synaptogenesis (Bednarek and Caroni, 2011), axonal sprouting/ pruning 
and dendritic remodeling (Selemon, 2013), as well as (neurogenesis) and recruitment (Ganguly and Poo, 
2013) many of which have been shown to be influenced by gut microbes (984). Most importantly, any senso-
ry, motor, inter or CNS neuron-neuron connection is a synaptic connection. Therefore, any mechanism that 
can alter the plasticity of the synapse can be considered as having a potential impact on the phenotype asso-
ciated with the synapses involved; in the CNS neuronal synapse, this includes cognitive and emotional pheno-
types. For example, the hippocampus is highly responsive to glucocorticoids (Lupien et al., 2005), which can 
be metabolized by the microbiota (Ridlon et al., 2013) into the steroid and pro-hormone 11β-hydroxy-andro-
stenedione (11β-OHAD) (Bokkenheuser et al., 1984; Ridlon et al., 2013). Hormone binding to receptors in the 
CA1 region of the hippocampus leads to multiple cellular responses, including changes in synaptic function 
and, in excess, neuronal injury (Chen et al., 2006). Many models of microbiota perturbation have been used 
in the study of synaptic plasticity and cognitive function. However, in totality, this area has lagged behind 
other physiological or behavioral readouts in parsing the role of the microbiome in brain function. 
Germ-free animal studies of CNS and the implications for synaptic plasticity and behavior
GF animals have been utilized in examining the involvement of the microbiota in CNS synaptic plasticity (see 
Table 2). However, for perhaps logistical reasons for setting an electrophysiological rig within a germ-free 
setting there has been limited direct plasticity measures published. Nonetheless, GF animals have altered 
expression of genes implicated in neurophysiology in the amygdala (Stilling et al., 2015) and hippocampus 
(Chen et al., 2017a) (see Table 2). This ultimately leads to an altered transcriptional profile, combined with 
a marked increase in immediate-early gene (Fos, Egr2, Fosb, Arc) expression in the amygdala (Hoban et al., 
2018), as well as enhanced expression of gene splicing factors and alternative exon usage (Stilling et al., 
2018). A recent study, utilizing the GF mouse model, linked maternal diet, gut microbiota imbalance, and 
ventral tegmental area plasticity with behavior modifications (Buffington et al., 2016). 
BDNF is an important plasticity-related protein. It has been shown to be involved in synaptogenesis (Cunha et 
al., 2010) and neurogenesis (Taliaz et al., 2010), as well as restoring LTP in aged rats when overexpressed (Rex 
et al., 2006), but see (Edelmann et al., 2014). Moreover, BDNF is believed to play an important role in anxi-
ety and depression in humans and has been reported to be expressed in lower than normal levels in the GF 
mouse cortex and hippocampus (Clarke et al., 2013; Diaz Heijtz et al., 2011). The gut microbiota have been 
shown to directly moderate brainstem and hypothalamic expression of BDNF, where conventionally raised 
mice differed significantly from GF mice (Schele et al., 2013). Moreover, studies from Gareau and colleagues 
showed BDNF expression as measured by immunohistochemistry was decreased in the CA1 hippocampal 
brain area in GF stressed mice compared to stressed controls (Gareau et al., 2011). GF studies also show 
that microbes can also regulate NMDA receptors (NMDAR) (Neufeld et al., 2011), and these proteins have an 
important role in brain development and neural plasticity (Bercik et al., 2010; O’Sullivan et al., 2011; Sudo et 
al., 2004). Further studies into microbiota driven modulation of neuronal NMDAR and BNDF expression are 
warranted.
Antibiotics in animal studies of the CNS and implications for synaptic plasticity and behavior
As previously stated, antibiotic-induced ablation of the gut microbiota in rodents results in long-term ef-
fects on neurochemistry and behavior (Champagne-Jorgensen et al., 2019; Desbonnet et al., 2015; Guida 
et al., 2018; Neufeld et al., 2011) (see Table 3). In a recent long-term treatment regime, application of a 
broad-spectrum antibiotic for seven weeks (Mohle et al., 2016) resulted in behavioral deficits in the hippo-
campus-reliant novel object recognition (NOR) task as well as decreased neurogenesis. These deficits were 
corrected with adoptive transfer of Ly-6chi monocytes into antibiotic-treated animals, coupled with access to 
a running wheel (voluntary exercise), or probiotic treatment. In another study, two weeks of antibiotic cock-
tail administration resulted in marked changes in hippocampal BDNF tropomyosin receptor kinase B (TrkB) 
signaling, transient receptor potential vanilloid 1 (TRPV1) phosphorylation and overall heavily reduced hip-
pocampal CA3-CA1 synaptic activity. This was somewhat ameliorated by treatment with the probiotic L. casei 
DG probably via a gut anti-inflammatory mechanism (Guida et al., 2018). Results such as these demonstrate 
that neurogenesis (Ogbonnaya et al., 2015; Sawada et al., 2018), apoptosis, and synaptic pruning, and hence 
synaptic plasticity, can be regulated by microbiota signaling.
Prebiotics, probiotics and CNS implications for synaptic plasticity and behavior
A number of studies have shown that administration of pre- or probiotics can alter components of neuroplas-
ticity (see Section II and Tables 4, 5). Indeed, the prebiotic B-GOS® elevated rat brain NMDAR levels (Savignac 
et al., 2013) and enhanced cortical responses to PFC-NMDAR activation. The electrophysiological phenotype 
induced by the prebiotic was consistent with improved behavioral attentional set-shifting and increased cor-
tical glutamate [NMDA] receptor subunit epsilon-2(GRIN2) A/B-containing populations of NMDAR’s (Gronier 
et al., 2018), rather than increased cortical glutamate levels per se (Savignac et al., 2013). Further, prebiotics 
and probiotics were recently shown to act therapeutically in middle-aged rats, improving spatial memory 
(Romo-Araiza et al., 2018).
The potential for coordinated hypothalamic synaptic plasticity modulation by a probiotic combination has 
also recently been shown. The combination treatment of B. longum (R0175) and L. helveticus (R0052) on 
neural plasticity genes, hypothalamic BDNF was increased whereas Growth Associated Protein 43 (GAP43), 
GFAP (glial fibrillary acid protein), Vim (vimentine), Syt4 (synaptotagmin), Snap25 (synaptic-associated pro-
tein 25 kDa) and cell adhesion markers (Reln, Sema [semaphorine]) were all decreased relative to a stressed 
control cohort (Ait-Belgnaoui et al., 2014). Hippocampal NMDAR expression was also increased in the DG 
and CA1 following daily consumption of the probiotic L. fermentum strain NS9, which also enhanced radial 
maze memory compared to antibiotic-treated rat (Wang et al., 2015). In a seminal in vivo, hippocampal elec-
trophysiology experiment neurophysiological and behavioral impairments in a diabetic rat model of diabetes 
mellitus were rescued with the probiotic treatment of L. acidophilus, B. lactis and L. fermentum (Davari et 
al., 2013). 
A novel probiotic formulation of bifidobacteria (SLAB51) partially restores deficits in autophagy and the ubiq-
uitin-proteasome system, two neuronal proteolytic pathways that influence neuroplasticity in a mouse mod-
el of AD (3xTg-AD) (Bonfili et al., 2017). Moreover, chronic administration of L. rhamnosus (JB-1) induced 
region-specific alterations in GABAB1b and GABAAα2 mRNA (Bravo et al., 2011). Further, L. rhamnosus and B. 
longum reversed antibiotic-induced reductions in GABAA receptor α5 and δ subunits in the juvenile rat hip-
pocampus (Liang et al., 2017). One further study found that L. reuteri, could reverse observed social behavior 
deficits and restore hypothalamus oxytocin immunoreactive neurons to control levels as well as correct defi-
cits in synaptic plasticity (Zhu et al., 2017). 
Interestingly, memory dysfunction observed following short-term colitis, induced via infection with Citro-
bacter (C.) rodentium, was prevented following daily probiotic (mixture composed of an L. rhamnosus and L. 
helveticus) administration (Gareau et al., 2011). These changes were coincident with changes in BDNF and 
c-Fos modulation in the hippocampus. Synbiotic approaches (combining specific potential probiotics with 
prebiotics) have also been utilized to investigate the effect of microbiota on synaptic plasticity. In a combined 
pre/pro-biotic study, L. casei and inulin fed rats enhanced 5-HT1A mRNA levels in the DG and CA1 areas of 
the hippocampus in healthy juvenile rats, indicating an early behavioral change as a direct result of synbiotic 
administration (Barrera-Bugueno et al., 2017).
Multispecies approaches have also been used to examine brain plasticity modulation via microbiota. A recent 
study utilized a probiotic mixture comprising eight different gram-positive bacterial strains, VSL#3, which is 
believed to have an anti-inflammatory effect (Mimura et al., 2004)-(Kim et al., 2003; Reiff et al., 2009) and re-
duce pain in an animal model of visceral hypersensitivity (Distrutti et al., 2013)Wistar</keyword><keyword>-
Real-Time Polymerase Chain Reaction</keyword><keyword>Visceral Pain/etiology/*prevention &amp; con-
trol</keyword></keywords><dates><year>2013</year></dates><isbn>1932-6203 (Electronic. VSL#3, which 
contains Streptococcus (S.) thermophilus DSM24731, B. breve DSM24732, B. longum DSM24736, B. infantis 
DSM24737, L. acidophilus DSM24735, L. plantarum DSM24730, L. paracasei DSM24733, L. delbrueckii sub-
species Bulgaricus DSM24734, was shown to rescue age-related deficits in LTP (Distrutti et al., 2014). VSL#3 
was also able to modulate the expression of a cohort of genes in the cortex associated with age-related de-
cline. Here, they witnessed an increase in hippocampal BDNF and synapsin expression, suggesting that VSL#3 
exerted a neuro-synaptotrophic effect. This is consistent with the fact that  VSL#3 acted as an anti-inflamma-
tory in the mouse gut, which was mirrored in the brain, as noted by a reduction in CD11b and CD68 mRNA 
expression (two markers of microglial activation) in the hippocampus in VSL#3-treated aged rats (Distrutti et 
al., 2014). While it is obvious that gut microbiota can influence central neuroplasticity, much has yet to be 
discovered, especially in terms of mechanistic insight and whether microbiota interventions have a clinically 
relevant therapeutic option for modulating neuroplasticity in humans  
S. Synaptic Plasticity in the ENS
As previously mentioned (Section IV.), the ENS encompasses a large part of the ANS. Due to the organization 
and structure of the number, morphology, and neurochemical nature of the ENS networks within the ANS, it 
is believed to be more analogous to the CNS than other networks within the peripheral nervous system (Ger-
shon, 2018; Timmermans et al., 1997; Wood, 2008, 2016). Much like the CNS, the ENS maintains its capacity 
to adapt and reorganize its synapses throughout the host’s lifetime, similar to synaptic plasticity in the CNS 
(Demir et al., 2013; Lomax et al., 2005). It has been shown that enteric ganglia share some morphological 
similarities to CNS astrocytes (Jessen and Mirsky, 1983), which lie adjacent to enteric neuronal cell bodies, 
which are very much like glia in the CNS (Yoo and Mazmanian, 2017). 
One specific example of ENS plasticity includes increased sensitivity at sensory nerve terminals in the gut, 
either directly or indirectly, by both chemical and mechanical stimuli (Grundy et al., 2006). It is possible that 
bacterial infections can enhance pain signaling and induce a plastic state in the gut by directly activating 
sensory neuron afferents and modulating inflammation (Chiu et al., 2013). It is believed that plasticity of a 
heightened pain response, known as central sensitization, contributes to chronic pain. The processes are 
remarkably similar to LTP in the hippocampus where increased synaptic transmission, and hence sensory 
neuronal plasticity, can be promoted via the application of glutamate (Larsson and Broman, 2011), sub-
stance P (Yu et al., 2016) or calcitonin gene-related peptide (CGRP), (Iyengar et al., 2017), onto ascending 
excitatory pathways, leading to CNS sensitization on second-order spinal neurons. However, an unintended 
consequence of enhanced signaling and sensitization promotes abnormal processing of pain (see Section 
VIII. L.). Interestingly, L. reuteri (DSM 17938) has been shown to attenuate jejunal spinal nerve firing evoked 
by distension or capsaicin via TRPV1 channel recruitment (Perez-Burgos et al., 2015). 
It is worth contextualizing some of the commonalities between plasticity in CNS and ENS. An important neu-
rodevelopment and plasticity-related protein growth-associated protein-43 (GAP-43) is expressed in both 
the CNS and the ENS; it is found in high levels throughout the lifespan in the hippocampus (Simmons et al., 
2008), as well as in the myenteric and submucous ganglia (Giaroni et al., 1999; Stewart et al., 1992). Further, 
the neurotransmitter vasoactive intestinal peptide (VIP), which is involved in pre- and postsynaptic GABAer-
gic enhancement to hippocampal interneurons, resulting in an increase of excitatory synaptic transmission in 
hippocampal pyramidal cells (Cunha-Reis et al., 2004; Yang et al., 2009), a process involved in the expression 
of LTP, is also present in inhibitory muscle motoneurons (Benarroch, 2007). Another CNS active neurotrans-
mitter, acetylcholine, is active at excitatory enteric motoneuron synapses (Zhu et al., 2011). Further, the 
neurotransmitter dopamine is also found in both the central and enteric nervous systems (Gershon, 2018; Li 
et al., 2006). It has been suggested that enteric crest-derived stem cells, believed to be largely responsible 
for synaptic plasticity in the ENS, could one day be used to seed the CNS in order to mitigate neuronal loss 
in neurodevelopmental disease (Schafer et al., 2009). As one would expect, much research examining ENS 
plasticity has been carried out on the various models of gut perturbation. 
Germ-free animal studies of the ENS and implications for synaptic plasticity 
GF animals have been used extensively in the search for alterations in ENS plasticity (see Table 2). These ani-
mals appear to have altered mesenteric nerve firing rates (McVey Neufeld et al., 2015), as well as decreased 
basal neural excitability, as evidenced by an augmented post action potential, as well as altered intrinsic 
primary afferent neuron excitability, as measured in the form of an enhanced slow afterhyperpolarization, 
when compared to SPF and conventionally re-colonized GF control animals (McVey Neufeld et al., 2013). It 
is now understood that the microbiota plays a crucial role in moderating normal expression of the intracel-
lular calcium-binding protein calbindin (McVey Neufeld et al., 2015). Furthermore, network activity of host 
physiology in myenteric sensory neurons differed greatly in GF mice from conventional and SPF strains in a 
study examining jejunum intracellular current-clamp recordings (McVey Neufeld et al., 2013), indicating a 
fundamental shift in synaptic efficacy in the absence of microbiota. GF animals have been and will continue 
to be, instrumental in uncovering the fundamentals of ENS mechanisms of plasticity.
Currently, to our knowledge, there are no known studies directly examining ENS physiology utilizing 
antibiotics but clearly such studies are warranted.
Prebiotic, probiotics and ENS implications for synaptic plasticity 
Some of the best links with gut neuroplasticity and microbiome come from studies focused on visceral pain. 
In a rat model of acute colorectal distension (CRD)-evoked pain, there was an increase in the number of 
spikes discharged, and a decrease in the threshold for action potential generation, during a standard de-
polarizing test stimulus. Prior treatment with L. rhamnosus (JB-1) (formally misidentified as a L. reuteri) 
blocked the CRD-mediated gut electrophysiological changes usually associated with acute visceral pain (Ma 
et al., 2009), where usually the myenteric intrinsic sensory neurons become hyperexcitable. From an earlier 
study, (Kamiya et al., 2006) this strain was known to decrease CRD-evoked bradycardia and single unit dorsal 
root fiber discharge in the anesthetized rat. Direct gastric administration of L. casei Shirota strain has been 
shown to potentially act on the afferent vagal nerve, decreasing sympathetic nerve outflow and regulating 
tissue-specific efferent sympathetic nervous activity via the CNS (Tanida et al., 2016). It has become apparent 
that commensal bacteria can signal to local sensory neurons to alter their excitability state, which itself can 
last long after the bacteria have been removed (Tanida et al., 2005), somewhat reminiscent of hippocampal 
synaptic plasticity. Even though much advancement has been accomplished examining the effect microbio-
ta-gut-brain perturbations have on neuronal plasticity, and vice versa, much more investigation is still neces-
sary to elucidate this integral and intricate communication pathway. 
IX. Factors Influencing the Microbiota-Gut-Brain Axis
There are many factors that have been shown to have a modulating effect on both the brain and microbiota, 
including socioeconomic status (Bowyer et al., 2019), host diet, congenital factors, environmental factors, 
exercise and level of host activity, medications and mode of delivery at birth (Fig. 5). In the following section, 
we will delve into the currently known consequences that each of these factors have upon the microbio-
ta-gut-brain axis and consider future possible directions of investigation. 
A. Genetics and Epigenetics
The relationship between host genetics and microbiota composition is an important and understudied area 
of research especially in the context of brain health. There is a growing number of studies examining the 
relationship between host genetics in humans and mice and the variation of the microbiota and its individ-
ual constituent taxa (Bonder et al., 2016). For example, taxa abundance was significantly more correlated in 
monozygotic twins than in dizygotic twins, with Christensenellaceae being the most highly heritable family, 
while also being associated with low body mass index (BMI) (Goodrich et al., 2014), thus confirming the gut 
microbiota is an important mediator of the interaction between host-genetics and phenotype (Rothschild et 
al., 2018; Wang et al., 2018b). Therefore, it may be possible that gut-microbial products could affect neuronal 
transcription, and hence host behavior (Stilling et al., 2014b). The microbiota may act as an important modu-
lator of the host genome via gene-environment interactions (Stilling et al., 2014a), and in time be recognized 
as a separate epigenetic entity (Hoban et al., 2018; Stilling et al., 2018). 
The microbiota is predominantly in direct contact with epithelial cells, but can also indirectly interact with 
peripheral neurons and immune cells (Stilling et al., 2014b). In gut epithelial cells, HDAC3 was shown to be 
critical in maintaining host-commensal signaling (Alenghat et al., 2013). Furthermore, pharmacological inhi-
bition of HDAC activity reversed early-life stress-induced visceral hypersensitivity and anxiety (Moloney et al., 
2015), behaviors dependent on appropriate microbiota-gut-brain axis signaling (De Palma et al., 2014; O’Ma-
hony et al., 2011). Future studies should focus on whether bacterial-derived modulators of HDAC activity can 
modify such physiological and behavioral outcomes. 
Another component of genetic-microbiome interactions is at the level of regulatory RNAs or non-coding 
RNAs which represent a cornerstone of molecular regulation of transcription, gene expression and protein 
abundance (Ambros, 2001; O’Connor et al., 2016). Animal models of microbial manipulation, including the 
GF mouse (see Table 2), have become invaluable tools in the study of the microbiota-gut-brain axis, and they 
have been key in studying one branch of the non-coding RNA network, microRNAs (miRNA). miRNAs regulate 
gene expression through translational repression and inhibition, and they are viable targets for intervention 
in neuropsychiatric disease (Issler and Chen, 2015; O’Connor et al., 2013; Scott et al., 2015). The gut mi-
crobiota has been shown to regulate the expression of microRNA (miRNA) in the amygdala and PFC of GF 
mice (Hoban et al., 2017). Similarly, depletion of the gut microbiota with an antibiotic cocktail also impacted 
miRNA expression levels in these specific brain regions. For example, within the amygdala, miR-183-5p was 
decreased in GF mice, but in recolonized mice, the expression of this miRNA returned to control levels. Also, 
the hippocampus has demonstrated susceptibility towards gut microbiota diversity and abundance modula-
tion with expression of 7 miRNA’s altered in GF mice which were subsequently restored to control levels in 
re-colonized mice (Chen et al., 2017a). 
T. Mode of Delivery at Birth
Mode of delivery has a tremendous impact on the establishment of the microbiota of infants, as the moment 
of birth is the first opportunity for large-scale bacterial colonization. The initial seeding of microbiota during 
vaginal-delivery (i.e., natural birth) occurs during parturition, as the infant passes through the birth canal, 
where they are exposed to the maternal vaginal microbiota. A seminal study has shown that there is vertical 
transmission of bacteria from the mother to the newborn, with the microbiota of vaginally-delivered babies 
closely resembling the vaginal microbiota of their mothers (Dominguez-Bello et al., 2010). 
On the other hand, when a C-section is performed, vertical transmission of vaginal microbiota from the 
mother to the baby is circumvented, as the C-section delivered newborn does not pass through the birth 
canal. Instead, the initial colonization of bacteria in C-section delivered babies seems to be dominated by 
bacteria typically present on the skin and in the environment, with increased levels of Staphylococcus spp. 
(Dominguez-Bello et al., 2010). Moreover, in that study there was no relation between the specific skin mi-
crobiota of the mother and the microbiota of their C-section born infants, demonstrating that bacterial col-
onization originates from non-maternal sources. In comparison to vaginal delivery, the C-section procedure 
is associated with decreased colonization rates of Bifidobacterium, Bacteroides and Lactobacillus (Biasucci et 
al., 2010; Penders et al., 2006), and with a decrease in diversity and richness of the microbiota (Azad et al., 
2013; Jakobsson et al., 2014; Stewart et al., 2018). Interestingly, a recent study has shown that in addition to 
these differences in bacterial representation, mode of delivery has an impact on the fecal virome of infants, 
with increased viral and bacteriophages diversity in babies born per vaginum (McCann et al., 2018).
Despite at least 14 different cohorts showing differences in the microbiota of infants depending on the de-
livery mode, the full impact of the C-section procedure on the microbiota is still unclear; there are several 
confounding factors that can influence the results. Specifically, it has recently been shown that differences 
in microbiota may be dependent on body site (Chu et al., 2017). Another crucial factor to be taken into con-
sideration is whether the C-section is elective or performed for a medical need, and if so, whether labor was 
initiated before the C-section procedure. In this case, the microbiota of the C-section born babies seems to 
be similar to vaginally delivered newborns as these infants come into contact with the birth canal during the 
early stages of labor (Azad et al., 2013; Chu et al., 2017). 
Longitudinal studies have shown that the differences between microbiota attributed to mode of delivery 
are transitory. Some studies report that birth mode effects on the microbiota can be absent as little as 6-8 
weeks after birth (Chu et al., 2017; Hill et al., 2017) or as late as the first two years of life (Bokulich et al., 
2016; Jakobsson et al., 2014; Palmer et al., 2007). However, despite this transient nature, early life differen-
tial colonization has a long-lasting effect and several studies show a correlation between birth by C-section 
and increased risk of developing a variety of disorders including obesity, type 1 diabetes, as well as immune 
disorders such as asthma or allergies (Bisgaard et al., 2011; Blustein et al., 2013; Jakobsson et al., 2014; Mon-
toya-Williams et al., 2018; Roduit et al., 2009). C-section born babies also have a higher risk of developing 
neonatal infections by methicillin-resistant Staphylococcus aureus, (Dominguez-Bello et al., 2010) or C. diffi-
cile (Penders et al., 2006). Consequently, there appears to be a minor correlation between C-section delivery 
and poor school performance in adolescents (Curran et al., 2017). In animal models, delivery by C-section 
leads to transient alterations in the neural development including decreased dendritic arborization (Chiesa 
et al., 2018; Juarez et al., 2008) and increased neuronal cell death at birth (Castillo-Ruiz et al., 2018). Both 
neurodevelopmental alterations are associated with early-life changes in vocalization. Further, C-section can 
also induce long-term changes to dopamine function (Boksa and El-Khodor, 2003).
Independent of the elective or emergency nature of the C-section procedure, more studies are needed to 
understand the impact of delivery mode and how this impact can be minimized. It has been suggested that 
using vaginal seeding to transfer vaginal microbiota from the mother to the newborn may be an effective in-
tervention (Dominguez-Bello et al., 2010). Although this technique seems to partially restore the microbiota 
in these babies, safety concerns have been raised (Cunnington et al., 2016; Stinson et al., 2018) and further 
studies must be done to evaluate the effects. In addition to this, supplementation with probiotics and prebi-
otics can be used to decrease the impact of delivery mode on the microbiota (Chua et al., 2017; Moya-Perez 
et al., 2017a). Factors such as diet (breastfeeding versus formula), environment and antibiotic use also need 
to be taken into consideration as possible modulators of the microbiome in early-life.
U. Diet 
Diet has been shown to be one of the most critical factors modulating gut microbiota composition, and 
hence the brain and behavior (Turnbaugh et al., 2008). Clinical and preclinical data have shown how different 
sources of diet significantly affects the composition of the gut microbiota (Sandhu et al., 2017), and mood in 
non-mood disorder diagnosed individuals (Taylor et al., 2019). Moreover, the effects of diet can be dramatic 
in terms of both drastic compositional changes and the immediacy of such effects. For instance, individuals 
on either an animal- or plant-based diet, when switched to the other diet, experienced substantial changes 
in the gut microbiota composition, within 24 hours (David et al., 2014). A different dietary pattern has been 
shown to influence β diversity of the gut microbiota composition, but not α diversity (Basso et al., 2016), 
which was quite divergent in individuals on an animal-based diet (David et al., 2014). Changes in our lifestyle 
and food preferences have had a drastic impact on our diet (Aslam et al., 2018; Dinan et al., 2018; Miranda et 
al., 2016; Moya-Perez et al., 2017a; Reichelt et al., In Press). Indeed, different types of diet have been associ-
ated with different impacts on the composition of the gut microbiota. In fact, dietary iron has been shown to 
regulate insulin resistance to affect susceptibility to infection, highlighting the importance of evolved co-op-
erative mechanisms (Sanchez et al., 2018). However, much more research is needed to delineate if the effects 
of diets or dietary components on the microbiota are driving changes in overall brain function or happiness 
or if they are occurring in a microbiota-independent fashion.
Western diet
The Western diet, a diet rich in sugar, salt and/or fat, has been widely regarded as a major contributing 
factor in the onset of metabolic disorders and associated pathological conditions. Individuals on a Western 
diet share a similar gut microbiota profile to that observed in obese individuals (David et al., 2014). Intake 
of an HFD consisting of only animal-based products, including meat and cheese, profoundly shifted their gut 
microbiota community and altered β diversity, within 48 hours of consumption (Carmody et al., 2015). In an-
other study, five different inbred mouse strains and four different transgenic strains (Rag-/-, MyD88-/-, NOD2, 
and ob/ob) crucial for host-microbiota interaction, combined with over two hundred outbred mice, were 
administered a Western high-fat and high-sugar diet. They reported a dramatic shift in the gut microbiota 
composition in animal groups due to consumption of the western diet (Carmody et al., 2015). 
Further, animal models fed an HFD demonstrated an alteration in their gut microbiota profile with a reduc-
tion in Bacteroidetes levels and an increase in both Proteobacteria and Firmicute levels (Hildebrandt et al., 
2009). This was also reported in a similar study where the animals fed with a diet rich in animal-derived satu-
rated fats demonstrated a significant increase in Proteobacteria (Bilophila wadsworthia) abundance (Devko-
ta et al., 2012). It is worth noting that B. wadsworthia is a major member of sulfidogenic bacteria found in 
the human gut and have been shown to induce systemic inflammation (Feng et al., 2017). However, one must 
consider this increase could be attributed to the source of fat being animal based which is rich in saturated 
fats and salt. This further illustrates the critical role diet has on gut microbiota function (Wilck et al., 2017) 
and such strong shifts in gut microbiota profiles are subsequently poised to affect brain and behavior. 
Mediterranean diet
The Mediterranean diet has garnered a lot of media attention for its numerous potential health benefits. 
A Mediterranean diet consists mostly of cereals (whole grains), nuts, legumes, vegetables and fruits with 
moderate consumption of poultry and fish (Estruch et al., 2013), and results in distinctive and identifiable gut 
microbiota characteristics (Mitsou et al., 2017). Human intervention studies have shown that the consump-
tion of a Mediterranean diet can dramatically reduce the incidence of neurodegenerative disorders (Karstens 
et al., 2019; Romagnolo and Selmin, 2017; Scarmeas et al., 2006), psychiatric conditions, cancer (Schwing-
shackl et al., 2017) and cardiovascular disease (CVD (Bonaccio et al., 2013; Tsivgoulis et al., 2015; Wu and 
Sun, 2017)). Interestingly, the Mediterranean diet has been shown in a number of studies to correlate with a 
reduced risk of depression (Akbaraly et al., 2009; Estruch et al., 2013; Lassale et al., 2018; Milaneschi et al., 
2011; Sanchez-Villegas et al., 2006), probably due to the rich source polyphenols present in different com-
ponents. The positive impacts of a Mediterranean diet are mediated by its anti-inflammatory potential but is 
also associated with marked changes at the level of the gut microbiota, resulting in an increase in the abun-
dance of Bacteroides and Clostridium phyla, and a reduction in Proteobacteria and Firmicutes phyla (Marlow 
et al., 2013) and associated metabolome (De Filippis et al., 2016). Further, consumption of a Mediterranean 
or Western diet resulted in distinct mammary gland microbiota and metabolite profiles, with Lactobacillus 
in greater abundance in Mediterranean diet-fed monkeys, indicating that diet can influence mammary gland 
microbiota, indicating a potential novel avenue for breast cancer prevention (Shively et al., 2018).
A randomized controlled trial of dietary intervention in major depression (SMILES) confirmed a poor diet cor-
related with a depressed cohort (N=67) and furthermore showed that the Mediterranean diet intervention 
(ModiMedDiet) improved depression scores (Jacka et al., 2017). An earlier study in a cohort of 119 depressed 
patients, which again focused on providing dietary advice, provided some evidence of a beneficial effect of 
diet to the individual. However, participants in this study were at a mild level of depression at baseline and 
may have had less scope for improvement (Forsyth et al., 2015).  
These studies are just the beginning of a new era of nutritional psychiatry (Jacka, 2017) However, much more 
work is needed to define what the contribution of the microbiome in mediating such effects is and to deter-
mine how diet and its components imbue their effect on the microbiota-gut-brain axis. 
Ketogenic diet
The ketogenic diet is a high-fat, low-carbohydrate diet that mimics the metabolic effects of starvation by 
forcing the body to use its primary fat reserves (Barañano, 2008).   It was devised based on the observation 
that fasting had anti-seizure properties.  Administration of the ketogenic diet resulted in increased levels 
of the ketone bodies β-hydroxybutyrate, acetoacetate, and acetone in the peripheral blood and urine. This 
elevation in the serum ketones has been shown to inhibit apoptotic proteins and improve mitochondrial 
activity and thus reducing apoptosis in neurodegenerative diseases (Cavaleri and Bashar, 2018). Moreover, a 
ketogenic diet mediates its neuroprotective function through the attenuation of oxidative stress and induc-
tion of protein expression of antioxidants (Greco et al., 2016), as well as the modulation of neurotransmitter 
levels such as GABA, monoamines and glutamate (Hartman et al., 2007; Yudkoff et al., 2008). Therefore, a 
ketogenic diet can offer beneficial health effects towards ameliorating symptoms of neurological conditions 
including autism, depression, epilepsy, cancer, Alzheimer’s and Parkinson’s diseases (Bostock et al., 2017; 
Gasior et al., 2006; Lange et al., 2017). However, more recently the microbiome has emerged as a key player 
in the mechanism of action of the ketogenic diet.
One study showed the ketogenic diet increasing the relative abundance of Akkermansia, Parabacteroides, 
Sutterella and Erysipelotrichaceae levels in the gut microbiota in mice compared to a control group, and that 
the gut microbiota is required for ketogenic diet-mediated protection against acute epileptogenic seizures 
(Olson et al., 2018). Furthermore, colonization of GF mice with ketogenic diet-associated strains, Akkerman-
sia and Parabacteroides, restored seizure protection. They also reported alterations in colonic luminal, se-
rum, and hippocampal metabolomic profiles that also correlate with seizure protection (Olson et al., 2018). 
This evidence demonstrates that different dietary components can induce differential effects on the brain via 
their actions on the gut microbiota. Further studies of the ketogenic diet in animal models of autism (Newell 
et al., 2016) and schizophrenia (Kraeuter et al., In Press) are also encouraging that such effects extend beyond 
epilepsy.
Carbohydrates
Carbohydrates contribute to a major portion of the human diet. A culture-based study showed changes in 
staple carbohydrate acutely altered gut microbiota composition (Li et al., 2017a), in just one week. For in-
stance, wheat and oat-based diets resulted in increases in B. catenulaturm, B. adolescentis with a reduction 
in Latobacillus, Runimococcus and Bacteroides; whereas the consumption of rice suppresses B. adolescentis 
and B. longum levels (Li et al., 2017a).
Carbohydrates come in two forms: digestible and indigestible. Digestible carbohydrates include starch and 
sugars, which are enzymatically degraded (glucose, fructose, sucrose and lactose) and readily absorbed into 
the bloodstream and can stimulate insulin release into the bloodstream (Singh et al., 2017). A diet rich in 
glucose, fructose, and sucrose can significantly increase the abundance of Bifidobacterium with a significant 
reduction in Bacteroides (Eid et al., 2014). Mice fed a fructose-rich diet demonstrated significant increases 
in Coprococcus, Ruminococcus and Clostridium, and a reduction in Clostridiaceae family (Crescenzo et al., 
2017). However, various Clostridium cluster species have been shown to be associated with inflammatory 
bowel syndrome (Bassotti et al., 2018), metabolic disorders (Woting and Blaut, 2016) and psychiatric condi-
tions (Li et al., 2017b).
Undigested carbohydrates i.e. resistant carbohydrates, which are often fermented by the microbiota residing 
in the distal part of the colon (Sandhu et al., 2017; So et al., 2018), are often a source of microbiota accessible 
carbohydrates (Joyce and Gahan, 2016), which are a rich carbon source for the microbes and are known to 
influence the intestinal environment (Lozupone et al., 2012; Sonnenburg and Sonnenburg, 2014). As a result, 
most prebiotics are undigested carbohydrates known to induce beneficial effects on the host GI system via 
stimulating the growth of healthy gut microbiota. 
Protein 
Protein is an important component in our diet as it is the prime source of amino acids, the building blocks 
of life. Amino acids are critical for the synthesis of neurotransmitters and brain health. There are different 
sources of protein based on their origin, such as plant or animal-based protein (Singh et al., 2017). Numer-
ous studies have shown a strong correlation between protein intake and overall microbial diversity (Madsen 
et al., 2017). Individuals on a plant-based protein diet reported low levels of Firmicutes: Bacteroidetes ratio 
with higher microbiota diversity compared to individuals on high-fat, high-sugar diet (De Filippo et al., 2010). 
Different sources of protein in a diet has been shown to influence different gut microbiota profiles (Singh et 
al., 2017). Rats treated with fish and chicken meat reported a significant increase in Firmicutes with a reduc-
tion in Bacteroidetes abundance in the gut microbiota profile. In contrast, intake of a soy-rich diet resulted in 
an increase in abundance of Bacteroidetes in the microbiota of rats. Furthermore, intake of chicken protein 
showed an increase in abundance in Actinobacteria whereas administration of beef increased the abundance 
of Proteobacteria (Zhu, 2015).
An increase in a protein-based diet has been associated with increases in SCFAs and branched chain amino 
acids (Singh et al., 2017). For example, consumption of pea protein increases intestinal SCFA levels, which 
have been associated with anti-inflammatory effects and is critical for the maintenance of the mucosal bar-
rier (Kim et al., 2014). On the contrary, consumption of a protein-rich diet is associated with increases in 
the abundance of Bacteroides because they are crucial for the initial proteolysis of protein into amino acids 
in the gut. Intake of an animal-based diet showed significant increases in bile-tolerant anaerobes including 
Alistipes, Bilophila and Bacteroides (Cotillard et al., 2013; David et al., 2014). A similar effect was observed in 
a culture-based study comparing Italian children fed animal protein to children from rural Africa fed an agrar-
ian diet; the Italian children showed an increased abundance of Alistipes and Bacteroides in their microbiota 
corresponding to protein intake (De Filippo et al., 2010). Clinical data have shown an increased abundance 
of Alistipes in the gut microbiota of individuals with depression (Jiang et al., 2015). This further supports the 
role of diet in the modulation of the microbiota-gut-brain axis. Recent research has suggested long-term 
animal-based diets have a deleterious effect on the gut microbiota (Moreno-Perez et al., 2018). Therefore, 
more research is required to further dissect the underlying mechanisms of the effect of various components 
of a protein-based diet on the gut microbiota and its metabolites. 
Fats
Diets rich in saturated and trans-fat are associated with a high incidence of CVD and an increase in total blood 
low-density lipoprotein cholesterol. For example, administration of an HFD to healthy subjects caused a de-
crease in Bacteroidetes levels with an increase in both Firmicutes and Proteobacteria levels of gut microbiota 
(Hildebrandt et al., 2009; Zhang et al., 2012a). Similar changes in the phylum were observed with mice fed 
on a high-fat and high-sucrose diet (Parks et al., 2013). 
Healthy fats, also known as polyunsaturated fatty acids (PUFAs), such as omega-6 and omega-3, have been 
shown to induce beneficial effects by lowering the onset of CVD and can be protective against depression, 
some cancers, arthritis and cognitive decline (Costantini et al., 2017), as well as to support visual, cognitive, 
motor, and social development in mice (Carlson et al., 2019). Studies show intake of PUFAs increase the 
abundance of healthy microbiota including Roseburia, Bifidobacterium and Lactobacillus spp. PUFAs have 
also been shown to prevent alteration of the gut microbiota (Devillard et al., 2007). For instance, early-life 
exposure to omega-3 prevented the onset of metabolic disorders known to be mediated through a perturbed 
gut microbiota profile post-antibiotic treatment (Kaliannan et al., 2016). Similarly, in adult mice chronic ex-
posure to omega-3 showed a significant increase in Bifidobacterium and Lactobacillus spp. with higher bi-
fidobacteria to enterobacteria ratio in adult mice exposed to omega-3 (Robertson et al., 2017a). A recent 
study comparing 876 middle aged female subjects showed that the administration of omega-3 was able to 
modulate gut microbiota by significantly increasing α diversity (Menni et al., 2017). Docosahexaenoic acid 
levels from subjects on an omega-3 diet strongly correlated with 38 operational taxonomic units from the 
Lachnospiraceae family (Menni et al., 2017), which have been reported to be in abundance in herbivorous 
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word>Humans</keyword><keyword>Polymerase Chain Reaction/*methods</keyword><keyword>RNA, 
Ribosomal, 16S/genetics</keyword><keyword>Sensitivity and Specificity</keyword><keyword>Sequence 
Analysis, DNA</keyword></keywords><dates><year>2009</year><pub-dates><date>Jun</date></pub-
dates></dates><isbn>1574-6941 (Electronic. In humans, members belonging to the Lachnospiraceae family 
have been shown to be protective against C. difficle (Petrof, 2013) and metabolic disorders (Cho et al., 2012). 
The members of Lachnospiraceae are potent producers of SCFAs (Duncan et al., 2002). Overall, more work is 
needed in understanding the relative contribution of the effects of fats on the microbiota to their impact on 
brain function. 
D. Environment
The environment we live in has perhaps one of the greatest impacts in shaping cross-cultural differences in 
health outcomes and microbiota composition. For example, different members of the gut microbiota have 
been shown to be involved in metabolizing more than 40 different environmental chemicals utilizing the 
enzymes azoreductase, nitroreductase, β-glucuronidases, sulfatases and β-lyases (Claus et al., 2016). Con-
versely, these chemicals also modulate the gut microbiota composition (Claus et al., 2016), which may thus 
have effects on brain and behavior through the microbiota-gut-brain axis. For instance, bisphenol A (BPA) 
is an endocrine-disrupting chemical widely used in the manufacture of plastic containers. Exposure to BPA 
through diet results in a dramatic reduction in species diversity of gut microbiota in rodents, while increasing 
the abundance of Proteobacteria and Helicobacteraceae, and reducing Clostridia (Lai et al., 2016). 
Heavy metals such as cadmium, mercury, arsenic, and lead are potent toxicants to a living organism (Lu 
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and cause oxidative stress (Bajaj et al., 2013; Jin et al., 2017; Valko et al., 2006). Exposure to heavy met-
als can also alter the gut microbiota composition in both animals and humans (Claus et al., 2016; Lu et 
al., 2014; Zhang et al., 2015). Administration of heavy metals to animals dramatically perturbed their gut 
microbiota and metabolomic profile, increasing relative levels of Lactobacillaceae and Erysipelotrichaceae 
while reducing relative levels of Lachnospiraceae (Breton et al., 2013). Low levels of Lachnospiraceae have 
been associated with human depression (Naseribafrouei et al., 2014)Hedmark University College, Hamar, 
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ants.
Finally, extensive abuse of antibiotic usage by humans has contributed to an increase in the concentration of 
various antibiotics in our natural environment, including lakes, rivers, agriculture soil, waste and surface wa-
ter (Dong et al., 2016; Ferro et al., 2016; Qian et al., 2016). In combination with the high levels of antibiotics 
in many food sources, this will likely have wide-spread consequences not only for individual host health but 
also from a broader planetary health perspective (Prescott and Logan, 2019).
E. Exercise
Regular exercise is synonymous with good health including brain health. Moderate amounts of exercise can 
make a meaningful difference to brain structures and their function; for example, in rodents, voluntary ex-
ercise impacts the rate of neurogenesis (Adami and Bottai, 2016; van Praag et al., 1999). Exercise has also 
demonstrated a capacity to overcome age-dependent depletion of hippocampal neurogenesis (van Praag et 
al., 2005), offering a prospective potential for the reversal of aging within brain structures. Despite the extent 
of research looking at the relationship between exercise and brain structures/function, there is relatively 
little information currently available on the effect of exercise on the gut, its microbiota and the influence of 
exercise upon the gut-brain axis. Exercise along with a number of different factors, such as diet, infection, 
disease, antibiotics (Grenham et al., 2011; Mackie et al., 1999) also modulates the health and α-diversity of 
gut microbiota. Moderate levels of exercise are particularly beneficial in reducing levels of stress and building 
immunity along with positive changes in energy homeostasis and regulation (Bermon et al., 2015; Mika et al., 
2015). It is reasonable to think of exercise as being crucial to healthy interactions within the gut microbiota 
(Choi et al., 2013). The extent of beneficial effects of exercise on the brain via the gut microbiota remains 
unclear.
Research examining the reciprocal relationship between exercise and gut microbiota composition is still in 
its infancy, as such little is known about how the gut microbiota may contribute to an individual’s exercise 
performance (Mach and Fuster-Botella, 2017). To date, the majority of studies undertaken have been pre-
clinical animal studies that only indirectly address how exercise positively influences gut microbiota compo-
sition. The potential role of exercise-induced microbial changes in preventing HFD induced obesity has been 
investigated in mice (Evans et al., 2014). The authors reported that voluntary exercise had significant effects 
on the relative balance of the major bacterial phyla (Bacteroidetes and Firmicutes) that was concurrent with 
prevention of dietary-induced obesity and normalization in glucose tolerance and that the change in ratio 
between Firmicutes: Bacteroidetes phyla was proportional to the distance ran (in the HFD fed mice). In a 
case-control study, free access to exercise was associated with a significant increase Lactobacillus, Bifidobac-
terium, and Blautia coccoides – Eubacterium rectale species, in principle, improving the α-diversity of the gut 
microbiota (Queipo-Ortuno et al., 2013), with potential subsequent brain and behavior effects. Exercise was 
reported to cause massive shifts in mice gut microbiota at nearly the same magnitude as an HFD, with exer-
cise reducing the phyla Bacteroidetes, and increased Firmicutes, Proteobacteria and Actinobacteria. Exercise 
increased cognitive abilities but was not able to prevent a significant increase in anxiety associated with the 
HFD. Similarly, the effects of controlled exercise training on gut microbial composition in obese, non-obese, 
and hypertensive male rats has been studied (Petriz et al., 2014). 
Recent human clinical studies have attempted to elucidate how exercise modifies gut microbiota composi-
tion using different approaches to stratify the level of physical activity or fitness. In the American Gut Project 
1493 participants fecal samples were categorized based on exercise frequency (Never, Rarely, Occasionally 
(1-2 times per week), Regularly (3-5 times per week) and Daily), and analyses reported that groups who exer-
cised more frequently had a greater α diversity, with an elevation in certain members of the Firmicutes phy-
lum (McFadzean, 2014). A finding along similar lines was reported in a recent study of professional athletes 
from the Irish international rugby union squad suggested that professional athletes in comparison to the 
sedentary individuals (Clarke et al., 2014) had a significantly higher diversity of gut microbiota, that positively 
correlated with protein and creatine kinase consumption, than both control groups matched for physical size, 
age, and gender. Notably, both the athletes and low BMI group had significantly higher proportions of the 
genus Akkermansia than the high BMI group, a factor generally associated with a healthier metabolic profile 
(Le Chatelier et al., 2013). Furthermore, indices of microbiota diversity of the athletes positively correlated 
with protein intake and levels of plasma creatine kinase with support for the protein and microbiota diversity 
relationship provided by a positive correlation between urea levels - a by-product of diets that are rich in 
protein and microbiota diversity - suggesting that both diet and exercise are drivers of biodiversity in the gut. 
An increase of microbial diversity was once again reported in individuals who performed a 4-day cross-coun-
try ski-march in Arctic conditions compared to controls, by (Karl et al., 2017), amongst other changes. To 
determine whether increasing physical activity and/or increased protein intake modulates gut microbial 
composition and function, a recent study (Cronin et al., 2018) challenged healthy sedentary adults with an 
8-week combined exercise regime, with and without concurrent daily whey protein consumption. A com-
bined aerobic and resistance training exercise regime led to modest alterations in the composition and ac-
tivity of the gut microbiota of the sedentary individuals. The link of such changes to brain function requires 
further analysis. 
Perhaps the most compelling argument for the benefits of exercise can be taken from studies that show 
the negative consequences during withdrawal of regular exercise, where symptoms of increased negative 
mood and fatigue were seen in healthy individuals in as little as 14 days, compared to controls (Kop et al., 
2008). It may be that changes in mood and fatigue are associated more with the ability of the gut microbi-
ota to control host tryptophan metabolism and levels of plasma kynurenine, which are strongly correlated 
with depression (Claes et al., 2011). A recent preclinical study investigated a potential peripheral mechanism 
through which exercise may bring about its beneficial effects via the kynurenine pathway of tryptophan me-
tabolism and exercise-related PGC-1a1 expression (Agudelo et al., 2014; Harkin, 2014); increased expression 
of muscle-specific PGC-1a1 in transgenic mice was associated with greater resilience to chronic stress and 
stress-induced CNS inflammation (Agudelo et al., 2014).
Taken together, although exercise has many potential beneficial effects upon the gut microbiota there is a 
need for longitudinal studies to resolve the many gaps in current knowledge and to fully understand the 
mechanisms that regulate changes in the composition and functions of microbiota especially in the context 
of brain health. 
V. Medications and the Microbiome
Among the different therapeutic classes, antibiotics represent the most direct and effective way of targeting 
the gut microbiota (Antunes et al., 2011; Jakobsson et al., 2010) (see Table 3). However, a growing body of 
evidence suggests that non-antibiotic drugs can also affect the composition of the gut microbiota, with po-
tential implications for behavior, as well as the involvement of the microbiota in drug pharmacokinetics in 
general (Clarke et al., 2019). In a recent large-scale observational study, the use of medical interventions was 
associated with a significant variation in the microbiota. Of the 69 microbiota covariates from the Belgian 
Flemish Gut Flora Project, 13 were drugs belonging to the following classes: antibiotics, osmotic laxatives, 
IBD medications, female hormones, benzodiazepines, antidepressants, and antihistamines (Falony et al., 
2016). In another population-based study, deep-sequencing of the gut microbiotas revealed a relationship 
between the microbiota and 44 categories of drugs (Zhernakova et al., 2016). As expected, antibiotics were 
significantly associated with altered microbiota composition; more surprising was the number of other drug 
categories, including proton pump inhibitors (PPIs), metformin, statins, and laxatives that were also shown 
to have robust effects on the gut microbiota. 
Polypharmacy, the concurrent use of multiple medications by a patient, has also been associated with gut 
microbiota changes. One study demonstrated that there was a significant negative correlation between the 
number of different drugs consumed and microbial diversity, although it is unknown if the lower diversity 
resulted in reduced cognitive function (Ticinesi et al., 2017). Specifically, the drug classes that had the stron-
gest association with single taxa abundance were PPIs, antidepressants and antipsychotics. Gut microbiota 
samples exposed to different drugs have also been analyzed through metatranscriptomic approaches. The 
impact of short-term exposure of human feces to various non-antibiotic drugs including cardiac glycosides, a 
gastric-acid suppressant (nizatidine), an anthelmintic (levamisole), an analgesic (phenacetin), and sulfasala-
zine, significantly changed the expression of microbial genes linked to drug import and metabolism (Maurice 
et al., 2013). Several studies have been performed in vitro in order to determine the antimicrobial activity 
of non-antibiotic drugs (Gunics et al., 2002; Gunics et al., 2001; Kruszewska et al., 2000, 2002), all of which 
have been shown to possess antimicrobial activity, with a strong potential for subsequent functional neural 
effects. 
Given the rise of interest in the microbiota-gut-brain axis, it is unsurprising that in recent years much effort 
has been placed on understanding the role of psychotropic medications. The antidepressant SSRIs (selec-
tive-serotonin reuptake inhibitors), including sertraline, paroxetine and fluoxetine (Jin et al., 2018), have an-
timicrobial activity against gram-positive bacteria such as Staphylococcus and Enterococcus (Ayaz et al., 2015; 
Coban et al., 2009). In addition, the antimicrobial activity of some antidepressants has been confirmed by 
the synergistic effect of some SSRIs in combination with antibiotics, as well as their effects against some anti-
biotic-resistant bacteria (Bohnert et al., 2011; Munoz-Bellido et al., 1996, 2000). In one recent study chronic 
fluoxetine administration induced a depletion of cecal levels of Prevotella and Succinivibrio (Cussotto et al., In 
Press), while another witnessed a reduction in Lactobacillus johnsonii and Bacteroidales S24-7 which belong 
to a phyla that has been associated with the regulation of body mass (Lyte et al., 2019b). Another class of 
antidepressants, tricyclic antidepressants (TCAs), have been shown to prevent the growth of gut pathogens 
such as E. coli, Yersinia enterocolitica (Csiszar and Molnar, 1992; Molnar, 1988) and the parasite Giardia lam-
blia (Weinbach et al., 1992). 
Antipsychotics belonging to the non-antibiotic phenothiazines class and their derivatives have been shown 
to protect mice from E.coli infection (Komatsu et al., 1997). This action has been confirmed in a clinical study 
where promethazine was shown to exert a synergistic effect when combined with gentamycin in children 
with frequently recurring pyelonephritis (Molnar et al., 1990). In a large cohort study in elderly hospitalized 
patients, antipsychotics were one of the three drug classes that exhibited the strongest association with 
single taxa abundance, together with PPIs and antidepressants (Ticinesi et al., 2017). Another recent study 
of patients with bipolar disease found that atypical antipsychotics induced a decrease in microbial diversi-
ty, with the effect being present in females but not in males (Flowers et al., 2017). At the microbiota genus 
level, individuals in this bipolar cohort treated with atypical antipsychotics exhibited a significant increase 
in Lachnospiraceae abundance and a significant decrease in Akkermansia. Finally, in the large-scale study of 
> 1000 drugs mentioned above nearly all subclasses of the chemically diverse antipsychotics exhibited an-
ticommensal activity (Maier et al., 2018), raising the possibility that direct bacterial effects might be part of 
the mechanism of action of these drugs. This is in line with animal studies on antipsychotics whereby chronic 
administration of olanzapine and risperidone affects the gut microbiota composition (Davey et al., 2013; 
Davey et al., 2012; Kao et al., 2018; Morgan et al., 2014). Overall, one cannot neglect the pressing need to 
examine any potential effect all orally consumed medications may have on our microbiota, and subsequent 
efficacy of the active compounds thereafter. 
W. Stress
Stress is a state in which the normal homeostasis of an organism is disturbed due to an actual or perceived 
threat (de Kloet et al., 1994; McEwen et al., 2016). Acute stress activates the HPA axis (see Section IV. J), 
resulting in an immediate release of cortisol (or corticosterone in rodents; (Dickerson and Kemeny, 2004; 
Smith and Vale, 2006)). This is an evolutionarily conserved response that prepares the individual to defend 
against or escape from threat. After the threat subsides, normal homeostasis should return. However, when 
that fails to occur chronic activation of the stress response results in dysregulation of the HPA axis (Dickerson 
and Kemeny, 2004) and an increased risk of subsequent maladies. In humans, stress-related disorders such 
as anxiety and depression cost the European Union upward of €160 million in 2010 (Olesen et al., 2012). As 
such, chronic stress is rapidly becoming a global societal challenge. 
More than four decades ago, a link between stress and the abundance of lactobacilli in mice was discovered 
for the first time (Tannock and Savage, 1974). This finding was subsequently replicated in the rhesus monkey 
(Bailey and Coe, 1999), or rat models of early life maternal separation stress (Gareau et al., 2007; O’Mahony 
et al., 2011; Rincel et al., 2019). Many preclinical studies have since demonstrated that stress impacts gut 
microbial composition in a number of different hosts, including rodents (Bharwani et al., 2016; Golubeva et 
al., 2015; Partrick et al., 2018), pigs (Mudd et al., 2016), horses (Mach and Fuster-Botella, 2017) and non-hu-
man primates (Bailey and Coe, 1999; Bailey et al., 2004) (see Table 1). In one instance, chronic psychosocial 
stress induced an increase of Helicobacter pylori in the gastric mucosa, concurrent with an increase in serum 
corticosterone levels in mice (Guo et al., 2009). These effects appear to be replicated across different stress 
models. Psychological stressors ranging from water avoidance to maternal separation, heat and acoustic 
stress and overcrowding have all been shown to change the composition of the gut microbiota (Bailey et al., 
2011; Bharwani et al., 2016; De Palma et al., 2015; Hsiao et al., 2013; O’Mahony et al., 2009; Sun et al., 2013). 
In addition, maternal stress during pregnancy display a distinct fecal microbiota profile (Hantsoo et al., 2019; 
Hechler et al., 2019), that has generational consequences. The maternal microbiota influences offspring mi-
crobiota and correlates with hyper-reactivity of the HPA axis, together with other perinatal factors, as a key 
determinant of offspring outcomes (see Section III. A). Furthermore, the transfer of the maternal vaginal mi-
crobiota from stressed dams to non-stressed pups is sufficient to alter their response to stress in adulthood 
(Jasarevic et al., 2018). These findings also translated to humans in a population-based study whereby infants 
born to mothers with high cumulative stress during pregnancy exhibited an aberrant microbial composition 
(Zijlmans et al., 2015). It has become quite clear that many factors one comes in contact with daily can have 
an impact on our microbiota-gut-brain axis, some as subtle as food cravings to as long-lasting and impacting 
as congenital heredity and mode of delivery. In the following section (see Section VII), we will delve further 
into behaviors modified directly and indirectly by the microbiota, after which we will examine the role of the 
microbiota-gut-brain axis in disease. 
X. Circadian Rhythm
The circadian rhythm describes the 24-hour cycle that regulates bodily functions, from rest/wake timing to 
cellular level metabolic processes in the majority of organisms, including humans, mice, and bacteria (Voi-
gt et al., 2016a). Modern day lifestyles contain many unavoidable and harmful disruptions to the circadian 
rhythm including jet lag and shift work. Both have been linked to metabolic (Arble et al., 2010; Maury et al., 
2010) and psychiatric (Pantazopoulos et al., 2018; Wulff et al., 2010) illness. Recently, the interplay between 
circadian rhythm and the microbiome is being investigated in the context of obesity, CVD, diabetes, psychi-
atric disorders, and neurodegenerative disorders (Dyar et al., 2018; Liang and FitzGerald, 2017; Voigt et al., 
2016a) which may have key implications for our understanding of the microbiota-gut-brain axis.
The mammalian circadian clock follows a feedback loop of transcription and translation. The positive tran-
scription factors CLOCK and BMAL1 regulate expression of the inhibitory transcription factors Period (PER1/2) 
and cryptochrome (CRY1/2), which in turn repress CLOCK and BMAL1, restarting the cycle (Takahashi, 2017). 
Interestingly, the average human circadian rhythm is 24.2 hours which is amenable to the endogenous bio-
logical clock zeitgebers, light and food (Voigt et al., 2016a). Recent evidence has identified the microbiota as a 
potential circadian clock modulator, effecting change to the peripheral and central clocks (Liang and FitzGer-
ald, 2017; Thaiss et al., 2014). Furthermore, it appears that circadian disruption can alter the intestinal micro-
biota (Voigt et al., 2014). When there is a change in the light, food (diet), or the microbiome, the peripheral 
clocks are affected. Further, disruption or dysregulation of the peripheral or central clocks can lead to serious 
negative consequences, including microbiome dysregulation, as one recent study has demonstrated utilizing 
transgenic mice containing deletions of circadian clock genes (Voigt et al., 2014). The researchers witnessed 
significant changes to the microbiome, and a dampening or abolishment of microbiota compositional oscilla-
tions (Liang et al., 2015b; Thaiss et al., 2014; Voigt et al., 2016b). In one study in particular, the dysregulation 
of the microbiota was rescued by specifically timed feeding (Thaiss et al., 2014). From a human perspective, 
it has been reported that patients with IBD have an overall reduction in circadian clock gene transcripts 
(Hill-Burns et al., 2017a). Since both circadian disruption and microbiome dysregulation express complex 
bidirectional regulation leading to immune activation and inflammation, it may be that inflammation acts 
as an intermediary between the circadian rhythm and the microbiome (Hill-Burns et al., 2017a; Voigt et al., 
2016a). The mammalian circadian clock may be modulated by the microbiome by tuning the amplitude of 
the circadian gene NFIL3 with the microbial metabolite LPS, potentially resulting in microbially controlled 
energy storage and body-fat accumulation (Wang et al., 2017)
Upon examination of circadian clock mRNA in GF mice, it was reported that the microbiota was required for 
correct integration of liver clock-oscillations, which in turn regulate metabolic gene expression for optimal 
liver function (Montagner et al., 2016). Moreover, conventional mice treated with antibiotics demonstrated 
systemic disruption of microbiota diurnal rhythmicity (Thaiss et al., 2016). Indeed, host homeostatic colo-
nization disruption leads to a loss in microbiota compositional and biogeographical rhythmicity, which in 
turn disrupts hosts rhythmicity (Thaiss et al., 2016). Further, a human study examining jet lag and mouse 
models of shift work found an arrhythmic microbiome that had a significantly altered microbiota composi-
tion that promoted metabolic imbalance, which was transferrable to GF mice via FMT (Thaiss et al., 2014). A 
contemporaneous study reported that mice undergoing a 12-hour phase shift, mimicking human shift work 
when fed a high-fat and high-sugar diet, experienced a significant decrease in microbial diversity and marked 
changes to their microbiota (Voigt et al., 2014). The exacerbation of shift work and jet lag’s adverse metabolic 
effects by a high-fat diet, or a high-fat and high-sugar diet, is especially poignant considering these lifestyles 
are often accompanied by poor eating habits, and the microbiota modulation presents as a potential thera-
peutic avenue for these conditions. More work is needed to understand the relationship between circadian 
rhythms, microbiota and brain health but it is clear that inter-relationship will be physiological and perhaps 
clinically relevant.
X. Behavior and the Microbiota-Gut-Brain Axis
The microbiota-gut-brain axis is poised to affect and be reciprocally affected by many factors, including social 
and cognitive behavior, fear, stress and food intake (Fig. 6.) We are slowly beginning to understand the rela-
tive contribution this axis has to such complex physiology and behavior. In this section, we will examine these 
behaviors and propose possible therapeutic avenues. 
A. Food Intake
What we eat and when we eat is likely affected by the composition and function of our microbiota, where an 
array of orexigenic (i.e., ghrelin, NPY) and anorexigenic hormones (i.e., GLP-1, PYY, CCK, and CRF; see Section 
VII D and F) play a crucial role (Fetissov, 2017; van de Wouw et al., 2017). This is supported by the fact that 
many conditions wherein food intake behavior is dysregulated, like anorexia nervosa and obesity (see Sec-
tion XI J), are associated with an altered gut microbiota (Kleiman et al., 2015; Le Chatelier et al., 2013; Mack 
et al., 2016; Morita et al., 2015; Turnbaugh et al., 2008; Turnbaugh et al., 2006; Turnbaugh et al., 2009). In 
addition, amelioration of obesity by bariatric or Roux-en-Y gastric bypass surgery results in a change in gut 
microbial composition (Gralka et al., 2015; Tremaroli et al., 2015; Zhang et al., 2009), even though this is 
not the case for weight gain in anorexia nervosa (Mack et al., 2016). Many conditions in which food intake 
behavior is dysfunctional share co-morbidities with other psychiatric disorders (Klump et al., 2009; Lopresti 
and Drummond, 2013). As such, it is important to note that levels of depression, anxiety, and eating disorder 
psychopathology correlate with various measures of gut microbiota composition (Kleiman et al., 2015).
One of the most provocative propositions has been that gut microbes are under a selective and evolutionary 
pressure to manipulate the eating behavior of the host to enhance their own fitness, which can be done by 
inducing dysphoria until we consume the nutrient these microbes thrive on, or by generating cravings for 
food that specifically promote their own growth and survival (Alcock et al., 2014). Gut microbial diversity 
plays a key role in this theory, as decreased diversity inherently has an increased prevalence of specific bac-
terial species, which might allow them to affect the host more efficiently. This is because these microbes 
have relatively less competition and have to spend fewer resources on survival while having more resources 
available for the manipulation of host eating behavior (Alcock et al., 2014). Such theories are difficult to 
prove experimentally. However, an intriguing study in Drosophila points to a key role for the microbiota in 
food choice behavior, as when GF flies were given Acetobacter pomorum and Lactobacillus spp., it changed 
their overall food preference (Leitao-Goncalves et al., 2017).
Various mechanisms through which the microbiota can affect food intake behavior have been suggested. 
Gut microbes can produce protein sequences of ≥5 amino acids that share an arrangement identical to var-
ious appetite-regulating peptides in the host (Ericson et al., 2015; Fetissov et al., 2008), which could trigger 
the production of immunoglobulins. These immunoglobulins can inhibit the degradation of such hormones, 
which has been reported for the orexigenic hormone ghrelin (Takagi et al., 2013).  As mentioned earlier (Sec-
tion VII. D.), E. coli has been reported to produce caseinolytic protease B (ClpB), a small protein sequence 
and antigen-mimetic of α-MSH (Breton et al., 2016a; Tennoune et al., 2014; Tennoune et al., 2015). Increased 
ClpB levels have been reported in anorexia nervosa, bulimia nervosa, and binge-eating disorder and were 
correlated with various psychopathologic traits (Breton et al., 2016a). Administration of ClpB-producing E. 
coli decreases short-term body weight and food intake compared to ClpB-deficient E. coli (Tennoune et al., 
2014). As such, gut microbial-derived peptide sequences provide a pathway in which the gut microbiota can 
influence host-eating behaviors.
Another likely mechanism by which the microbiota can influence food intake behavior is by affecting the 
ability to sense and taste nutrients. Interestingly, obesity is associated with a decreased responsiveness to 
sweet and fatty tastes, which results in needing a higher intensity of such stimuli to attain the same level of 
taste perception (Berthoud and Zheng, 2012). Anorexia nervosa is also associated with an impaired taste 
perception (Dazzi et al., 2013; Szalay et al., 2010), and weight gain has been shown to ameliorate these im-
pairments (Aschenbrenner et al., 2008; Nozoe et al., 1996). Signals conveying taste are mediated through 
taste receptors on the tongue, which can be either transmitted directly through the solitary tract to the thal-
amus (Breslin and Huang, 2006; Rolls, 2015), or by the local secretion of anorexic hormones like GLP-1, PYY 
and CCK (Feng et al., 2008; Martin et al., 2009; Shen et al., 2005). The role of these anorexigenic hormones is 
supported by the fact that PYY transgenic mice have a decreased behavioral response to fat- and bitter-tast-
ing compounds, of which their response to fat-taste is improved after reconstitution of salivary PYY (La Sala 
et al., 2013). A continuous supply of oral taste receptor cells plays a crucial role in this process, and the dis-
ruption hereof can be detrimental for taste signaling (Feng et al., 2014). Particularly the immune system is 
implicated in taste receptor cell renewal, as its activation results in the decrease of cell renewal and lifespan 
(Cohn et al., 2010; Kim et al., 2012; Wang et al., 2007). Moreover, systemically administered LPS results in 
decreased taste cell lifespan (Cohn et al., 2010), as well as decreased taste preference (Aubert and Dantzer, 
2005; Cross-Mellor et al., 2005; Larson, 2006), indicating systemic immunity additionally plays a role in taste 
perception. Overall, data indicate that the GI microbiota can affect taste perception, although more studies 
on microbiota-dependent mechanisms need to be performed to further validate this theory.
B. Social Behavior
Sociability may be classified as any form of interaction between more than one animal. It is a fundamental 
behavior for all species as it facilitates many beneficial outcomes such as learning, cooperation, protection, 
and mating. Interestingly, social behavior across the animal kingdom appears to be strongly influenced by the 
microbiota. Studies in GF mice showed they spend less time interacting with a novel conspecific compared 
with a conventionally colonized mouse (Buffington et al., 2016; Desbonnet et al., 2014; Sgritta et al., 2019; 
Stilling et al., 2018), but see (Arentsen et al., 2017). Moreover, while a conventionally colonized mouse will 
prefer to spend more time interacting with a novel conspecific over a familiar one, GF mice are unable to 
distinguish between either animal, which represents a cognitive deficit in the identification of social novelty 
(Desbonnet et al., 2014; Stilling et al., 2018). These findings of social deficits in the absence of a microbiota 
have been corroborated with studies of antibiotic administration in rodents. Several studies have document-
ed that antibiotic administration, resulting in a marked reduction in gut microbial diversity, is associated with 
deficits in social behavior (Degroote et al., 2016; Desbonnet et al., 2015). The precise mechanisms that un-
derlie microbiota-mediated regulation of social behavior are unknown and most likely involves a multitude 
of biological pathways acting cooperatively. 
However, several studies have taken great strides in elucidating how gut bacteria may influence social behav-
iors. For instance, knockdown of Pglyrp2 in mice resulted in a greater level of social interaction with conspe-
cifics, which suggests that bacterial components such as peptidoglycan are capable of crossing from the gut 
into the brain (see Section IV. K.) and influencing social behavior circuitry via this signaling cascade (Arentsen 
et al., 2017). The amygdala appears to be a brain region that is central to the influence of the microbiota on 
social behavior. GF mice display heightened expression of transcription factors related to neuronal activation 
(e.g., fos) in the amygdala relative to conventional controls (Stilling et al., 2015). Moreover, morphologi-
cal analysis of the murine GF amygdala reveals extensive neuronal hypertrophy and dendritic arborization 
leading to an overall increase in the volume of the various amygdalar sub-nuclei (Luczynski et al., 2016a). In 
response to social interaction, there are profound alterations in the transcriptome and spliceosome in the 
amygdala of GF mice, which may contribute to the social deficits observed (Stilling et al., 2018). These genetic 
and functional changes in the amygdala of GF mice demonstrate that this brain region is not only a crucial 
node in the neuronal circuitry underlying social behavior, but it is also the focal point through which the mi-
crobiota modulates this behavior.
As the microbiota appears to be an influential factor in shaping social behavior, it stands to reason that mod-
ulation of the microbiota through diet or probiotic administration can also affect sociability. Indeed, adminis-
tration of L. reuteri, to mice resulted in an increase in the circulation levels and expression of oxytocin, which 
was associated with an increase in social behavior (Buffington et al., 2016; Poutahidis et al., 2013). In another 
experimental rodent model, bile duct ligation-induced social withdrawal behavior in mice was ameliorated 
following treatment with the probiotic mixture, VSL#3, in addition to lowering circulating levels of proinflam-
matory cytokines (i.e., TNF-α) (D’Mello et al., 2015). Consequently, modulation of immune signaling to the 
brain may also be an additional means through which the microbiota may influence social behavior. Dietary 
mediated alterations in the microbiome may also have an important bearing upon neurocircuitry of social 
behaviors, especially during development. Experimental dietary deficiency in polyunsaturated omega-3 fatty 
acids resulted in social behavior impairments in adult, but not adolescent, rats (Robertson et al., 2017a). 
Moreover, supplementation of mice with omega-3 fatty acids prevented social behavior impairments follow-
ing induction of allergy (de Theije et al., 2014a). While a polyunsaturated fatty acid-rich diet may be exerting 
its prosocial effects via modulation of fatty acid membrane levels in the brain, it has also been shown to 
positively affect the composition of the microbiota (Pusceddu et al., 2015; Robertson et al., 2017b)  and thus 
a role for the microbiota is likely (Robertson et al., 2018). Future studies should focus on translating these an-
imal studies to the human disorders of social behavior such as ASD, schizophrenia and social anxiety disorder.
C. Cognition
There is increasing evidence supporting the idea that changes in the composition of the gut microbiota can 
influence cognitive function at multiple levels. 
Rodent Studies
The complete absence of microorganisms can induce numerous disruptions of host cognition. It has been 
shown that GF mice exhibit an impaired ability to remember a familiar object when presented with a novel 
object (Gareau et al., 2011; Luk et al., 2018), as well as impaired working memory in remembering a familiar 
environment in the spontaneous alternation task (Gareau et al., 2011). In addition, these animals exhibit al-
tered BDNF expression in the hippocampus (Bercik et al., 2011a; Diaz Heijtz et al., 2011; Gareau et al., 2011), 
which as stated earlier has an important role in synaptic plasticity and cognition (Baj et al., 2013; Lu et al., 
2014; Neufeld et al., 2011), suggesting a crucial involvement of microbes in regulating hippocampal-depen-
dent memory function. 
Antibiotics are known to disrupt the intestinal microbial community, which can result in detrimental effects 
on brain function and behavior (see Table 3). It has been shown that antibiotic administration from weaning 
age and onwards can induce gut microbiota changes, along with subsequent object recognition memory 
impairments and altered BDNF expression in the hippocampus when measured during adulthood (Desbon-
net et al., 2015). More recent studies have found similar impairments in object recognition memory after 
the administration of antibiotics in adulthood. An 11-day exposure to an antibiotic cocktail disrupted object 
recognition memory in adult male mice (Frohlich et al., 2016). This memory impairment was associated with 
changes in the expression of signaling molecules relevant to cognition (i.e., BDNF, GRIN2B, 5-HT transporter 
and neuropeptide Y) within the hippocampus among other memory-related brain regions. Similarly, chronic 
long-term antibiotic treatment was found to induce similar memory deficits in adult female mice (Mohle et 
al., 2016), along with decreased hippocampal neurogenesis. 
Such findings highlight the importance of the gut microbiota in recognition memory performance and hippo-
campal function. Nonetheless, antibiotic-induced microbiota depletion has generated mixed results in other 
types of hippocampal-dependent memories. While chronic antibiotic treatment impaired spatial memory in 
the Morris Water Maze in adult rats (Hoban et al., 2016a; Wang et al., 2015) acute treatments did not affect 
this type of memory when administered in early life in rats (O’Mahony et al., 2014), nor when administered 
during adulthood in mice and tested in the Barnes maze (Frohlich et al., 2016). This suggests differential ef-
fects based on rodent background, behavioral task, and especially in the type and/or duration of antibiotic 
treatment. Hence, further research is needed to clarify the effects of gut microbiota depletion on spatial 
memory. 
A large number of studies have focused on exploring the beneficial effects of probiotic and prebiotic treat-
ments in modulating health and preventing or restoring cognitive deficits associated with changes in gut 
microbiota (see Table’s 4 and 5). In this regard, Lactobacillus strains have been widely used for this purpose. 
Indeed, different Lactobacillus strains were capable of restoring deficits in object recognition memory in-
duced by chronic restraint stress (Liang et al., 2015a), as well as preventing these deficits in GF mice (Gareau 
et al., 2011), in a mouse model of colitis (Emge et al., 2016), and in immunodeficient mice (Smith et al., 2014). 
These strains also proved effective in restoring spatial memory impairments induced by diet in immunode-
ficient mice (Ohland et al., 2013), age (Jeong et al., 2015), hyperammonemia (Luo et al., 2014), and by gut 
microbiota depletion after chronic antibiotic treatment (Wang et al., 2015).  It has been found that probiotic 
treatment with selective Bifidobacterium strains in healthy mice can selectively improve object recognition 
memory, decrease the number of errors in a spatial memory test, and induce better long-term learning in 
fear conditioning (Savignac et al., 2014) indicating the beneficial effects of a rich microbiota in cognitive 
behavior. Furthermore, a recent study found a pro-cognitive effect of the prebiotic B-GOS® in healthy rats 
(Gronier et al., 2018). B-GOS® fed rats showed an improved performance in the attentional set-shifting task, 
thereby indicating greater cognitive flexibility, along with an increase in cortical NMDAR function within the 
frontal cortex. 
Other probiotic strains were able to induce similar beneficial effects. For example, probiotic supplemen-
tation with a mixture of Lactobacillus and Bifidobacterium strains considerably improved spatial memory 
deficits in diabetic animals (Davari et al., 2013). VSL#3, a commercially available probiotic mixture consisting 
of Streptococcus, Bifidobacterium and Lactobacillus strains restored object recognition memory impairment 
induced by chronic antibiotic treatment (Mohle et al., 2016), and cafeteria-diet supplementation (Beilharz et 
al., 2018). More recently, a mixture of ‘infant type’ Bifidobacterium strains had the same beneficial effects 
improving the cognitive deficits in GF mice (Luk et al., 2018), suggesting the importance of early-life microbi-
ota in adult cognitive behavior. Together, these data demonstrate the substantial impact of enriching the gut 
microbiota in reverting cognitive deficits associated with diverse factors.
Human Studies
Although there is abundant evidence from animal research supporting the role of the gut microbiota in 
modulating cognitive function, only a few studies have examined the influence of gut microbes on human 
cognition. Most of these studies are relatively small, but some are promising nonetheless. One of these stud-
ies showed that the gut microbiota composition of obese and non-obese subjects was linked with scores in 
speed, attention, and cognitive flexibility in a Trail Making Test coupled with alterations in neural activity in 
the thalamus, hypothalamus, and amygdala, suggesting that obesity affects the microbiota composition and 
subsequent cognitive performance (Fernandez-Real et al., 2015). In a more recent study, the microbiota com-
position in one-year-old babies was associated with cognitive development tested with the Mullen Scales of 
Early Learning showing differences in brain volume (Carlson et al., 2018). They identified three groups de-
pending on the microbial composition (i.e., high levels of Faecalibacterium, Bacteroides, and Ruminococca-
ceae), and found better performance in the group with higher levels of Bacteroides. This group was also less 
likely to be born via C-section, which fits with previous studies linking mode of delivery with child cognitive 
development (Polidano et al., 2017), highlighting the importance of gut microbiota colonization in cognitive 
development and function.
Probiotics have also been employed in humans demonstrating beneficial effects on cognitive performance 
in both healthy and diseased individuals. Treatment with Lactobacillus strains in healthy elderly subjects 
induced an improvement in cognitive test performance compared to a placebo group (Chung et al., 2014). 
In healthy women, consumption of a fermented milk product supplemented with a probiotic modulated 
the activity in brain regions involved in cognitive performance during an emotional attention test (Tillisch et 
al., 2013). Improvements in memory tasks and subjective improvements in mood were observed in a study 
on healthy individuals receiving a prebiotic of oligofructose-enriched inulin (Smith et al., 2015). B. longum 
1714 which had shown pro-cognitive effects in mice (Savignac et al., 2014) was shown to attenuate stress-in-
duced cortisol increases reducing perceived and subjective anxiety, and moderately enhancing hippocam-
pus-dependent visuospatial memory performance (Allen et al., 2016). Moreover, L. plantarum P8 was also 
found to alleviate stress and anxiety while reducing levels of pro-inflammatory cytokines in stressed adults, 
accompanied by enhanced social-emotional cognition and verbal learning and memory (Lew et al., 2018). 
Recently, a probiotic mixture containing B. longum and different Lactobacillus strains positively affected cog-
nitive function and metabolic status in Alzheimer’s disease patients (Akbari et al., 2016). Further, cognitive 
improvements in impulsive choice and decision-making were observed in patients diagnosed with Fibromyal-
gia after receiving a multispecies probiotic intervention (Roman et al., 2018), a group of patients that present 
with an altered microbiome as measured by disrupted microbiota metabolites (Malatji et al., 2019). These 
results taken together indicate the potential efficacy of probiotics for improving cognitive function in both 
healthy and AD clinical populations. However, much more work is needed to understand why specific strains/
interventions have the potential to modulate cognition and the constraints that exist on this. Moreover, it is 
clear that the combination of brain imaging techniques with neuropsychological and cognitive measures will 
greatly enhance our understanding of the microbiota-gut-brain axis in regulating cognition in healthy and 
vulnerable populations.
D. Fear
One aspect of cognition that warrants deeper examination is that of fear regulation. Exaggerated fear is a 
core symptom of clinical anxiety and fear responding is closely linked to stress (Maren and Holmes, 2016; 
McEwen et al., 2016; Raio and Phelps, 2015), which (as described in Sections VI. G. and VII. H.) is tightly 
intertwined with gut-brain axis function. The expression and inhibition of learned fear is largely regulated 
by the amygdala, hippocampus, and PFC in adult rodents and humans (Knapska et al., 2012; LeDoux, 2003; 
Maren and Quirk, 2004; Tovote et al., 2015) and these brain regions are all modulated by changes in the mi-
crobiota (Bercik et al., 2011a; Clarke et al., 2013; Cowan et al., 2018; Gacias et al., 2016; Hoban et al., 2017; 
Hoban et al., 2016b; Luczynski et al., 2016b; Neufeld et al., 2011; Ogbonnaya et al., 2015; Stilling et al., 2015). 
Despite this, studies of the microbiota in fear regulation remain relatively scarce. 
In humans, there are now a few fMRI studies linking the gut microbiota to functional brain activity during 
observation of threat stimuli (negatively valanced emotional images). The initial study in this area demon-
strated, in a sample of healthy women, that intake of a fermented milk product containing multiple probiotic 
strains could reduce the neural response to faces showing negative affect (fear or anger) (Tillisch et al., 2013). 
Specifically, brain reactivity was reduced across a distributed network of brain regions including the PFC and 
parahippocampal gyrus. Another study from the same group later showed that natural differences in the mi-
crobiota composition of healthy women were associated with altered reactivity of the right hippocampus to 
negative emotional images (Tillisch et al., 2017).  Finally, in a recent study of adversity-exposed, and control 
children, variation in Bacteroides and Lachnospiraceae were associated with brain reactivity to fear faces, 
particularly in the PFC (Callaghan et al., 2019).
Using animal models, emerging research is beginning to delineate the links between the microbiota and 
learned fear responses, or more specifically fear memory and extinction. With GF mice, short-term fear 
recall was shown to be impaired in the absence of the microbiota (Hoban et al., 2018). Adult convention-
ally-colonized, GF, and ex-GF mice underwent classical fear conditioning, whereby a previously innocuous 
conditioned stimulus was paired with an innately aversive unconditioned stimulus. Six hours later, GF animals 
exhibited low levels of conditioned fear responding relative to conventionally-colonized animals, but this 
deficit was rescued in the ex-GF mice that were re-colonized at weaning. These behavioral changes were 
accompanied by altered amygdala gene expression, specifically indicating elevated baseline amygdala activ-
ity and reduced responsiveness to the fear stimuli in the GF animals. Similar impairments of fear recall and 
additional enhancements of fear extinction are observed following acute antibiotic exposure in humans and 
rodents (Bach et al., 2018; Davis et al., 2006; Rodrigues et al., 2014). Although the broad-spectrum antibiotics 
used in these cases (doxycycline and D-cycloserine) were chosen for their direct neuromodulatory proper-
ties, the similarities to GF function suggest that it is worthwhile considering the possibility of an alternate 
microbiota-mediated mechanism in these cases as well.
Providing further support for microbial modulation of learned fear, fear responding is also altered by probi-
otic treatments, at least in rodents. These effects are strain-dependent, with different outcomes depending 
on the chosen probiotic. For example, B. longum 1714 enhanced fear learning and short-term memory in 
adult mice, without affecting extinction, while B. breve 1205 had no effect on either measure (Savignac et al., 
2015). Another probiotic strain, L. rhamnosus (JB-1), slowed extinction learning in adult mice (Bravo et al., 
2011), whereas heat-killed Mycobacterium vaccae has the opposite effect, accelerating extinction learning in 
adult rats (Fox et al., 2017). Finally, administration of a probiotic formulation containing L. rhamnosus R0011 
and L. helveticus R0052 has been shown to prevent the effects of early-life stress on fear behavior and its sup-
porting neural network during development (Callaghan et al., 2016; Cowan et al., 2016). Specifically, young 
rats exposed to early-life stress exhibit a phenotype characterized by persistent fear memory and high rates 
of fear relapse following extinction (Callaghan and Richardson, 2013; Cowan et al., 2013), a profile that is 
passed down the male line for at least two generations (i.e., the grand-offspring of the stressed males exhibit 
the same high-fear phenotype despite never directly experiencing stress) (Callaghan et al., 2016). Probiotic 
treatment rescued the normal trajectory of fear memory development in stressed rats, restoring an age-ap-
propriate normal phenotype of rapid forgetting and low rates of fear relapse not only in probiotic-exposed 
neonatal rats but also their offspring (Callaghan and Richardson, 2013; Cowan et al., 2013).
E. Stress-Related Behaviors
As described previously (see Section VI. G.), an ever-growing body of preclinical studies using a variety of 
animal models has shown that stress can alter the gut microbiota (see Tables 2-5). This relationship, like the 
microbiota-gut-brain axis itself, is bidirectional – the microbiota can modulate stress-induced alterations in 
anxiety, memory, cognition and neuroinflammation (for reviews, see Cussotto et al., 2018; Farzi et al., 2018; 
Foster et al., 2017; Rea et al., 2016; Sherwin et al., 2016a). Many studies were conducted using GF mice (see 
also Section II. A. and Table 2) (Clarke et al., 2013; Crumeyrolle-Arias et al., 2014; Diaz Heijtz et al., 2011; 
Luczynski et al., 2016a; Neufeld et al., 2011; Sudo et al., 2004). Their collective findings were critical in shed-
ding light on the existence of a link between the microbiota and stress. Moreover, this work paved the way 
for further research on the stress-microbiota link to explore potential therapeutic benefits for microbiota 
manipulations in the context of stress.
Stress Susceptibility
Given the link between the microbiota and the stress response, a relationship between resilience and micro-
biota composition has also been proposed (Kentner et al., 2018). Current studies are exploring whether basal 
microbiota composition itself can predict stress susceptibility. For example, a single exposure to social stress 
in Syrian hamsters was sufficient to induce changes in the microbiota, where multiple encounters exacerbat-
ed the effect (Partrick et al., 2018). Microbiota was differentially affected depending on the outcome of the 
chronic social defeat encounter. Further, using a chronic social defeat stress protocol, mice with higher social 
avoidance scores had greater correlational changes in cecal microbiota taxa than controls (Szyszkowicz et 
al., 2017). When analyzing the fecal microbiome from rats more vulnerable to repeated social defeat stress, 
compared to those classified as more resilient, shotgun metagenome sequencing identified an increase in 
the expression of immune-modulating microbiota, including Clostridia, in the vulnerable rats (Pearson-Leary 
et al., 2019). The depressive-like behavioral phenotype was transferrable via FMT from stress vulnerable to 
naïve rats, where ventral hippocampal microglial density and IL-1β expression were enhanced, when com-
pared to naïve rats receiving FMT from stress resilient donors (Pearson-Leary et al., 2019). In a different 
study, defeated mice displayed increased depressive-like behaviors that correlated with a reduction in the 
abundance of specific bacterial genera (McGaughey et al., 2019). Future studies should focus on whether the 
microbiota provides a mechanism for stress susceptibility or resilience in both rodents and humans.
Probiotics and stress-related changes 
There is growing evidence that specific manipulations of the microbiota might modulate the negative ef-
fects of stress, including stress-related behavior and HPA axis activation (Sarkar et al., 2016). Much of this 
work has focused on administration of probiotics, and particularly Bifidobacterium and Lactobacillus species, 
with promising effects observed on stress and related anxiety and depression in both preclinical and human 
studies (see also Sections VIII:E & VIII:F and Table 5) (Butel, 2014; Pirbaglou et al., 2016; Wallace and Milev, 
2017). 
In a randomized placebo-controlled fMRI study, a multispecies probiotic increased a buffer against stress-re-
lated negative effects on working memory, specifically in PFC recruitment, identifying the use of probiotics as 
a support for cognition under stressful situations in healthy individuals (Papalini et al., 2019). In a preclinical 
study, oral administration of L. rhamnosus (JB-1) reduced stress-induced corticosterone responses as well 
as anxiety- and depression-related behavior in mice, effects that were prevented by vagotomy (Bravo et al., 
2011). Further, L. farciminis prevented hyper-activation of the HPA axis in response to acute stress, proba-
bly due to the prevention of excessive gut permeability (Ait-Belgnaoui et al., 2012). Recently, a two-strain 
probiotic, L. helveticus and B. longum, significantly improved measures of HPA axis responsiveness to CRD, 
an acute stressor, rather than with either strain alone (Ait-Belgnaoui et al., 2018). Conversely, infection with 
pathogenic C. rodentium, enhanced vulnerability to stress-induced memory impairments in mice, which was 
ameliorated by pretreatment with a combination of probiotics (L. rhamnosus and L. helveticus) (Gareau et 
al., 2011). 
Similar attenuation of stress responses has also been observed in chronic stress paradigms. For example, 
administration of L. helveticus NS8 to Sprague Dawley rats improved behavior following chronic restraint 
stress (Liang et al., 2015a). A different strain of L. helveticus, MCC1848, was also shown to ameliorate social 
defeat stress-induced anxiety- or depressive-like behaviors in mice (Maehata et al., 2019). L. rhamnosus ab-
rogated anxiety-like behaviors due to chronic social defeat stress. However, the gut microbiota alterations 
that manifested due to the stressor remained unchanged (Bharwani et al., 2017). Another recent study has 
shown that supplementation with L. plantarum successfully abrogated heightened stress responses due to 
chronic unpredictable stress and sleep deprivation stress and resulting in increases in host gut Lactobacillus 
species (Dhaliwal et al., 2018). Likewise, administration of C. butyricum prevented depressive-like behaviors 
associated with chronic unpredictable stress (Sun et al., 2018).
The studies discussed so far were conducted in adult animals following acute or chronic stress, but probiotic 
treatments also ameliorate the effects of stress during vulnerable periods, such as in early-life stress. Several 
different probiotic strains have been tested in the maternal separation model with rats. A combination of L. 
rhamnosus and L. helveticus normalized fear behavior in stressed, maternally-separated pups and their later 
offspring (Callaghan et al., 2016; Cowan et al., 2016). The probiotic, B. infantis, normalized behavioral deficits 
in adult rats exposed to maternal separation (Desbonnet et al., 2010). Interestingly, the same strain did not 
affect depressive-like behavior in animals reared in a stress-free early environment (Desbonnet et al., 2008). 
Intervention with B. animalis and Propionibacterium jensenii restored some gut microbial perturbations in 
adult maternally-separated animals exposed to a “second hit” of stress in adulthood (Barouei et al., 2012). 
Finally, the administration of B. bifidum G9-1 concomitantly to the maternal separation stress prevented ju-
venile hypersensitivity to acute stress (Fukui et al., 2018).
The evidence for translating psychobiotic therapies into the clinic is becoming hard to ignore; studies are 
beginning to address the question of translation to humans. A combination probiotic L. helveticus R0052 and 
B. longum R0175 given to both rats and humans had an anxiolytic-like effect in rats and reduced urinary cor-
tisol levels 24 hours following administration in humans, suggesting a normalization of the HPA axis response 
to stressors (Messaoudi et al., 2011a; Messaoudi et al., 2011b). Additionally, a study using the probiotic L. 
plantarum 299v resulted in decreased cortisol levels in a group of healthy adult students undergoing sup-
plementation of probiotic during a period of exam stress (Andersson et al., 2016), and L. plantarum DR7 was 
shown to alleviate stress and anxiety in a randomized, double-blind, placebo-controlled study with stressed 
adults (Chong et al., 2019). A B. longum species, already proven to reduce anxiety and stress responses 
during acute stress in mice (Savignac et al., 2014), similarly reduced stress and anxiety measures in a popu-
lation of healthy adults as well as improving cognition (Allen et al., 2016). Physical symptoms of exam stress, 
such as the onset of stress-induced GI symptoms and head-colds, proved amenable to probiotic treatment 
with L. casei (Kato-Kataoka et al., 2016) and B. bifidum (Langkamp-Henken et al., 2015). Studies in related IBS 
cohorts have also shown an improvement in stress-related GI symptoms due to probiotic treatments (Diop et 
al., 2008). While not all potential probiotic interventions showing promise in preclinical studies have translat-
ed successfully to human studies (Kelly et al., 2017; Romijn and Rucklidge, 2015), there is enough evidence 
to warrant further investigation of potential probiotics as a therapeutic strategy to alleviate the detrimental 
effects of stress. 
Prebiotics
Although it is accepted that certain prebiotics can alter the gut microbiota (Bindels et al., 2015; Dewulf et 
al., 2013), their effect on stress is less well understood. Administration of sialyl lactoses (human milk oligo-
saccharides) to mice exposed to social disruption prevented stress-induced colonic microbial disruption and 
anxiety-like behavior (Tarr et al., 2015). The prebiotics FOS and GOS have been shown to have anxiolytic 
effects in naïve animals, protecting mice from the impact of chronic stress on the microbiota (Burokas et al., 
2017). In humans, one important small-scale placebo-controlled study in healthy individuals demonstrated 
that intervention with B-GOS® decreased waking salivary cortisol levels as well as increased positive process-
ing of emotional information (Schmidt et al., 2015). In light of these results, it could be hypothesized that 
prebiotic intake could also modulate the HPA axis and have beneficial effects on stress-related disorders.
Other Microbiota Interventions
In addition to prebiotics and probiotics, other strategies to modify or deplete the microbiota have also been 
shown to alter stress responses. Although the mechanism is not clear, microbiota depletion using antibiot-
ics has been shown to impact stress-related behaviors. Administration of non-absorbable antibiotics during 
pregnancy alters the maternal microbiota and can influence the behavior of the offspring, including increased 
anxiety-like behavior (Tochitani et al., 2016). However, prenatal and early postnatal administration of peni-
cillin decreases anxiety-like behavior and sociability in a sex-specific way (Leclercq et al., 2017). Moving to a 
later time window of administration, exposure to antibiotics from early adolescence decreases anxiety and 
impairs cognition in mice (Desbonnet et al., 2015). However, antibiotics are not the only interventional strat-
egy that can modulate stress related behavior. An FMT from stress-prone BALB/c to GF Swiss Webster mice 
increased anxiety-related behavior, whereas performing the transfer from the more stress-resilient Swiss 
Webster mice to GF BALB/c reduced the anxiety-like phenotype (Bercik et al., 2011a). Recently, FMT from 
mice exposed to chronic immobilization stress to conventional C57’s induced anxiety-like behavior and sup-
pressed hippocampal BDNF expression (Jang et al., 2018). From a more translational approach, FMT from 
depressed patients to microbiota-depleted rats was sufficient to increase anhedonia and anxiety-like behav-
iors in the rodent recipients (Kelly et al., 2016). Although these studies did not include any measurement of 
the neuroendocrine response to stress, they demonstrate that microbiota composition may play a causative 
role in stress-related behavioral changes. A clearer understanding is needed to elucidate the role neurohor-
mones play in these behavioral outcomes. Intriguingly, excessive stress combined with the use of stomach 
acid suppressants have also been shown to additively and independently affect the composition of stomach 
microbiota (MacLaren et al., 2019). Indeed, multiple neurocognitive processes in the hippocampus were co-
incident with such changes in the microbiota composition (MacLaren et al., 2019). 
XI. Diseases and Disease Processes
As the field of microbiota-gut-brain research has progressed and matured, the microbiota has been implicat-
ed in a growing list of psychological and neurological diseases and disease processes (Fig. 7). Of note, many 
disorders of brain and behavior are related to exogenous stressor exposure, dysregulation of the HPA axis 
stress response (see Section IV. J.), and individual coping mechanisms, or resilience to stress, all of which 
are components of stress responding, that are now recognized as being modulated by the microbiota as de-
scribed previously (see Sections VI. G., VII. H. and X.D). As we will outline below, the state of the evidence 
varies between disorders, with some in a preliminary stage of research where studies have been limited to 
correlational observations of altered microbiota composition in clinical populations, while there is stronger 
support for a causal role of the microbiota in other disease processes.
A. Autism Spectrum Disorder
Autism spectrum disorder is a heterogeneous group of neurodevelopmental disorders characterized by pro-
found deficits in sociability, stereotyped or repetitive behavior in addition to anxiety and cognitive distur-
bances (Masi et al., 2017). With a worldwide prevalence of 1 in 68 children, it is more common in males, 
who are four times more likely to develop the condition than females (Mandic-Maravic et al., 2015). The 
behavioral disturbances are accompanied by profound alterations in key central physiological processes such 
as neuroinflammation, neurogenesis, neurotransmission and in the production of pro-social hormones, oxy-
tocin and vasopressin (Sherwin et al., 2016b). Although ASD may be classically thought of as primarily neu-
rological in its pathology, there is growing evidence to demonstrate a role for the GI system and its resident 
microbiota in aspects of ASD symptomatology also. Approximately 70% of children with ASD report comorbid 
GI disturbances such as bloating, constipation and diarrhea, indicating that gut physiology is indeed altered 
(Stephen et al., 2017). Interestingly, in a small open-label study in which children with ASD were treated with 
the broad-spectrum antibiotic, vancomycin, there was a marked improvement in behavioral symptoms (Kang 
et al., 2017; Sandler et al., 2000). Although antibiotics are not a viable long-term intervention strategy for 
the management of ASD, this study provided the field with a critical insight that the gut microbiota may con-
tribute to the behavioral disturbances in this neurodevelopmental disorder. Several additional studies have 
observed significant alterations to the composition of the microbiota and in the production of microbial me-
tabolites in children with ASD (Finegold, 2011; Finegold et al., 2010; Kang et al., 2018; Parracho et al., 2005; 
Wang et al., 2014). Of note, there is a reduced abundance of the beneficial bacteria genus, Bifidobacterium, 
along with an increased abundance of potentially pathogenic Desulfovibrio and Clostridia genera in the gut 
microbiota of children with ASD, a result that was consistent across all studies. A more recent study identified 
that the gene cpb2, which encodes for the clostridial toxin b, is significantly more expressed in C. perfringens 
isolated from the fecal microbiota of children with ASD relative to controls (Gora et al., 2018). The β2 toxin has 
been shown previously to cause GI-related illnesses (i.e., diarrhea) and the increased presence of this gene 
in clostridial species in the ASD microbiota may thus help to explain the GI-related comorbidities observed in 
this neurodevelopmental condition. While several studies to date have characterized the alterations of the 
microbiota in individuals with autism, there is limited evidence to demonstrate whether targeting the micro-
biota through probiotic or dietary interventions can improve symptoms of ASD in humans. However, a small 
open-label clinical intervention demonstrated that FMT of a standardized microbiota cocktail to children with 
ASD was efficacious in improving the GI and behavioral symptoms (Kang et al., 2017). Although the sample 
size was small and the experimental design lacked a randomized, double-blind structure, the study provided 
promising preliminary evidence to demonstrate that the microbiota may indeed be a viable target as a treat-
ment strategy for ASD. A more recent randomized, double-blind, placebo-controlled study demonstrated 
that a combination of a casein/gluten free diet along with the prebiotic, B-GOS®, led to an improvement 
in the behavioral symptoms of autistic children (Grimaldi et al., 2018). These behavioral changes were ac-
companied by an increase in the relative abundance of the beneficial strain, B. longum, in the microbiota of 
autistic children. Further clinical trials are required with larger sample sizes and more rigorous study design. 
Preclinical studies have been invaluable in providing the field with an insight into how the microbiota-gut-brain 
axis may be involved in ASD. Knock out of the shank 3 (autism candidate) gene results in profound autistic-like 
behavior in mice (Sgritta et al., 2019; Tabouy et al., 2018)  In addition to this, shank 3 transgenic mice also dis-
play alterations to the composition of their GI microbiota, with notable reductions in Lactobacillus, Prevotella 
and Veillonella. Interestingly, treatment with L. reuteri improved social deficits in male, but not female, shank 
3 transgenic mice. This corresponded with an increased expression of oxytocin mRNA expression within the 
hypothalamus of male shank 3 transgenic mice. However, the probiotic strain reduced expression of the neu-
ropeptide in the hypothalamus of female mice, which may explain the absence of any improvement in social 
behavior in these animals (Tabouy et al., 2018). Moreover, such results suggest that, other than modulation 
of oxytocin expression, there may sexual dimorphic factors underlying L. reuteri’s mechanism of action. 
The BTBR mouse, which displays an inherent autistic-like phenotype across multiple behavioral domains also 
exhibits altered GI physiology similar to what is reported in the clinical setting (Golubeva et al., 2017). For 
instance, BTBR mice display prolonged intestinal motility indicative of constipation. Moreover, it has been re-
ported that there is a breakdown in the permeability of the small and large intestine of these animals (Coretti 
et al., 2017). This permeability deficit phenomenon may contribute towards bacterial or related component, 
translocated to systemic circulation, whereby they can elicit an inflammatory response (Golubeva et al., 
2017). Profound alterations in the microbiota composition characterized by deficits in the relative abundance 
of Bifidobacterium and Blautia genera are also observed compared to C57BL/6 mice. The absence of these 
two bacterial genera was linked to additional deficits in bile acid signaling in these mice, which may contrib-
ute towards its observed GI physiology. 
While genetic models such as the Shank 3 and BTBR are important tools in elucidating any genetic compo-
nent to the alterations in the microbiota-gut-brain axis in ASD, it is also vital to model how environmental 
factors may contribute towards the neurodevelopmental disorder and their impact upon the GI microbiota. 
For instance, in utero exposure to the viral component and TLR3 agonist, Poly I:C, facilitated the development 
of autistic-like behavior in mice, while also increasing intestinal permeability and altering the composition of 
the gut microbiota (Hsiao et al., 2013). Moreover, exposure to the teratogen valproic acid (VPA) In utero has 
been shown to result in intestinal inflammation (Rosenfeld, 2015), and dysregulation to the GI microbiota 
observed as changes in the Firmicutes: Bacteroidetes ratio (de Theije et al., 2014c) and an increase in the 
abundance of the species Desulfovibrio (Finegold, 2011)DNA</keyword></keywords><dates><year>2011</
year><pub-dates><date>Aug</date></pub-dates></dates><isbn>1532-2777 (Electronic. Further, VPA expo-
sure leads to a deficit in social interaction in mice while also affecting serotonergic turnover in the amygdala 
(de Theije et al., 2014b; de Theije et al., 2014c). Given the influence that the microbiota has upon central 
processes such as serotonergic neurotransmission (O’Mahony et al., 2015), alterations to the gut microbiota 
through environmental insults such as in utero VPA or Poly I:C exposure may contribute towards the ob-
served behavioral deficits in these models. Further, considering the neuroactive properties of microbial me-
tabolites, such as SCFAs (Stilling et al., 2016), their role in modulating autism-related behavior should not be 
overlooked. Indeed, several preclinical studies have documented how neurotoxic doses of the SCFA propionic 
acid induces autism-like behavior in rodents (MacFabe et al., 2011; Shultz et al., 2015). Whether elevated 
levels of SCFAs, such as propionate, contribute towards what is observed clinically in autistic individuals is 
unknown but warrants further attention. Further, while studying the loss-of-function mutation in the histone 
demethylase KDM5 Drosophila found in ASD, social behavior appears to be modulated via immunoregulation 
and microbiota maintenance (Chen et al., 2019).
Preclinical models of ASD have also provided considerable information into the potential efficacy of candi-
date probiotic strains in improving autism-related behavior and their underlying mechanism of action (Sgritta 
et al., 2019). Mice from mothers fed a HFD during pregnancy exhibit deficits in social behavior and social cog-
nition (Buffington et al., 2016). Analysis of the microbiota of these mice revealed the absence of several key 
lactobacillus species. Interestingly, supplementation of one of these strains, L. reuteri, in mice from mothers 
fed a HFD resulted in a restoration of their behavioral deficits that was also associated with an increase in 
expression of the prosocial hormone, oxytocin, in the PVN of the hypothalamus (Buffington et al., 2016). The 
finding that L. reuteri increases oxytocin production has been shown to be dependent upon the integrity of 
the vagus nerve in addition to IL-10 signaling (Poutahidis et al., 2013; Varian et al., 2017). 
Other candidate probiotic strains have been shown to improve other facets of autism-related behavior in 
animals. For instance, in the maternal immune activation model of ASD B. fragilis administration early in 
life resulted in an improvement in stereotyped and anxiety-like behavior, but not in sociability (Hsiao et al., 
2013). Given that each bacterial species possesses its own unique biochemical properties, these contrasting 
effects of potential probiotics on autism-related behaviors are most likely due to such strains modulating 
different aspects of the microbiota-gut-brain axis (e.g. immune system, vagus nerve, microbial metabolites, 
peptides, etc.).
Y. Major Depressive Disorder (MDD)
Depression is the leading cause of disability worldwide, affecting 4.4% of the world’s population (World 
Health Organization Human Reproduction Programme, 2015). It is now known that Major Depressive Dis-
order (MDD) correlates with increases in pro-inflammatory cytokines (Ticinesi et al., 2017), which in turn 
activate the HPA axis possibly accentuating its hyper-activation associated with depression (Chopra et al., 
2011). Effective therapies for depression abrogate the heightened inflammatory response and decrease HPA 
axis activation (Chopra et al., 2011; Pariante, 2017).
There is burgeoning evidence of a role for the microbiota-gut-brain axis in MDD (Foster and McVey Neufeld, 
2013; Horne and Foster, 2018). However, there is a need for better-designed studies with clear psychiatric 
and psychological phenotyping when it comes to depression and anxiety and the microbiota-gut-brain axis 
in patient populations. Currently, most of the studies have been conducted in preclinical models (Dinan and 
Cryan, 2017). As stated earlier alterations in the microbiota composition and inflammation has been seen in 
the maternal separation model (O’Mahony et al., 2009) and the Flinders sensitive rat model of depression 
(Tillmann et al., 2018). Evidence from GF mice has provided further insight into the role of the microbio-
ta-gut-brain axis in depression, showing that the absence of a microbiota reduces depressive-like behavior in 
the forced swim test (FST) (Zheng et al., 2016a). Certain probiotic and prebiotic interventions have also been 
shown to reduce depressive-like behaviors in rat and mouse models, in addition to ameliorating inflamma-
tory responses (Bravo et al., 2011; Burokas et al., 2017; Desbonnet et al., 2010; Tillmann et al., 2018) (see 
Table’s 4 and 5).
There are now a number of human studies that have found differences in fecal microbiota in MDD patients 
when compared to healthy controls (Aizawa et al., 2016; Jiang et al., 2015; Kelly et al., 2016; Naseribafrouei 
et al., 2014; Zheng et al., 2016a). However, there is limited consensus between them in relation to the type 
of changes seen. In one study, Bifidobacterium and Lactobacillus were reduced in 43 depressed individuals 
(Aizawa et al., 2016). Another study witnessed increased fecal bacterial α-diversity, present in a cohort of 46 
concurrently depressed patients, which was not seen in patients who had responded to treatment (Jiang et 
al., 2015). One observation noted that Bacteroidetes, Proteobacteria, and Actinobacteria were increased, 
and Firmicutes were decreased, and negatively correlated with severity of the depressive symptoms (Jiang et 
al., 2015). While inter-individual variability was apparent, there were significant differences found in a variety 
of genera when compared to controls. The order Bacteroidales were significantly increased, and the family 
Lachnospiraceae were significantly decreased in another cohort of 37 depressed patients versus healthy con-
trols (Naseribafrouei et al., 2014)Hedmark University College, Hamar, Norway.</auth-address><titles><ti-
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pub-dates></dates><isbn>1365-2982 (Electronic, at the moment, all correlative. Elevated cortisol output in 
addition to decreased fecal microbial richness was reported in a study of 34 MDD patients (Kelly et al., 2016), 
and significantly different gut microbiota were noted in an MDD cohort when compared to matched controls 
(Zheng et al., 2016a). Furthermore, a human FMT to rats resulted in a transfer of the depressive and anxious 
phenotypes (Kelly et al., 2016; Zheng et al., 2016a), which was not observed with FMT from healthy human 
controls. Currently, it is difficult to reconcile the variations seen across the studies and it may be reflective 
of the small sample size as well as medication effects. Largescale studies in drug naïve depressives is now 
warranted.
In an effort to address this a recent study examined the microbiota composition of > 1,000 individuals en-
rolled in Belgium’s Flemish Gut Flora Project and clustered individuals into four enterotypes based on their 
microbiome composition (1534). Intriguingly, those who had depression, or lower quality of life score were 
over represented in an enterotype characterized by lower relative abundance of the genus Faecalibacterium, 
in addition to an overall reduced microbial load. On deeper analysis, the researchers found that there was an 
association between bacteria that produce the SCFA butyrate (Faecalibacterium and Coprococcus) and higher 
quality of life indicators. On the other hand, the levels of Coprococcus and Dialister were significantly lower 
in people with depression. Many of the findings were replicated the Dutch LifeLinesDEEP cohort as well as in 
a small cohort of clinically refractory depressed patients. Additionally, identified potential microbial-derived 
metabolites that have neuroactive potential from the literature, identified relevant pathways in the shotgun 
metagenome data, and clustered them into a modular framework. In total, they curated and annotated 56 
different gut–brain modules, each corresponding to a single neuroactive compound production or degrada-
tion process. These included modules involved in the potential ability of the gut microbiome to synthesize 
the dopamine metabolite 3,4-dihydroxyphenylacetic acid (DOPAC). Two other modules relevant to glutamate 
and GABA pathways also tended to be altered in depression. Interestingly, bacteria that have the capacity to 
generate or breakdown GABA have been implicated in changes in brain function and behaviour (108, 1206, 
1429). Although still correlative, they are among the most convincing to date to show a relationship between 
microbiota composition and mental health. Moreover, they agree with recent crowdsourced funding ap-
proaches such as the American Gut Project, which have shown a link between microbiota composition with 
depression (1015). 
A probiotic intervention study using an L. casei strain described improvements to mood ratings in a healthy 
elderly cohort following treatment, with most benefit for those who had lower mood at baseline (Benton et 
al., 2007). Furthermore, a triple-strain probiotic (L. acidophilus, L. casei, and B. bifidum) resulted in improve-
ments in depression scores, in addition to beneficial metabolic effects in an MDD cohort (Akkasheh et al., 
2016). Importantly, L. rhamnosus HN001 supplementation during pregnancy resulted in significant lowering 
of anxiety and postnatal depression (Slykerman et al., 2017). One recent study examined the effects of the 
prebiotic GOS combined with a probiotic containing L. helveticus and B. longum on mild to moderate MDD 
in a placebo-controlled parallel study (Kazemi et al., 2019). Beneficial effects of the probiotic were observed, 
including decreases in depression scores as well as improvements in tryptophan signaling. Another recent 
open-label study in patients with treatment-resistant depression has shown promise for the probiotic C. bu-
tyricum as an adjunct therapy, used in combination with anti-depressant drugs (Miyaoka et al., 2018). Cog-
nitive performance was further enhanced upon treatment of MDD patients with the probiotic L. Plantarum 
299v (Rudzki et al., 2019). 
Several studies in the literature failed to show any benefit to depression scores upon administration of pro-
biotics in patients presenting with MDD (Chung et al., 2014; Romijn et al., 2017). However, promising results 
in healthy controls and preclinical studies warrant further investigation in clinical populations (Messaoudi et 
al., 2011a; Messaoudi et al., 2011b). Overall, systematic reviews of probiotics as a potential adjunct therapy 
in MDD are encouraging, describing that probiotics effectively improve mood in humans (Huang et al., 2016; 
Pirbaglou et al., 2016; Wallace and Milev, 2017) although another recent meta-analysis calls into question 
the significance of these findings, highlighting the confounding comparability of studies due to strain differ-
ences and severity of disease (Ng et al., 2018). It is of note that poor diet is now accepted as a risk factor for 
depression, as well as a therapeutic target (Jacka, 2017; Jacka et al., 2017).  Improvements in diet will likely 
lead to an increase in consumption of prebiotic foods. There are limited studies on the effects of prebiotics in 
depression. Nonetheless, there is some evidence for a reduction of stress in human studies, which is intrinsi-
cally linked with depression (Schmidt et al., 2015; Silk et al., 2009). One study recently described no benefit 
from an eight-week GOS interventional therapy for mild to moderate MDD (Kazemi et al., 2019). Polyphenols, 
such as resveratrol, have been described to reduce depressive-like behaviors, in addition to ameliorating 
increases in corticosterone and pro-inflammatory cytokines (Yang et al., 2017), preclinically. Curcumin has 
described benefits in MDD patients (Ng et al., 2018), but further clinical studies on potential benefits of poly-
phenols in MDD are needed. 
Z. Anxiety
Anxiety and depression frequently go hand-in-hand, and most studies of the microbiota-gut-brain axis in 
anxiety include measures of depression and vice versa. Much of the evidence for a link between anxiety and 
the microbiota-gut-brain axis comes from preclinical studies (Foster and McVey Neufeld, 2013), whereby 
an anxious-like phenotype may be inferred from the animal’s behavior in certain environments, such as the 
open-field test, elevated plus maze, light/dark box, or in reaction to certain stressors (see Tables 2-5). GF 
mice display diminished anxiety-like behavior in comparison with conventionally reared animals (Clarke et 
al., 2013; Diaz Heijtz et al., 2011; Neufeld et al., 2011) alongside exaggerated corticosterone responses to 
stress indicating altered HPA-axis function, although GF rats exhibit exaggerated anxiety responses (Crumey-
rolle-Arias et al., 2014). It is important to note that changes in anxiety due to probiotic treatment are species 
and strain-dependent (Bravo et al., 2011; Savignac et al., 2014).
Improvements in specific anxiety measures have been shown in a small number of probiotic intervention 
studies of healthy control participants (Messaoudi et al., 2011b) and in chronic fatigue syndrome (Rao et 
al., 2009). Furthermore, a multi-strain probiotic (S. thermophilus (2 different strains), L. bulgaricus, L. lactis 
subsp. Lactis, L. acidophilus, L. plantarum, B. lactis, L. reuteri) was recently demonstrated to have anxiolytic 
effects in a small study of healthy controls (Colica et al., 2017). Interestingly, B-GOS® significantly improved 
anxiety levels in individuals with IBS (Silk et al., 2009). Intriguing recent work has identified Lactobacillus 
plantarum DR7 as a possible psychobiotic, where it alleviated anxiety and stress associated symptoms in a 
randomized, double-blind, placebo-controlled study (Chong et al., 2019). However, there is a clear need for 
further translational studies to specifically examine the effects of psychobiotics on anxiety.
AA. Schizophrenia
Schizophrenia is a complex and heterogeneous debilitating neural disorder, which has proven to be one of 
the most difficult psychiatric conditions to treat. It is characterized by both positive and negative neurobe-
havioral dysfunctions including, but not limited to, psychosis, cognitive dysfunction, delusion, apathy, and 
social withdrawal (Owen et al., 2016). There have been ideas circulated purporting a role for the GI tract im-
mune response in the pathogenesis of schizophrenia (Patterson, 2009; Severance et al., 2015; van Kesteren 
et al., 2017), where risk factors include Toxoplasma gondii infection, food intolerances, GI inflammation and 
cell barrier defects. There is evidence for both genetic and environmental etiological factors in the presen-
tation of schizophrenia symptoms (Demjaha et al., 2012; European Network of National Networks studying 
Gene-Environment Interactions in et al., 2014). As a result of the immune system role associated with this 
psychotic disease and the key role the microbiota plays in establishing and maintaining immune function, 
much recent effort has examined possible influences of the microbiota in schizophrenia (Belkaid and Hand, 
2014; Hooper et al., 2012; Schwarz et al., 2018). One recent study performed a metagenomic analysis of 
the oropharyngeal microbiota in schizophrenic individuals and healthy controls, identifying large differences 
at the phylum and genus levels (Castro-Nallar et al., 2015). Proteobacteria, Firmicutes, Bacteroidetes, and 
Actinobacteria presented with the most divergence between the two cohorts, with the fungi Ascomycota 
present in greater abundance in schizophrenia patients. Further, α-diversity was decreased in medicated and 
unmedicated patients, and FMT into germ-free mice had reduced hippocampal glutamate, and increased lev-
els of glutamine and GABA, suggesting that the schizophrenic microbiome itself can affect neurochemistry, 
which may be relevant to the human condition (Zheng et al., 2019). Intriguingly, antibiotic use reduced mi-
croglia-mediated synapse engulfment in an in vitro assay, where reduced synapse density is a hallmark seen 
in postmortem cortical tissue from schizophrenia patients (Sellgren et al., 2019). Upon examining electronic 
health records of a cohort of young adults, minocycline usage correlated with a modest decrease in incident 
schizophrenia (Sellgren et al., 2019), indicating that much more work is needed to examine the involvement 
of the microbiome in schizophrenia. 
No study has yet proven successful in altering any positive or negative behavioral symptoms while examining 
the potential for probiotic intervention in schizophrenia, in line with the severe nature and complexity of the 
disorder. However, some reports have indicated that at least some probiotic-induced alleviation of bowel 
problems commonly associated with schizophrenia are possible. In one human study, severe bowel difficulty 
was reduced over the course of the trial in a small group of outpatients (Dickerson et al., 2014), even though 
there were no assessed psychiatric symptoms altered. Further, another human study found an association 
between levels of Candida albicans and gut discomfort (Severance et al., 2017), where a trend for improved 
positive psychiatric symptoms occurred in males treated with a probiotic formulation (containing L. rhamno-
sus GG and B. animalis subsp. lactis Bb12), and who were seronegative for Candida albicans. Combined, ac-
cruing information is helping uncover a whole new array of potential treatment options for severe psychiatric 
illness, including consideration of bowel comfort in therapeutic analyses. More work is needed to increase 
the understanding of microbiota-gut-brain axis contributions in schizophrenia, increasing sample size and 
longitudinal analysis.
AB. Bipolar Disorder
Another serious neuropsychiatric illness, bipolar disorder is also hypothesized to have some origin associated 
with microbiota influence (Bengesser et al., 2019). Implications for the microbiome have emerged whereby 
patients presenting with bipolar mania were nearly twice as likely as other patients to have been recently 
treated with systemic antibiotics (Yolken et al., 2016). Fecal microbiome analysis has identified decreased 
abundance of Firmicutes, specifically Faecalibacterium, in patients presenting with bipolar disorder (Evans 
et al., 2017), which also correlated with self-reporting symptom severity, indicating a potential therapeutic 
avenue for these people. In a first of its kind, a recent probiotic clinical intervention indicated that probiotic 
therapy could reduce the rate of rehospitalization of patients who were recently discharged following hospi-
talization for mania (Dickerson et al., 2018).
AC. Anorexia Nervosa & Cachexia
Anorexia nervosa has one of the highest mortality rates amongst psychiatric illnesses with the greatest im-
pact on quality of life (Arcelus et al., 2011; Huas et al., 2011). It is characterized by a perverted self body-im-
age resulting in self-imposed food intake restriction leading to subsequent severe weight loss, associated 
with hyperactivity and hypothermia (Hebebrand et al., 2003). Currently, there is no definitive understanding 
of its etiology, nor are there any effective medication. Further, there is no clear gut microbiota role or involve-
ment ascribable in this disorder. Nonetheless, some recent evidence has seen potential gut microbiota in-
volvement and identifies it as a possible intervention target (for reviews see (Kleiman et al., 2015; Ruusunen 
et al., 2019).
Cachexia is a metabolic condition characterized by the loss of skeletal muscle mass, both dependent and in-
dependent of fat mass loss and is usually associated with severe illness including cancer and AIDS (Fearon et 
al., 2013). The pathophysiology of cancer cachexia includes reduced food intake and abnormal metabolism, 
leading to a negative energy/protein balance (Fearon et al., 2011), where the primary drivers are mediated 
via inflammatory pathways and the CNS (Fearon et al., 2013). However, the role of the microbiota in shaping 
such responses needs further attention.
AD. Addiction
Recent research has investigated the microbiota-gut-brain axis in the context of addiction, which is defined 
as a chronic relapsing disorder where an individual continues to engage in a maladaptive behavior, despite 
negative consequences (Koob, 2015). Most studies to date have focused on the impact of drug use on the 
gut microbiota. In addition to drugs of abuse having a direct effect on gut microbiota (Peterson et al., 2017), 
addiction includes a myriad of comorbidities that have previously been linked to the microbiota-gut-brain 
axis, including stress and anxiety (Bailey et al., 2011; Bravo et al., 2011; Burokas et al., 2017; Xiao et al., 2018), 
depression (de Timary et al., 2015; Temko et al., 2017), and chronic inflammation (Allais et al., 2016; Lee et 
al., 2018b; Littman and Pamer, 2011; Lowe et al., 2017; Panduro et al., 2017). 
The impact of substance abuse on the microbiota has been most extensively studied in alcohol abuse. Re-
search has linked alterations in gut microbiota during alcohol consumption to increased intestinal permeabil-
ity and hepatic inflammation (Bjorkhaug et al., 2019; Chandler J.A. et al., 2018; Lowe et al., 2017),(Bull-Otter-
son et al., 2013; Llopis et al., 2016; Mutlu et al., 2009; Mutlu et al., 2012; Yan et al., 2011), but a reduced gut 
microbiome can also protect from alcohol-induced neuroinflammation resulting in the alteration of intestinal 
and brain inflammasome expression (Lowe et al., 2018b). Preclinical supplementation with L. rhamnosus GG 
has been shown to lessen the severity of alcoholic hepatitis (Bull-Otterson et al., 2013). Furthermore, altered 
microbiota composition with alcohol administration occurs not only with oral, but also vapor administration 
(Peterson et al., 2017), indicating that other non-orally administered drugs of abuse have the potential to 
impact the microbiota. Phenotyping of compulsive alcohol-seeking behavior shows intriguing correlations 
between specific gut bacteria and striatal dopamine expression in rats (Jadhav et al., 2018). Clinical research 
has linked negative affect during alcohol withdrawal to increased intestinal permeability, inflammation, and 
microbiota composition (Leclercq et al., 2014). 
Available data on the effects of other substances of abuse on the gut microbiota indicate similar effects to 
alcohol. Clinical studies investigating tobacco smokers have associated smoking and cessation to changes in 
the gut microbiome and inflammation (Allais et al., 2016; Benjamin et al., 2012; Biedermann et al., 2014; 
Biedermann et al., 2013). Chronic exposure to tobacco smoke in mice alters the microbiome and mucin 
gene expression (Allais et al., 2016). Murine-models of opioid use have suggested a role for gut microbi-
ota in the progression of morphine-dependence and disruption of GI function (Kang et al., 2017; Lee et 
al., 2018b; Plein and Rittner, 2018; Wang et al., 2018a). Also, studies have linked the microbiota to altered 
intestinal permeability, inflammation, and metabolic processes in opioid-treated mice (Kang et al., 2018; 
Lee et al., 2018b; Wang et al., 2018a). In a  place preference task rodents that received methamphetamine 
where shown to have reduced abundance in a genus of propionate-producing bacteria as well as decreases 
in propionate, compared to saline controls (Ning et al., 2017)China.</auth-address><titles><title>Gut Micro-
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antibiotic in rodents enhanced cocaine place preference and locomotor sensitivity at low doses (5mg/kg) of 
cocaine, but this effect was not seen at higher doses (10mg/kg) (Kiraly et al., 2016). Interestingly, antibiotic 
intervention in alcohol and opioid studies reduced drug-associated increases in intestinal permeability, in-
flammation, and enteric neuron signaling (Kang et al., 2017; Lowe et al., 2017). Chronic treatment with the 
major psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol (THC), changed gut microbiota compo-
sition in mice (Cluny et al., 2015). These changes contributed to a reduction in energy intake and prevention 
of HFD-induced increases in body weight and adiposity. This preliminary research suggests that there is an 
intriguing connection between gut microbiota and addiction. However, much work is still needed to defini-
tively illustrate that gut microbiota composition can influence addictive behavior. Future research will need 
to investigate microbiota composition prior to drug administration in order to eliminate the confound of 
drug-induced microbiota changes and define “at risk” addictive phenotypes. The identified “at risk” pheno-
types should be studied longitudinally to investigate how the microbiota changes before drug administration, 
during, and following abstinence. Furthermore, this mechanism should be investigated with a focus on the 
dopaminergic system, which is intricately involved in reward learning, locomotor sensitivity, and reinforce-
ment of addictive behavior (Rudzki et al., 2019)
AE. Attention Deficit Hyperactivity Disorder (ADHD)
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder that presents as inattention 
(i.e., difficulties in organization and focus), hyperactivity and impulsivity, or a combination of both (American 
Psychiatric Association, 2013). As yet there are limited studies on the role of the microbiome in ADHD but 
there is a long history of investigations into the effects of diet on ADHD symptoms, with a Western-style diet 
being considered a predisposing factor for the disorder (Howard et al., 2011) and elimination diets, particu-
larly exclusion of artificial food color, resulting in positive outcomes (Millichap and Yee, 2012; Pelsser et al., 
2017; Pelsser et al., 2011). As discussed in Section VIII.IX, diet has a profound influence on the gut microbiota 
(Gutierrez-Martos et al., 2018; Ma et al., 2014; Rincel et al., 2018), suggesting that the microbiota may play 
a role in ADHD symptomology (Sandgren and Brummer, 2018). An analysis of a small clinical cohort of adults 
and adolescents presenting with ADHD supported this hypothesis, finding an increase in the genus Bifido-
bacterium compared to healthy controls, potentially via differential regulation of gut-based dopamine pre-
cursors (Aarts et al., 2017). Promisingly, a perinatal probiotic intervention reduced risk for ADHD diagnosis 
later in childhood (Partty et al., 2015), reflecting the potential for microbiota-based interventions in ADHD.
AF. Post-Traumatic Stress Disorder (PTSD)
Despite strong preclinical and recent clinical evidence, for microbiota modulation of acute and chronic stress 
(see Section’s VI. G. and VII. H.), direct investigations of the microbiota in clinical PTSD have been lacking; 
nonetheless, conceptually PTSD has been receiving increasing attention to be a target for microbiome-based 
strategies (Leclercq et al., 2016). Several authors have hypothesized that there is a link between PTSD and the 
microbiota, yet to our knowledge, there has been only one published study (Hemmings et al., 2017). Further 
investigation into the human gut microbiome profile in situations of chronic stress is warranted.
AG. Obsessive-Compulsive Disorders (OCD)
Much speculation currently surrounds the possible involvement of the gut microbiota in obsessive-com-
pulsive disorders (OCD; (Rees, 2014; Turna et al., 2016); however, little current research exists. Stress and 
exposure to antibiotics both of which affect microbiota composition are proposed mechanisms coinciding 
with the onset of symptoms in patients presenting with OCD (Karakas Ugurlu et al., 2013), both of which 
have been shown to negatively impact gut microbiota (Foster et al., 2017; Guida et al., 2018). Further, rodent 
behavior in the marble-burying test, which highlights perseverative, compulsive and repetitive actions, can 
be influenced by the implementation of pre- and pro-biotics suggesting a potential therapeutic benefit in fu-
ture OCD treatment (Kantak et al., 2014; Nishino et al., 2013; Savignac et al., 2014). Clearly more longitudinal 
human studies are needed to understand to what extent the microbiome is contributing to the symptoms of 
OCD (Rees, 2014; Turna et al., 2016).
AH. Obesity 
Obesity is a major public health issue, increasing risk for a range of serious health problems and ultimately 
increasing morbidity of the individual at a substantial economic cost to society (Tremmel et al., 2017). Obe-
sity is known to express comorbidly with other centrally regulated disorders such as depression (Carey et al., 
2014), bipolar disorder (Goldstein et al., 2013b), anxiety disorders (van Dammen et al., 2018) and altered 
social behavior (Leroux et al., 2013). Alarmingly, the prevalence of obesity has increased recently in many 
countries worldwide, particularly countries where a Western-style diet is dominant ((NCD-RisC), 2016). As 
described earlier (see Section’s VIII. C and X. A.), the microbiota is highly influenced by diet (Marungruang 
et al., 2018)and plays a key role in the central regulation of food intake. Thus, it is not surprising that the 
microbiota is also implicated as a key factor in obesity (For review see (Bruce-Keller et al., 2015; Castaner 
et al., 2018; Cox et al., 2015; Torres-Fuentes et al., 2017)). To date, most of the focus on microbiota-obesity 
interactions have focused on adiposity, glycemic response, and peripheral regulation of metabolism. How-
ever, there is a growing appreciation that the microbiota-gut-brain axis is involved (Sugino et al., 2019; Tor-
res-Fuentes et al., 2017). For example, over the course of a single day, the gut microbiota of humanized mice 
can experience a shift in both composition and function which may explain the influence of the western-
ized diet in obesity (Turnbaugh et al., 2009)Inbred C57BL</keyword><keyword>Molecular Sequence Data</
keyword><keyword>RNA, Ribosomal, 16S/genetics</keyword></keywords><dates><year>2009</year><-
pub-dates><date>Nov 11</date></pub-dates></dates><isbn>1946-6242 (Electronic. Through both human 
and mouse models of obesity, an alteration in microbiota composition is observed, namely an increase in 
the relative abundance of Firmicutes and a decrease in Bacteroidetes compared to lean controls. Interest-
ingly this observation is reversed when individuals are put on a lower calorie diet, which has been shown 
to affect metabolic potential and increase the capacity to harvest energy from food (Turnbaugh et al., 2006; 
Turnbaugh et al., 2009).
The presence of food in the gut results in a cascade of signaling events that is essential in regulating energy 
homeostasis. Vagal afferent neurons facilitate communication between the gut and the brain via NTS (Ber-
thoud, 2008b). In obese rat models, a reduction in c-fos activation in the NTS is seen following food intake, 
suggesting a decrease in vagal signaling from the gut to the NTS (Covasa et al., 2000). Sensitivity of the va-
gal nerve to peripheral neuropeptides involved in food intake is also seen in diet-induced obesity (Daly et 
al., 2011) with vagal neurons becoming resistant to leptin, reducing its sensitivity to CCK and subsequently 
affecting the regulation of meal size (de Lartigue et al., 2012). Given the role of the vagus in signaling from 
microbiota to brain it is highly likely to also play a role in microbial regulation of food intake.
Bariatric surgery is an alternative intervention often used to treat morbid obesity and has been shown to 
alter the gut microbiota (Aron-Wisnewsky and Clement, 2014; Kong et al., 2013). This surgery has been 
shown to increase the hormonal and inflammatory status, reduce adiposity and improve insulin sensitivity, 
as well as increase the bile acid pool and microbiota composition diversity (Aron-Wisnewsky and Clement, 
2014). The overall abundance of Gammaproteobacteria and Verrucomicrobia (Akkermansia) was increased, 
and Firmicutes decreased, in both human (Aron-Wisnewsky and Clement, 2014) and rodent (Zhang et al., 
2009) bariatric studies. In one intriguing study, FMT from mice that underwent gastric bypass surgery into 
GF animals resulted in decreased fat mass and an overall reduction in body weight in the GF mice (Liou et 
al., 2013). From this study one can hypothesize that bariatric surgery can lead to alterations in gut micro-
biota, resulting in variations in SCFA composition, which in turn can affect host metabolism, gut hormone 
secretion, and insulin sensitivity. Thus, targeting these effects could play a central role in treating obesity, 
metabolic syndrome, and diabetes. For review see (Aron-Wisnewsky and Clement, 2014; Berthoud, 2008b). 
Compounding the potential success of bariatric surgery for treating obesity, post-operative treatment with a 
course of probiotics has been shown to increase bacterial diversity and enhance further weight loss (Wood-
ard et al., 2009). 
Orexigenic peptides such as ghrelin are known to be altered in obesity, notably circulating ghrelin is de-
creased in obese patients indicating changes to ghrelin synthesis in the gut and possible upregulation of the 
ghrelin receptor (Tschop et al., 2001). Oxyntomodulin, an anorexigenic gut-derived hormone is being consid-
ered a viable target for obesity treatment (Wynne et al., 2006). For example, oxyntomodulin has been shown 
to reduce food intake resulting in weight loss, and reduced sensitivity and expression of anti-obesity gut-de-
rived peptides, and is observed within the hypothalamus when conventionally raised mice are compared to 
leaner GF mice (Schele et al., 2013). Given the role of gut peptides in signaling from microbiome to brain (see 
Section IV) they are poised to play a key role in microbial regulation of food intake too, but more research is 
needed to delineate the exact nature of this crosstalk
A common side-effect of many medications includes a change in patient bodyweight and as described ear-
lier in Section IX. F. many of these medications also affect microbiota composition. For example, atypical 
antipsychotics are known for weight gain and metabolic dysfunction as prominent side-effects (Birkenaes et 
al., 2008; Citrome et al., 2011; Davey et al., 2013; Davey et al., 2012; Morgan et al., 2014; Oriot et al., 2008; 
Perez-Iglesias et al., 2009). Moreover, a recent prebiotic approach was also shown to reverse olanzapine-in-
duced weight gain (Kao et al., 2018). Risperidone, a second-generation antipsychotic often prescribed for the 
treatment of schizophrenia and bipolar disorder in children and adolescents (Bishop and Pavuluri, 2008), has 
been shown to upregulate pathways involved in weight gain, and alter gut microbial composition after chron-
ic treatment (Bahra et al., 2015). Furthermore, this phenotype was transmissible via FMT as well as through 
treatment with phages that was isolated from risperidone-treated microbiota (Bahra et al., 2015). Future 
focus will concentrate on developing probiotic and prebiotic interventions which act on the gut microbiota 
composition to restore normal gut-brain signaling to act as novel treatments for obesity (Torres-Fuentes et 
al., 2017).
AI. Irritable Bowel Syndrome (IBS)
IBS is one of the most common types of functional gastrointestinal disorder (FGID) and can significantly im-
pact quality of life for these patients. Symptoms include alterations in bowel habits, abdominal pain, bloat-
ing, distention and excessive flatulence (Enck et al., 2016; Saha, 2014). In addition, IBS frequently presents 
co-morbidly with behavioral, psychosocial, psychological and environmental factors (Jeffery et al., 2012a; 
Rodino-Janeiro et al., 2018; Stanisic and Quigley, 2014) with microbiota-gut-brain interactions being a prime 
target in patients with IBS (Collins, 2014; Kennedy et al., 2014; Mayer et al., 2015a). Moreover, with the ad-
vent of Rome IV criteria, IBS has been formally recognized as a disorder of the gut-brain axis (Collins, 2014; 
Quigley, 2018), with a possible role for diet-microbiota interactions in the genesis of core symptoms (Rajil-
ic-Stojanovic et al., 2015).
One particular pathway of importance in IBS is that of 5-HT signaling. As described earlier (Section VII.D), it 
has been demonstrated that a functional GI-tract involves 5-HT signaling between ECs (Mawe et al., 2006; 
Mawe and Hoffman, 2013) acting as sensory transducers and the majority of 5-HT is synthesized, stored, 
and released by these cells, which interact with intrinsic and extrinsic sensory nerve afferents in the muco-
sal layer of the gut (Demjaha et al., 2012; Severance et al., 2015). Any change to this signaling can result in 
altered gut function, especially when considering EC-directed gut 5-HT signaling controls many GI functions 
including secretion, vasodilation, peristalsis as well as sensory perception such as pain and nausea (Belkaid 
and Hand, 2014; Castro-Nallar et al., 2015; European Network of National Networks studying Gene-Environ-
ment Interactions in et al., 2014; Hooper et al., 2012; Schwarz et al., 2018). Moreover, serotonergic function 
and tryptophan metabolism is known to be altered in IBS patients (Anderson and Maes, 2015; Clarke et al., 
2009; Clarke et al., 2012b; Dacquino et al., 2015; Dickerson et al., 2014; Fitzgerald et al., 2008; Lichtenstein 
et al., 2009; Severance et al., 2017).
Microbial- and diet-based treatments for IBS have given cause for hope (Dimidi et al., 2017; Simren and 
Tack, 2018; Whelan et al., 2018). A probiotic-based clinical treatment has been shown to be effective in 
ameliorating stress-related GI complaints when using a combination of L. acidophilus Rosell-52 and B. long-
um Rosell-175 (Diop et al., 2008). Another study reported marginally increased positive outlook scores in 
patients with IBS B. longum, indicative of reduced depression (Pinto-Sanchez et al., 2017b). However, a study 
using a L. rhamnosus strain failed to find benefits on depression scores in another cohort of IBS patients 
(Dapoigny et al., 2012). It has been proposed that probiotic amelioration of IBS symptomology may be acting 
indirectly through an anti-inflammatory mechanism (Ticinesi et al., 2017; World Health Organization Human 
Reproduction Programme, 2015). Such anti-inflammatory mechanisms may also be partially responsible for 
the positive effects of dietary restriction, such as that seen in the low FODMAP (fermentable oligosaccha-
rides, disaccharides, monosaccharides and polyols) diet in IBS (Chopra et al., 2011; Dinan and Cryan, 2017; 
Foster and McVey Neufeld, 2013). Here, it is believed that high doses of certain FODMAPs can result in in-
creased luminal water in the small intestine (Marciani et al., 2010; Murray et al., 2014), or increased colonic 
gas production resulting from microbiota fermentation (Murray et al., 2014; Ong et al., 2010), which can lead 
to pain, bloating and diarrhoea. An alternate method for IBS treatment involves FMT from non-IBS individ-
uals to patients with IBS (Halkjaer et al., 2018; Holvoet et al., 2017). FMT has become a popular treatment 
method for IBS (Mizuno et al., 2017; Pinn et al., 2015; Zheng et al., 2016a), as well as of chronic constipation 
(Bravo et al., 2011; Ding et al., 2018; Tian et al., 2017) and refractory IBS (Desbonnet et al., 2010; Zoller et al., 
2015), although the relative success is questionable given current data (Halkjaer et al., 2018). 
AJ. Pain Disorders
A common theme throughout this review is that the microbiota can communicate through neural, endocrine, 
immune and neuropeptide/neurotransmitter systems, along the gut-brain axis. This also likely holds true 
for pain response. Facilitation or inhibition of pain processing is mediated at a central level, with ascending 
afferents from the viscera (including the gut) mediated through the spinal cord as a consequence of primary 
afferent nociceptor activation, and microbial inflammatory mediators, proteins, and peptides all contributing 
to the manifestation of pain. 
Crudely, pain types can be categorized as nociceptive pain, inflammatory pain (which is associated with tissue 
damage and the infiltration of immune cells) or pathological pain, which is a disease state caused by damage 
to the nervous system or by its abnormal function (examples including neuropathic pain, fibromyalgia, mi-
graine and headache) (Woolf et al., 1998). Within these categories, the pain can be further sub-characterized 
as somatic (skin and deep tissue) or visceral (relating to internal organs). While the anatomical pathways 
and signaling mechanisms involved in somatic/musculoskeletal pain (skin and deep tissue) and responses to 
acute nociceptive insults and acute inflammatory pain are relatively well defined, the mechanisms underly-
ing visceral, neuropathic and chronic pain and their treatment are proving a difficult target for therapeutic 
intervention.
Much of the evidence for gastrointestinal microbiota in pain response has focused on nociceptive disorders 
of the gut (Holzer et al., 2017; Pusceddu and Gareau, 2018), in particular, inflammatory pain disorders includ-
ing C. difficile infection and IBD, and FGIDs including IBS (see Section IX. L). Chronic visceral pain is one of the 
predominant symptoms of FGID and IBD. It is apparent that both involve centrally and peripherally regulated 
mechanisms and are therefore often referred to as disorders of the gut-brain axis. However, it is as yet un-
clear how, or to what extent microbiota that are confined to the gastrointestinal tract can influence visceral 
pain behavior associated with FGIDs (Moloney et al., 2016; Rea et al., 2017) or IBD (Holzer et al., 2017).
A number of diagnostic studies have determined an altered GI microbiota profile in patients with chronic or 
recurrent visceral pain, including inflammatory pain in IBD (Conte et al., 2006; Frank et al., 2007; Manichanh 
et al., 2006) and IBS (Carroll et al., 2012; Jeffery et al., 2012b; Kassinen et al., 2007; Matto et al., 2005; Noor et 
al., 2010; Shankar et al., 2015; Simren et al., 2013). A common finding across these studies is a decreased rel-
ative abundance of the genera Bifidobacterium and Lactobacillus, and increased Firmicutes:Bacteriodetes ra-
tios at the phylum level (Clarke et al., 2012a). The correlational nature of these cross-sectional studies means 
it is unclear whether these microbiota changes are causative of the nociceptive/inflammatory response, or 
whether the altered microbiota profile occurs in response to tissue injury or inflammation in the host. 
Inflammatory Pain
While antibiotics including metronidazole, vancomycin or fidaxomicin remain first line treatment for C. dif-
ficile infection, FMT is medically accepted as a highly successful procedure for the eradication of infection 
and associated symptoms including abdominal pain (Culligan and Sleator, 2016; Smits et al., 2016). A recent 
review (Basso et al., 2018) and metadata analysis (Paramsothy et al., 2017) captures the efficacy of micro-
bial-based treatments including probiotic treatments, and FMT in the treatment of IBD. FMT was reported 
as having >50% clinical remission in some studies while having < 50% clinical remission in others. While pro-
biotics were efficacious in some but not all C. difficile infection studies where pain and intestinal discomfort 
were key comorbidities.
IBD is a chronic, relapsing and remitting painful inflammatory disorder of the gastrointestinal tract compris-
ing ulcerative colitis and Crohn’s disease. A recent review has captured the efficacy of FMT in the treatment 
of IBD (Levy and Allegretti, 2019) with studies reporting 20-33% clinical remission in pain in ulcerative colitis, 
reduction in pain index in 50-75% Crohn’s disease individuals, and mixed effects 0-80% in pouchitis. To date, 
there are no probiotics demonstrating efficacy in the treatment of Crohn’s disease (Knox et al., 2019) while 
for ulcerative colitis there mixed reports of efficacy of probiotics, with VSL#3 possibly having effect in preven-
tion of relapse in quiescent ulcerative colitis (Derwa et al., 2017). Similarly, in pouchitis, some probiotic inter-
ventions were reported as effective or ineffective (Knox et al., 2019) in prevention or alleviation of symptoms.
Arthritic pain is also associated with inflammation. Despite evidence for a role for microbiota, in particular 
Prevotella copri in untreated new-onset rheumatoid arthritis patients (Human Microbiome Project, 2012; 
Qin et al., 2010; Scher et al., 2013) and evidence from animal studies (Maeda et al., 2016; Scher et al., 2016) 
human studies are only now being undertaken to investigate the effects of FMT in arthritis (Kragsnaes et al., 
2018) and the limited randomized control trials and relatively low participant numbers in probiotic studies 
have not yielded any clear consensus to the efficacy of probiotics in arthritis (Lowe et al., 2018a).
Visceral Pain
Despite the preclinical evidence for a role for gut microbiota in visceral pain, clinical studies remain incon-
clusive with a large ‘non-responder’ population observed in many probiotic and FMT trials. A good example 
is provided by the range of therapeutic responses to the somewhat controversial technique of FMT from 
healthy donors to patients with FGIDs. In one study involving patients with IBS (Borody et al., 1989), FMT 
was effective in 36% of the patients, mildly improved discomfort in a further 16% and was non-effective in 
the remaining 47%. In a recent double-blind, randomized, placebo-controlled parallel group study design 
(n=90), FMT was shown to alleviate IBS symptoms three months after transplantation although this was not 
apparent 12 months after transplantation. Further clinical trials and case studies have utilized FMT for the 
alleviation of chronic constipation (Andrews and Borody, 1993; Cao et al., 2017; Ding et al., 2018; Tian et al., 
2017), refractory IBS (Holvoet et al., 2017; Pinn et al., 2015), and the pain-component of IBD (Angelberger et 
al., 2013; Bennet and Brinkman, 1989; Kellermayer et al., 2015; Moayyedi et al., 2015; Rossen et al., 2015) 
with varied success. The efficacy of FMT and probiotic supplementation in the treatment of visceral pain is 
synthesised in a recent review (O’Mahony et al., 2014).
Neuropathic and Pathological Pain
There is a sparsity of microbiota-related research on many pain types that lack a clear causal localized insult 
including diabetic neuropathy, stroke-related pain, cancer pain, migraine and headache, or MS-related pain. 
One case study reported an improvement in diabetic neuropathy following FMT (Cai et al., 2018). Another 
study reported an improvement in post-chemotherapy abdominal pain following probiotic treatment in col-
orectal cancer (Osterlund et al., 2007), an event that is caused by chemotherapy-induced gastrointestinal 
toxicity of the gut microbiome-host immune system (Secombe et al., 2019). Clinical studies have reported a 
moderate reduction in number, duration and/or intensity of migraine events with probiotic administration 
(de Roos et al., 2017; Sensenig et al., 2001), while individuals suffering from fibromyalgia, a chronic wide-
spread muscle and joint pain disorder, had no alleviation of pain following probiotic administration (Roman 
et al., 2016).
Preclinical evidence for a role of microbiota in pain response
GF mice exhibit a blunted response to inflammatory pain (Amaral et al., 2008). When reared in an SPF envi-
ronment, SKG mice - an animal model of spontaneous Th17-cell dependent arthritis -remained healthy until 
exposed to zymosan, a fungal β-glycan (Yoshitomi et al., 2005). Similarly, antibiotic-induced depletion of the 
microbiota decreased visceral pain responses elicited by intraperitoneal acetic acid injection or intracolon-
ic capsaicin infusion in mice (Aguilera et al., 2015). On the other hand, GF animals exhibit an exaggerated 
response to visceral pain in the CRD model (Luczynski et al., 2017), while antibiotic administration in early 
postnatal life or in adulthood has been shown to increase susceptibility to CRD in adult rats (Hoban et al., 
2016a; O’Mahony et al., 2014). In a seminal FMT study where fecal matter from IBS patients characterized 
by hypersensitivity to CRD was transplanted to GF rats, an exaggerated response to CRD was observed in the 
recipient animals (Crouzet et al., 2013), further fueling the gathering interest in the role of the gut microbiota 
in visceral pain. Together, these findings suggest that depletion of the gut microbiota may be beneficial in 
reducing sensitivity to inflammatory, but not mechanical, nociceptive information.
There is evidence for positive modulation of pain responses to both inflammatory and mechanical stimuli 
through probiotic administration (although evidence for prebiotic effects is limited) (Kannampalli et al., 2014; 
Larauche et al., 2012). B. infantis 35624 (McKernan et al., 2010), L. paracasei NCC2461 (Verdu et al., 2006) 
and L. reuteri (Kamiya et al., 2006) have all been shown to be effective in blunting nociceptive responses to 
CRD in naïve rodents. Probiotics have also been successfully used to prevent stress-induced exaggeration of 
the pain response to CRD in the maternal separation model of early-life stress (specifically using L. paracasei 
NCC2461 in mice and VSL#3 in rats) (Distrutti et al., 2013; Eutamene et al., 2007) and in adults exposed to 
restraint stress (using B. lactis CNCM I-2494) (Agostini et al., 2012). Similarly, different probiotic species have 
been shown to ameliorate visceral hypersensitivity to CRD in a rat model of colitis, perhaps through protec-
tive effects on intestinal barrier function (restoration of barrier integrity and tight junction protein levels) 
and/or reductions in circulating inflammatory cytokines (Johnson et al., 2011; Laval et al., 2015; Martin et 
al., 2016). Finally, prophylactic administration of the probiotic mix VSL#3 suppressed visceral hypersensitivity 
induced by inflammation via intracolonic instillation of 4% acetic acid (Dai et al., 2012). 
While such studies implicate the microbiota in alleviating certain symptoms associated with GI discomfort or 
pain sensitivity, further research is needed to establish whether FMT results in long-lasting changes in micro-
biota composition or immune, endocrine, inflammatory or neurotransmitter systems. Further double-blind, 
randomized control trials would also clarify the effectiveness of FMT in the treatment of FGIDs and poten-
tially provide insight into the reasons for individual differences in treatment response. At the level of the gut, 
the sensitization of primary afferent nociceptors is thought to lead to visceral hypersensitivity. A number of 
different receptor types are involved in the process of peripheral sensitization including the transient recep-
tor potential channel (TRPV) family, proteinase-activated receptors, CCK receptors, 5-HT receptors, cannabi-
noid receptors, as well as an array of ion channels including ATP-gated ion channels, voltage-gated sodium 
and calcium channels, acid-sensing ion channels and pH-sensitive receptors (Akbar et al., 2009; Vermeulen 
et al., 2014). A range of physiologically active agents including substance P, glutamate, aspartate, vasoactive 
intestinal peptide, CCK, somatostatin, calcitonin gene-related peptide and galanin are released from nerve 
terminals of the visceral primary afferents of the gut to propagate the nociceptive signal to second-order 
neurons at the dorsal horn of the spinal cord.
There are many potential mechanisms by which the GI microbiota could activate these receptor systems or 
agents either directly or indirectly. These include local immune-mediated events at the mucosal-epithelial 
interface during infection, inflammation and autoimmunity (Cassel et al., 2008; El Aidy et al., 2014; Kamada 
et al., 2013b; Mazmanian et al., 2005; Round and Mazmanian, 2009), or through other chemical messen-
gers including formyl peptides (Husebye, 1997), proteases (Cenac, 2013; Vergnolle, 2009) and PUFA release 
(Cenac et al., 2015), SCFA production (Cummings and Macfarlane, 1997), neurotransmitter and neuropep-
tide release (Lyte, 2014) or hormone secretion (Cani et al., 2013; Cani and Knauf, 2016). Microbially-derived 
biomolecules involved in vasoconstriction could potentially contribute to migraine development. Evidence 
suggests that the gut microbiota can also stimulate the release of the body’s endogenous pain-suppressing 
compounds including opioids from innate neutrophils and monocytes (Boue et al., 2014), endocannabinoids 
from colonic tissue (Muccioli et al., 2010), as well as other pain modulators including monoamines (Oleskin 
and Shenderov, 2016).
AK. Parkinson’s disease
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by tremor, rigidity of 
movement and distinctive gait. Motor impairment and characteristic brain pathology do not present as 
symptoms until quite an advanced stage of the disease. By this time much of the dopaminergic neurons in 
the substantia nigra, cells responsible for motor control, have been lost or have degenerated axons (Cheng 
et al., 2010). Recent evidence from a number of labs (Bedarf et al., 2017; Hasegawa et al., 2015; Hill-Burns 
et al., 2017b; Keshavarzian et al., 2015; Sampson et al., 2016; Scheperjans et al., 2015; Unger et al., 2016) 
propose a relationship between the complexity and diversity of the microorganisms that inhabit our gut and 
PD. Indeed, even an appendectomy was recently seen as a potential prophylactic for PD initiation (Killinger 
et al., 2018). These studies suggest that, along with an altered GI microbiota profile, a shift to a pro-inflam-
matory state occurs, with possible detrimental effects in the gut and brain (Perez-Pardo et al., 2018). This 
supports the frequently observed occurrence of functional GI symptoms such as constipation which often 
occur prodromal, years before motor symptoms emerge (Felice et al., 2016; Poewe, 2008). Fifteen years ago, 
it was first postulated that the etiology of PD might begin in the gut (Braak et al., 2006). A widely used staging 
tool for PD, the Unified Parkinson’s disease Rating Scale (UPDRS), uses semi-quantitative descriptors of motor 
impairments, but additionally contains measures of non-motor symptoms, including gut effects, reflecting 
the common occurrence of gut dysbiosis in the disease. Preclinical studies have provided further evidence 
that microbiota may be causally related to PD symptomatology and pathophysiology, whereby FMT from 
parkinsonian patients into GF mice overexpressing the PD-linked protein α-synuclein resulted in two hallmark 
symptoms of PD: motor deficits and neuroinflammation (Sampson et al., 2016), suggesting that distinct mi-
crobes are associated with PD. It was notable that symptoms improved when the mice were treated with 
antibiotics. Altogether, a role for gut microbiota in PD in the initiation and progression of PD seems more and 
more compelling (Dinan and Cryan, 2017; Perez-Pardo et al., 2017). 
An aggregation of the protein α-synuclein in the brain is a hallmark of PD pathology. This has been seen in 
the mucosal and submucosal nerve fibers and ganglia of PD patients (Forsyth et al., 2011; Hilton et al., 2014). 
There is also preclinical evidence suggesting that a-synuclein in the gut can transport to the brain via the 
vagus nerve (Holmqvist et al., 2014), known to be the main conduit for signals from the gut to the brain (see 
Section IV. A.). a-synuclein may exert its effects via microbial influence, or via prion-like translocation to the 
brain, and may act as a store for pathogenic forms of α-synuclein, increasing the risk of PD development (Kill-
inger et al., 2018). Further, a-synuclein aggregation appears to be modulated by the gut microbial metabolite 
LPS, a well-characterized interaction associated with this alternative pathway of PD progression (Bhattacha-
ryya et al., 2019). Epidemiological studies have shown that truncal vagotomy in Danish and Swedish patients 
is protective against PD (Liu et al., 2017a; Svensson et al., 2015). Somewhat ironically, the utilization of vag-
otomy was stopped when it was discovered that peptic ulcers were caused by Helicobacter pylori and could 
be treated with antibiotics. Further, there is also evidence linking H. pylori infection to the development of 
PD symptoms through degenerating dopaminergic neurons in the brain (Dobbs et al., 2016). Intriguingly, 
eradication of H. pylori has been shown to enhance the onset time of levodopa (first line pharmacological 
treatment for PD symptoms) while also improving, rigidity, walking ability and tremor (Camci and Oguz, 
2016; Hashim et al., 2014). 
The original work describing alterations in gut microbiota profile compared PD patients to healthy controls 
(Scheperjans et al., 2015) and paved the way for further studies on gut microbiota profile in PD. The PD 
cohort were sampled at a median of 5 years from the appearance of motor symptoms. The authors found 
that Provotellaceae was significantly reduced in the PD patient cohort, which was unrelated to constipation 
measures. Furthermore, there was an increased abundance of Enterobacteriaceae, which was positively as-
sociated with increased levels of postural instability and gait disturbance. A valuable study of gut microbiota 
from treatment-naïve PD patients (Keshavarzian et al., 2015), also described differences in gut microbiota 
composition between PD patients and healthy controls. Bacteroidetes, Proteobacteria, and Verrucomicrobia 
were higher in PD fecal samples at the phylum level, and putative pro-inflammatory bacteria were present 
at higher abundance at the genus level in the PD samples. They described an association between duration 
of PD and microbiota profile, although no correlation was found with disease severity, making it difficult to 
determine if the noted changes were causative or correlative. Another study focused on 19 specific groups/
genera/species and determined that the number of Lactobacillus was higher in the fecal samples of PD pa-
tients, while C. coccoides and B. fragilis groups were lower than that of healthy controls (Hasegawa et al., 
2015). This group also attempted to model the disease duration using the microbiota data and observed that 
increased L. gasseri and decreased C. coccoides correlated with disease duration, albeit not with constipation 
levels, which historically correlate with disease duration in PD. An altered microbiota profile in PD was con-
firmed in another study, where a defined number of bacteria were quantified using PCR (Unger et al., 2016). 
Utilizing current metagenomic shotgun analysis techniques, one group discovered that Verrucomicrobia-
ceae and Firmicutes were increased and Prevotellaceae and Erysipelotrichaceae decreased in a PD patient 
cohort, who were diagnosed within the previous year and were L-DOPA-therapy naïve (Bedarf et al., 2017), 
although other concomitant medications were in use. Importantly, key microbial species differences were 
identified between the PD and control groups, and the authors were able to model PD status using six of the 
taxa. Further, the effect of 39 potential confounders, including PD medications, were examined in an exciting 
recent study using a larger cohort of participants (197 PD patients and 130 healthy controls) (Hill-Burns et al., 
2017a). This robust study determined that there is a large effect of PD medication on the microbiota profile. 
The study also confirmed that PD status alone was responsible for significant alterations in gut microbiota. 
Findings of gut microbe compositional differences in PD have more recently been confirmed in a Chinese 
population, with the genera Clostridium IV, Aquabacterium, Holdemania, Sphingomonas, Clostridium XVIII, 
Butyricicoccus and Anaerotruncus found to be increased in PD patients compared to matched controls, and 
a negative correlation of Escherichia/Shigella with disease duration (Qian et al., 2016). Finally, a study which 
also took into account a cohort of a presumptive prodromal PD state, namely Idiopathic Rapid Eye Movement 
Sleep Behavior Disorder, which has a high conversion rate to PD, showed changes in gut microbe composition, 
which were very similar to the PD cohort, and significantly different from healthy controls (Heintz-Buschart 
et al., 2018). This offers a tantalizing prospect of being able to utilize gut-microbial profiling as a biomarker 
for PD in the future. Furthermore, specific operational taxonomic units were associated with both motor and 
non-motor symptoms, as well as depressive co-morbidities (Heintz-Buschart et al., 2018).
Of note, samples for these human studies were entirely cross-sectional, patients were not followed longitu-
dinally and most of the studies used small cohorts. This strongly identifies a need for larger, prospective and 
longitudinal studies to confirm these findings and determine whether gut microbiota profile continues to 
alter throughout disease progression. Interestingly, epidemiological studies of individuals who underwent a 
full truncal vagotomy for treatment of peptic ulcer disease, which would prevent certain microbiota signals 
reaching the brain have a diminished risk of Parkinson’s disease as they age (Liu et al., 2017a; Svensson et al., 
2015). Probiotic interventions to benefit the symptoms of PD are also of interest, with one study published 
on the benefits of a fermented milk drink containing multiple strains of probiotics in addition to prebiotics in 
treating constipation in the disease (Barichella et al., 2016). A preclinical study on a nutritional supplement 
containing prebiotic fibers (FOS and GOS), in addition to other nutrients, has also shown benefit on motor, 
cognitive and gut symptoms in a mouse model of PD (Perez-Pardo et al., 2017). Much research is needed to 
help understand how changes in the microbiota can moderate both the non-motor and motor symptoms of 
Parkinson’s disease as well its co-morbidities (Dinan and Cryan, 2017; Lionnet et al., 2018).
AL. Alzheimer’s disease and Dementia
Alzheimer’s disease is the most common neurodegenerative disorder and the leading cause of dementia. The 
characteristic brain pathology, including Aβ plaques and hyperphosphorylated tau protein, appears in stages 
starting in the trans-entorhinal cortex, followed by progression to the hippocampus, and later widespread 
progression to cortical regions (Braak et al., 1993). The possibility of a microbial origin for the disorder has 
been discussed for years (Balin et al., 1998; Balin et al., 2008; Friedland, 2015; Itzhaki et al., 2016; Miklossy, 
1993, 2016; Zhao et al., 2015) and new evidence continues to emerge in support of this concept (Alonso et 
al., 2017; MahmoudianDehkordi et al., 2018; Pisa et al., 2018; Pisa et al., 2016). There is now a strong case 
to be made for a link between pathogenic microbes and the development and progression of AD (succinctly 
reviewed in (Hill et al., 2014).
Experimental evidence (Soscia et al., 2010) has supported other research identifying the amyloid protein 
acting as a possible antimicrobial peptide in the brain (Kumar et al., 2016; Stilling and Cryan, 2016). Howev-
er, from a Koch’s postulate perspective, it is ethically difficult to prove that there is an infective etiology to 
the neuroinflammation, and neurodegeneration observed. The relationship between gut proteins and brain 
health is receiving much-needed attention. Intriguingly, amyloid-like proteins can be produced by bacteria 
and have been shown to increase α-synuclein pathology in aged rats and worms (Friedland, 2015). However, 
much more work is needed to validate such strategies in humans.
While the accumulation of Aβ peptide, and abnormal forms of tau protein, present as traditional indicators 
of AD (Braak and Braak, 1991) they do not necessarily infer causality. As an infectious agent, viruses are 
present in the brains of most elderly people and tend to co-localize with areas of AD pathology (Jamieson 
et al., 1991), and Herpes Simplex Virus 1 (HSV-1) has been associated with AD (Eimer et al., 2018; Itzhaki et 
al., 1997). Furthermore, examination of the humoral response to the HSV-1 virus revealed that anti-HSV-1 
Immunoglobulin M (IgM) antibodies increased the risk of developing AD, whereas IgG antibodies did not, 
suggesting that persistence of the virus may not play a role in AD but that reactivation of the virus may be 
contributing to its development (Lovheim et al., 2015). Also, elements of AD are transmissible as shown by 
inoculation of AD homogenates from humans to the brains of primates and mice (Baker et al., 1994). Further 
evidence for the role of viruses in AD etiology comes from work showing Aβ deposition and tau aberrations 
following infection with HSV-1 (Wozniak et al., 2007; Wozniak et al., 2009). 
The impact of the microbiota on AD is not restricted to viruses, as bacteria have also been associated with AD 
pathogenesis. GF APP-PS1 mice (Radde et al., 2006) have a reduced Aβ pathology compared to conventional 
animals from the same background, indicating that the microbiota may play a role in Aβ biology, and subse-
quently AD pathogenesis (Harach et al., 2017). Moreover, Aβ has demonstrated anti-microbial properties in 
murine models of AD (Kumar et al., 2016; Soscia et al., 2010). Many questions remain unanswered regarding 
the role of viruses and bacteria in the pathogenesis of AD. It appears clear that microorganisms are involved 
at key nodes of the pathogenic cycle of AD and further research must focus on whether Aβ accumulation is a 
malfunctioning immune response or a driver of disease (Stilling and Cryan, 2016). 
Concerning microbiota composition in individuals with AD, there are two studies describing alterations in the 
gut microbiota profile of AD patients compared to matched controls (Vogt et al., 2017; Zhuang et al., 2018). 
The first analyzed samples from 25 AD patients, the majority of whom had very-mild to mild dementia, along 
with 25 matched controls, and described a reduction in richness and diversity of gut microbiota in the AD 
samples (Vogt et al., 2017). A variety of taxa were affected, with decreased Firmicutes, increased Bacteroi-
detes, and decreased Bifidobacterium (Vogt et al., 2017). The alterations in microbiota correlated strongly 
with a pathological load of Aβ and phosphorylated tau species in a subgroup of patients who underwent 
lumbar puncture for AD markers. The second study also found microbiota composition changes at a variety 
of taxonomic levels in AD, albeit with some differences from the initial study, including Bacteroides, Actino-
bacteria, Ruminococcus, Lachnospiraceae, and Selenomonadales (Zhuang et al., 2018). A difference between 
the Firmicutes: Bacteroidetes ratio was also noted in this latest study, which has previously been described 
in obesity and is intriguing in light of the well-described link between AD and type II diabetes mellitus (Ar-
nold et al., 2018). Furthermore, cognitively impaired but otherwise healthy older adults have alterations in 
Bacteroidetes, Firmicutes, Proteobacteria, and Verrucomicrobia compared to age-matched cognitively intact 
individuals (Manderino et al., 2017). Cognitively impaired elderly participants with no definitive AD diagnosis 
at the time of the sampling, but with a high Aβ load, had a lower abundance of B. fragilis and E. rectale but 
higher abundance of Escherichia/Shigella compared with both healthy controls and individuals with cogni-
tive impairment but no Aβ pathology (Cattaneo et al., 2017). All microbiota descriptions were observational 
and not intended to define correlation or causation at this stage. 
There are a number of mouse models of AD, which are useful tools for the study of potential microbial-based 
AD therapeutics. Importantly, GF mice with AD mutations (APP/PS1 model) display markedly diminished Aβ 
pathology in comparison to conventionally housed AD animals (Harach et al., 2017). This study also described 
differences between gut microbiota in the aged APP/PS1 mouse model versus wild-type animals. A recent 
study described how early antibiotic treatment in APP/PS1 mice resulted in reduced Aβ deposition later in 
life (Minter et al., 2017). Intervention with a B. breve strain in an Aβ intracerebroventricular model prevent-
ed Aβ-induced cognitive deficits, partially restored memory function, and improved inflammatory status 
(Kobayashi et al., 2017). A study utilizing the triple transgenic mouse model (3xTg) of AD determined that a 
probiotic cocktail (a mixture of lactic acid bacteria and bifidobacteria, SLAB51) reduced oxidative stress in the 
rodent (Bonfili et al., 2018). Another multi-strain probiotic, containing L. acidophilus, L. fermentum, B. lactis, 
and B. longum abrogated memory and learning deficits in an intra-hippocampal Aβ model of AD (Athari Nik 
Azm et al., 2018). Lastly, L. plantarum protected against cognitive decline (Nimgampalle and Kuna, 2017). 
Interestingly, this strain had previously been determined in the 1940s as being able to produce acetylcholine 
(Stephenson and Rowatt, 1947), the neurotransmitter which is reduced to very low levels in the disease, and 
upregulation of which comprises the bulk of current pharmacological therapy available for AD. 
The translational value of microbiota-gut-brain axis therapeutics for AD patients remains an open question. 
One randomized, double-blind, placebo-controlled trial of a multi-strain probiotic (a milk drink containing L. 
acidophilus, L. casei, B. bifidum, and L. fermentum species) described improvements in the Mini Mental State 
Exam (Akbari et al., 2016). However, another study showed no improvement in cognition following 12 weeks 
of consumption of a multi-strain probiotic, containing Lactobacillus and Bifidobacterium strains, in severe AD 
patients (Agahi et al., 2018). Much work remains to be done to determine whether targeting the microbio-
ta-gut-brain axis can result in clinically significant improvements that slow or halt AD progression. The cur-
rent literature provides some preliminary evidence that psychobiotic therapy may one day be considered a 
possible adjunct therapy in the treatment of AD symptoms, or even in the prevention of disease progression 
at the prodromal stage. It is possible that an altered gut microbiota profile, or indeed any other biomarker, 
could more reliably predict AD in the prodromal stages. However, we are still far from this and much work 
needs to be done to describe better the effects of microbiota-gut-brain axis signaling in AD. 
AM. Stroke and Brain Injury 
Inadequate blood flow to the brain, resulting in cell death, is a hallmark signature of stroke (Peisker et al., 
2017), and a common response to brain injury (Sater et al., 2018). Peripheral and systemic factors, including 
an enhanced inflammatory response, can worsen outcomes after stroke (Samary et al., 2017; Stoll et al., 
1998). Investigating the potential involvement of microbiota-related inflammation in stroke outcomes or re-
covery is thus a burgeoning area of brain injury research. In a Chinese patient group presenting with stroke or 
a transient ischemic attack, fecal abundance of three major commensal microbes (Bacteroides, Prevotella, & 
Faecalibacterium), were severely depleted, with a concomitant enhancement in abundance of opportunistic 
pathogens such as Enterobacter, Megasphaera, and Desulfovibrio (Yin et al., 2015). Moreover, patients pre-
senting with severe stroke had a greater abundance of Proteobacteria over those with milder stroke. 
Gut permeability, GI motility, and microbiota composition are all drastically altered in mouse models of 
stroke (Houlden et al., 2016; Singh et al., 2016; Stanley et al., 2016). Further, FMT into GF mice from a cere-
bral ischemia model transmitted functional deficits of pro-inflammatory T-lymphocyte (Th1 and Th17 Thelper 
phenotype) trafficking and the ischemia-induced cerebral lesion volume (Singh et al., 2016). Administration 
of broad-spectrum antibiotics pre-ischemic injury is associated with significantly worse outcomes (Winek et 
al., 2016). Moreover, antibiotic-induced microbiota dysregulation resulted in a reduction in the trafficking of 
the pro-inflammatory IL-17+ gd T cells, which was associated with a reduction in IL-17 associated chemokine 
expression in brain parenchyma, along with reduced neutrophil accumulation and a reduction in infarct vol-
ume of the ischaemic site (Benakis et al., 2016). Thus, the gut microbiota appears to influence the magnitude 
of post-stroke neuroinflammation by modulating intestinal T cell trafficking to the meninges.  On the other 
hand, probiotic supplementation seems to have the potential to benefit brain injury patients; C. butyricum 
had neuroprotective effects in a mouse model of traumatic brain injury (Li et al., 2018a; Sun et al., 2016b). 
The probiotic treatment was shown to act by protecting intestinal barrier integrity, increasing the expression 
of cerebral GLP-1R and the secretion of intestinal GLP-1, a 5-HT and appetite-modulating hormone. Although 
this area needs more investigation, there is great interest in the potential for pre- or probiotic -enriched 
treatments to mitigate some of the morbidities associated with stroke and cerebral ischemia (Brenner et al., 
2017). 
 
AN. Multiple Sclerosis (MS)
Multiple sclerosis (MS) is a CNS related autoimmune disorder defined by accruing motor deficits, blurred vi-
sion, and changes in sensibility that appear spontaneously with little to no prodromal signals (Dendrou et al., 
2015). Based on the immune etiology of MS, much interest is now focused on possible therapeutic interven-
tion via the gut microbiota (Berer et al., 2011; Tremlett and Waubant, 2018). Remarkably, when fecal matter 
from MS patients was transplanted into mice, the animals began to exhibit one of the hallmark symptoms of 
MS: autoimmune encephalomyelitis (Berer et al., 2017; Cekanaviciute et al., 2017). GF mice also exhibited 
resistance to developing experimental autoimmune encephalomyelitis in a mouse model of MS, which was 
promoted by gram-positive segmented filamentous bacteria in the gut (Berer et al., 2017; Lee et al., 2011). It 
was noted that the symptom expression correlated with an increase in relative abundance of Akkermansia. 
This fits with a recent study showing that A. muciniphila and Acinetobacter calcoaceticus are present in rela-
tively higher abundance in fecal samples from MS patients, (Cekanaviciute et al., 2017). The MS patients also 
exhibited reduced levels of Parabacteroides distasonis, a species associated with anti-inflammatory activity. 
It appears that the gut microbiota of MS patients has a notable role in the disease expression, which may be 
amenable to dietary intervention. Future studies with targeted microbiota interventions are needed to vali-
date such a hypothesis. Interestingly, in further support of such a concept is the fact that the manifestation of 
experimental autoimmune encephalomyelitis has also been linked to diet-induced changes in the microbiota 
(Libbey et al., 2018). 
AO. Obstructive sleep apnea
Obstructive sleep apnea (OSA) is defined as breathing interruptions during sleep due to the collapse of the 
upper respiratory tract, resulting in sleep disturbances (Randerath et al., 2018). Apneic events cause tran-
sient hypoxia, decreased oxygen levels in blood, and hypercapnia, increased carbon dioxide in blood. OSA 
is highly prevalent in the obese and aged populations and represents a risk factor for many cardiometabolic 
disorders, such as diabetes mellitus type 2 and hypertension (Franklin and Lindberg, 2015). Nevertheless, the 
mechanisms connecting OSA and its comorbidities remain elusive. Recent studies have examined if changes 
in gut microbiota are connected to OSA and associated metabolic disturbances, which have been already 
linked to modifications in gut microbiota composition (Benedict et al., 2016; Tripathi et al., 2018). Two meth-
ods utilized in the examination of this potential relationship are sleep fragmentation, and induction of hypox-
ia and hypercapnia, both of which are defining characteristics of OSA. 
Further evidence comes from a recent rodent study, mice that underwent four weeks of sleep fragmenta-
tion displayed changes in gut microbiota composition, including an increase in the Firmicutes: Bacteroidetes 
ratio (Poroyko et al., 2016), similar to that seen in aging and obesity (Castaner et al., 2018; Xia et al., 2016). 
Mice that underwent sleep fragmentation also exhibited increased Lachnospiraceae and decreased Lacto-
bacillaceae abundancies, as well as colonic barrier disruption, prompting a rise in peripheral inflammation 
markers (Poroyko et al., 2016). In a recent study, antibiotic treatment depressed the ventilatory response to 
hypercapnic stress in awake, responsive animals (O’Connor et al., 2019). Further, FMT also disrupted the gut 
microbiota composition that was associated with depressed ventilatory responsiveness to hypercapnia. In 
this instance, both antibiotic treatment and FMT resulted in significant disruptions to brainstem monoamine 
neurochemistry, which correlated with the abundance of several bacteria of six different phyla (O’Connor et 
al., 2019). Moreover, in a recent guinea pig study, chronic intermittent hypoxia (CIH)-induced hypertension 
which models human sleep apnea was shown to alter gut microbiota richness and composition, brainstem 
neurochemistry, and autonomic control of heart rate, suggesting modulation of breathing and autonomic 
homeostasis via the microbiota-gut-brainstem axis (Lucking et al., 2018).
From a translational perspective a human clinical study, two nights of partial sleep deprivation raised the 
Firmicutes: Bacteroidetes ratio in a cohort of healthy young adults (Benedict et al., 2016), a translationally 
similar result to that seen in rodents. Both geriatric and pediatric patients suffering from OSA present with 
elevated blood levels of an immune marker of intestinal barrier disruption, LPS-binding protein (Kheiran-
dish-Gozal et al., 2014; Kong et al., 2018). These indirect impacts on the gut microbiota could potentially 
trigger downstream pathways, leading to metabolic dysfunction. While other recent work was unable to 
reproduce such results with their sleep restriction model (Zhang et al., 2017b), OSA-derived hypoxia and 
hypercapnia resulted in gut microbiota functional and compositional alterations in humans (Moreno-Perez 
et al., 2018) affecting intestinal molecules such as bile acids, phytoestrogens and fatty acids, the synthesis 
of which is dependent on gut microbiota (Tripathi et al., 2018). Although the connection between OSA and 
gut microbiota appears strong using the sleep fragmentation model, it appears that hypoxic state may be 
integral to the effects of OSA on the gut microbiota. Further research is needed to determine the role of the 
gut microbiota in OSA.
AP. Epilepsy 
Even though there are many studies in GF mice examining neural changes in the key brain regions implicated 
in epileptogenesis (Cowan et al., 2018; Diaz Heijtz et al., 2011; Hoban et al., 2018; Luczynski et al., 2016a; 
Luczynski et al., 2016b; Olson et al., 2018; Spinelli and Blackford, 2018), there is a paucity of knowledge on 
the specific involvement of the microbiota in epilepsy. As referred to earlier, there is a strong link between a 
ketogenic diet and its effects on microbiota composition (Newell et al., 2016; Xie et al., 2017), a common di-
etary treatment prescribed to patients with epilepsy (Masino and Rho, 2019). GF mouse research has shown 
the beneficial effects, as well as dependency on the microbiota, a ketogenic diet can have, where a reduced 
fiber content diet similar to the FODMAP diet can improve symptoms but also be detrimental to the microbi-
ota (Olson et al., 2018), indicating a potential role for the microbiota as a mediator of epileptogenesis.
AQ. Amyotrophic Lateral Sclerosis (ALS) 
ALS is a fatal neurodegenerative motor neuron disease characterized by CNS and systemic inflammation 
resulting in rapid and progressive loss of peripheral motor functions; most patients die within five years 
of diagnosis (Zhang et al., 2017c). A lower abundance of butyrate-producing bacteria, associated with gut 
permeability, has been detected in a murine model of the disorder (Zhang et al., 2017c). However, human 
studies have thus far failed to find a link between the gut microbiota and disease progression in ALS (Brenner 
et al., 2018). 
AR. Huntington’s disease 
Huntington’s disease is a congenital progressive brain disorder of genetic origins, caused by a dominant mu-
tation in the Huntingtin gene (McColgan and Tabrizi, 2018). Symptoms include progressive motor, cognitive 
and psychiatric decline, caused by neuronal dysfunction and cell death. Sadly, there are currently no treat-
ment options for Huntington’s disease, other than symptom management and pain alleviation. Interestingly, 
intrinsic and extrinsic environmental factors have been shown to modify progression of the disease (van 
Dellen and Hannan, 2004). Altered gut microbiota-derived metabolites have been observed in subjects ex-
hibiting early symptoms of Huntington’s disease, indicating the possibility for microbiota-based interventions 
(Kong et al., In Press). Further, recent work highlighted that the lack of a microbiome in a mouse model of HD 
(BACHD-GF) resulted in changes in corpus callosum myelin thickness and plasticity (Radulescu et al., 2019). 
Further research is needed to uncover any specific role that the microbiome may play in this disease. 
AS. Infections and the Brain
Infections of the CNS have been the one area in medicine that the disciplines of microbiology and neuropsy-
chiatry have converged whether it was in the case of neurosyphilis, a major problem in the 19th and early 
20th century (Hackett, 1963; Tampa et al., 2014), or the realization of the cognitive effects of the HIV virus 
(Watkins and Treisman, 2015; Woods et al., 2009). Infections can be caused by bacterial, viral, fungal or para-
sitic pathogens and their effects can be devastating (Engelhardt and Sorokin, 2009). Thus, understanding the 
mechanisms of how brain infections occur will have an impact on how the microbiome could influence the 
brain. Moreover, the presence of a microbiome within the brain itself is very controversial and much more 
work is needed in this regard (Servick, 2018).
Pathogens can enter the brain via three main routes. Firstly, pathogens enter the brain via the blood or CSF; 
under physiological conditions, this passage is prevented by the BBB or the blood-CSF barrier. However, dis-
eases such as endocarditis (Ruttmann et al., 2006) and HIV (Atluri et al., 2015) can result in bacteria or viruses 
entering the brain. Also, long-term use of steroids and organ transplant can also compromise the BBB and 
blood-CSF barrier resulting in bacterial translocation (Coureuil et al., 2017). Secondly, direct entry during an 
ear infection, sinusitis, mastoiditis, and osteomyelitis amongst others, can take place. Lastly, pathogens can 
enter the brain following skull fracture or traumatic brain injury (TBI). Not every bacterium has the potential 
to enter the brain and those that do have adapted specific molecular methods to allow translocation. Indeed, 
TBI itself has been shown to result in an alteration in fecal microbiota (Treangen et al., 2018). While these 
barriers represent an important obstacle against infection, they also prevent the access of important drugs 
to the brain. Current and future research must define the exact mechanisms that pathogens use and harness 
these tactics for improved drug delivery to the CNS. 
Bacterial infections of the brain are typically confined to the meninges, three important membranes that 
enclose the brain and spinal cord (Honda and Warren, 2009). One of the most common bacterial infections 
of the brain is bacterial meningitis, usually caused by extracellular pathogens such as S. pneumonia, (pneu-
mococcal meningitis) Neisseria meningitidis (meningococcal meningitis) and Haemophilus influenzae, the 
most common causes of bacterial meningitis in adults and children worldwide (Heckenberg et al., 2014). 
Bacteria responsible for meningitis are frequently considered commensals at mucosal surfaces and only pose 
an infectious threat when they enter the brain via the bloodstream or CSF (Coureuil et al., 2017). Not all bac-
teria responsible for meningitis have the same tendency to infect the meninges. For example, meningitis is 
common during meningococcal disease whereas S. pneumoniae while capable of causing meningitis is rarely 
seen in pneumococcal disease (Coureuil et al., 2017). Furthermore, it is clear that bacteria may enter the 
brain at different sites using different methods, implying that different bacteria employ different techniques 
to breach the barriers to the brain (Huang and Jong, 2001). 
A clearer picture of how the brain is affected by infection is essential to understand the mechanisms by which 
neurological disease occurs and how the microbiome-gut-brain axis may regulate it. The brain has a specific 
mechanism in place that have been exploited by bacteria, viruses and parasites, understanding the methods 
these pathogens use will present a clearer understanding about how outside threats can penetrate the brain 
and cause devastating disease. 
XII. Beyond the “Bacteriome”
Bacteria have long been the primary subjects of microbiota research, but the remaining members within the 
gut microbiota have begun to garner more interest as their presence not only impacts the consortia of bac-
teria but also can also directly impact the host. The highest fraction of the gut microbiota are viruses, which 
outnumber their mammalian and microbial hosts by a large margin; thus, they cannot be ignored. Fungi are 
found in lower numbers but may impart a large effect on the function of the microbiota and host, particular-
ly in immunocompromised individuals. The virome (collection of viruses) and the mycobiome (collection of 
fungi) within the microbiota, each serves complex roles, which we will now explore.
The Virome 
The gut virome is comprised of viruses capable of infecting host mammalian cells, as well as eukaryotic, bac-
terial, fungal, and archaeal cells. Viruses that infect bacteria (ie. bacteriophage or simply phage) predominate 
in both number and diversity in the virome. Characterizing the virome has proven challenging as the phage 
community contains divergent genomes, and retain no conserved gene region utilizable for identification, 
similar to the bacterial 16S rRNA genes. Some phage in the gut are lytic (virulent) where they hijack host cell 
transcription/ translation machinery to generate many more phage components before lysing the host cell 
membrane and releasing phage particles into the local environment. However, more commonly phages in the 
gut are lysogenic, where they incorporate their DNA into the plasmid or genome of the host cell and replicate 
along with the host over time. In addition to replicating with their host through successive divisions, lysogen-
ic phage can also drive diversification and evolution by imparting new genes to their bacterial host that can 
increase substrate utilization range, induce virulence, protect from phage superinfection, provide resistance 
against antimicrobials, and many other positive and negative growth factors (Manrique et al., 2017). The 
most prolific phages in the gut are temperate phages and can be both lytic and lysogenic, whereas virulent 
phages are obligately lytic (Foca et al., 2015; Kim and Bae, 2018). Temperate phages can transition between 
lytic and lysogenic states depending on environmental factors. For example, lysogenic phages can become 
lytic when environmental stressors cause DNA injury (Monk and Kinross, 1975) or loss of host fitness (Rok-
ney et al., 2008), such as with antibiotics (Cowlishaw and Ginoza, 1970), oxidation (Figueroa-Bossi and Bossi, 
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(Wollman et al., 1956), and heat (Rutberg, 1973). The lytic and lysogenic lifestyles of viruses make it difficult 
to unravel many of the potential interkingdom interactions within the gut microbiota, but the intrinsic pre-
dation of bacteria by bacteriophages drives adaptation and diversification for bacterial resistance and phage 
infection (De Sordi et al., 2019). Since the phage population is dependent on available hosts, extrinsic factors 
that can alter bacterial community dynamics can also shape the phage population. A bloom of one strain of 
bacteria will increase phage diversity targeting predation on that bacterial group, thus increasing bacterial 
diversity through kill-the-winner dynamics (also described as the Red Queen effect and in the Lotka-Volterra 
model dynamics (Rodriguez-Valera et al., 2009; Thingstad and Lignell, 1997)). This is exemplified in IBD where 
reduced bacterial diversity leads to increased phage expansion and diversification (Lepage et al., 2008; Nor-
man et al., 2015). Interestingly, human phage community profiles show low temporal intrapersonal diversity, 
but high interpersonal diversity (Reyes et al., 2010), further complicating the picture.
Phages in the gut environment are capable of playing a large role in shaping the microbiota as the gut eco-
system is suggested to be one of the densest phages habitats in the world, where up to 1015 phage particles 
have been estimated in the GI tract (Dalmasso et al., 2014; Lepage et al., 2013; Mills et al., 2013). Identifica-
tion of phage capable of utilizing quorum sensing molecules of their bacterial host has shown that phage are 
capable of making lysis-lysogeny decisions dependent on communication systems of bacteria that may infer 
bacterial growth trajectory (Silpe and Bassler, 2019). The most commonly studied and identified phages in 
the gut are of the order Caudovirales within the families Siphoviridae, Podoviridae, and Myoviridae (Lepage 
et al., 2008). More recent studies have identified crAss-like Bacteriophages as the most abundant viruses 
in the gut, where indirect evidence suggests they primarily infect bacteria of the genus Bacteroides (Dutilh 
et al., 2014; Shkoporov and Hill, 2019; Yutin et al., 2018). Phage are similarly ubiquitous in feces, reported 
at a concentration of approximately 108 per gram and equaling the number of bacteria, further indicating 
their importance for consideration during FMT (Kim et al., 2011)Kyung Hee University, 1 Hoegi-dong, Dong-
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bacterial fraction filtered out have been shown to result in similar treatment efficacy and resolution of C. 
difficile infection (Ott et al., 2017; Zuo et al., 2018). In individuals with C. difficile infection that were success-
fully treated with FMT, there was stable engraftment of bacteriophages from donors to recipients for up to 
12 months following treatment (Draper et al., 2018). This long-term colonization is evidence that phages play 
an active role in the microbiota since inactive phages would be quickly washed out.
Elucidation of safe and effective phage therapy has been a desired paradigm for decades, and in the age 
of increasing antibiotic resistance, is of growing importance. The utmost care must be taken regarding the 
effects that phage therapy can have longitudinally on the mammalian host directly, or indirectly via the gut 
microbiota. One recent study showed that phage cocktails generated from a number of bacterial isolates 
resulted in increased intestinal permeability in rodents (Tetz and Tetz, 2016; Tetz et al., 2017). Further, it has 
been demonstrated in rodent models that phages are capable of crossing the GI barrier following gavage 
(Duerr et al., 2004; Hamzeh-Mivehroud et al., 2008). Additionally, phages have been shown to cross through 
epithelial cell layers via transcytosis, allowing access to various regions in the body that are usually consid-
ered sterile (e.g. blood, lymph, organs; (Nguyen et al., 2017). Phages were not believed to directly invoke an 
immune response in humans (Sarkar et al., 2016), but they can be removed through innate immunity mech-
anisms (Merril, 2014), and play an important role in antibacterial innate immunity. A recent study showed 
that bacteriophage proliferation is linked to intestinal inflammation and colitis in a preclinical IBD model, 
suggesting that phage can modulate varying effects on the host including TLR9 mediated IFN-γ immune 
response specific to Bacteroides bacteriophages and phage DNA (Gogokhia et al., 2019). The ‘bacteriophage 
adherence to mucus’ model proposes that phage provide antibacterial immunity to the host through mucin 
glycoproteins binding with proteins exposed on phage capsids. Therefore, concentrated phage in the mucus 
layer may provide a defense system against bacteria for the epithelial cells below (Barr et al., 2013). Since 
phages are capable of modulating proliferation of their bacterial hosts, sculpt microbiota composition, and 
modulate inflammation in the mammalian host, their effects on other aspects of human health and cognition 
will continue to be a burgeoning new area of research for years to come. 
The Mycobiome
Fungi resident in the gut mycobiome are less prevalent than both their bacterial and viral counterparts, and 
like viruses, their role in the gut microbiota is not as well understood as bacteria. Fungi in the GI tract have 
been reported to comprise 0.001-0.1% of the total population (approximately a billion organisms; (Huseyin 
et al., 2017), and about 106 / gram in stool (Bojanova and Bordenstein, 2016)). In a number of studies many 
members of the mycobiome have been reported, yet few would be considered common, leading some re-
searchers to question the role, and true colonization of the gut by fungi, since the presence of most mem-
bers in stool can be explained by oral colonization and transient passage through the gut in a healthy indi-
vidual (Auchtung et al., 2018; Hallen-Adams and Suhr, 2017). This perspective argues that gut colonization 
by fungi could be indicative of a diseased and immunocompromised individual, which could certainly help 
explain why some of the most common members identified (Candida, Malassezia, Geotrichum, Cladospori-
um) are also opportunistic pathogens. Other fungi unable to colonize such as Saccharomyces, Aspergillus, 
and Penicillium, are common either in diets or the environment and are expected to impact the ecology of 
the myco- and microbiota (Hallen-Adams and Suhr, 2017). In IBD, fungal communities have been described 
as having increased diversity and a varied composition compared to the mycobiomes of healthy individuals 
(Ott et al., 2008). In one study in both humans and rodents, a change in fungal composition was correlated 
with increased visceral hypersensitivity, supporting the notion that IBS related visceral hypersensitivity may 
be treated with antifungal medication (Botschuijver et al., 2017). Given the potential for interaction of no-
ciceptive sensory pathways by the mycobiome, fungi may well play a larger role in the gut-brain axis than 
previously thought. Similar to the other less frequently studied microbes in the gut, a gold standard approach 
for culture-independent metagenomic analysis is lacking. Undoubtedly, more work is needed to better un-
derstand the presence and purpose of fungi in the gut.
XIII. Conclusions 
Expansion of the Gut-Brain Axis into Microbiota-Gut-Brain Axis or Diet- Microbio-
ta-Gut-Brain Axis  
Understanding how gut microbes influence gut-brain axis communication has been the subject of significant 
research over the past decade. There is a growing effort to dissect out the mechanisms of this communica-
tion at all nodes of the axis. It is now widely believed that the gut microbiota is critically important for the 
appropriate development and maintenance of brain function. Moreover, as outlined above there is accumu-
lating evidence from both animal and clinical studies implicating the microbiota in a variety of psychiatric, 
neurological and neurodegenerative diseases. However, it is still very much early days in this field and caution 
is needed in over-interpreting such studies. Whether changes in the microbiota are central to the pathophys-
iology of at least some psychiatric and neurological disorders is currently unproven, though the subject of 
considerable speculation. To date, IBS is the only clinical condition where targeting the microbiota has been 
shown to result in clinical improvement in placebo-controlled trials. There also remain many unanswered 
questions regarding psychobiotics, with much work required to test optimal dosing, strain, and timing in 
therapeutic applications. It will be important for the field to move away from just correlative analysis towards 
prospective longitudinal studies, causative and mechanistic analyses, and larger scale trials of potential ther-
apeutic approaches. Without doubt, studies across a wide spectrum of disorders will be available shortly, 
which is an exciting prospect for the promise of therapeutic applications for the microbiota is great.
One of the big conundrums in microbiota-based medicine is how to define a healthy microbiota. Inter-indi-
vidual differences in microbiota composition can be great, which makes a “one size fits all” approach to tar-
geting the microbiota challenging. However, it also offers opportunities as the microbiota may be the conduit 
for effective personalized medicine approaches in the future (but see (Zmora et al., 2018)).
Given the role of diet in modulating the microbiota, we may really be focusing on a diet-microbiota-gut-brain 
axis in mediating health and disease across the lifespan. Thus, in addition to the quote at the beginning of 
this review, Hippocrates was also reported to have said: “let food be thy medicine.” Perhaps a modified ver-
sion now warrants consideration “let food for your microbes be thy brain medicine.” 
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XVI. Figure Legends
Figure 1. Schematic outlining the myriad of changes recorded in Germ-free mice compared to conventional-
ly housed mice with specific emphasis on neural alterations. 
 Indicates an increase and       signifies a decrease in the relative process.  
Figure 2. Sequential schematic illustrating the steps involved in modern bioinformatic analysis of microbiota 
samples.  The process begins with the extraction of a bacterial genome which is sequenced and digitized; 
upon identification of the species involved, diversity and abundance are analyzed delivering a functional 
analysis chart and a PCAnalysis plot for reference and inference. 
Figure 3. Timeline graph indicating changes in microbial diversity across the human lifespan, from birth 
through aged, including infancy, childhood, adolescence, and adulthood, accompanied by typical changes 
in neural development, indicating concomitant neuronal processes occurring during specific stages of life. 
Blue bar depth means to signify time period where indicated processes are greatest. 
Figure 4. Schematic outlining the various known bidirectional pathways of communication between the 
gut-microbiota and the brain, including hepatic and gallbladder metabolism, immune-modulatory respons-
es, neuronal innervation enteroendocrine and microbial metabolite signaling. 
Figure 5. Illustration identifying common factors known to impinge on microbiota-gut-brain activity, includ-
ing diet, congenital heredity and associated epigenetics, environment, medications, exercise and mode of 
delivery at birth, as well as the various behaviors known to be affected by microbiota-gut-brain axis pertur-
bation, including cognitive and social behaviors, stress, fear and food intake. 
Figure 6. An outline illustrating the variety of disease and disease processes the microbiota are currently 
implicated in; examples include psychiatric and neurodegenerative disorders, pain, stress, IBS, stroke, ad-
diction and obesity. 
XVII. Tables
Table 1: Model organisms currently utilized for the study of the microbiota-gut-brain axis. 
Table 2: Germ-free animal studies of the microbiota-gut-brain axis, categorized by model organism.
Table 3: Antibiotic studies of the microbiota-gut-brain axis, categorized by model organism.
 
Table 4: Prebiotic studies of the microbiota-gut-brain axis, categorized by model organism.
 
Table 5: Probiotic studies of the microbiota-gut-brain axis, categorized by model organism.
Table 6: Tools used in the analysis of the gut microbiome
Table 1: Model organisms currently utilized for the study of the microbiota-gut-brain axis. 
Species Influence on brain & be-
havior
Intervention Advantages Disadvantages Ref.
Humans (Homo 
sapiens)
Modulation of stress 
hormones secretion, stress 
perception, autism-related 
behavior, and cognition. 










-High degree of genetic 
variability, confounding 
covariates (environ-
ment, diet, lifestyle), 



































versus the wild, sympat-
















and behavior: cognition, 
sociability, anxiety, depres-
sion-related, addiction and 





















-Behavior readouts are 










je et al., 
2014b; 
de Thei-





























Similar to mouse, 
Unique animal model of 
early life stress: maternal 
separation


















-Behavior readouts are 
different from those 















Used in stress studies. Probiotic Stress
-Control for 
age, sex, diet, 
treatment com-
pliance.
-Behavior: live in isola-
tion/ non-social behav-
ior. Less Validation. 












and sociability in zebrafish.






















Ants (from the 
Lasius genus)
↑ social - social behavior. 


























Enteric bacteria influence 
on mating behavior. 



















-No adaptive immune 
system. 
- GI system is vastly dif-
ferent to that of mam-
















Table 2: Germ-free animal studies of the microbiota-gut-brain axis, categorized by model organism.









OFT: ↑anxiety-like behavior. Not reversible 
via colonization. NSF: ↓latency. 
Differences in miRNA and mRNA expres-
sion. Most altered pathway: axon guidance. 
Few miRNA and mRNA transcript levels 
restored after colonization.




OFT, MB: ↑anxiety-like behavior. ↓spon-
taneous motor activity. Brautia coccoides 
↓MB, 
no effect on locomotion test. B. infantis 
↓the locomotor activity, no effect on MB.




↓Bdnf ↓glucocorticoid receptor expres-
sion. 




(Sudo et al., 
2004)
Brain Size Brain weight did not ↑with age as it did in 
SPF mice.




No differences with IC inoculation, but mice 
lived longer.




BBB ↑BBB permeability, ↓tight junction pro-
teins.
Partially reversed by colonization of certain 
species or SCFA.
BBB (Braniste et 
al., 2014)




Microglia Time and sex-specific changes in coloniza-
tion, chromatin accessibility.








Monocolonization with L. reuteri reversed 
social deficits.
Vagus Nerve (Sgritta et al., 
2019)
♀ EAE More resistant to EAE than control mice. 
This was reversed via microbiota coloniza-
tion.






Fear retention: ↓freezing/impaired memo-
ry. ↑ plasticity IEG. 
Unique transcriptional response to fear 
stimulus.
Reversed with post-weaning colonization.




↓Gcg in brainstem, ↑ transcription of 
obesity producing neuropeptides in hypo-
thalamus. 









3 Chamber: Reciprocal Interaction: ↓socia-
bility, social novelty, social interaction. 
Reversed via colonization, or with just L. 
reuteri.
Brain (Buffington et 
al., 2016)
Chinese Kun Ming 
(KM), ♂




Neurogenesis ↓ BrdU incorporation: ↓proliferation.





♂ and ♀ Anxiety 
BDNF 
TST, step-down, LD: ↓anxiety-like behavior 
following maternal separation in LD test, 
↑ Step-down, ↓immobility in TST. ↓Bdnf.
Partial rescue of phenotype via colonization 




(De Palma et 
al., 2015)
C57BL/6 NarI, ♂ Anxiety Loco-
motion 
EPM, FST, OFT: ↑anxiety-like behavior. 
No change via FST. ↓locomotor activity 
relative to probiotic group. Reversible via 
Lactobacillus plantarum PS128.
Striatum (Liu et al., 
2016a)
Chinese Kun Ming 
(KM), ♂
Schizophrenia FMT from human schizophrenia patients 
(SCZ). OFT: ↑ activity, ↓ anxiety. FST: ↓ 
immobility.
Exaggerated startle response to high-deci-
bel tones (120 db) in SCZ mice. 
↑ Hippocampal GABA. ↑ hippocampal and 
serum glutamine. 
↓ Hippocampal and stool glutamate. Al-




(Zheng et al., 
2019)




OFT, EPM: ↓anxiety-like behavior. ↑ac-
tivity ↓ PSD95, synaptophysin expression. 
↑NA, DA, 5-HT turnover. ↓Ngfi-a & Bdnf.
DA D1 receptor: ↑expression in hippocam-











Anxiety Step-down, light/dark box: no change.
↑ Anxiety after recolonization
Brain (Bercik et al., 
2011a)
Swiss Webster Anxiety mRNA dysregulation




(Hoban et al., 
2017)












EPM, OFT 3 Chamber: anxiolytic behavior, 
sociability deficit and hyperlocomotion in 
♀. 
NOR: memory deficit.
Some parameters reversed via early-life 
colonization with Bifidobacterium or com-
plex microbiota.




No differences in seizure susceptibility. Brain (Olson et al., 
2018)
BDNF ↓Brain Bdnf levels when compared to ♂ 
not ♀.
Hippocampus (Clarke et al., 
2013)
Myelination ↑ Myelination genes regulation, regional 
and sex-specific differences in gene expres-
sion, hypermyelination in PFC.













LDB: no change. ↓BDNF in CA1. ↓c-fos 
expression after acute stress.
NOR, T-Maze: ↓exploration, memory. Re-
versible with C. rodentium.






3 Chamber: ↑ sociability. ↓Bdnf.
Amygdala (Arentsen et 
al., 2015)













Social Food Transmission impairment: 
↑grooming.
3 Chamber: ↓sociability and social novel 
preference. 
Reversal via colonization, of social cogni-







↑ Neuronal IEG’s & Bdnf IV, ↓ neurotrans-
mission-related genes. 
Not reversed by colonization after weaning.






↑ Certain regions but no significant differ-
ence in total volume.
Aspinal interneuron and pyramidal neu-
ron atrophy. short, thin, mushroom shape 
dendrites. 











3 Chamber: ↓sociability and social novel 
preference. High variability between indi-
viduals.




Aβ ↓in Aβ deposition, ↓in neuroinflamma-
tion, ↑Aβ degradation enzymes. 
Reversal via colonization was most effective 
from other transgenic Aβ mice.
Brain (Harach et al., 
2017)
SJL/J EAE GF cannot develop EAE, microbiota re-











Unreactive microglia, less pathology.
Colonization with human microbiota of 
individuals with PD also had more physical 
impairment than from healthy individuals.













Microglia ↓ Immune response altered gene expres-
sion, immaturity.
Reversed by microbiota colonization or 
SCFA administration.
Tested: corpus callosum, cortex, hippocam-
pus, olfactory bulb, and cerebellum.
Brain (Erny et al., 
2015)
CD11 Scrapie Resistance to IC injection.
↑Survival rate, ↓ incidence of symptoms.
Brain,
whole body
(Lev et al., 
1971)
Scrapie Susceptible to IC injection.
↑ Survival rate, ↓ incidence of symptoms.
Brain,
Whole body
(Lev et al., 
1971)
GF Mouse Stroke Restraint stress: ↑lesion size, ↓amount of 
microglia/macrophages.
Reversed via microbiota colonization.










↑Axon myelin thickness in BACHD-GF mice 
compared to BACHD-SPF in CC.
↑Proportion of small diameter axons in 
BACHD-GF 
↓Myelin-related proteins and mature oli-
godendrocytes in all GF mice.










More irregular splitting in myelin in B6 defi-
cient GF mice relative to conventional.
PNS (Sumi et al., 
1977)
Sprague Dawley Serotonergic 
System






OFT: ↑anxiety-like behavior, lower DA turn-
over rate. ↓sniffing in first two minutes 
of meeting, other behaviors (grooming, 








Danio rerio Anxiety Loco-
motion
OFT: ↑time that larva was mobile, no 
change in speed, ↑anxiety-like behavior, 
less thigmotactic behavior.
This was reversed via colonization.
Brain,
Whole larva








Novel Object Test: more time spent in 
near-object zone.
Social separation test: ↓reactivity.
Brain (Kraimi et al., 
2018)





Effects of antibiotic treatment Ref.
Mouse









-Social transmission of 
food preference
-Corticosterone re-
sponse to restraint 
stress
Tested between 7-11 
weeks
Altered gut microbiota composition in 
adulthood.
↓Anxiety-related behavior.
Cognitive deficits in novel object dis-
crimination and communication of cued 
food information.
Alteration in the tryptophan/kynurenine 
metabolic pathway.















Tested between 8-11 
weeks
Altered gut microbiota composition.
↓Novel object (but not spatial) discrim-
ination.
Brain-region specific changes in expres-
sion of relevant signaling molecules (i.e. 

















↓Hippocampal adult neurogenesis. 
Exercise was shown to ↑ neurogenesis.
These effects are partially mediated by 
Ly6Chi Monocytes.










Tested between 9-10 
weeks
Depressive-like behavior observed in 
the FST and TST.
↓ Ability to discriminate social novelty.
↓ Hippocampal BDNF protein levels.
↑ Hippocampal TrkB protein levels.
Altered spiking in hippocampal CA3. 
↑Activated microglia/astrocytes in the 
hippocampus.







Tested between 4-7 
weeks
Altered gut microbiota composition.
↓Locomotor activity in OFT.
No difference in social behaviors be-
tween groups.
Cross-fostering abolishes the behavioral 
differences at wk. 4.
(Tochitani et 
al., 2016)










Tested between 8-10 
weeks 
Altered gut microbiota composition.
Anxiolytic-like effect in light/dark box 
and step-down inhibitory avoidance.
↑ Hippocampal BDNF expression.
(Bercik et al., 
2011a)
BALB/c -Penicillin V -Locomotor activity
- EPM
-3-Chamber SIT
Tested at 6 weeks
Altered gut microbiota composition.
Anxiolytic-like effect observed in the 
EPM.
↑Aggression and ↓social avoidance 
behavior.
↑Avpr1b and cytokine expression in 
the frontal cortex.
↑Tight junction protein levels in the 














Mice were culled for 
immunohistochemistry 
at 5- 6 months 
Altered gut microbiota composition.
Altered inflammatory cytokine compo-
sition.
↓Aβ plaque deposition.
↑Concentration in soluble Aβ levels.
↓Reactive gliosis surrounding Aβ 
plaques.









-Beam Traversal, -Pole 
descent, -Adhesive 
removal
-Hind Limb Clasping re-
flex sore, -Inverted Grid 
Tested at 12-13 weeks
Antibiotic administration ameliorated 
locomotor deficits induced by a-synu-
clein overexpression.
↓Microglial diameter in the cau-












- None Altered expression of miRNAs in the 
amygdala and PFC.
Amygdala: ↓ miR-206-3p & miR-219a-
2-3p, ↑ miR-369-3p.
PFC: ↓ miR219a-5p.









- OFT, EPM, FST
- MWM, CRD
-Hotplate
Tested at 17-22 weeks
↓ Spatial memory observed in the 
MWM.
↑ Visceral sensitivity observed in CRD.
Depressive-like behavior observed in 
the FST.
Alterations in CNS serotonergic turn-
over.
↓ Hippocampal CRHR1 expression, ↑in 
amygdala BDNF expression.















Tested at 8-11 weeks 
Neonatal vancomycin significantly al-
tered gut microbiota composition.
↑ Visceral sensitivity observed in CRD.
Behavior in adulthood was not affected 
by early-life antibiotic administration.










- Assessment of cardio-
respiratory measures
4 weeks
Blunts the ventilatory response to hy-
percapnia due to decreased respiratory 
frequency.
Blunts respiratory frequency during the 
peak hypoxic ventilatory response.
Respiratory timing variability unaltered.
↓Systolic blood pressure
Cardiorespiratory responsiveness to 
vagal afferent nerve stimulation is unaf-
fected.
Altered brainstem monoamine and 
monoamine metabolite concentrations.
↑ Distal ileum permeability.
(O’Connor et 
al., 2019)
Wistar Dams were 
fed either 
control diet, 
or diet with 
1% SST 
- OFT, SIT, EPM, PPI
- Marble burying
Tested at 6-7 weeks
↓ Social interactions.


















Tested at 3 months
↓ Social cohesion behavior.
↑ Anxiety-like behavior observed as a 
↓in shoaling.
Alterations in the expression of genes 
associated with locomotion.








Multiple choice mating 
tests
♂ and ♀ mating preference was abol-
ished.
(Sharon et al., 
2013)










Acute ↓ Striatal anticipatory reward responses to high-energy 
foods.
(Byrne et al., 
2016)
Healthy RPS, RMS 
and inulin 
2 weeks ↑Total SCFA with RPS and inulin.
↑Butyrate and acetate only with RPS.
No changes seen with RMS.
(Baxter et al., 
2019)
Type 2 diabe-




8 weeks ↑ Depression, anxiety and stress (DASS). ↓ Cortisol, KYN, 
KYN/TRP ratio. Altered peripheral immune markers.
(Farhangi et 
al., 2018)
IBS    ♂ ♀ Short-chain 
FOS
4 weeks ↓ Anxiety scores. (Azpiroz et 
al., 2017)
Autism    ♂ ♀ B-GOS® 
mixture
6 weeks Improvement in social behavior symptoms and sleep in 







or both FOS 
and GOS
3 weeks ↓ Anxiety- and depressive-like behavior, stress-respon-
siveness, hypothalamic Nr3C1 and hippocampal Crhr1 
expression. ↑ Pro-social behavior, hippocampal, 5-HT in 





6 weeks ↓ Chronic stress-induced social avoidance, cognitive dys-
function, anhedonia, 









3 weeks ↓ Stressor-induced anxiety-like behavior and ↑ stress-in-
duced ↓DCX+ immature neurons.












8 weeks ↓ Neuronal signaling in the ventromedial hypothalamus 
and PVN.
(So et al., 
2007)
β- glucan 8 weeks ↓ Neuronal signaling in the arcuate nucleus, ventromedial 
hypothalamus, PVN, 
periventricular nucleus and the NTS.







9 weeks ↑ Neuronal signaling in the arcuate nucleus. (Anastasovs-
ka et al., 
2012)
CD1 B-GOS® 3 weeks ↓ LPS-induced anxiety-like behavior and HT2AR expres-
sion in the frontal cortex.
(Savignac et 
al., 2016)
BALB/cJ FOS 7 weeks ↓ Aβ deposition and BAC levels. ↑ Hippocampal-depen-
dent learning.




GOS 74 days ↓ Motor neuron death and spinal cord inflammatory 
markers.
















5 weeks ↑ Operant Conditioning and LTP, PSD-95 protein levels 
in hippocampus and frontal cortex, as well as CaMKII and 









65 Days ↑ Hypothalamic POMC expression. (Shen et al., 
2009)
FOS or GOS 5 weeks ↑ Hippocampal BDNF and NR1 subunit expression. ↑ Hip-
pocampal NR2A subunit and frontal cortex NR1 expression 
and d-serine levels by GOS.
(Savignac et 
al., 2013)
B-GOS® 3 weeks ↑ Cortical GluN2A subunit. (Kao et al., 
2018)







10 Days ↑ Hippocampal-dependent memory. 
↓ Hippocampal neuronal apoptosis, 8-OHdG, TNF-α and 
IL-1β levels.
(Jia et al., 
2016)






















4 weeks ↓ Stress-induced learned helplessness and cFOS expres-
sion in the DRN. ↑ Basal BDNF in prefrontal cortex by GOS, 
polydextrose and lactoferrin.
(Mika et al., 
2017)
GOS, PLWC  40 Days ↑ Dendritic spine density of rat hippocampal neurons. (Waworuntu 
et al., 2016)
Pig
♂ Sialyllactose 3 weeks No effect on recognition Memory or diurnal Activity. (Fleming et 
al., 2018)
Lactoferrin 5 weeks ↑ Hippocampal BDNF and cognitive function. (Chen et al., 
2015)



















B. longum 1714 4 weeks ↑ Neurocognitive performance (paired asso-
ciative learning).
↑ Fz mobility.
↓ Cz theta power after end of probiotic ad-
ministration.




4 weeks Does not significantly impact HPA axis, stress, 
and cognition.









L. lactis subsp 
lactis
4 weeks ↓ Reactivity in widely distributed network 
during emotional attention task.
↓ BOLD signal in amygdala, mid insula cortex, 
primary somatosensory cortex in emotional 
attention task.
Altered PAG resting state network. 
(Tillisch et al., 
2013)
♂ ♀ Ecologic®825: L. 
casei, L. paracasei,
B. lactis, L. sali-
varius, B. lactis, L. 
plantarum 
B. bifidum, L. aci-
dophilus, L. lactis
4 weeks Change in gut microbiota profile.
↓ Some anxiety and depressive measures.





4 weeks Changes in functional connectivity but no 
changes in structural connectivity.
(Bagga et al., 
2018a)
Ecologic®Barrier:
B. bifidum, B. lactis, 
L. acidophilus,
L. brevis, L. casei, L. 
salivarius, L. lactis 
4 weeks ↓ Aggression and rumination in response to 
depressive thoughts (LEIDS-r test).
(Steenbergen 
et al., 2015)
L. casei Shirota 
(Yakult)
3 weeks Only improvement in depression in POMS 
scale for people at the lowest end of the mood 
scale.
(Benton et al., 
2007)
Group 1: Probiotic 
yogurt
L. acidophilus 
LA5, B. lactis 
BB12 
Group 2: Capsule
L. casei, L. 
acidophilus , L. 









L. helveticus R0052 
and B. longum 
R0175
30 days ↓ Anxiety via HADS score. (Messaoudi et 
al., 2011a)
B. subtilis: contain-
ing 75% in spore 
form and 25% in 
vegetative form
4 weeks Only impacted microbiota composition.
No effect on GI symptoms or general wellness.













12 weeks ↑ Cognitive performance in RVIP and Stroop 
Color-Word task (cognitively demanding tasks).
(Chung et al., 
2014)
Alzheimer’s 
Disease            ♂ 
♀
Capsule: 
L. acidophilus, L. 
casei, B. bifidum, L. 
fermentum
12 weeks ↑ MMSE score. Change in blood lipid profile 
and carbohydrate metabolism factors.
(Akbari et al., 
2016)
Chronic fatigue     
♂♀
syndrome
L. casei strain Shi-
rota




50ng/ml (low)   
♂ ♀
L. helveticus R0052 
and B. longum 
R0175
30 days ↑Perceived stress score, hospital anxiety, de-
pression scale score.
↑HSCL-90 subscores for obsessive-compulsive, 
anxiety, and depression.







L. plantarum, S. 
thermophiles, B. 
breve, L. paraca-
sei, L.delbrueckii  
subsp. Bulgaricus, 
L. acidophilus, B. 
longum, B. infantis  
6 months ↑ Neurocognitive performance. (Ceccarelli et 
al., 2017a)
♂ ♀ Vivomix®: (See 
composition above)
6 months ↑ Verbal and visual memory. (Ceccarelli et 
al., 2017b)
IBS            ♂ 
♀
B. longum NCC3001 6 weeks ↓ HAD-A and D scores indicating ↓ in anxiety/
depression. 
↑ Quality of life.
(Pinto-Sanchez 
et al., 2017b)
L. paracasei, ssp. 
paracasei F19
L. acidophilus La5 
B. lactis Bb12
8 weeks No significant psychological changes. (Simren et al., 
2010)
MDD            ♂ 
♀
Capsule:
L. acidophilus, L. ca-
sei, and B. bifidum
8 weeks ↓ BDI score. (Akkasheh et 
al., 2016)
L. helveticus R0052 
and B. longum 
R0175 (CNCM 
strain I-3470)
8 weeks ↓ BDI score (depressive index).
↓ Kynurenine: Tryptophan ratio.
(Kazemi et al., 
2019)
L. Plantarum 299v 8 weeks ↑ APT and CVLT total recall of trials 1–5 
↓ Kynurenine concentration
↑ 3-hydroxykynurenine: kynurenine ratio
(Rudzki et al., 
2019)
MS            ♂ 
♀
Capsule: L. aci-













1 “bag”: S. thermo-
philes, B. animalis 
subsp. Lactis, S. 
thermophilus, B. 
bifidum 
L. delbrueckii spp. 
Bulgaricus , L. lactis 
subsp. Lactis, L. ac-
idophilus, L. planta-
rum , L. reuteri
3 weeks ↓ positivity to BUT.
↓ EDI-2 responses.
(De Lorenzo et 
al., 2017)




24 weeks ↑ Body esteem in ♀s, ↓ Depression score in 
♀s.
(Sanchez et al., 
2017)








Bifiform Balance: L. 
rhamnosus strain 
GG B. animalis sub-
sp. lactis Bb12
14 weeks ↓ C. albicans antibodies in ♂ serum, 




L. rhamnosus strain 
GG 
B. animalis subsp. 
lactis strain Bb12
14 weeks No changes in frequency of psychotic symp-
toms.
↓ Incidence of severe bowel difficulties.
↓ Acute von Willebrand factor, ↑ MCP-1, 
BDNF, RANTES, MIP-1.
(Tomasik et al., 
2015)
Bifiform Balance: L. 
rhamnosus strain 
GG B. animalis sub-
sp. lactis Bb12
2 weeks No differences in PANSS total symptom score.
↓ Incidence of severe bowel difficulties.
(Dickerson et 
al., 2014)
Pregnancy L. rhamnosus GG, L. 
rhamnosus LC705, 










Analyzed 81 randomly selected colostrum sam-
ples from a bank of 500.
↑ Human milk oligosaccharides: 3-fucosyllac-
tose and 3′-sialyllactose in colostrum
↓ Human milk oligosaccharides: difucosyllac-
to-N-hexaose, lacto-N-tetraose, lacto-N-fuco-
pentaose I, and 6′-sialyllactose.









3 weeks ↓ Stress-induced abdominal pain and nausea/
vomiting.
↓ Flatulence, gas production.
No effect on other symptoms (physical, psy-
chological, sleep).
(Diop et al., 
2008)
Stress/       ♂ ♀
Exhaustion
Multiobionta: Pro-
biotic culture blend 
L. acidophilus, 
B. bifidum, B. 
longum




L. plantarum DR7 4, 8 and 
12 weeks
↓ Stress and anxiety using DASS-42, but not 
PSS-10, questionnaires.
No effect on depression. 
↑ Anti-inflammatory cytokines and ↓pro-in-
flammatory cytokines in young adults.
↓ Pro-inflammatory cytokines in normal 
adults over 12 weeks.
↑ Verbal learning and memory in young adults
↑ Basic attention, social emotional cognition 
and associate learning in normal adults over 12 
weeks.
↓ IDO/TDO, kynurenine, cortisol, IFN-γ and 
TNF-α.
↑ TPH, Serotonin, IL-4, IL-10.
(Chong et al., 
2019)
Student      ♂ ♀
exam stress
L. casei strain Shiro-
ta YIT 9029
8 weeks ↓ Physical symptoms of stress/anxiety (Takada et al., 
2016)
B. bifidum R0071 or 
L. helveticus or B. 
infantis
6 weeks ↑ Healthy days (i.e. no flu/cold) only from B. 
bifidum.
↓ Reports of symptoms lasting more than a 
day in participants receiving B. bifidum.
Proportion of participants reporting cold/flu 
between weeks 2 and 3 lower in those receiv-




L. plantarum 299v 14 days No difference in perceived stress.








8 weeks No change in psychological parameters (anxi-
ety, depression scales). ↓ Physical symptoms 





240 ml of fer-
mented milk with 
the
L. johnsonii





↓ Infection rate, length of stay in ICU, days on 
mechanical ventilator.
(Falcao de 
Arruda and de 
Aguilar-Nasci-
mento, 2004)
Type 2 Diabetes Capsule: L. aci-




12 weeks Improved BDI, BAI, GHQ scores (↓anxiety and 
depression).
(Raygan et al., 
2018)
Low mood        
♂♀
L. helveticus, B. 
longum







36 days No effect on tonic immobility induced by fear.
No effect in OFT, ↑ Memory (not due to emo-
tional reactivity).




B. longum NCC3001 2 to 3 
weeks
↓ Anxiety-like behavior in DSS. (Bercik et al., 
2011b)
B. longum NCC3001 ↓ AH neuron excitability, 





B. longum 1714 or 
B. breve 1205
6 weeks ↓ Bodyweight gain from B. longum.
↓ Body temperature ↑during stress-induced 
hyperthermia.
↓ Anxiety in marble burying with either strain.
↓ Anxiety via EPM in B. breve but no differ-
ence in locomotion.
↓ Latency in OFT in B. longum group.
↓ Immobility time in FST for B. longum group.
↑ Spleen weight in B. breve.
(Savignac et 
al., 2014)
L. rhamnosus 29 days ↓ Stress-induced hypothermia, anxiety (EPM).
↓ GABAB1b mRNA in basolateral and central 
amygdala, locus coeruleus, DG, CA3, CA1.
↓ GABAAα2 mRNA in CG1, PrL and IL cortical 
areas, and BLA, CeA.
↑ GABAAα2 mRNA in the DG. Effects abol-
ished through vagotomy.






philes, B. longum, 
B. breve, B. infan-
tis, L. acidophilus, 
L. plantarum, 
L. paracasei, L. 
delbrueckii subsp. 
bulgaricus, L. brevis
4 months ↓ Oxidative stress in brain.
↓ Cognitive decline, brain damage, Aβ peptide 
accumulation.




model            
C. butyricum 6 weeks ↑ Spatial memory, ↓ Neuronal apoptosis, ↑ 
Butyrate in brain.
(Liu et al., 
2015)
ICR:   
♂
Ischemia Injury     
C. butyricum 2 weeks ↓ Neurological deficit score,↓ Hippocampal 
neuron karyopyknosis. ↓ Apoptosis in CA1 via 
TUNEL.





L. reuteri 3 weeks GABAR expression correlated with L. reuteri 
in mice. Probiotic modifies social (in ♂s) and 
repetitive behavior (♂s and ♀s), ↑GABAR 
(regional and sex-dependent magnitudes) and 
oxytocin expression.





L. plantarum MTCC 
9510
28 days ↓ SD-induced anxiety and depression (FST, 
EPM).
↑ Learning and memory (MWM), ↓ BBB 
permeability.
Abolished Bdnf decrease in hippocampus.










L. reuteri 4 weeks In all three strains, rescued impaired sociability 
as measured by three-chamber sociability, re-
ciprocal social interaction and/or social novelty 
tests. 






B. CECT 7765 21 days Partially attenuated exaggerated HPA stress 
response.
↓ Vulnerability to stress in adulthood.
↓ Anxiety, catecholaminergic hyperactivity in 
adulthood.










Ameliorated neurological deficits and brain 
edema size.
↓ Degenerating neurons, ↑ Occludin and 
ZO-1 expression at BBB to ameliorate ↑per-
meability from TBI.
↑ P-Akt/Akt, Bcl-2 along with ↓ Bax indicat-
ing less neuronal. apoptosis, ↑ GLP1 in colon, 
GLP1-R in brain.
(Li et al., 
2018a)
C. rodentium 
infection         
♀
Lacidofil:
L rhamnosus and L 
helveticus 
10 days Attenuates WAS non-spatial memory deficit.
Ameliorates BDNF and c-Fos in hippocampus 
after WAS.











Reversed memory impairments (spontaneous 
alteration in Y-Maze). Restored some microbio-
ta perturbations.
↑ Bdnf and↓ NFKB activation in hippocampus 
and LPS in blood.
(Lee et al., 
2018a)
Chronic social 




28 days ↓ Stress-induced anxiety.












stress      ♂
L. helveticus 
MCC1848
24 days restored normal sucrose consumption in the 
sucrose preference test
↓ Anxiety-like behavior in the SIT.
No effect on polydipsia-like behavior.




DSS- colitis      ♂ 
♀
L. rhamnosus and L. 
helveticus
20 days Rescued some decreases in NOR, anxiety and 
c-fos in CA1.




L. helveticus R0052 
or /and B. longum 
R0175
14 days Combination of both probiotics reversed dis-
tension pain hypersensitivity at larger volumes.
Prevented GR decrease in hypothalamus and 
hippocampus if pretreated with both probiot-
ics or B. longum.








L. plantarum PS128 28 days Restores sucrose preference (↓in ELS/no 
probiotic). 
↑ Locomotor activity, ↓ anxiety in EPM in 
naïve mice. 
↑ DA and DAergic metabolites in PFC in early 
life stress. 
↓ HVA: DA ratio. No change in DAergic activity 
in striatum.




L. plantarum PS128 16 days ↓ Anxiety-like behavior, ↑ Locomotor activity. (Liu et al., 
2016a)
6N: MIA B. fragilis 6 days Corrected microbiota changes in MIA offspring.
Prevented/↓MIA-induced anxiety (OFT, mar-
ble burying), ↓deficits in sensorimotor gating.
Did not improve social deficits.




L. helveticus R0052 
and B. longum 
R0175
2 weeks ↓ cFos+ neurons responding to WAS in PVN, 
CA3, and amygdaloid nucleus (↑in non-WAS/
probiotic compared to other control animals).
↑ Bdnf in hypothalamus in response to WAS.
↓ Expression of cytoskeleton organization, 
microglia activation, synaptogenesis and cell 








L. reuteri DSM 
17938
9 days ↓ Spontaneous mesenteric nerve firing activ-
ity.
Effect not inhibited by smooth muscle relax-
ation or vagotomy.
Partial evoked antagonism of TRPV1.
↓ Distension evoked firing via TRPV1 antago-
nism.
Supernatants also able to exhibit antagonism.










Prevented and treated depressive-like or anxi-
olytic-like behaviors caused by CUMS. Rectified 
CUMS-induced weight loss. 
↑ Cecal acetate, propionate and n-butyrate 
levels.
↓ CUMS-induced circulating corticosterone 
and CRP increase.
↑ IL-10 level, and ↓IL-6 induced by CUMS.









N/A ↑Firing rate of mesenteric afferent bundles.
70% of single unit afferent nerves also had an 
↑ firing rate.
Administration does not reduce firing rate after 
distension. 






(WAS)      ♂
Lacidofil Powder: 
95% L. rhamnosus 
R0011
         
5% L. helveticus 
R0052
7 days Prevents stress induced bacterial adherence to 
enterocytes.
Prevents bacterial translocation to mesenteric 
lymph nodes after WAS. No apparent effect on 
intestinal histology.
Inhibit chronic stress elevation of ion secretion 
in intestines.
No impact on permeability in ileum or colon.







B. lactis, L. 
acidophilus, L. 
brevis, L. casei, 
L. salivarius, L. 
lactis 
12 weeks Protected against depressant effects of HFD in 
FSL (FST).
No effect on locomotor activity.
(Abildgaard et 
al., 2017a)
Aging Probiotic Mixture 
KF (1:1 ratio):
L. curvatus HY7601 
L. plantarum 
KY1032
Reversed age-dependent ↓in spontaneous 
alteration (Y Maze).
No significant effect on escape latency 
(MWM).
↑Hippocampal DCX, BDNF and phosphorylat-
ed CREB relative to control aged mice, ↓acti-
vation of mTOR pathway.




B. breve 6330 42 days ↑ BDNF IV mRNA in control rats given probiot-






B. infantis 35624 45 days Normalized effects of maternal separation in 
FST. 







L. helveticus NS8 ~27 days ↓ Anxiety-like and depressive-like behavior.
↑ Recognition memory.
↑ Hippocampal bdnf, NE, 5-HT.





95% L. rhamnosus 
R0011
 






Restored ion transport and permeability after 
WAS in adult life (persisting effect). Abolished 
MS-induced HPA overactivation.
(Gareau et al., 
2007)
♂ Lacidofil Powder: 
95% L. rhamnosus 
R0011
         








Restored age-appropriate forgetting (infantile 
amnesia) and relapse-resistant extinction of 
aversive memories during infancy (P17).
No effect on anxiety or locomotor activity in 
pups or dams.
No effect on maternal care behavior (pup 
retrieval).
(Cowan et al., 
2016)
♂ Lacidofil Powder: 
95% L. rhamnosus 
R0011
    






Restored age-appropriate neural activity in the 
pre-frontal cortex following fear expression 
and inhibition during infancy (P17).
(Cowan et al., 
2019)
♂ ♀ Lacidofil Powder: 
95% L. rhamnosus 
R0011
         








Restored normative timing of physical pu-
berty onset in both sexes (reversed stress-in-
duced delay in preputial separation for males, 





♂ ♀ L. rhamnosus GG ~4 weeks Ameliorate ↓ in exploration and ↑ in anxiety 
from stress.
Altered gene expression in hippocampus (no 
behavior in ♀s).
(McVey 
Neufeld et al., 
2017)
♂ B.  infantis 14 days No effect in FST. ↓ 5-HIAA in frontal cortex.
↓ DOPAC in amygdaloid cortex.





B. lactis, L. 
acidophilus, L. 




11 weeks ↓ Depression (FST).
No locomotor effect (OFT).
↓ Expression of HPA axis genes in hippocam-
pus.




L. reuteri 9 ↓ Firing threshold of afterhyperpolarization 
myenteric neuron.
↓ Slow after-hyperpolarization potential of 
sensory neurons.
↓ Potassium-dependent calcium channel 
opening.
(Kunze et al., 
2009)
L. rhamnosus and 
B. longum
12 days ↓ Depression-like behavior.
↑ Expression of GABA-A Receptor subunits in 
hippocampus.
(Liang et al., 
2017)
L. casei 54-2-33 14 days ↑ Anxiety (OFT).
↓ Expression of 5-HT1A mRNA in hippocampus.
(Barrera-Bu-




tial  ♀ 
restraint stress
L. farciminis 14 days Probiotic prevented ↑ in c-Fos expression in 











↓ Myeloperoxidase activity in colon.
Alleviated ampicillin-induced anxiety (EPM).
Alleviated memory deficits seen in MWM in 
ampicillin-treated animals. Prevented ampi-
cillin-induced MR and NMDA-R decrease in 
hippocampus.




mation model  
♂
L. helveticus NS8 2 weeks ↓ Anxiety-like behavior (EPM).
↑ Learning and memory (MWM). 
↓ 5-HT in cerebellum and hippocampus but 
did not restore regional. ↑ 5-HIAA in HA brain.







4 weeks ↓ Bax/Bcl-2 and Caspase-3 levels in DG, medi-
al amygdala and lateral amygdala but not CA1 
or CA3 ↓ apoptosis.
Differences in phopsho-Akt:Akt ratios in these 
regions.




L. reuteri 9 days Inhibition of ↑ heart rate in response to CRD.
↓ Single unit discharge of PNS neurons in 
response to distention.
No effect on pain via tail flick or paw pressure 
tests.





L. rhamnosus GG 40 days Measurements taken in adulthood after ear-
ly-life colitis induction.
↓ Visceromotor response to distension.
No change in DA or its metabolites in brain-
stem.
↑ DA and DOPAC in frontal cortex.
↑ NA and 5-HIAA in cerebellum.
↓ His in brainstem ↓ Glu and Lys in subcortex.
↓ Glu, Lys, His, Taurine in frontal cortex.








95% L. rhamnosus 
R0011
       






Restored age-appropriate forgetting and re-
lapse-resistant extinction of aversive memories 







UCC118, B. infantis 
35624, or B. breve 
UCC2003
14 days ↑ Pressure threshold in Sprague-Dawley rats 
in response to distension if given B. infantis or 
B. breve.
↑ Pressure threshold in WKY rats given B. 
infantis.




Wistar   
♂
L. helveticus, B. 
longum 
7 days ↓ Anxiety in marble burying. (Messaoudi et 
al., 2011a)
L. helveticus, B. 
longum 
7 days No rewarding properties of probiotic in condi-
tioned place preference relative to morphine.




VSL #3 6 weeks Effect on brain gene expression (>300 genes).
Attenuate age-related decrease in LTP.
↓ Microglial activation in hippocampus.
(Distrutti et al., 
2014)




AD L. plantarum 60 days ↑ Performance in MWM in AD+Probiotic 
group.
(Nimgampal-




Mix: L. acidophilus, 
B. lactis, L. fermen-
tum
8 weeks ↑ Performance on MWM in diabetes probiot-
ic.
↑ Synaptic transmission (electrophysiology).





L. rhamnosus 4 weeks ↑ Exploration, attention.
↑ Brain bdnf, serotoninergic system genes.





L. plantarum L168 2-3 days ↑ Social behavior in kdm5-deficient flies.
↓ Intestinal permeability
↓ Number of intestines with defects in 
kdm5-deficient flies.
↓ 5-HT levels in kdm5-deficient flies.
Restored intestinal barrier integrity.
KDM5 demethylase affects social behavior 
through the gut-microbiome-brain axis.
3.5-fold increase in median survival of 
kdm5-deficient flies.
Only GF flies with kdm5-deficiency were viable. 
(Chen et al., 
2019)
Table 6: Tools used in the analysis of the gut microbiome.
Tool Function Based on: Platform Advantages Disadvantages
Biomarker Pro-
filing Microbiota Composition DNA NGS












Metabolomics Metabolic Productivity Metabo-lites
LC/GC-
MS







Microbial Functional Gene Ex-
pression
RNA
NGS Host and Microbial Gene Transcripts
- Requires RNA 
Preservation
- Host Genes 
may Dominate
Metaproteom-







↓ - decrease/ reduction/ downregulation
↑ - increase/ enhancement/ upregulation
5-HIAA - 5-Hydroxyindoleacetic acid
5-HT – 5-hydroxytryptamine or serotonin 
5-HT1A/2AR - Serotonin 1A/2A receptor 
8-OHdG - 8-Oxo-2’-deoxyguanosine
Aβ - Amyloid β
AH – Afterhyperpolarization 
APT - Attention and perceptivity test
ASD – Autism spectrum disorder
ASF - Altered schaedler flora
B. acidophilus– Bifidobacterium acidophilus
B. adolescentis – Bifidobacterium adolescentis
B. animalis – Bifidobacterium animalis
B. bifidum – Bifidobacterium bifidum
B. breve – Bifidobacterium breve
B. catenulaturm– Bifidobacterium catenulaturm
B. dentium– Bifidobacterium dentium
B. fragilis – Bifidobacterium fragilis
B. infantis– Bifidobacterium infantis
B. lactis – Bifidobacterium lactis
B. longum – Bifidobacterium longum
B. subtilis – Bifidobacterium subtilis
B-GOS® - Bimuno-galactooligosaccharide
BACHD - Bacterial artificial chromosome model of HD
BAI - Beck anxiety inventory
BBB – Blood-brain barrier 
BDF1 - Bromodomain-containing factor 1
BDI - Beck depression inventory
BDNF – Brain-derived neurotrophic factor
BLA – Basolateral amygdala
BOLD - Blood-oxygen-level dependent 
BrdU – Bromodeoxyuridine
BUT - Body uneasiness test
C. rodentium – Citrobacter rodentium
C. butyricum - Clostridium butyricum
C. perfringens - Clostridium perfringens
C. difficile - Clostridium difficile
CA1/3 - Cornu Ammonis 1/3
CaMKII – Calcium calmodulin-dependent protein kinase
CC - Corpus callosum
CeA - Central nucleus of the amygdala
CNS – Central nervous system
Cog – Cognition
CRD – Colorectal distension
CREB - cAMP response element-binding protein
CRF - Corticotropin-releasing factor
CRHR1 - Corticotropin-releasing hormone receptor 1
CRP - C-reaction protein
CUMS - chronic unpredictable mild stress
CVLT - California verbal learning test
DA – Dopamine
DAergic – Dopaminergic
DASS - Depression anxiety stress scales
DCX – Doublecortin
DG – Dentate gyrus
DHQ - Diet history questionnaire
DNA - Deoxyribonucleic acid
DOPAC - Dihydroxyphenylacetic acid
Drd3 - Dopamine receptor D3
DREADD - Designer receptors exclusively activated by designer drugs
DRN - Dorsal raphe nucleus
DSS - Dextran sulphate sodium
EAE - Experimental autoimmune encephalomyelitis
EDI - Eating disorders inventory
EDSS - Expanded disability status scale
ELS - Early life stress
FOS – Fructooligosaccharide
EPM – Elevated plus maze
FMP - Fermented milk product
FMT - Fecal microbiota transplant  
FRL - Flinders resistant line
FSL - Flinders sensitive line
FST - Forced-swim test
GABA - γ-Aminobutyric acid
Gcg – Glucagon
GF – Germ-free




HADS - Hospital anxiety and depression scale
HCL – Hydrochloric acid
HD - Huntington disease
HFD – High-fat diet
HIV - Human immunodeficiency virus
HPA - Hypothalamic-pituitary-adrenal
HSCL - Hopkins symptom checklist
Htr1a - Serotonin 1A receptor
Ht2ar – Serotonin 2A receptor
HVA - Homovanillic acid
Hyperammonemia (HA)
IBS - Irritable bowel syndrome
IC – Intracerebral
ICR - Institute of Cancer Research
IDO - Indoleamine 2,3-dioxygenase 
IEG – Immediate early gene
IFNγ - Interferon gamma
IL (Immunology) – Interleukin
IL (Cortex) - Infralimbic cortex
KDM5 - Histone demethylase kdm5
KM - Chinese kun ming mouse
KYN - Kynurenine
L. acidophilus – Lactobacillus acidophilus 
L. brevis– Lactobacillus brevis
L. bulgaricus – Lactobacillus bulgaricus 
L. casei – Lactobacillus casei
L. curvatus – Lactobacillus curvatus
L. delbrueckii – Lactobacillus delbrueckii 
L. farciminis– Lactobacillus farciminis
L. fermentum– Lactobacillus fermentum
L. helveticus – Lactobacillus helveticus  
L. johnsonii– Lactobacillus johnsonii
L. paracasei – Lactobacillus paracasei 
L. plantarum – Lactobacillus plantarum 
L. reuteri – Lactobacillus reuteri
L. rhamnosus – Lactobacillus rhamnosus
L. salivarius– Lactobacillus salivarius
LA – Lateral amygdala
LC/GC-MS - Liquid chromatography/ gas-chromatography-mass spectrometry
LDB – Light/dark box
LD - Light/dark preference
LEIDS-r - Leiden index of depression sensitivity-revised
LPS – Lipopolysaccharides
LTP – Long-term potentiation
MB – Marble burying
MCP-1 - Monocyte chemoattractant protein-1
MDD - Major depressive disorder
MeA - Medial amygdala
MGBA – Microbiota-gut-brain axis
MMSE - Mini mental state exam
MIA – Maternal immune activation
MIP-1 - Macrophage inflammatory protein-1
MiR/ miRNA - microRNA
mRNA - Messenger ribonucleic acid
MS - Multiple Sclerosis
MR - Mineralocorticoid receptor
mTOR - Mammalian target of rapamycin
MWM – Morris water maze
NA – Noradrenaline
NAc – Nucleus accumbens 
NE – Norepinephrine 
NFKB - Nuclear factor kappa-light-chain-enhancer of activated B cells
Ngfi-a - Nerve growth factor inducible A
NGS – Next-generation Sequencing
NIH - National Institutes of Health
NMRAR - N-methyl-D-aspartate receptor
NMRI - Naval medical research institute
NOR – Novel object recognition
NPY - Neuropeptide Y
NR1/2 – NMRAR 1/2
Nr3C1 - Nuclear Receptor Subfamily 3 Group C Member 1
NSF - Novelty suppressed feeding
NTS - Nucleus tractus solitaris (the nucleus of the solitary tract)
OFT - Open-field test 
PAG - Periaqueductal gray
PANSS - Positive and negative syndrome scale
PD - Parkinson’s disease
PFC - Prefrontal cortex
PLWC - Polydextrose, lactoferrin and whey protein concentrate
PND – Postnatal day
PNS - Peripheral nervous system
POMS - Profile of mood states scale
PPI – Prepulse inhibition
PrL - Prelimbic cortex
PS1 – Presenilin 1
PSD95 - Postsynaptic density protein 95
PSS - Perceived stress scale
PVN - Paraventricular nucleus
RANTES - Regulated on activation, normal T cell expressed and secreted
REM – Rapid eye movement
RMS - Resistant maize starch
RNA - Ribonucleic acid
RPS - Resistant potatoes starch 
RVIP - Rapid visual information processing
SCFA – Short-chain fatty acid
sCSDS - Subchronic social defeat stress
SD - Sleep deprivation 
SGZ - Subgranular zone
SIT - Social interaction test
SPF – Specific pathogen free
SPT – Social preference test
SYN – Synuclein
TBI – Traumatic brain injury
TDO -  tryptophan 2,3-dioxygenase
Thy1 - Thymidylate synthase complementing protein 1
TNBS - 2,4,6-trinitrobenzene sulfonic acid
TNF-α/β - Tumor necrosis factor alpha/beta
TPH - Tryptophan hydroxylase
TRP – Tryptophan
TrkB - Tropomyosin receptor kinase B
TRPV1 - Transient receptor potential vanilloid 1
TST – Tail suspension test
TUNEL - Terminal deoxynucleotidyl transferase dUTP nick end labeling
VTA - Ventral tegmental area
WAS - Water avoidance stress
WKY - Wistar Kyoto
Call out box 
“This is a comprehensive review of current knowledge of the influence that the microbiota has on brain and be-
haviour. In particular we focus on the pathways involved and the models used in the field. Moreover, we highlight  
what still remains to be understood in order to fully realize the potential for the development of microbiota-based 
therapeutic strategies for brain disorders.”
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